# Genome Evolution: a study of MHC paralogous genes in the human genome 

Vikki Rand

## This dissertation is submitted for the degree of Doctor of Philosophy

September 2003

Gonville and Caius College, University of Cambridge

Wellcome Trust Sanger Institute<br>Wellcome Trust Genome Campus, Hinxton, Cambridge


#### Abstract

One of the interesting findings of the Human Genome Project was that approximately $10 \%$ of the genome has arisen by duplication. This is exemplified by the clusters of genes, on chromosomes 1q21-q25, 9q32-q34.3 and 19p13, paralogous to genes located within the Major Histocompatibility Complex (MHC) region, on 6p22.2p21.3. By definition, paralogues are genes within the same species that have originated through duplication of an ancestral gene. The survey of the human genome identified 82 MHC paralogues based on sequence similarity and conserved gene structure. Analysis of the distribution of the paralogues identified clusters on chromosomes 1q21-q25, 9q32-q34.3 and 19p13 (38/82), and revealed paralogues located elsewhere in the genome (44/82). In total, $44 \%$ of the paralogues identified are novel discoveries, of which $89 \%$ are located outside the previously known clusters.


Evidence from my phylogenetic analyses indicates that the MHC paralogues located within the regions on 1,9 and 19 arose by two ancient duplication events, either by duplication of the whole genome or of chromosomal segments, prior to vertebrate emergence. Expansion of paralogous gene families has occurred by additional duplications involving individual loci or chromosomal regions resulting in paralogues outside the clusters. In-depth analysis of the chromosomal region 9q32-q34.3 revealed that the order of paralogues is not conserved and that they are interspersed by other genes, indicating the region has been subjected to genomic rearrangements.

Comparison of the expression profiles of a selected set of MHC paralogues revealed that some have functionally diverged since duplication; with members of the same paralogous gene family being ubiquitously expressed, and others, having an
expression profile restricted to only a few tissues. Evidence of co-expression of paralogues in some tissues suggests a similar function and involvement in the same pathways. This thesis highlights the importance of understanding paralogy, particularly for future investigations of phenotypes associated with paralogous genes.

## Acknowledgements

I would like to thank my supervisor Stephan Beck for his tireless enthusiasm, encouragement and support throughout this project. Particular thanks go to my second supervisor at Cambridge University, John Trowsdale. I am also grateful to the past and present members of the Immunogenomics group (a.k.a Team 50) who have helped me throughout my PhD: Karen Novik, Ruth Younger, Roger Horton, Melanie Stammers, Karen Crum, Karen Halls, Jennifer Sambrook, Penny Coggill, Marcos Miretti and Vardhman Rakyan. Thankyou for all your advice, encouragement and help. I am also very grateful for your tolerance - particularly of my moaning over the last few months - and for providing regular distractions in the form of tea breaks, coffee breaks, lunch, pub $\qquad$ this also goes for the members of team 30 , Gavin Wright, Mark Bushall and Nick Bockett, who foolishly share our lab and office!

I am indebted to everyone who has contributed to the mapping and sequencing of the human genome - without this data the work in this thesis would not have been possible. I would also like to thank everyone who has helped me with the different aspects of the project. Special thanks goes to Sean Humphray and the members of the Chromosome 9 Sequencing and Mapping group who helped me with the work presented in chapter 3. Particular thanks go to Andrew Knight for his help with the sub-cloning, Keith Porter for the fingerprinting and the Sanger Institute Cytogenetics laboratory, namely Sheila Clegg and Pawan Dhami, who helped me with the fluorescent in-situ hybridisation (FISH) experiments. I am also very grateful to the members of team 41 and, the now extinct, team 49 who helped me with the sequencing and to Gavin Laird and Adrienne Hunt for their 'finishing' tutorials.

Thanks also go to Rosemary Ward for all her assistance with the tissue culture, Alison Coffey for her help with the blots and to Dave Vetrie, Cordelia Langford and the Sanger Institute Microarray Facility for all their help and guidance with the microarray experiments. Thanks also go to Ewan Birney and Michele Clamp for their help with ENSEMBL and to Kevin Howe for maintaining the FINEX database and writing some useful perl scripts. I realise I have been privileged to have worked in an environment where help has been offered so freely.

On a personal note, thanks must go to all my family and friends who have put up with me over the last few months - and years! Particular thanks go to my mam, dad and brother Simon for their pillar-like support and their unwavering belief and confidence in me - without this I don't think I would have made it this far! This also goes for all my friends who have offered encouragement and wine along the way!!! Cheers!

## Table of contents

Abstract ..... ii
Acknowledgements ..... iv
Table of contents ..... vi
List of tables ..... xv
List of figures ..... xvii
Abbreviations ..... xxi
Chapter 1 Introduction ..... 1
1.1 Genome evolution ..... 1
1.2 Homologues, paralogues and orthologues ..... 2
1.3 Paralogous genes and the evolution of the human genome ..... 2
1.4 Genome sequencing projects ..... 6
1.5 The Human Genome Project ..... 6
1.6 Analysis of the human genome sequence ..... 8
1.6.1 Gene numbers ..... 8
1.6.2 1-to-4 gene rule ..... 9
1.6.3 Paralogy and the human genome ..... 10
1.6.4 Evolutionary analysis of paralogous gene families ..... 11
$1.7 \quad$ Polyploidy ..... 12
1.8 Mechanisms of gen(om)e duplication ..... 13
$1.9 \quad$ What happens after gen(om)e duplication? ..... 17
1.10 The extended Major Histocompatibility Complex ..... 18
1.10.1 The extended class I region ..... 19
1.10.2 The class I region ..... 20
1.10.3 The class III region ..... 21
1.10.4 The class II region ..... 23
1.10.5 The extended class II region ..... 24
1.11 Origin of the extended MHC ..... 25
1.12 MHC Paralogy ..... 26
1.12.1 Origin of the extended MHC paralogous regions ..... 28
1.13 Thesis aims ..... 30
Chapter 2 Materials and Methods ..... 31
$2.1 \quad$ Materials ..... 31
2.1.1 Solutions, buffers and media ..... 31
2.1.2 Loading dyes ..... 36
2.1.3 Nucleotides ..... 37
2.1.4 Size markers and ladders ..... 37
2.1.5 Sources of DNA and RNA ..... 39
Methods ..... 40
2.2 Agarose gel preparation and electrophoresis ..... 40
$2.3 \quad$ Sequencing gel ..... 40
Mapping and sequencing ..... 41
2.4 Restriction Digest Fingerprinting ..... 41
2.4.1 Filterprep isolation of BAC DNA ..... 41
2.4.2 Restriction digest fingerprinting (Hind III) of BAC DNA ..... 42
$2.5 \quad$ Fluorescent in-situ hybridisation (FISH) mapping ..... 43
2.5.1 Labelling of FISH probe using Nick translation ..... 44
2.5.2 Preparation of microscope slides ..... 45
2.5.3 Hybridisation of FISH probes ..... 46
2.6 Production of shotgun libraries for shotgun sequencing ..... 48
2.6.1 Sonication and subfragment end repair of plasmid DNA ..... 48
2.6.2 Selection of suitably sized DNA fragments for subcloning ..... 50
2.6.3 Ligation into $\mathrm{pUC18}$ vector ..... 51
2.6.4 Transformation of $\mathrm{pUC18}$ vector ..... 52
2.7 Shotgun sequencing ..... 53
2.7.1 Vacuum preparation of template DNA in pUC18 vector ..... 53
2.7.2 The sequencing reaction ..... 55
2.7.3 Sequencing instrumentation ..... 56
2.7.3.1 ABI PRISM 373 DNA sequencer set-up ..... 56
2.7.3.2 ABI PRISM 377 DNA sequencer set-up ..... 57
2.7.4 Data analysis of shotgun sequencing reactions and clone assembly ..... 57
2.7.5 Contiguation or 'finishing' of a clone ..... 58
2.7.5.1 'Finishing' PCR reaction ..... 59
Expression profile analysis ..... 61
$2.8 \quad$ Design of paralogue specific primers ..... 61
2.9 PCR amplification of paralogue specific PCR products ..... 62
2.10 Total RNA extraction from mammalian cell-lines ..... 62
2.11 DNase treatment of RNA ..... 64
2.12 First strand synthesis cDNA synthesis and amplification of target cDNA using paralogue specific primers ..... 65
$2.13 \quad$ Overview of microarray experiments ..... 66
2.13.1 Description of microarrays used ..... 67
2.13.2 Generation of paralogue specific PCR products with a Universal Adaptor for use on microarrays ..... 68
2.13.3 Generation of fluorescently labelled DNA ..... 69
2.13.3.1 Generation of fluorescently labelled paralogue-specific PCR products using the ..... 69
Cyanine 3-dCTP dye for hybridisation onto the 'Paralogue Microarray'
2.13.3.2 Generation of fluorescently labelled single- stranded cDNA target using direct incorporation of Cyanine dyes for ..... 70
hybridisation onto the ' $10 \mathrm{~K} /$ Paralogue Microarray'
2.13.4 Hybridisation, washing and scanning of microarrays ..... 71
2.13.5 Analysis of microarrays ..... 72
$2.14 \quad$ Overview of blot expression analysis ..... 73
2.14.1 Radioactive labelling of DNA ..... 74
2.14.1.1 Radioactive labelling of paralogue-specific PCR products ..... 74
2.14.1.2 Radioactive labelling of DNA using MegaPrime ${ }^{\mathrm{TM}}$ DNA labelling system
2.14.2 Probe verification ..... 75
2.14.2.1 Assessment of radiolabel incorporation using thin-layer chromatography ..... 75
2.14.2.2 Measurement of radioactively labelled PCR product concentration ..... 75
2.14.3 Manufacture of Southern Blots ..... 76
2.14.3.1 Restriction digest of human genomic DNA ..... 76
2.14.3.2 Transfer of digested genomic DNA onto filter ..... 76
2.14.4 Hybridisation of radiolabelled PCR product to blots ..... 77
2.14.5 Washing ..... 77
2.15 Computational analysis ..... 79
2.15.1 General programs used in this thesis ..... 79
2.16 Identification of extended MHC paralogous genes in the human genome ..... 81
2.16.1 Identification of extended MHC paralogues based on protein sequence homology ..... 81
2.16.2 Identification of extended MHC paralogues with increasing levels of confidence ..... 83
2.16.2.1 Filter 1: Domain-masking ..... 83
2.16.2.2 Filter 2: FINEX ..... 84
2.17 In-silico expression analysis ..... 85
2.18 Clustering methods ..... 87
2.19 Phylogenetic analysis ..... 88
2.19.1 Protein sequence alignments ..... 88
2.19.2 Estimation of the gamma distribution ..... 89
2.19.3 Bootstrapping and tree-puzzling steps ..... 89
2.19.4 Phylogenetic analysis using distance methods ..... 90
2.19.4.1 PHYLIP ..... 91
2.19.4.2 MEGA2 ..... 91
2.19.5 Phylogenetic analysis using the maximum likelihood ..... 92 method
2.19.5.1 PHYLIP ..... 92
2.19.5.2 TREE-PUZZLE ..... 93
$2.20 \quad$ Useful web-sites ..... 93
Chapter 3 Characterisation of 9q32-q34.3 ..... 95
3.1 Introduction ..... 95
3.2 Results ..... 97
3.2.1 Identification of genes on 9q32-q34.3 ..... 97
3.2.2 Mapping of the Olfactory Receptor gene cluster to ..... 98 9q33.1-q34.12
3.2.3 Identification of the Allograft Inflammatory Factor 1 ..... 101 (AIF1) paralogue
3.2.4 Problems associated with using mapping data and draft ..... 105 sequence
3.2.5 Orientation of contigs containing putative paralogues ..... 107
3.2.6 Current status of $9 \mathrm{q} 32-\mathrm{q} 34.3$ ..... 109
3.2.7 Comparison of the MHC paralogous region on 9q32- ..... 110 q34.3 and the MHC region on 6 p22.2-p21.3
3.2.7.1 Gene and paralogue content ..... 110
3.2.7.2 Genomic landscape ..... 114
3.2.7.3 Evidence of gene and segmental duplication ..... 116
3.2.7.4 Diseases associated with $9 \mathrm{q} 32-\mathrm{q} 34.3$ ..... 119
3.3 Discussion ..... 121
Chapter 4 Identification of the extended MHC paralogues in the human genome
4.1 Introduction ..... 124
4.2 Strategy used to identify MHC paralogues ..... 125
4.2.1 MHC genes used in the whole-genome survey ..... 125
4.2.2 Identification of MHC paralogues with increasing ..... 128 levels of confidence
$4.3 \quad$ Definitions ..... 131
4.3.1 L0-paralogues ..... 131
4.3.2 L1-paralogues ..... 131
4.3.3 L2-paralogues ..... 132
4.3.4 L3-paralogues ..... 133
4.4 Results ..... 134
4.4.1 Identification of MHC paralogues: RXRB as an ..... 134 example
4.4.2 Identification of all the MHC paralogues in the human ..... 137 genome
4.4.3 Distribution of MHC paralogues in the human genome ..... 142
4.4.4 MHC paralogues located on chromosome 1, 9 and 19 ..... 144
4.4.4.1 Chromosome 1 paralogues ..... 146
4.4.4.2 Chromosome 9 paralogues ..... 148
4.4.4.3 Chromosome 19 paralogues ..... 150
4.4.4.4 Putative paralogues not identified in the ..... 152 genome-wide survey
4.4.4.5 Comparison of the order of L2- and L3- ..... 153 paralogues located on chromosomes 1, 9 and 19
4.4.5 Paralogues located outside the paralogous regions ..... 157
4.4.6 L0- and L1-paralogues ..... 159
4.4.7 Caveats associated with my strategy ..... 160
4.5 Discussion ..... 164
Chapter 5 Phylogenetic analysis of extended MHC paralogous gene ..... 167 families
5.1 Introduction ..... 167
5.2 MHC paralogous gene families used in phylogenetic analysis ..... 170
5.3 Results ..... 173
5.3.1 Phylogenetic analysis of the BRD paralogous gene ..... 174 family
5.3.2 Phylogenetic analysis of the PBX paralogous gene ..... 175 family
5.3.3 Phylogenetic analysis of the NOTCH paralogous gene ..... 176 family
5.3.4 Phylogenetic analysis of the complement paralogous ..... 178 gene family
5.3.5 Phylogenetic analysis of the RXR paralogous gene ..... 179 family
5.3.6 Phylogenetic analysis of the tenascin paralogous gene ..... 181
family
5.3.7 Phylogenetic analysis of the AIF paralogous gene ..... 183 family
5.3.8 Phylogenetic analysis of the $\beta$-tubulin paralogous gene ..... 184 family
5.3.9 Phylogenetic analysis of the GPX paralogous gene ..... 189 family
5.3.10 Phylogenetic analysis of the CLIC paralogous gene ..... 191 family
5.4 Discussion ..... 193
Chapter 6 Expression analysis of extended MHC paralogous gene ..... 196 families
6.1 Introduction ..... 196
6.2 Terminology ..... 199
6.3 Results ..... 200
6.3.1 Cross-hybridisation (control) experiments ..... 200
6.3.2 Expression profiling ..... 203
6.3.2.1 In-silico analysis ..... 203
6.3.2.2 Dot-blot analysis ..... 206
6.3.2.3 Northern blot analysis ..... 209
6.3.2.4 Microarray analysis ..... 212
6.3.2.5 Importance of designing specific microarray ..... 218 targets
6.3.3 Interpretation of expression data ..... 219
6.3.3.1 Tenascin paralogous gene family ..... 219
6.3.3.2 Microarray expression data ..... 220
6.3.3.3 In-silico expression data ..... 223
6.3.3.4 Dot-blot expression data ..... 225
6.3.3.5 Comparison of the expression profiles of the ..... 227 MHC paralogues located in the paralogous regions on chromosomes 1,9 and 19
6.3.3.6 Comparison of the methods used to generate ..... 228 expression profiles
6.4 Discussion ..... 230
Chapter 7 Conclusions and future work ..... 234
7.1 Conclusions ..... 234
7.2 Future work ..... 241
Bibliography ..... 244
Appendices ..... 263
Appendix 1 9q32-q34.3 annotation ..... 264
Appendix 2 Whole-genome survey results ..... 272
Appendix 3 Primers ..... 287
Appendix 4 Primers ..... 289
Appendix 5 In-silico results ..... 291
Appendix 6 Dot blot results ..... 294
Appendix 7 Northern blot results and transcript sizes ..... 297
Appendix 8 Microarray results ..... 299
Appendix 9 Comparison of methods ..... 300

## List of tables

## Chapter 1 Introduction

1.1 Gene number and genome size for a range of organisms ..... 8

## Chapter 3 Characterisation of 9q32-q34.3

3.1 Summary of the first MHC paralogues identified in three other ..... 96 regions of the genome
3.2 Summary of the exon and intron sizes and comparison of ..... 103 splicing phases of the two AIF1 paralogues
3.3 Summary of the gene content and sizes of chromosomes 6 and ..... 111 9 and the paralogous regions
3.4 Comparison of the repeat content of the $6 \mathrm{p} 22.2-\mathrm{p} 21.3$ and ..... 116 9q32-q34.3
3.5 Summary of some of the disorders associated with 9q32-q34.3 ..... 120
Chapter 4 Identification of the extended MHC paralogues in the human genome
4.1 Distribution of genes in the extended MHC region ..... 127
4.2 Summary of the MHC genes with paralogues with increasing ..... 137 levels of support
4.3 Summary of the distribution of MHC paralogues in the human ..... 142 genome
4.4 Summary of the L2- and L3-paralogues on chromosome 1 ..... 146
4.5 Summary of the L2- and L3-paralogues on chromosome 9 ..... 149
4.6 Summary of the L2- and L3-paralogues on chromosome 19 ..... 151
4.7 Summary of the putative MHC paralogues not identified in my ..... 153 genome-wide survey
4.8 Summary of the MHC paralogues located outside the ..... 158 paralogous regions on chromosomes 1, 9 and 19
4.9 Summary of the P-values obtained for the HLA class I-like ..... 161 genes from the BLAST similarity search using HFE, HLA-A, HLA-E, MICA and MICB, and the percentage sequence identities determined from a global sequence alignment
Chapter 5 Phylogenetic analysis of extended MHC paralogous gene families
5.1 Summary of the MHC paralogous gene families used to ..... 173 generate phylogenetic trees
5.2 Summary of the TUBB paralogues in the human genome ..... 185
Chapter 6 Expression analysis of extended MHC paralogous gene families
6.1 Comparison of three methods used to generate the expression ..... 228 profiles for nine MHC paralogous gene families

## List of figures

## Chapter 1 Introduction

1.1 The 2R hypothesis ..... 4
1.2 Distribution of Hox gene clusters in the human genome ..... 5
1.3 Time-line of a range of genome sequencing projects ..... 6
1.4 Progress of the Human Genome Project from the launch in 1990 ..... 7 to its completion in 2003
1.5 Models of genome duplication by autotetraploidisation and ..... 15 allotetraploidisation
1.6 Karyotype of a male tetraploid Tympanoctomys barrerae from ..... 16 Mendoza, Argentina taken from Gallardo et al (1999)
1.7 Schematic representation of the extended MHC class I region ..... 19
1.8 The MHC class I region ..... 21
1.9 The MHC class III region ..... 22
1.10 The MHC class II region. ..... 24
1.11 The extended MHC class II region ..... 25
1.12 Summary of the MHC paralogous regions in the human genome ..... 27

## Chapter 2 Materials and Methods

2.1 The 10K/Paralogue Microarray 69

## Chapter 3 Characterisation of 9q32-q34.3

3.1 FISH analysis of bA465F21 ..... 99
3.2 Localisation of the clone bA465F21 to the chromosome 9 tiling path
3.3 Computational identification of the AIF1 paralogue ..... 102
3.4 ClustalX sequence alignment of the two AIF 1 paralogues ..... 104
3.5 Overview of the gene content of region analysed to identify a ..... 106 putative GPX5 paralogue
3.6 Overview of methods used to order and orientate the contigs ..... 108 containing RALGDS and BRD3 putative paralogues
3.7 Schematic representation of the status (August 2003) of the MHC paralogous region on 9q32-q34.3
3.8 Comparison of the order of paralogues between the MHC region ..... 112 on 6 p22.2-p21.3 and the paralogous region on 9q32-q34.3
3.9 Evolution of the lipocalin paralogous gene family on 9q34118
Chapter 4 Identification of the extended MHC paralogues in the human genome
4.1 Overview of the strategy used to identify MHC paralogues with increasing levels (L0 to L3) of confidence and definitions
4.2 Alignment of the exon fingerprints of the extended MHC class I ..... 129 gene RXRB and its paralogues, RXRA and RXRG, identified in the genome survey
4.3 Protein sequence alignment of the extended MHC class II ..... 130 encoded protein, RXRB, and its two paralogues, RXRA and RXRG
4.4 Summary of the results of the initial (A) and domain-masked ..... 135
(B) TBLASTN search of the human genome using the RXRB protein sequence
4.5 Summary of the FINEX search using the RXRA fingerprint ..... 136
4.6 Summary of the results of the whole-genome survey using 128 ..... 138 MHC genes
4.7 Summary of the proportion (\%) of BLAST hits corresponding to ..... 139 the paralogues with different levels of confidence
4.8 Summary of the MHC genes with L0- to L3-paralogues ..... 140
4.9 Summary of the percentage (\%) of MHC genes with no, $1,2,3$, ..... 141 4 or more L0, L1, L2 and L3-paralogues in the human genome
4.10 Distribution of MHC paralogues in the human genome ..... 143
4.11 Summary of MHC paralogues on chromosomes 1,9 and 19 ..... 144
4.12 Comparison of the order of L2- and L3-paralogues on ..... 154 chromosomes 1, 9 and 19
4.13 Comparison of the MHC paralogues with copies on all four ..... 156 paralogous regions
Chapter 5 Phylogenetic analysis of extended MHC paralogous gene families
5.1 Summary of the 2R hypothesis ..... 168
Schematic representation of the effects of two rounds of gene, or ..... 169Schematic representation of the effects of two rounds of gene,
genome, duplication on the topology of the phylogenetic treeand the resulting number of paralogues in 'key' species
5.3 Schematic representation of the 'ideal' phylogenetic tree in support of the 2 R hypothesis
5.4 Summary of the MHC genes and paralogues selected for further ..... 171 investigation
5.5 Phylogenetic tree of the BRD paralogous and orthologous ..... 175 family
5.6 Phylogenetic analysis of the PBX paralogous gene family ..... 176
5.7 Phylogenetic analysis of the NOTCH paralogous gene family ..... 177
5.8 Phylogenetic analyses showing the relationship of the C4 paralogues and orthologues
5.9 Phylogenetic tree showing the evolutionary relationship between ..... 180 the RXRB paralogues and orthologues
5.10 Phylogenetic analyses of the TNXB paralogues and orthologues ..... 182
5.11 Phylogenetic tree of the AIF1 paralogues and orthologues ..... 183
$5.12 \quad$ Phylogenetic analysis of the $\beta$-tubulin paralogues and ..... 186 orthologues
5.13 Phylogenetic tree showing the ancient duplication events that ..... 188 have shaped the present day $\beta$-tubulin paralogues and orthologues
5.14 Phylogenetic analysis of the GPX family ..... 190
5.15 Phylogenetic analysis of the CLIC family ..... 191
Chapter 6 Expression analysis of extended MHC paralogous gene families
6.1 Fates of duplicated genes ..... 197
6.2 Verification of probe specificity ..... 202
6.3 Summary of the results of the in-silico expression analysis of the ..... 205 BRD2 gene and its three paralogues
6.4 Transcription pattern of the AIF1, AIF1L and $\beta$-actin control ..... 207 genes after hybridisation with paralogue-specific probes to the dot blot with RNA from different tissues
6.5 Transcription pattern and splice variants of the BRD2, BRD3 ..... 210 BRD4, BRDT and $\beta$-actin control genes after hybridisation with specific probes to a Northern blot with eight different tissues
6.6 Assessment of the quality of the eleven RNAs used in the ..... 213 expression microarray experiments
6.7 Results of a hybridisation with the standard Stratagene RNA to ..... 214 the '10K/Paralogue Microarray'
6.8 One of the 48 sub-arrays of the ' $10 \mathrm{~K} /$ Paralogue Microarray’ ..... 215 after hybridisation using the Stratagene standard RNA
6.9 Microarray results confirmed by RT-PCR ..... 217
Comparison of the expression profiles of the paralogue specificPCR products designed in this thesis and those already on thestandard Sanger Institute 10 K microarray corresponding toGPX4 and BRD3 genes and the key to the tissues and cell-linesused
6.11 Expression profile of the TNXB gene indicates that it is adrenal ..... 220 gland specific
6.12 Summary of the microarray expression data and the result of ..... 221 applying Hierarchical clustering methods
6.13 Clustering of the in-silico expression profile results ..... 223
6.14 Clustering of the dot-blot expression profile results ..... 225
6.15 Comparison of the expression profiles of the paralogues located ..... 227within the paralogous regions on chromosomes 1,9 and 19 withthe MHC genes using in-silico and dot blot analysis in 28normal human tissues.

## Abbreviations

aa
AIF
ATP
BAC
BLAST
bp
BRD
${ }^{\circ} \mathrm{C}$
cDNA
CLIC
CTP
dbEST
DNA
dNTP
DTT
EDTA
EMBL
EST
FISH
FPC
GPX
GTP
HGMP
HGP
HLA
IHGSC
kb
1
-L
LB
LINE
amino acid
Allograft inflammatory factor adenosine 5 '-triphosphate
bacterial artificial chromosome
basic local alignment search tool
base pair
Bromodomain containing protein
degrees Celsius
complementary deoxyribonucleic acid
Chloride intracellular chloride channel
cytidine 5'-triphophate
database of expressed sequence tags
deoxyribonucleic acid
2'-deoxyribonucleoside 5'-triphophate
dithiothreitol
ethylenediamine tetra-acetic acid
European Molecular Biology Laboratory
expressed sequence tag
Fluorescent in-situ hybridisation
fingerprinting contig
Glutathione peroxidase
guanine 5'-triphosphate
Human Genome Mapping Resource Centre
Human Genome Project
human leukocyte antigen
International Human Genome Sequencing Consortium
kilobase pairs
litre
-like
Luria-Bertani
long interspersed nuclear element

| M | molar |
| :--- | :--- |
| mA | milliamps |
| Mb | megabase pairs |
| $\mu \mathrm{g}$ | microgram |
| $\mu \mathrm{l}$ | microlitre |
| $\mu \mathrm{M}$ | micromolar |
| min(s) | minute(s) |
| MIPS | Munich Information Centre for Protein Sequences |
| mg | milligram |
| MHC | Major Histocompatibility Complex |
| ml | millilitre |
| mm | millimetre |
| mM | millimolar |
| NCBI | National Centre for Biotechnology Information |
| ng | nanogram |
| NOTCH | Neurogenic locus Notch homologue |
| OR | Olfactory receptor |
| PCR | polymerase chain reaction |
| PFAM | protein family database |
| PBX | Pre-B cell leukaemia transcription factor |
| RNA (mRNA, rRNA, tRNA) ribonucleic acid (messenger-, ribosomal-, transfer-) |  |
| rpm | revolutions per minute |
| RT-PCR | reverse transcription polymerase chain reaction |
| RXR | Retinoic acid receptor |
| SDS | sodium dodecyl sulphate |
| sec(s) | second(s) |
| SINE | short interspersed nuclear element |
| STS | sequence tagged site |
| TEMED | n, N', N'-tetramethylethylenediamine |
| Tris | unstroxymethyl)aminomethane |
| U |  |
| UTR |  |

## Chapter 1

## Introduction

### 1.1 Genome evolution

Genomes have evolved and increased in complexity owing to a number of evolutionary processes acting upon them, such as insertions, deletions and inversions. Gene duplications are also believed to have played a major role in the evolution and development of vertebrate genomes. Susumu Ohno (1970) first suggested that the increase in organismal complexity during vertebrate evolution could only have occurred if there was a considerable increase in gene number and proposed that this happened by the duplication of entire genomes in a process termed polyploidisation.

When Ohno first proposed the theory of polyploidisation it generated a lot of excitement and outrage in the field of genetics, but, by the late 1980s, many had lost interest owing to the lack of evidence. With the expansion of genomic information generated during the 1990s, duplicated genes and chromosomal regions were identified in the human, and other genomes, and the theory became popular again although it remains controversial. Duplicated genes and regions are believed by some to represent remnants of whole-genome duplication events, whilst others have argued that they are the result of the duplication of chromosomal regions or of individual genes brought together by selective forces (reviewed by Wolfe, 2001; Lundin et al, 2003; Hughes and Friedman, 2003).

### 1.2 Homologues, paralogues and orthologues

Three definitions are commonly used to describe the relationship between genes: homologues, paralogues and orthologues (reviewed by Sharman, 1999). Homologous genes are members of the same family or superfamily and share a common ancestor at some point back in evolutionary time. Homologues can be further subdivided into two groups; orthologues, genes that have been separated by speciation, and paralogues, genes that have resulted from a duplication event. Orthologues can be traced by descent to the common ancestor of two organisms and will both encode equivalent evolutionarily conserved proteins. Paralogues, however, are genes within the same species that have originated through duplication of an ancestral gene; whether as part of a whole genome, chromosomal segment or a single gene duplication event. The evolutionary fate of paralogues and orthologues are very different. Orthologues often take over the function of the precursor gene in the species of origin and thus tend to be conserved. In contrast, young paralogues have redundant functions, which are an evolutionary unstable situation, thus, in the long run - with a few exceptions paralogues either diverge functionally, or all but one of the versions are lost.

### 1.3 Paralogous genes and the evolution of the human genome

Paralogous genes have been identified throughout the human genome. Ohno (1973) identified duplicated chromosomal segments within the human genome containing two pairs of duplicate genes on chromosomes 11 and 12, which he proposed as being evidence of polyploidisation. In the 1990s, molecular mapping data was used to identify a number of chromosomal regions containing clusters of paralogues in the human and mouse genomes that were believed to be remnants of genome duplication
events (termed paralogous regions; Lundin, 1993).

Intriguingly, the number of paralogous regions and paralogous genes investigated at the time was generally four (this phenomenon was termed tetralogy), or less, suggesting that at least two rounds of large-scale block or genome duplications have occurred during the course of mammalian evolution. For example, Spring and coworkers (1994) found that vertebrates have four copies of a gene for a cell-surface protein called syndecan, whereas the fruit fly Drosophila has only one. More than fifty examples of this so-called 1-to-4 gene rule have now been identified (Spring, 1997). Independently, Sidow (1996) observed the 1-to-4 gene rule during phylogenetic and sequence surveys of developmental regulator families, in which he concluded that two large-scale gene duplication events, most likely of entire genomes, occurred in an ancestor of vertebrates (Sidow, 1996).

Ohno (1970) originally suggested that there were large-scale gene duplication events, possibly involving the whole genome, in early chordates; specifically on the lineage leading to both cephalochordates (including amphioxus) and vertebrates (including hagfish, lampreys and jawed vertebrates). He also suggested a second, and maybe a third, large-scale duplication event at the time of fish or amphibian divergence. The number of duplications and the mechanisms involved have been heavily debated, and many modifications of Ohno's model have been proposed. For example, Holland and co-workers (1994) proposed that there were two phases of duplication on the vertebrate lineage, but suggested that the first duplication occurred on the vertebrate lineage after divergence of the amphioxus lineage, and the second on the jawed vertebrate lineage after the divergence of jawless fish. Kasahara and colleagues (1996) proposed that two polyploidisation events occurred later in the vertebrate
lineage, after the divergence of lampreys. The most popular version of events has been termed the 2 R hypothesis as it involved two rounds of polyploidisations; one prior to the divergence of agnatha (jawless fish, exemplified by lampreys and hagfish) and gnathostomata (jawed vertebrates), while the second occurred after the divergence of agnatha but before the divergence of chondryichthyes (cartilaginous fish) (Sidow, 1996). This is simplified in figure 1.1.


Figure 1.1 The 2R hypothesis. The two rounds of duplication are indicated by arrows. 1 R corresponds to the first round of whole-genome duplication, after the emergence of amphioxus, and 2R corresponds to the second round of whole-genome duplication prior to the emergence of jawed vertebrates, more specifically cartilaginous fish.

The four Hox gene clusters in the human genome exemplify the 2R hypothesis (figure 1.2). The homoeotic complex (HOM-C) occurs as a single cluster in invertebrates such as Drosophila, Caenorhabditis elegans and amphioxus, but is found as four paralogous Hox gene clusters in vertebrates like mice and humans (Schughart et al,
1988). Interestingly, not only was the order of genes in the mammalian Hox clusters found to be conserved between human and mouse, but it was also conserved among the four mammalian clusters. The quadruplication of the Hox genes and the discovery of other paralogous genes linked to the Hox clusters provide evidence to support the involvement of large-scale chromosomal or whole-genome duplications in the evolution of vertebrate genomes (Larhammar et al, 2002).


Figure 1.2 Distribution of Hox gene clusters in the human genome (represented by the red circles).

The 2 R hypothesis is controversial and continues to be heavily discussed in the literature (reviewed by Wolfe, 2001). It was widely believed that the debating over the evolution of the human genome would be resolved once the entire human genome sequence was available. However, the initial analysis of the draft human genome sequence did not reveal overwhelming evidence for tetralogy and the 2 R hypothesis remains controversial (International Human Genome Sequencing Consortium (IHGSC), 2001; Venter et al, 2001).

### 1.4 Genome sequencing projects

Between 1977 and 1982 the genomes of the bacterial virus $\Phi$ X174 (Sanger et al, 1977a, 1978), bacteriophage lambda (Sanger et al, 1982), animal virus SV40 (Fiers et al, 1978) and the human mitochondrion (Anderson et al, 1981) were successfully sequenced and assembled. During the early 1990s, the genomes of the yeast Saccharomyces cerevisiae (Oliver et al, 1992) and the nematode worm Caenorhabditis elegans (Wilson et al, 1994) were sequenced, thus demonstrating the feasibility of large-scale genome sequencing. By September 2003, the sequencing of 160 genomes had been completed, with 393 prokaryotic and 242 eukaryotic genomesequencing projects still ongoing (http://igweb.integratedgenomics.com/GOLD/). The time-line of a number of genome sequencing projects is shown in figure 1.3.


Figure 1.3 Time-line of a range of genome sequencing projects. The arrows signify ongoing sequencing projects.

### 1.5 The Human Genome Project

The Human Genome Project (HGP) was established in 1990 with the aim of
sequencing the entire human genome by 2005. In 1999, the year I started this project, the HGP effort moved into full-scale production, and the overall sequencing output increased significantly (figure 1.4). By 2000, the 'draft' human sequence was completed consisting of mainly 'unfinished' sequence covering approximately $90 \%$ of the human genome. Two 'draft' sequences were published by separate organisations (IHGSC, 2001; Venter et al, 2001) offering the chance to compare the genomic data produced. The data generated by the International Human Genome Sequencing Consortium (IHGSC) was a collaborative effort involving 20 groups from around the world. Venter and colleagues were part of the biotechnology company Celera Genomics which was formed in 1998. The completion of the HGP was announced by the IHGSC in 2003, two years ahead of schedule.


Figure 1.4 Progress of the Human Genome Project from the launch in 1990 to its completion in 2003. The $\%$ of finished (red) and unfinished (grey) sequence was calculated for January of each year using the Genome Monitoring Table (http://www2.ebi.ac.uk/genomes/mot/). Finished sequence is the final stage of the sequencing project when the sequence is contiguous with reads covering depths of greater than 8 times redundant sequence with $99.99 \%$ accuracy. Unfinished sequence is a working draft covering depths of 2-4 times redundant sequence and contains gaps.

### 1.6 Analysis of the human genome sequence

The sequence of the entire human genome has enabled a number of key aspects of the genome to be investigated in order to test the theory of polyploidisation and the 2 R hypothesis. These are discussed below.

### 1.6.1 Gene numbers

One of the most important pieces of information revealed by sequencing projects is the number of genes. Ohno (1970) first observed that the gene number and genome sizes increased when looking at more complex organisms. This observation has been confirmed by various sequencing projects (table 1.1).

Table 1.1 Gene number and genome size for a range of organisms.

| Organism | Genome <br> size (Mb) | Gene <br> Number | Reference |
| :--- | :--- | :--- | :--- |
| Homo sapiens | 3000 | $\sim 30,000$ | IHGSC, 2001 and Venter et al, 2001 |
| Mus musculus | 3000 | 30,000 | Marshall, 2001 |
| Fugu rubripes | 365 | 31,059 | Aparacio et al, 2002 |
| Drosophila <br> melanogaster | 135.6 | 13,061 | Adams et al, 2000 |
| Caenorhabditis elegans | 97 | 19,099 | C.elegans Sequencing Consortium, 1998 |
| Saccharomyces <br> cerevisiae <br> Escherichia coli | 12.1 | 6,034 | Mewes et al, 1997 |

The human genome was originally estimated to have over 80,000 genes while invertebrates have less than 20,000. The fourfold increase between human and invertebrate gene numbers was previously used as evidence in support of the 2 R hypothesis (Makalowski, 2001). One of the most interesting discoveries in the human
sequencing projects has been the identification of only approximately 30,000 proteincoding genes in the human genome (IHGSC, 2001; Venter et al, 2001). On average, this would give only two paralogues in humans for every invertebrate gene and would support only one round of genome duplication. However, it could be argued that extensive gene loss may follow genome duplication i.e. if two rounds of duplication occurred then a significant proportion of duplicate genes were lost after each duplication event leaving no obvious trace of two genome duplication events.

### 1.6.2 1-to-4 gene rule

Initial analysis of the protein coding genes in the draft human genome does not support a strict 1-to-4 gene rule (IHGSC, 2001; Venter et al, 2001). The International Human Genome Sequencing Consortium employed an all-against-all sequence comparison to identify orthologous groups in human, C. elegans and Drosophila genomes. A total of 1308 groups were identified with a mean of 2.4 genes per human orthologue group and 1.1 genes per group in C. elegans or Drosophila. On closer analysis, almost half of the identified orthologue groups had just a single gene in the human genome, and the remainder had two, three, four or more genes. When the ratio of the number of orthologue groups with a single gene in C. elegans and Drosophila and the number of genes in human were plotted for each analysis, the peak of this distribution was found over the $1: 1$ ratio and not the $1: 4$ ratio needed to support a strict 1-to-4 gene rule. In both cases, there are a significant number of gene families (greater than $50 \%$ ) with two or more members implying that gene families have expanded via duplication (IHGSC, 2001; Venter et al, 2001). These gene family expansions could have been generated through whole-genome duplication events.

### 1.6.3 Paralogy and the human genome

With the advent of the 'draft' human genome sequence, a number of analyses have now been performed to identify all the paralogous regions. Prior to the release of the draft sequence several lists of paralogous regions had been published and were believed to represent only a small percentage of the total (Lundin, 1993; Lundin and Larhammar, 1998; Skrabanek and Wolfe, 1998; Pollard and Holland, 2000).

The International Human Genome Sequencing Consortium (2001) concluded that approximately $5 \%$ of the human genome consists of paralogous regions. The duplicated regions tend to be large, greater than 10 kb , and highly homologous. Evidence of ancient duplications, characterised by high sequence similarity between coding regions, were identified along with evidence of more recent segmental duplications. The latter duplicated regions share high sequence identity between both exons and introns, with many showing less than $6 \%$ nucleotide divergence between paralogous regions. Such duplications seem to have emerged very recently in evolution as they are absent from closely related species.

Analysis of the draft human genome sequence by Venter and co-workers (2001) using a multiple alignment algorithm, identified 1077 blocks of paralogy spread throughout the genome. Out of the 1077 blocks, 159 contained only three genes, 137 contained four genes and 781 contained five or more genes thus illustrating the extent of duplications in the human genome. McLysaght and colleagues (2002) conducted one of the most thorough investigations into duplicate genes in the human genome. Of the 24,046 genes used in the analysis, 6,120 (almost a quarter) were identified located in 1642 paralogous regions containing two or more linked duplicated genes. The Hox gene clusters were amongst the largest paralogous regions identified; they found 28
paralogous genes on chromosomes 7 p and 17 q , and 26 genes on chromosomes 2 q and 12q. Owing to the number and sizes of the paralogous regions identified in all three analyses the most likely explanation is that they arose by whole-genome or large-scale block duplication events rather than through duplication of individual genes.

### 1.6.4 Evolutionary analysis of paralogous gene families

A number of phylogenetic studies have been conducted in order to understand the evolutionary histories of the paralogous gene families. The 2 R hypothesis proposes that one round of duplication occurred after the divergence of cephalochordates (exemplified by amphioxus) and the second after the divergence of jawless fish (including hagfish and lamprey). Therefore, the phylogenetic trees of the gene families should show similar histories.

The phylogenetic analyses of gene families supporting the 1-to-4 (or less) gene rule revealed that the evolution of the human genome is complicated. Wang and Gu (2000) analysed 49 vertebrate gene families, each consisting of three or four gene members, generated in the early stages of vertebrates, and/or shortly before the origin of vertebrates, including the early growth response protein, EGR, and the glycine receptor, GLR. Of the 49 gene families studied, they determined that 26 families with three members were consistent with the 2 R hypothesis but the evolution of the remaining 23 gene families with four members was more complicated. Of these 23, only five were consistent with the 2 R hypothesis, with 11 families supporting a third round of genome duplication and the remaining seven families suggesting at least one round of duplication prior to the divergence between Drosophila and vertebrates.

In contrast, Friedman and Hughes (2001) found that of a total of 134 families with four members $70 \%$ were not consistent with the 2 R hypothesis. Similar results were also reported for a smaller number of gene families by the International Human Genome Sequencing Consortium (2001). However, it is considered by some that organisms, such as amphioxus, hagfish and lamprey, are more appropriate to study vertebrate evolution than Drosophila as they are actually on the vertebrate lineage (Holland, 2003). Escriva and colleagues (2002) investigated 33 gene families, where the sequence was available for both lamprey and hagfish. According to their phylogenetic analyses, all 33 families were found to support the 2 R hypothesis.

### 1.7 Polyploidy

Humans and other species are generally diploid and have two copies of each gene; one from each parent. As stated earlier, it has been suggested that the vertebrate genome evolved via whole-genome duplication events, in which the chromosome complement doubled at some point in time. Therefore, the vertebrate genome underwent a stage when it was polyploid, then, through processes such as gene silencing and mutation, reverted to a diploid-like state. Several polyploid species have been identified in both the animal and plant kingdoms. One example is the amphibian, Xenopus laevis, which is tetraploid and has double the number of chromosomes than its cousin, Xenopus tropicalis. In 1999, the first polyploid mammal, the red viscacha rat (Tympanoctomys barrerae) was discovered (Gallardo et al, 1999). The rodent is unaffected by having double the number of chromosomes showing that the vertebrate genome can duplicate and that organisms can survive with multiple copies of a genome.

In addition to the two rounds of genome duplication in the vertebrate lineage Ohno (1970) proposed a round of genome duplication in fish; after the divergence of lobedfin fish that led to land-based organisms. Evidence in support of the third duplication was detected in zebrafish (Postlethwait et al, 1998) and Medaka (Wittbrodt et al, 1998) based on the observation that they generally have larger multigene families than mammals. In particular, Amores and co-workers (1998) observed that zebrafish had seven Hox gene clusters in comparison to the four present in mammals and one in amphioxus (Garcia-Fernandez and Holland, 1994). Further mapping and sequence data has shown that for any four paralogous (or tetralogous) genes or regions in mammals there are probably an additional three or four in teleost fish.

### 1.8 Mechanisms of gen(om)e duplication

Gene duplication has played a major role in the evolution of the human genome. Duplication may involve part of a gene, a single gene, part of a chromosome, an entire chromosome, or the whole genome. The duplication of part of, or a whole, gene is also referred to as a tandem duplication event. Chromosomal regions are duplicated as part of either a block or segmental duplication event. Segmental duplications are defined as involving the transfer of genomic sequence to one or more locations in the human genome and, because of the strong sequence identity between both exons and introns, are relatively recent events (IHGSC, 2001). More ancient duplication events are characterised by similarities only in the coding regions and, in this thesis, are referred to as block duplication events.

The duplication of an entire chromosome is also known as aneuploidy or polysomy. There are several examples of trisomy of human chromosomes that are linked to a
number of conditions. A well known example of this is the trisomy of chromosome 21, which causes Down's syndrome. As discussed previously in this thesis the duplication of an entire genome is referred to as whole-genome duplication or polyploidisation.

There are several mechanisms by which duplication can occur; they are unequal crossing-over, unequal sister chromatid exchange, duplicative transposition, replication slippage and polyploidisation. Unequal crossing-over is a recombination event initiated by similar nucleotide sequences that are not at identical places in a pair of chromosomes. Unequal sister chromatid exchange is essentially the same as unequal crossing-over except that it involves chromatids from a pair of homologous chromosomes. The result can be duplication of a segment of DNA in one of the recombination products. This mechanism can create both small families, such as the five related genes of the $\beta$-globin cluster on chromosome 11, and large ones, such as the olfactory receptor gene clusters, which together contain nearly 1,000 genes and pseudogenes.

Transposition is defined as the movement of genetic material from one chromosomal location to another. During the process termed duplicative transposition, the transposable element is copied, therefore if this element contains a gene, the original copy is retained at the original site while a new copy is inserted elsewhere in the genome. The process, replication slippage is more commonly associated with the duplication of very short sequences, such as repeat units in microsatellites, but can also result in gene duplication if the genes are relatively short. In either case, the recombination occurs between two different copies of a short repeat sequence leading to duplication of the sequence between the repeats.

Whole-genome duplication occurs as a consequence of the lack of separation between all daughter chromosomes following DNA replication. Since it immediately doubles the size of a genome it is considered as the most effective mechanism for increasing genome size. Whole-genome duplication can occur via two mechanisms; allotetraploidy and autotetraploidy (figure 1.5). Autotetraploidy occurs within a single species and allotetraploidy occurs between genomes from different individuals (Wendel, 2000).
A.

Autotetraploid species
B. Diploid Diploid


Figure 1.5 Models of genome duplication by (A) autotetraploidisation and (B) allotetraploidisation.

In plants, polyploidy is widespread and numerous studies have been conducted to understand the prevalence and consequence of polyploidy. Artificially produced autopolyploids are generally inferior to their diploid progenitors, and have lower fertility and, often, lowered ability to compete with diploid species owing to physiological effects such as, genetic imbalances and irregularities in chromosomal segregation (reviewed by Li, 1997).

Polyploidy is extremely rare in bisexually reproducing animals. Muller (1925) proposed that this is because in bisexual animals the two sexes are differentiated by means of a process involving the diploid mechanism of segregation and combination, and polyploidy invariably disturbs this process. In amphibians and fish, where there is evidence of successful polyploidy, the chromosomal determiners of the opposite sexes are still in a rather initial state of differentiation, and the X and the Y or Z and the W chromosomes can substitute for each other (Ohno, 1970). In these animals, genome duplication would not result in sexual imbalance, and many tetraploid species have been found (Ohno, 1970; Bogart, 1980; Schultz, 1980). It is interesting to see that, the only example of a tetraploid mammal identified to date is tetraploid for all autosomal chromosomes but is diploid for the sex chromosomes (figure 1.6; Gallardo et al, 1999).


Figure 1.6 Karyotype of a male tetraploid Tympanoctomys barrerae from Mendoza, Argentina taken from Gallardo et al (1999). The karyotype contains 36 pairs of metacentric to submetacentric chromosomes and 14 pairs of subtelomeric autosomes. The X chromosome is the largest element (present in two copies in females) and the Y chromosome is the only acrocentric element of the karyotype.

Ohno (1970) argued that genome duplication has been more important than tandem duplication because the latter may duplicate only parts of the genetic system of structural genes and regulatory genes. This may disrupt the function of the duplicate genes, whereas polyploidisation duplicates the entire genetic system. However, evidence from the human genome has shown that most genes do not exist as a single copy in the genome but rather as clusters. Thus, showing that tandem duplication has played an important role in moulding the present-day structure of the human genome. It has also been seen that tandem duplication is both important for increasing the number of genes with the same function, exemplified by the HLA class I genes, and for generating genes with new functions, such as the human $\beta$-globin genes.

### 1.9 What happens after gen(om)e duplication?

Gene duplication is an important mechanism for the creation of new gene function (Ohno, 1970; Lynch and Conery, 2000; Wagner, 2001). After gene duplication the two resulting paralogues can evolve in different ways. The classical model of functional diversification after duplication indicates that one copy of a gene maintains the original function of the ancestral gene whereas the other gene is redundant and will either diverge functionally or be lost from the genome altogether by the accumulation of random mutations (Ohno, 1970). More recently an alternative model has been proposed, in which the two gene copies acquire complementary loss-offunction mutations and develop independent sub-functions, such that both genes are required to produce the full complement of functions of the ancestral gene (Force et al, 1999). The process is known as both the sub-functionalisation model and the duplication-degeneration-complementation (DDC) model.

### 1.10 The extended Major Histocompatibility Complex

The human Major Histocompatibility Complex (MHC) is located on the short arm of chromosome 6 ( $6 \mathrm{p} 22.2-\mathrm{p} 21.3$ ). The region was identified in humans over 50 years ago because of its role in tissue transplant rejection (Dausset, 1958) and is now one of the best characterised and studied regions in the human genome. It contains a high density of immune-related genes responsible for recognising foreign antigens and eliciting an adaptive immune response. The region has been linked with more diseases than any other region in the human genome (Price et al, 1999). It is of particular biological importance due to its association with a number of autoimmune diseases, including insulin dependent diabetes mellitus, multiple sclerosis, systemic lupus erythmatosus and rheumatoid arthritis (Thomson, 1995). In addition it has been linked with a range of aetiologies from cancer to sleeping disorders (The MHC Sequencing Consortium, 1999).

The MHC has traditionally been divided into three regions: the class I (most telomeric), class III and class II (most centromeric). The complete 3.6 Mb contiguous sequence of the three MHC regions was published in 1999 by the MHC Sequencing Consortium prior to the release of the 'draft' human genome sequence. It was estimated that $40 \%$ of the 224 genetic loci (of which 128 are expressed) have an immune function, although many still have an unknown function. Work on these three regions revealed that sequence conservation and possibly linkage disequilibrium extended further; the immediate flanking regions were termed the extended class I region and extended class II regions of the MHC (Stephens et al, 1999). The region of the human genome encompassing all five regions is now termed the 'extended Major Histocompatibility Complex' and spans almost 8 Mb and contains over 390 genetic
loci. The extended MHC represents a well characterised region of the human genome and is one of the best examples for the involvement of gene duplication events during its evolution.

### 1.10.1 The extended class I region

The extended MHC class I region (figure 1.7) has been defined as the region between the hereditary haemochromatosis locus (HFE) and the MOG locus, spanning almost 4 Mb of genomic sequence (Stephens et al, 1999). The region is characterised by a number of gene clusters suggesting that this region has evolved via numerous local duplication events, or through the recruitment of similar genes into the region.


Figure1.7 Schematic representation of the extended MHC class I region. Gene clusters and individual genes are coloured according to family: histones (yellow), ribosomal proteins (green), butyrophilin receptors (purple), zinc finger proteins (pink) and olfactory receptor genes (orange). The expressed genes (red) that do not belong to a gene family cluster are labelled accordingly. Pseudogenes that do not belong to a gene family cluster are coloured grey.

There are 55 histone genes within this region, which is the largest cluster of histone genes in the human genome (Marzluff et al, 2002). There are also over 160 small single exon (50-100 bp in length) tRNA genes which produce 18 out of the 20 commonly used amino acids and represents approximately $25 \%$ of the human tRNA repertoire (not shown on figure 1.7). Other clusters located within the extended MHC class I region include; 20 zinc-finger proteins, 10 ribosomal proteins, two clusters of olfactory receptor genes and seven butyrophilin genes. There is further evidence of
local duplication events involving the GPX5 gene and POM121L2 gene, which both have a pseudogene in close proximity. In addition, there are also a number of expressed single copy genes, as well as pseudogenes in the extended class I region.

### 1.10.2 The class I region

The MHC class I region (figure 1.8) contains the three functional, classical class I genes, HLA-A, HLA-B and HLA-C, which are highly polymorphic and are expressed by most nucleated cells. In addition, there are several other functional class I loci, including the non-classical class I genes, HLA-E, HLA-F and HLA-G, which are less poylmorphic and have restricted expression. These genes are termed HLA class I genes in this thesis. The HLA-H, HLA-J and HLA-K gene fragments are thought to be pseudogenes.

The HLA class I genes encode the heavy ( $\alpha$ ) chain of the cell-surface class I molecule which, along with the $\beta$ chain encoded by the $\beta 2$-microglobulin locus on chromosome 15, is responsible for presenting antigens (short, specific processed peptides) to T cells. The peptides loaded onto the class I molecules are generally derived from an endogenous (intracellular) source by the proteasome, of which PSMB8 and PSMB9 (both found within the MHC class II region; Driscoll et al, 1993) are subunits. The peptides are then transported to the endoplasmic reticulum by the TAP1/TAP2 molecules (also encoded by genes within the MHC class II region; Ortmann et al, 1994), where they are loaded onto MHC class I molecules and proceed as a complex to the cell surface via the Golgi apparatus. At the cell surface, the MHC class I molecule-peptide complex is accessible to $\mathrm{CD}^{+}$cytotoxic T lymphocytes that elicit an immune response, which results in the lysis of the cell presenting the antigen (for a
review of class I antigen presentation see Monaco, 1992).

Of the 50 or more non-HLA related genes within the class I region, there are genes that are distantly related to the conventional class I sequence, namely the MIC genes. There are also a large number of pseudogenes (almost half of the genes) and multigene families, such as the P5 and HCG families; suggesting that duplication events contributed to the evolution of the class I region (Shiina et al, 1999).





Figure 1.8 The MHC class I region. The expressed genes (red) are labelled above the gene track and the pseudogenes (grey) are labelled with a 'p' below the gene track.

### 1.10.3 The class III region

The MHC class III region (figure 1.9) spans approximately 0.7 Mb and is extremely
gene dense with 58 genes (this corresponds to 1 gene every 12 kb of DNA). The extent of gene density is demonstrated by the overlapping genes AGPAT1 and C6orf8, which are transcribed in different directions but overlap by 87 bp at their 3prime ends. Furthermore, the TNXB and CYP21A2 genes overlap in the 3-prime untranslated regions. The high gene content of the class III region is complemented by a corresponding high GC content (53\%). This produces a distinct boundary between the class III region and the rest of the MHC (reviewed by Beck and Trowsdale, 2000). The genes encoded in the class III region have a variety of functions and are associated with diseases, such as congenital adrenal hyperplasia and C2 deficiency (reviewed by Gruen and Weissman, 2001). There are a number of genes with an immune-related function, including members of the complement cascade ( $\mathrm{C} 2, \mathrm{C} 4$ and BF) and the tumour necrosis factor family (TNF, LTA and LTB). Genes that are expressed in specialised cells of the immune system, such as LST1 and 1C7, are located next to each other (Holzinger et al, 1995).


Figure 1.9 The MHC class III region. Expressed genes labelled in red are plotted from the most telomeric (BAT1) to centromeric (NOTCH4) end of the chromosome.

Gene duplication has occurred to a lesser extent in the class III region as compared with other regions of the MHC. Three genes, C4/CYP21A/TNX, have undergone
tandem duplications yielding a complex comprising overlapping genes and genes within genes (Bristow et al, 1993). There are also small clusters of gene families, including the three heat shock proteins located next to each other and members of the Ly6 superfamily. The class III region is unique compared with the rest of the MHC region as it does not contain any pseudogenes (with the exception of the C 4 duplicate in certain haplotypes), has few duplicated genes and the genes have diverse functions, suggesting a distinct origin of the class III region.

### 1.10.4 The class II region

The MHC class II region (figure 1.10) takes its name from the classical and nonclassical HLA class II genes, termed HLA class II genes in this thesis. The classical HLA class II genes (HLA-DP, HLA-DQ, HLA-DR) either encode proteins with $\alpha$ chains (HLA-DPA, HLA-DQA, HLA-DRA) or proteins with $\beta$ chains (HLA-DPB, HLA-DQB, HLA-DRB). The $\alpha$ and $\beta$ chains combine to form class II MHC molecules. The class II molecules are polymorphic and are expressed on specialised antigen-presenting cells (e.g. dendritic cells, B lymphocytes, macrophages) and present peptides mainly derived from extracellular proteins to $\mathrm{CD} 4^{+} \mathrm{T}$ cells.

MHC class II molecules differ from MHC class I molecules in that the groove of the peptide-binding region (PBR) is open-ended, thus allowing longer peptides to be bound. Prior to a peptide binding, the class II molecules are assembled in the endoplasmic reticulum (ER) with a membrane-bound chaperone protein (known as the MHC class II associated invariant chain or $\gamma$ chain) acting to stabilise the complex. This $\gamma$ chain is degraded by proteases in the trans-Golgi reticulum with the exception of a small fragment that is buried in the PBR. The removal of this small fragment
(prior to peptide binding) is catalysed by gene products of the HLA-DM gene - a nonclassical class II gene. After binding, the MHC class II molecule-peptide complex is transported to the cell surface where it is recognised by $\mathrm{CD} 4^{+}$helper T lymphocytes (for a review of class II antigen presentation see Neefjes and Ploegh, 1992 and Pieters, 1997).

Within the class II region there are also a number of other genes that have an immune related function. The PSMB8, PSMB9, TAP1 and TAP2 genes are involved with antigen processing of MHC class I molecules as described in section 1.10.2. There are also a number of genes with quite diverse functions, such as the butyrophilin-like gene BTNL2, the testis-specific basic protein TSBP and the bromodomain-containing protein BRD2. Furthermore, a number of pseudogenes are located within this region, including a ribosomal protein pseudogene and the pseudogene of the extended class II gene COL11A2.


Figure 1.10 The MHC class II region. The expressed genes are shown in red and are labelled above the gene track and the pseudogenes (labelled with a ' $p$ ') are in grey and are labelled below.

### 1.10.5 The extended class II region

The identification of the tapasin gene, required for antigen presentation by MHC class

I molecules, in the region flanking the MHC class II region suggested that the MHC extended further than previously thought (Herberg et al, 1998a; 1998b). Detailed analysis of the region centromeric to the MHC class II region, now termed the extended class II region (figure 1.11), revealed several other genes, including collagen gene type 11A2 (COL11A2), a ribosomal protein RPS18 and, the most centromeric gene in the extended MHC, KNSL2.


Figure 1.11 The extended MHC class II region. The expressed genes are shown in red and are labelled above the gene track and the pseudogenes (labelled with a ' $p$ ') are in grey and labelled below.

### 1.11 Origin of the extended MHC

There is conservation of some of the genes within the extended MHC regions between species suggesting that there is an evolutionary advantage in conserving the MHC as a unit. This MHC 'unit' can be observed in species evolving after the divergence of the jawless vertebrates. In particular, the MHC class I and class II region genes have been identified in all jawed vertebrates studied to date, but have not been identified in the jawless vertebrates, hagfish and amphioxus (Kasahara et al, 1996b; Flajnik et al, 1999). Jawless vertebrates also lack other molecules of the adaptive immune system, such as RAG1 and RAG2, as well as the lymphoid organs thymus and spleen. Thus, the adaptive immune system has arisen in a very short period of geological time since
the emergence of jawed vertebrates (Bernstein et al, 1996). Several MHC genes (including NOTCH4, RXRB and PBX2) are syntenic in invertebrate genomes, such as Drosophila and C. elegans indicating that the origin of the MHC locus predates the emergence of the adaptive immune system

The three classical regions of the human MHC (class I, class III and class II) appear to have been subject to different evolutionary mechanisms: whilst MHC class II and class III genes often appear to have direct orthologues, the MHC class I genes appear to have expanded and contracted in different species. The class III region is considered to be the oldest region of the MHC (reviewed by Beck and Trowsdale, 2000). It is evident that both the class I and class II regions have evolved via a series of duplications, but it is not known which region came first. One hypothesis claims the class II region evolved first (Hughes and Nei, 1993), whereas another hypothesis holds that the class I region originated first as a result of a recombination between an immunoglobulin-like C-domain and the peptide-binding domain of an HSP70 heat shock protein (Flajnik et al, 1991). Phylogenetic analysis supported the prior hypothesis, albeit with low statistical support (reviewed by Hughes and Yeager, 1997; Klein and Sato, 1998).

### 1.12 MHC Paralogy

MHC paralogous genes were observed during the study of MHC class III genes (Sugaya et al, 1994; Katsanis et al, 1996) and the class II proteasome genes (Kasahara et al, 1996a). It was concluded that the region 9q33-q34 was paralogous to the MHC. Furthermore, Katsanis and colleagues (1996) also noted two additional regions in the human genome, 1q21-q25/1p11-p32 and 19p13.1-p13.3, which contained MHC
paralogues (Figure 1.12). Initially, only a few genes were reported to have paralogues on chromosomes 1,9 and/or 19 but the number has increased to 40 , approximately one third of the expressed MHC genes (reviewed by Kasahara, 1999b).


Figure 1.12 Summary of the MHC paralogous regions in the human genome.

The MHC genes with paralogues reside in both the classical and extended regions of the MHC region and constitute a diverse group of genes in terms of structure, function and gene size. Some families, such as NOTCH and PBX, have copies in all four
regions, but most only have two or three copies. MHC paralogues may not be identified in all regions, for each gene, as duplicated genes are likely to be silenced or lost from the genome altogether (Nadeau and Sankoff, 1997). Interestingly, there are also a number of other gene families that have copies in the 1,9 and 19 paralogous regions but not in the MHC (reviewed by Kasahara et al, 2000).

### 1.12.1 Origin of the extended MHC paralogous regions

The origin of the MHC and the three paralogous regions is controversial. Currently there are two main hypotheses. The first is that they descended from a common ancestral region and emerged as a result of large-scale block duplications (Kasahara et al, 1996a; Kasahara, 1999a; Abi-Rached et al, 1999; Flajnik and Kasahara, 2001). The second is that they represent assemblies of independently duplicated genes and are grouped together by selective forces (Hughes, 1998). In general, the block duplication mechanism is preferred, as it can best explain why assortments of functionally and structurally varied genes are clustered on four specific regions of the human genome.

It is possible that the MHC and the paralogous regions on chromosomes 1, 9 and 19 arose from two rounds of whole-genome duplications (the 2 R hypothesis) based on the estimated timings and numbers of duplications that appear to have occurred (reviewed by Flajnik and Kasahara, 2001). It is believed that the first round of duplication occurred close to the origin of jawed vertebrates. This is supported by the identification of a single orthologue of the MHC paralogues, exemplified by the complement genes C3, C4 and C5. All have been identified in cartilaginous fish, however, jawless fish lack C4 and C5 but do have a C3-like gene that shares features
with the common ancestor of C3 and C4 (Kasahara, 1999a).

In order to understand the evolution of the MHC and associated paralogous regions, numerous genes have been analysed in a number of organisms, including Drosophila and amphioxus which are thought to predate the whole genome duplication events proposed by the 2 R hypothesis. The identification of 19 MHC paralogous genes in Drosophila (Danchin et al, 2003) and nine MHC paralogous genes in amphioxus (Abi-Rached et al, 2002) residing in close proximity to other genes found on human 1q21-q25/1p11-p32, $9 \mathrm{q} 33-\mathrm{q} 34$ and 19p13.1-p13.3 provides evidence for a block duplication event in vertebrates. Phylogenetic analysis has demonstrated that the duplications occurred prior to vertebrate emergence but after the divergence of amphioxus from the vertebrate lineage supporting the 2 R hypothesis.

If the paralogous regions have a common origin there should be evidence of conserved synteny between them. Preliminary analysis of the gene order within the paralogous regions indicated that the order is poorly conserved (Endo et al, 1997). This is no surprise considering that more than 500 million years have passed since the last duplication event occurred and each region has undergone major structural rearrangements, including inversions and translocations. Rearrangements are particularly dramatic on chromosome 1 , as the MHC paralogues are located on both arms of the chromosome. There is compelling evidence that chromosome 1 underwent a pericentromeric inversion after the divergence of the human and chimpanzee lineages and this is probably responsible for the occurrence of the paralogous genes on both arms (Maresco et al, 1996).

### 1.13 Thesis aims

With the discovery that approximately $10 \%$ of the human genome arose by duplication it is evident that this process has played a major role in the evolution of our genome. Whether the duplication events involved the entire genome (as proposed by the 2 R hypothesis), chromosomal segments or individual genes is unclear. Therefore, the aim of this thesis was to investigate the mechanism(s) that gave rise to the present-day organisation of the human genome.

Using the MHC region as a model a number of aspects of paralogy and the genome were investigated. Firstly, in order to study the genomic regions containing MHC paralogous genes, the chromosomal region 9q32-q34.3 was mapped, sequenced and analysed. Comparison of $9 \mathrm{q} 32-\mathrm{q} 34.3$ with the MHC region on $6 \mathrm{p} 22.2-\mathrm{p} 21.3$ will reveal the level of synteny between these two regions and determine whether they have a common origin. Secondly, a survey of the entire human genome sequence was conducted to identify the MHC paralogues and determine their distribution. Thirdly, phylogenetic trees were used to reconstruct the evolutionary histories of the MHC paralogues. Analysis of the topology of the trees and the arrangement of the paralogues and orthologues will determine the mechanism(s) of evolution. Finally, the expression profiles were generated to understand how the MHC paralogues have evolved since their emergence. In summary, the data presented in this thesis aims to provide a unique insight into the evolution of the MHC paralogous genes and the human genome.

## Chapter 2

## Materials and Methods

### 2.1 Materials

The majority of chemical reagents were bought from Sigma Chemical Co., BDH Chemical Ltd., and Difco Laboratories unless stated in the text. Similarly restriction enzymes were bought from New England Biolabs unless stated differently. The sources of the commercial kits used in this thesis purchased from various companies are stated in the text. All primers were synthesised in-house by the Sanger Institute Oligo Preparation laboratory. PCR was generally performed using Amplitaq® DNA Polymerase from Perkin Elmer.

### 2.1.1 Solutions, buffers and media

Solutions used in this thesis are listed according to the methods section they were used. All solutions were made up in double-distilled water $\left(\mathrm{ddH}_{2} 0\right)$, unless stated otherwise.

## used in section 2.4

$2 \times T Y: 15 \mathrm{mg} / \mathrm{ml}$ bacto-tryptone, $10 \mathrm{mg} / \mathrm{ml}$ yeast extract, $5 \mathrm{mg} / \mathrm{ml} \mathrm{NaCl}(\mathrm{pH} 7.4)$ $\mathrm{ddH}_{2} 0$ up to 1 litre and autoclave to sterilise.

Chloramphenicol: $30 \mathrm{mg} / \mathrm{ml}$ stock made up in $100 \%$ ethanol, filtered to sterilise and
stored at $-20^{\circ} \mathrm{C}$. Used at $30 \mu \mathrm{~g} / \mathrm{ml}$ final concentration.

GTE: 50 mM Glucose, 25 mM Tris ( pH 7.5 ), 10 mM EDTA
$\mathrm{NaOH} / \mathrm{SDS}: 0.2 \mathrm{M} \mathrm{NaOH}, 1 \%(\mathrm{w} / \mathrm{v})$ SDS

3 M KOAc (pH5.5): 300 mM potassium acetate ( pH 4.8 ), 11.5 ml glacial acetic acid, $28.5 \mathrm{ml} \mathrm{H}_{2} 0$

Boehringer buffer B: $50 \mathrm{mM} \mathrm{NaCl}, 10 \mathrm{mM}$ Tris- $\mathrm{HCl}, 10 \mathrm{mM} \mathrm{MgCl}_{2}, 1 \mathrm{mM}$ DTE, pH7.5.

6 x Buffer II: $0.25 \%$ bromophenol blue, $0.25 \%$ xylene cyanol, $15 \%$ ficoll

Vistra green solution: mix 5 ml 1 M Tris $\mathrm{HCl}, 0.5 \mathrm{ml} 0.1 \mathrm{M}$ EDTA, $50 \mu \mathrm{l}$ Vistra Green (Amersham Life Sciences) made up to 500 ml with $\mathrm{ddH}_{2} 0$.

## used in section 2.5

$10 x$ nick translation buffer: 0.5 M Tris- $\mathrm{HCl}(\mathrm{pH} 7.5), 0.1 \mathrm{M} \quad \mathrm{MgSO}_{4}, 1 \mathrm{mM}$ dithiothreitol, $500 \mu \mathrm{~g} / \mathrm{ml}$ bovine serum albumin

DNase I ( $1 \mu \mathrm{~g} / \mathrm{ml}$ ): dilute $10 \mathrm{mg} / \mathrm{ml}$ Deoxyribonuclease I (Sigma) stock to $1 \mu \mathrm{~g} / \mathrm{ml}$ working solution with enzyme diluent.

Enzyme diluent: $500 \mu \mathrm{l}$ glycerol, $100 \mu \mathrm{l}$ nick translation buffer, $400 \mu \mathrm{lddH}_{2} 0$

Fixative: 3:1 methanol/glacial acid

Formaldehyde fixative: $1 \% \mathrm{v} / \mathrm{v}$ formaldehyde (from $40 \%$ stock), $50 \mathrm{mM} \mathrm{MgCl}{ }_{2}$ in PBS. For 50 ml add 1.25 ml formaldehyde, $2.5 \mathrm{ml} 1 \mathrm{M} \mathrm{MgCl}_{2}$ and make-up to 50 mls
with 2 xSSC .

FISH Hybridisation buffer: 50\% deionised formamide, 2 x SSC ( pH 7.0 ), 10\% dextran sulphate, $0.1 \%$ SDS, 1 x Denhardt's solution, 40 mM sodium phosphate pH 7.0 .
$4 \times$ TNFM: $4 \times$ SSC, $0.05 \%$ Tween $20,5 \%$ non-fat milk powder, filtered through several layers of Whatman No. 4 filter paper

## used in section 2.6

Mung bean nuclease buffer: $100 \mu 13$ M sodium acetate, $250 \mu 12$ M sodium chloride, $10 \mu 11 \mathrm{M}$ zinc chloride, $140 \mu \mathrm{l}$ water, $500 \mu \mathrm{l}$ mung bean nuclease (Pharmacia), 500 $\mu 1$ glycerol

Buffered phenol: 1 ml phenol, $200 \mu 11 \mathrm{M}$ Tris-hydrogen chloride (shaken and placed on ice for 5 minutes, centrifuged, top layer removed and discarded, $200 \mu \mathrm{TE}$ added, mixed, shaken and centrifuged. Kept on ice until needed.

SOC: SOB $+200 \mu 120 \%$ glucose

SOB: 20 g tryptone, 5 g yeast extract, 10 ml 1 M sodium chloride, 0.5 g potassium chloride, water added up to 1 litre

TYE agar: 8 g tryprone, 5 g yeast extract, 8 g sodium chloride, 12 g agar, water upto 1 litre

TYE/Amp plates: 2 ml of $25 \mathrm{mg} / \mathrm{ml}$ ampicillin was added to 1 ml TYE autoclaved solution which was allowed to cool to $48^{\circ} \mathrm{C}$ before addition.
$I P T G: 40 \mathrm{mg} / \mathrm{ml}$ in DMSO. Sterilised by filtration and stored at $-20^{\circ} \mathrm{C}$.

Xgal: $50 \mathrm{mg} / \mathrm{ml}$ in $\mathrm{ddH}_{2} 0$. Sterilised by filtration and stored at $-20^{\circ} \mathrm{C}$.
$0.1 \%$ DMSO: Dimethyl sulfoxide diluted in $\mathrm{ddH}_{2} 0$ and autoclaved.

## used in section 2.7

$2 \times$ LB: $10 \mathrm{mg} / \mathrm{ml}$ bacto-tryptone, $5 \mathrm{mg} / \mathrm{ml}$ yeast extract, $10 \mathrm{mg} / \mathrm{ml} \mathrm{NaCl}(\mathrm{pH} 7.4)$ $\mathrm{ddH}_{2} 0$ up to 1 litre and autoclaved to sterilise.

Ampicillin: $25 \mathrm{mg} / \mathrm{ml}$ Ampicillin stock made up in $\mathrm{ddH}_{2} 0$, filtered to sterilise and stored at $-20^{\circ} \mathrm{C}$.

GET: 30 mM Glucose, 15 mM Tris- HCl (pH8.0), 30 mM Na 2 EDTA, $60 \mu \mathrm{~g} / \mathrm{ml}$ RNase A

Bind solution: (6.1 M Potassium Iodide) 40 g potassium iodide in 28 ml ddH 2 . Stored in the dark at room temperature.

Precipitation mix: $100 \mathrm{ml} \mathrm{96} \mathrm{\%}$ ethanol, 2 ml 3 M sodium acetate, 4 ml 0.1 mM EDTA

Sequencer Loading dye: 25 mM EDTA ( pH 8.0 ), $50 \mathrm{mg} / \mathrm{ml}$ Blue dextran, deionised formamide (5:1 formamide: EDTA/Blue dextran).
used in sections 2.8-2.13
$10 \times$ PCR buffer: $500 \mathrm{mM} \mathrm{KCl}, 50 \mathrm{mM}$ Tris ( pH 8.5 ), 25 mM MgCl 2 .

PBS: 10 g sodium chloride, 0.25 g potassium chloride, 1.44 g sodium hydrogen
phosphate (dibasic), 0.25 g potassium dihydrogen phosphate, made up to 1 litre with water and made to pH with sodium hydroxide. Stored at $4^{\circ} \mathrm{C}$.
$4 x$ Spotting buffer: 1 M sodium phosphate buffer pH 8.5, $0.001 \%$ sarkosyl

Bacterial mRNA "cocktail": pool of cDNA bacterial clones for B.subtilis trp gene (30 $\mathrm{ng} / \mu \mathrm{l})$, lysA gene ( $0.3 \mathrm{ng} / \mu \mathrm{l})$, thr $B$ gene ( $3 \mathrm{ng} / \mu \mathrm{l}$ ), dap $B$ gene ( $15 \mathrm{ng} / \mu \mathrm{l}$ ), pheB gene $(1.5 \mathrm{ng} / \mu \mathrm{l})$ all purchased from American Type Culture Collection (ATCC catalogue numbers 87482 to 87486 )

Microarray hybridisation buffer: $5 \times \mathrm{SSC}, 6 \times$ Denhardts solution, 60 mM Tris HCl (pH7.6), $0.12 \%$ sarkosyl, $48 \%$ formamide filter sterilised

100 x Denhardt's solution: $20 \mathrm{mg} / \mathrm{ml}$ Ficoll 400-DL, $20 \mathrm{mg} / \mathrm{ml}$ polyvinylpyrrolidine $40,20 \mathrm{mg} / \mathrm{ml} \mathrm{BSA}$ (pentax fraction V)

Microarray wash solution 1: $2 \times \mathrm{SSC}$, filter sterilised

Microarray wash solution 2: $0.1 \times$ SSC, $0.1 \%$ SDS, filter sterilised

Microarray wash solution 3: $0.1 \times$ SSC, filter sterilised

## used in section 2.14

Spermidine stock: $25.46 \mathrm{mg} / \mathrm{ml}$ spermidine (Sigma) in 10 mM Tris ( pH 7.4 )

1 x denaturation solution: $0.5 \mathrm{M} \mathrm{NaOH}, 1,5 \mathrm{M} \mathrm{NaCl}$

1 x neutralisation solution: $1.5 \mathrm{M} \mathrm{NaCl}, 1 \mathrm{M}$ Tris- $\mathrm{HCl}(\mathrm{pH} 7.4)$

MTN/Southern Wash solution I: $2 \times \mathrm{SSC}, 0.05 \%$ SDS, filter sterilised

MTE Wash solution I: $2 \times \mathrm{SSC}, 1 \%$ SDS, filter sterilised

MTN/Southern Wash solution II: $0.1 \times \operatorname{SSC}, 0.1 \%$ SDS, filter sterilised

MTE Wash solution II: $0.1 \times \mathrm{SSC}, 0.5 \%$ SDS, filter sterilised

## General solutions, buffers and media used in this thesis

10 x TBE: 890 mM Tris base, 890 mM Borate, 20 mM EDTA ( pH 8.0 )
$50 \times$ TAE: 2 M Tris base, $5.7 \% \mathrm{v} / \mathrm{v}$ glacial acetic acid, 50 mM EDTA
$20 \times$ SSC: 175.3 g sodium chloride, 88.2 g sodium citrate, made up to 1 litre with $\mathrm{ddH}_{2} 0$.
$1 x T_{0.1} E: 10 \mathrm{mM}$ Tris- $\mathrm{HCl}(\mathrm{pH} 8.0), 0.1 \mathrm{mM}$ EDTA
$1 \times$ TE: 2 ml Tris ( pH 7.4 ), $200 \mu \mathrm{l} 0.1 \mathrm{M}$ EDTA, $\mathrm{ddH}_{2} 0$ to 200 ml .

10 mM dNTPs mix: 1 ml of each dNTP $(100 \mathrm{mM})$ in 6 ml of $\mathrm{ddH}_{2} 0$. Stored at $-20^{\circ} \mathrm{C}$.
$1 \mu l 10 m M d A, T, G T P / 5 m M d C T P$ mix: $25 \mu \mathrm{l}$ dATP, $25 \mu \mathrm{l}$ dTTP, $25 \mu \mathrm{l}$ dGTP, $10 \mu \mathrm{l}$ dCTP and $15 \mu \mathrm{ddH} \mathrm{H}_{2} 0$.

### 2.1.2 Loading dyes

Loading dye: 5 mg bromophenol blue, 0.5 g Ficoll, 0.5 ml 10 x TBE, $4.5 \mathrm{ml} \mathrm{ddH}_{2} 0$

Loading buffer: $10 \mu \mathrm{l} 10 \mathrm{x}$ TBE, $20 \mu \mathrm{l}$ loading dye, $50 \mu \mathrm{l}$ water

Sequencer loading dye: 25 mM EDTA ( pH 8.0 ), $50 \mathrm{mg} / \mathrm{ml}$ Blue dextran, deionised formamide (5:1 formamide: EDTA/Blue dextran).

### 2.1.3 Nucleotides

| Amersham Biosciences | Redivue $^{\mathrm{TM}}$ deoxycytidine $5^{\prime}-\left[\alpha-{ }^{32} \mathrm{P}\right]-\mathrm{dCTP}-$ |
| :--- | :--- |
|  | triphosphate, triethylammonium salt (AA0075) |

Invitrogen
Renaissance R Cyanine 3-dCTP (NEL576)
Renaissance R Cyanine 5-dCTP (NEL575)

Pharmacia
100mM dATP, dCTP, dGTP, dTTP (27-2035-01)

Boehringer
Biotin-16-dUTP (1 mM) (1093-070)

### 2.1.4 Size markers and ladders

1kb DNA ladder ( $1 \mu \mathrm{~g} / \mu \mathrm{l}$ ) (Gibco BRL Life Technologies): $5 \mu \mathrm{l} 1 \mathrm{~Kb}$ DNA ladder mixed with $1 \mu \mathrm{l} 50 \times \mathrm{TAE}, 10 \mu \mathrm{l}$ Ficoll dye and $34 \mu \mathrm{ldd} \mathrm{d}_{2} 0$. The 1 Kb DNA ladder contains 1 to 12 repeats of a 1018 bp fragment and vector fragments from 75 to 1636 bp to produce the following sized fragments in bp: 75, 142, 154, 200, 220, 298, 344, 394, 516/506, 1018, 1635, 2036, 3054, 4072, 5090, 6108, 7125, 8144, 9162, 10180, 11198, 12216.

100 bp DNA ladder (1 $\mu \mathrm{g} / \mu \mathrm{l}$ ) (Gibco BRL Life Technologies): $50 \mu \mathrm{l}(1 \mu \mathrm{~g} / \mu \mathrm{l}) 100 \mathrm{bp}$

DNA ladder, $60 \mu$ loading buffer and $390 \mu 1 \mathrm{ddH}_{2} 0$. The 100 bp DNA ladder consists of 15 blunt-ended fragments between 100 and 1500 bp in multiples of 100 bp and an additional fragment at 2072 bp . The 600 bp fragment is approximately 2 to 3 times brighter that the other ladder bands to provide orientation.

Fingerprinting gel marker: $19.2 \mu \mathrm{~T} \mathrm{~T}_{0.1} \mathrm{E}, 1.5 \mu \mathrm{l}$ Analytical Marker DNA wide range (Promega), $0.2 \mu 1$ Molecular Weight Marker V (Boehringer-Mannheim) and 4.2 $\mu \mathrm{l}$ 6x loading dye were added to a 1.5 ml microfuge tube and stored at $-20^{\circ} \mathrm{C}$ ). The Analytical Marker DNA wide range provides an evenly spaced distribution of DNA fragments from 0.702 kb to 29.95 kb .

Lambda DNA-Hind III marker (Gibco BRL Life Technologies): $8 \mu 1$ lambda DNAHind III digest, $60 \mu \mathrm{lBE}$ buffer, $252 \mu \mathrm{ddH} \mathrm{d}_{2} 0$ was incubated at $65^{\circ} \mathrm{C}$ for 5 minutes then snap chilled on ice before $80 \mu \mathrm{l}$ loading dye was added. The Hind III digest of lambda DNA yields 8 fragments suitable for use as molecular weight standards for agarose electrophoresis of the following sizes; 125, 564, 2027, 2322, 4361, 6557, 9416, 23130.

Lambda Hind III/pBR322 marker: $8 \mu \mathrm{l}$ lambda Hind III (NEB), $60 \mu 110$ x TAE, 252 $\mu \mathrm{ldH} \mathrm{Cl}_{2} 0$ were heated at $65^{\circ} \mathrm{C}$ for 5 minutes then snap chilled on ice then $6 \mu \mathrm{l}$ pBR322 BstNI (NEB) and $80 \mu$ loading dye were added.

### 2.1.5 Sources of DNA and RNA

Human genomic DNA was purchased from Clontech (catalogue number 6550-1). Total RNA was extracted from Raji, Jurkat, 293T and U937 cell-lines (a kind gift from John Trowsdale, Division of Immunology, Department of Pathology, University of Cambridge) and a THP1 cell-line (kindly provided by Paul Lehner, CIMR, Cambridge). Total human Adrenal Gland, Brain, Skeletal Muscle, Spleen and Testis RNA were purchased from Ambion (catalogue numbers 7994, 7962, 7982, 7970 and 7972, respectively). Universal Human Reference RNA was purchased from Stratagene (catalogue number 740000). The human multiple tissue expression ( $\mathrm{MTE}^{\mathrm{TM}}$ ) array and the multiple tissue northern ( $\mathrm{MTN}^{\mathrm{TM}}$ ) were purchased from Clontech (catalogue numbers 7776-1 and 7760-1, respectively). Information regarding the sources of RNA can be found on the web-site http://www.clontech.com.

## Methods

### 2.2 Agarose gel preparation and electrophoresis

Unless stated otherwise in the text: agarose gels were prepared in either 1 x TBE or 1 x TAE buffer containing $250 \mathrm{ng} / \mu 1$ ethidium bromide and the appropriate percentage of agarose was used according to the size of fragments being separated; a $2.5 \%$ agarose gel was used for electrophoresis of fragments below 1 kb , and a $0.8-1.0 \%$ agarose gel for analysis of larger fragments. Electrophoresis was performed at 50-100 V for 15-45 minutes depending on separation required. The sizes of the DNA fragments were estimated by running either the 1 kb or 100 bp ladder size standards.

### 2.3 Sequencing gel

The denaturing acrylamide gel (6\%) was made up using 30 g urea in 9 ml acrylamide/bisacrylamide solution, $4 \mathrm{ml} 10 \times \mathrm{TBE}$ and $37 \mathrm{ml} \mathrm{ddH} \mathrm{H}_{2} 0$. The urea was dissolved by heating to $60^{\circ} \mathrm{C}$ and stirring. The solution was made up to 60 ml with water and placed in a dessicator for 4 minutes. Just prior to pouring the gel, $138 \mu \mathrm{l}$ of $25 \%$ ammonium persulphate and $138 \mu$ l TEMED were added. The gel was then carefully syringed between the glass plates whilst tapping the glass gently to get rid of air bubbles. The appropriate comb was inserted and the gel was left to set for at least 90 minutes prior to use.

## $\underline{\text { Mapping and sequencing }}$

### 2.4 Restriction Digest Fingerprinting

The BAC genomic clone, bA465F21 (AC006313) was fingerprinted using the HindIII digest fingerprinting method essentially as described by Olson et al, 1986.

### 2.4.1 Filterprep isolation of BAC DNA

1. $500 \mu \mathrm{l}$ of 2 x TY containing $30 \mu \mathrm{~g} / \mathrm{ml}$ of chloramphenicol were added to a 96well 1 ml Beckman box.
2. Each well was inoculated from a glycerol stock with either a 96-well inoculating tool, or a sterile cocktail stick. A plate sealer was placed on top of a plate to seal the wells and the cultures grown for $16-18$ hours at $37^{\circ} \mathrm{C}$ with gentle shaking ( 300 rpm ).
3. For each well, $250 \mu \mathrm{l}$ of the overnight growth were transferred to a clean round-bottomed Corning microtitre plate using a 50 - to 250 -multichannel pipette (Finnpipette). The cells were pelleted by centrifugation at 2500 rpm at $20^{\circ} \mathrm{C}$ from 4 minutes.
4. For each well, the supernatant was discarded and the pellet re-suspended in 25 $\mu 1$ of GTE and mixed gently by vortexing. $25 \mu 1$ of freshly prepared $\mathrm{NaOH} / \mathrm{SDS}$ solution was added and mixed by tapping the plate gently and left to stand at room temperature for 5 minutes.
5. $25 \mu \mathrm{l}$ of chilled $3 \mathrm{M} \mathrm{KOAc}(\mathrm{pH} 5.5)$ solution were added, mixed and left at room temperature for 5 minutes.
6. A microtitre plate containing $100 \mu \mathrm{l}$ of isopropanol was taped to the bottom of
$2 \mu \mathrm{~m}$ filter-bottomed plate (Millipore). The total well volume of the sample was transferred to the filter-bottomed plate.
7. These 2 plates were then spun at $2500 \mathrm{rpm}, 20^{\circ} \mathrm{C}$ for 2 minutes to ensure all liquid had been transferred from the filter plate to the lower plate; the filter plate was then discarded.
8. After separation from the filter plate, the lower (Corning) plate was left at room temperature for 30 minutes before being centrifuged at $3200 \mathrm{rpm}, 20^{\circ} \mathrm{C}$ for 20 minutes.
9. The supernatant was discarded from the plate and the DNA pellet was briefly dried by inverting the plate and placing on clean tissue paper.
10. $100 \mu \mathrm{l}$ of $70 \%$ ethanol were added to the dried DNA to wash the pellet, mixed gently, and the DNA precipitated by centrifuging at $3200 \mathrm{rpm} 20^{\circ} \mathrm{C}$ for 10 minutes. This step was repeated.
11. Finally, the supernatant was discarded and the DNA pellet was dried before being resuspended in $5 \mu \mathrm{l}$ of fresh $\mathrm{T}_{0.1} \mathrm{E}$ with RNase $(1 \mu \mathrm{~g} / \mathrm{ml})$.
12. Samples were stored at $-20^{\circ} \mathrm{C}$.

### 2.4.2 Restriction digest fingerprinting (Hind III) of BAC DNA

1. For one 96 -well microtitre plate of sample DNA, a premix containing $286 \mu 1$ $\mathrm{ddH}_{2} 0,99 \mu \mathrm{l}$ Boehringer buffer $\mathrm{B}, 55 \mu \mathrm{l}$ Hind III was prepared in a 1.5 ml microfuge tube, and mixed by vortexing.
2. $4 \mu \mathrm{l}$ of the premix was added to each well of a 96 well-microtitre plate containing previously prepared DNA (see section 2.4.1) and mixed gently by vortexing at $37^{\circ} \mathrm{C}$ for 2 hours.
3. The reaction was terminated by adding $2 \mu \mathrm{l}$ of 6 x Buffer II and either stored at $4^{\circ} \mathrm{C}$ or loaded immediately.
4. $0.8 \mu \mathrm{l}$ of the fingerprinting marker was added to the first well and then every sixth well of a freshly prepared $1 \%$ agarose $/ 1 \times$ TAE gel. $1 \mu 1$ of each sample was loaded (i.e. wells 2-5, 7-10 etc) between the marker lanes. Fragments were resolved by electrophoresis through the gel at $4^{\circ} \mathrm{C}$ in a cold room for 15 hours at 90 volts.
5. Following electrophoresis, the gel was cut down so the length was $19-20 \mathrm{~cm}$ and stained with Vistra Green solution for 30-45 minutes on a shaker. The gel was washed with $\mathrm{ddH}_{2} 0$ to remove excessive stain.
6. The gels were scanned on a FluorImager SI. The parameters were set to 530 nm for emission filter, the pixel size was 100 microns, detection sensitivity was normal, digital resolution was at 16 bits, dye was single label, excitation filter was 488 nm , Em filter 1530 nm and PMT voltage was 800 .
7. The gel image was transferred to a UNIX workstation and entered into the fingerprint 'IMAGE' analysis system (Sanger Institute in house software).The band pattern was extracted using 'IMAGE' and the data entered into another program, fingerprinted contigs, FPC (Soderlund et al, 1997), where the fingerprint patterns were compared to those already in the database and the position of the clone within a contig determined.

### 2.5 Fluorescent in-situ hybridisation (FISH) mapping

Cytogenetic mapping using FISH techniques were performed using chromosome 9 clones. The BAC clone, bA465F21, was fluorescently labelled and hybridised to
metaphase chromosomes to determine which chromosome it maps to (Pinkel et al, 1986). In addition, the orientation and order of 3 contigs were resolved by interphase FISH (Wilke et al, 1994) and the sizes of gaps between 5 contigs determined using extended DNA fibres using Fibre FISH (Heiskanen et al, 1994).

### 2.5.1 Labelling of FISH probe using Nick translation

1. $1 \mu \mathrm{~g}$ of clone DNA was labelled with 1 mM biotin-16-dUTP (Boehringer) in a $25 \mu 1$ reaction containing; $2.5 \mu 1$ nick translation buffer, $1.9 \mu 10.5 \mathrm{mM}$ dATP, dCTP and dGTP mix, $0.7 \mu 1 \mathrm{mM}$ biotin-16-dUTP, $1 \mu \mathrm{l}$ DNase I* (Sigma), 0.5 $\mu \mathrm{l}$ DNA polymerase I ( $10 \mathrm{U} / \mu \mathrm{l}$ Sigma) made-up to $25 \mu \mathrm{l}$ with $\mathrm{H}_{2} 0$.
*In order to determine the concentration of DNase I and incubation time a series of dilutions were carried out using different amounts of DNase I in $50 \mu \mathrm{l}$ reaction volumes containing; $2 \mu \mathrm{~g}$ test DNA, $5 \mu \mathrm{l}$ nick translation buffer, $1-2 \mu \mathrm{l}$ DNase I $\left(1 \mu \mathrm{~g} / \mathrm{ml}\right.$ working stock in enzyme diluent). The reactions were incubated at $14^{\circ} \mathrm{C}$ for 60 minutes. A $10 \mu \mathrm{l}$ aliquot was removed after 20 minutes with further $10 \mu \mathrm{l}$ aliquots removed at 10 minute intervals. All samples were run on a $1 \%$ agarose gel and the DNase I concentration and incubation time which gave fragment smears with a size range of 200-700 bp used.
2. The $25 \mu \mathrm{l}$ reaction was incubated at $14^{\circ} \mathrm{C}$ for 60 minutes and the labelling reaction terminated by adding $2.5 \mu \mathrm{l}$ of 0.5 M EDTA ( pH 8.0 )
3. $2.5 \mu \mathrm{l} 3 \mathrm{M}$ sodium acetate $(\mathrm{pH} 7.0)$ and $60 \mu \mathrm{l}$ of $100 \%$ ethanol were added to the reaction and the probe precipitated at $-70^{\circ} \mathrm{C}$ for 30 minutes.
4. The mixture was centrifuged at $13,000 \mathrm{rpm}$ for 10 minutes and the pellet washed twice with the addition of $500 \mu 170 \%$ ethanol and centrifuged at $13,000 \mathrm{rpm}$ for a further 2 minutes. The pellet was air-dried at $37^{\circ} \mathrm{C}$.
5. The pellet was resuspended in $10 \mu \mathrm{l} \mathrm{T}_{0.1} \mathrm{E}$ and $2 \mu \mathrm{l}$ of sample was run on a $1 \%$ agarose gel to check efficacy of the reaction.

### 2.5.2 Preparation of microscope slides

The slides containing the extended DNA fibres and the metaphase and interphase cellsuspensions were kindly provided by the Sanger Institute Molecular Cytogenetics group.

1. Microscope slides were washed in $2 \%$ Decon and sonicated in a sonicator bath then rinsed under cold running water for 60 minutes. Stored in $96 \%$ ethanol.
2. The slides were removed from the ethanol and polished with a dry, lint-free tissue.
3. The metaphase or interphase cell-suspension was mixed by gentle flicking of the tube and a single drop was dropped onto the slide using a Pasteur pipette.
4. A drop of fixative was added whilst the first drop was still spreading and the slide air-dried.
5. The slides were fixed in a coplin jar of fixative at room temperature for 30-60 minutes, air-dried and stored in a sealed box at room temperature until needed.
6. Prior to use the slides were incubated in $2 \times \mathrm{SSC}$ at $37^{\circ} \mathrm{C}$ for 5 minutes, followed by 5 minute incubation at $37^{\circ} \mathrm{C}$ in 0.01 M HCl and $10 \mu \mathrm{l}$ of $25 \%$ pepsin (in $\mathrm{ddH}_{2} 0$ ).
7. The slides were rinsed 3 times in $2 \times \operatorname{SSC}$ for 2 minutes each at room temperature and then fixed in formaldehyde fixative for 10 minutes also at room temperature.
8. The slides were rinsed again 3 times in $2 \times \mathrm{SSC}$ for 2 minutes at room
temperature then dehydrated through exposure to 3 concentrations of ethanol: slides were incubated at room temperature with $70 \%, 70 \%, 90 \%, 90 \%, 100 \%$ ethanol for 1 minute each.
9. The slides were air dried to evaporate the remaining ethanol.

### 2.5.3 Hybridisation of FISH probes

1. $1 \mu \mathrm{l}$ Cot 1 DNA $(1 \mu \mathrm{~g})$ and $11.5 \mu \mathrm{l}$ FISH hybridisation buffer was added to 0.5 $\mu 1$ labelled DNA ( $30-50 \mathrm{ng}$ ), mixed thoroughly and denatured at $65^{\circ} \mathrm{C}$ for 10 minutes.
2. The denatured probe was then incubated at $37^{\circ} \mathrm{C}$ for 1 hour.
3. Prior to hybridisation the slides were denatured in $70 \%$ formamide (in 2 x SSC) at $65^{\circ} \mathrm{C}$ for 2 minutes then quenched in ice cold $70 \%$ ethanol then dehydrated through an ethanol series $(70 \%, 70 \%, 90 \%, 90 \%, 100 \%$ for 1 minute each) and air-dried.
4. The hybridisation mix was placed onto the denatured slides and covered with $22 \times 22 \mathrm{~mm}$ cover slip. Rubber cement was used to seal the cover slips and the slides were incubated in a moist chamber at $37^{\circ} \mathrm{C}$ for 24 hours.
5. After hybridisation the cover slip was removed and the slides rinsed in 2 x SSC for 5-20 minutes.
6. The slides were washed twice at $42^{\circ} \mathrm{C}$ in $50 \%$ formamide (in $2 \times \operatorname{SSC}$ ) for 5 minutes.
7. Further washing was performed at $42^{\circ} \mathrm{C}$ in $2 \times \operatorname{SSC}$ for 5 minutes.
8. For detection of biotinylated probes $100 \mu \mathrm{l}$ of $4 \mu \mathrm{~g} / \mathrm{ml}$ avidin Texas Red DCS (Vector) was added and the slide covered with Nescofilm and incubated at
$37^{\circ} \mathrm{C}$ for 20-60 minutes in a humid chamber.
9. The slides were washed in $4 \times$ TNFM at $42^{\circ} \mathrm{C}$ for 5 minutes.
10. The slides were drained and $100 \mu \mathrm{l}$ of $4 \mu \mathrm{~g} / \mathrm{ml}$ biotinylated anti-avidin D plus 1:500 dilution of mouse anti-digoxin (Sigma) was added. The slide covered in Nescofilm and incubated at $37^{\circ} \mathrm{C}$ for $20-60$ minutes in a humid chamber.
11. The slides were washed in $4 \times$ TNFM at $42^{\circ} \mathrm{C}$ for 5 minutes.
12. The slide covered in Nescofilm and incubated at $37^{\circ} \mathrm{C}$ for $20-60$ minutes in a humid chamber.
13. The slides were drained and $100 \mu \mathrm{l}$ of $4 \mu \mathrm{~g} / \mathrm{ml}$ avidin Texas Red DCS plus 10 $\mu \mathrm{g} / \mathrm{ml}$ goat anti-mouse FITC conjugate (Sigma) was added. The slide covered in Nescofilm and incubated at $37^{\circ} \mathrm{C}$ for $20-60$ minutes in a humid chamber.
14. The slides were washed in $4 \times$ TNFM at $42^{\circ} \mathrm{C}$ for 5 minutes.
15. The slides were drained and $100 \mu \mathrm{l}$ of $4 \mu \mathrm{~g} / \mathrm{ml}$ avidin Texas Red DCS (Vector) was added and the slide covered with Nescofilm and incubated at $37^{\circ} \mathrm{C}$ for 20-60 minutes in a humid chamber.
16. The slides were washed in $4 \times$ SSC, $0.05 \%$ Tween 20 at room temperature and counterstained in $0.08 ~ \mu \mathrm{~g} / \mathrm{ml}$ DAPI (4',6'-diamidino-2-phenylindole hydrochloride) in $2 \times$ SSC for 2-3 minutes.
17. The slides were rinsed in $2 \times$ SSC then dehydrated through the ethanol series $(70 \%, 70 \%, 90 \%, 90 \%, 100 \%$ for 1 minute each) and air-dried.
18. $20 \mu 1$ of antifade solution (Citifluor AF1) was added to a clean $22 \times 32 \mathrm{~mm}$ cover slip and overlayed on the slide. The cover slip was sealed using nail varnish.
19. The slides were analysed using a Zeiss Axioscop fluorescence microscope equipped with a CCD camera. Separate images of the DAPI staining of the
chromosomes and the biotinylated probes were merged using SmartCapture software (Digital Scientific Ltd).

### 2.6 Production of shotgun libraries for shotgun sequencing (essentially as

 described by Bankier et al, 1987)The minimum set of clones to cover chromosome 9 were selected for sequencing using the large-scale maps produced by FPC fingerprinting methods. Each clone is divided into fragments by sonication which are then assembled so overlapping fragments of sequence provide the complete sequence across the clone. The random nature of sonication produces fragments that will be sequenced on average 6-8 times before a project is considered complete; this redundancy is necessary to ensure that sequencing errors are resolved. The chromosome 9 BAC clone DNA for bA18B16 was provided by the Sanger Institute Sub-cloning laboratory and sub-cloned by me.

### 2.6.1 Sonication and subfragment end repair of plasmid DNA

1. In order to estimate the concentration of DNA of the BAC clone, a $0.5 \%$ agarose, $1 \times$ TBE gel was run on a 10 x dilution of the BAC. The DNA sample was diluted $1 / 10$ in $\mathrm{T}_{0.1} \mathrm{E}$ and $1 \mu \mathrm{l}$ was run alongside lambda Hind $\mathrm{III} / \mathrm{pBR} 322$ marker. Samples were visualised by soaking the gel in 500 ml of $1 \times$ TBE containing $25 \mu \mathrm{l}$ ethidium bromide $(10 \mathrm{mg} / \mathrm{ml})$ for 5 minutes the de-stained in $\mathrm{ddH}_{2} 0$ for 10 minutes.
2. From the gel image, the amount of DNA required to obtain $10 \mu \mathrm{~g}$ was taken for sonication.
3. To the $10 \mu \mathrm{~g}$ DNA $\mathrm{ddH}_{2} 0$ was added to a final volume of $54 \mu \mathrm{l} .6 \mu \mathrm{l}$ of mung
bean buffer was added, mixed and collected by centrifugation.
4. The sample tube was placed in the 'cup-horn' of the sonicator containing ice cold water 1 mm from the face of the probe.
5. An output of approximately $12 \%$ on the 400 watt Virsonic 300 sonicator was used for 10 seconds in order to produce fragments of the required length.
6. $1 \mu \mathrm{l}$ of sonicated DNA was mixed with $4 \mu \mathrm{l}$ of loading buffer and the sample was run alongside lambda Hind $\mathrm{III} / \mathrm{pBR} 322$ markers on a $0.8 \%$ agarose gel with $1 \times$ TBE.
7. If sonication was successful the DNA was visible as a smear with no sign of a band of high molecular weight DNA. If a band was visible the samples were sonicated for a further 5 seconds and checked again on a $0.8 \% / 1 \times$ TBE agarose gel.
8. The ends of the sonicated DNA fragments were repaired by adding $0.3 \mu \mathrm{l}$ of mung bean nuclease buffer to the DNA. This mixture was placed in a $30^{\circ} \mathrm{C}$ water bath for 10 minutes.
9. The volume in the tube was made up to $200 \mu \mathrm{l}$ with $\mathrm{H}_{2} 0,20 \mu \mathrm{l}$ of 1 M sodium chloride, $550 \mu \mathrm{l}$ of ice cold $100 \%$ ethanol and $1 \mu \mathrm{l}$ of pellet paint (Novagen) were added to the DNA.
10. In order to precipitate the DNA, it was left for $2-18$ hours at $-20^{\circ} \mathrm{C}$ and then centrifuged for 30 minutes at $4^{\circ} \mathrm{C}$ at $13,000 \mathrm{rpm}$.
11. The supernatant was removed from the tube and the DNA pellet was washed in $1 \mathrm{ml} 100 \%$ ethanol by centrifugation for 10 minutes at $4^{\circ} \mathrm{C}$ at $13,000 \mathrm{rpm}$.
12. The ethanol was removed and the pellet was dried in a vacuum dryer for $10-15$ minutes.

### 2.6.2 Selection of suitably sized DNA fragments for subcloning

1. The pellet was thoroughly resuspended for loading in $6.25 \mu \mathrm{~T} \mathrm{~T}_{0.1} \mathrm{E}, 0.75 \mu \mathrm{l} 10$ x TAE and $2 \mu 1$ loading dye.
2. All $9 \mu \mathrm{l}$ of sample was loaded on a $0.8 \%$ agarose $/ 1 \times$ TAE gel with a lambda Hind III/pBR322 marker for 2 hours at $35 \mathrm{~mA}, 50-60 \mathrm{v}$.
3. The bands were visualised on an ultra violet transilluminator ( 312 nm ) and the bands corresponding to $1.4-2 \mathrm{~Kb}$ (ideal) size were cut out. Additional bands of $1-1.4 \mathrm{~Kb}$ and $2-4 \mathrm{~Kb}$ were also cut from the gel and stored at $4^{\circ} \mathrm{C}$. The pieces of gel were weighed to estimate the gel volume.
4. The $1.4-2 \mathrm{~Kb}$ gel fragment was placed in a tube and incubated at $65^{\circ} \mathrm{C}$ for 5 10 minutes.
5. $4 \mu 1$ of AgarACE (Promega) was added to the tube in a $42^{\circ} \mathrm{C}$ waterbath. The molten gel was incubated at $42^{\circ} \mathrm{C}$ for 15 minutes.
6. $15 \mu \mathrm{l}$ of sodium chloride, $150 \mu \mathrm{l}$ of buffered phenol and the appropriate volume of $\mathrm{T}_{0.1} \mathrm{E}$ buffer corresponding to the weight of the gel piece was added to the tube to a final volume of $135 \mu \mathrm{l}$.
7. The tube was mixed by vortexing and centrifuged at $13,000 \mathrm{rpm}$.
8. The upper (aqueous) phase (approximately $230 \mu \mathrm{l}$ ) was extracted and added to the tube containing the $1.4-2 \mathrm{~Kb}$ gel fragment. $30 \mu \mathrm{l}$ of $\mathrm{T}_{0.1} \mathrm{E}$ was added to the bottom layer, vortexed and centrifuged at $13,000 \mathrm{rpm}$ for 3 minutes.
9. The upper (aqueous) phase was removed and pooled with the first layer removed.
10. $1 \mu \mathrm{l}$ of pellet paint (Novagen) and $350 \mu \mathrm{l} 100 \%$ ethanol were added to the tube which was placed at $-20^{\circ} \mathrm{C}$ overnight.
11. The tube was centrifuged at $4^{\circ} \mathrm{C}$ at $13,000 \mathrm{rpm}$ for 30 minutes and the ethanol
was discarded.
12. The pellet was resuspended in 1 ml of ethanol and spun at $4^{\circ} \mathrm{C}, 13,000 \mathrm{rpm}$ for 10 minutes.
13. Ethanol was removed from the pellet which was vacuum dried for 5-10 minutes before resuspension in $5 \mu \mathrm{l}$ of $\mathrm{T}_{0.1} \mathrm{E}$.
14. To check for successful elution, $0.5 \mu \mathrm{l}$ DNA with $4.5 \mu \mathrm{l}$ loading buffer was run on a $0.8 \% / 1 \times$ TBE agarose gel with lambda Hind $\mathrm{III} / \mathrm{pBR} 322$ markers.

### 2.6.3 Ligation into $\mathrm{pUC18}$ vector

1. A premix of pUC18 (SmaI/CIP, Amersham) and buffer (provided with vector), consisting of $0.05 \mu \mathrm{l}$ of $\mathrm{pUC18}$ per reaction and $0.1 \mu \mathrm{l}$ of buffer (supplied with the $\mathrm{pUC18}$ ) was prepared by vortexing and placing the tube on ice.
2. $0.15 \mu 1$ of the pUC 18 -buffer mix was dispensed into the $600 \mu \mathrm{l}$ Sarstedt tube set-up for each reaction.
3. $0.7 \mu \mathrm{l}$ of DNA was added to each tube. In addition 3 control tubes were set-up with the following: (a) $0.7 \mu \mathrm{lddH} 20$ (b) $0.7 \mu \mathrm{lddH} 20$ and (c) $0.7 \mu \mathrm{l}$ Фx174/HaeIII (1.4 ng).
4. $5 \mu 1$ of mineral oil was added to each tube.
5. With the exception of tube (b), $0.15 \mu 1 \mathrm{~T} 4$ DNA ligase (Pharmacia) was dispensed to each tube, aiming for the 'bubble' under the oil, and the tubes were mixed and centrifuged for a few seconds.
6. Tubes were transferred to a $16^{\circ} \mathrm{C}$ incubator and left overnight to allow ligation to occur.
7. Tubes were heated to $65^{\circ} \mathrm{C}$ for 7 minutes before being left at room temperature for 5 minutes and centrifuged briefly.
8. $49 \mu \mathrm{l}$ of $\mathrm{ddH}_{2} 0$ was added to each reaction and tubes were stored at $-20^{\circ} \mathrm{C}$ until transformations were performed.

### 2.6.4 Transformation of $\mathrm{pUC18}$ vector

1. $1 \mu \mathrm{l}$ of ligated DNA was aliquoted into 15 ml glass test-tubes and $500 \mu \mathrm{l}$ of SOC was added to each 1 ml tube.
2. TG-1 cells (Invitrogen, maintained in $10 \%$ glycerol and stored at $-70^{\circ} \mathrm{C}$ ) were removed from the freezer and $150 \mu \mathrm{l} 10 \%$ glycerol was added to each tube of cells which were left on ice.
3. Cells and glycerol were mixed using a P200 Gilson pipette and $40 \mu \mathrm{l}$ of this mixture was added to the ligated DNA.
4. The cells, glycerol and DNA were aliquoted into a cuvette placed on ice, then electroporated using a Bio Rad Micropulser at 3.1 ms and 1.9 kv .
5. The cuvette was removed from the Micropulser and $400 \mu \mathrm{lSOC}$ (pre-warmed to $20-30^{\circ} \mathrm{C}$ ) was added to the cuvette: the mixture of SOC, cells and DNA was taken up and ejected into a test-tube.
6. The test-tubes were incubated in a shaker at $30^{\circ} \mathrm{C}$ for 1 hour with agitation.
7. TYE/Amp plates $(90 \mathrm{~mm})$ were placed at room temperature.
8. The test-tubes were removed from the shaker and $50 \mu \mathrm{IPTG}(40 \mathrm{mg} / \mathrm{ml}) 50$ $\mu \mathrm{Xgal}(50 \mathrm{mg} / \mathrm{ml})$ were added to each tube.
9. $125 \mu \mathrm{l}$ of the solution was dispensed into one TYE/Amp plate and $250 \mu \mathrm{l}$ was dispensed onto a second plate.
10. A sterile spreader was used to make the solution cover the plate in an even
manner.
11. Plates were placed in a $37^{\circ} \mathrm{C}$ incubator overnight and the number of recombinant (white) and non-recombinant (blue) colonies counted.
12. Successful ligations were stored at $-20^{\circ} \mathrm{C}$.

### 2.7 Shotgun sequencing

The chromosome 9 clones, bA18B16 and bA544A12, were sequenced using a modified version of the method described by Sanger et al (1977b). Essentially, the DNA was sequenced using the dideoxy termination system in which DNA polymerase uses directed primers to extend a DNA strand from a single stranded template. Extension occurs with the addition of deoxynucleotides complementary to the template strand until the dideoxynucleotide that inhibits further extension is incorporated. The latter are labelled with fluorescent dyes and visualised when separated by gel electrophoresis. The biochemistry will produce populations of products specifically terminating at either $\mathrm{A}, \mathrm{G}, \mathrm{C}$ or T .

### 2.7.1 Vacuum preparation of template DNA in pUC18 vector

1. 1 ml of $2 \times$ LB containing ampicillin was aliquoted into each well of a 96 well Beckman box, and separate (white recombinant) colonies were picked into each of these wells.
2. Boxes were sealed and the lids were pierced before boxes were placed in a $37^{\circ} \mathrm{C}$ incubator at 320 rpm and left to grow for 20-24 hours.
3. After growth, $100 \mu \mathrm{l}$ of the cells were removed from each well and added to a 96 well plate (Corning) containing $50 \mu \mathrm{l} 100 \%$ glycerol. The plates were
sealed and stored at $-70^{\circ} \mathrm{C}$.
4. Boxes were spun for 2 minutes at 4000 rpm , the supernatant was discarded and boxes were inverted on several layers of towels for 20 minutes to remove residual culture supernatant.
5. The pellets were resuspended in $120 \mu \mathrm{l}$ GET using a plate shaker (Luckham V400 Vortexer) completely resuspended.
6. $120 \mu \mathrm{NaOH} / \mathrm{SDS}$ solution was added, mixed thoroughly then incubated at room temperature for 2-5 minutes.
7. $120 \mu 13 \mathrm{M} \mathrm{KOAc}(\mathrm{pH} 5.5)$ was added and mixed gently.
8. A filter-bottomed plate (FB; Millipore catalogue number MAFBNOB50) was placed in the bottom of the vacuum manifold (Eppendorf). The lysate was removed from the Beckman box and dispensed into a Multiscreen-NA lysate clearing plate (NA; Millipore catalogue number MANANLY50) which was then placed on top of the manifold.
9. The lysate was drawn through the NA plate into the FB plate inside the manifold by applying the vacuum for 3 minutes not exceeding 8 Hg vacuum setting.
10. The NA plate was discarded and $150 \mu 1$ of Bind Solution added to the FB plate and mixed.
11. The FB plate was placed on the empty manifold and full vacuum $(30 \mathrm{Hg})$ was applied for 1 minute.
12. The plasmid DNA, bound to the FB plate, was washed with ice cold $80 \%$ ethanol and vacuum filtered at full vacuum for 1 minute.
13. The plasmid DNA was washed again with ice cold $80 \%$ ethanol and vacuum filtered at full vacuum for 3 minutes.
14. The FB plate was removed from the vacuum manifold and dried thoroughly at $90^{\circ} \mathrm{C}$ for 10 minutes or 2 hours at room temperature.
15. $50 \mu \mathrm{lddH} \mathrm{C}_{2} 0$ was added to the centre of each well and left to stand for 5 minutes at room temperature.
16. The plasmid DNA was eluted by placing the FB plate on top of a new microtiter plate (AB gene Thermo-fast ${ }^{\circledR} 96$ well skirted plate; catalogue number AB-0800) and centrifuging for 2-5 minutes at 4000 rpm .
17. The plasmid DNA was checked on a $0.8 \%$ agarose gel made up in $1 \times$ TBE.

### 2.7.2 The sequencing reaction

1. $2 \mu \mathrm{l}$ of DNA was added to $8 \mu \mathrm{l}$ of a mix made up of $1 \mu \mathrm{l}$ of forward primer (M13F-21F 5'-TGTAAAACGACGGCCAGT-3'; $6 \mathrm{pM} / \mu \mathrm{l}$ ) or reverse primer (pUC18R 5'-GCGGATAACAATTTCACACAGGA-3'; $6 \mathrm{pM} / \mu \mathrm{l}$ ), $4 \mu \mathrm{l}$ BigDye ${ }^{\mathrm{TM}}$ Terminator Ready Reaction mix (supplied by PE Applied Biosystems) and 3 $\mu \mathrm{l}$ water.
2. The mixture was centrifuged and placed on a PTC-225 Peltier Thermocycler (MJ Research) with the following program: (i) $96^{\circ} \mathrm{C}$ for 30 seconds (ii) $50^{\circ} \mathrm{C}$ for 15 seconds (iii) $60^{\circ} \mathrm{C}$ for 2 minutes 30 seconds, (iv) repeat (i) - (iii) for 25 cycles (v) $4^{\circ} \mathrm{C}$ until stopped.
3. To each reaction, $10 \mu 1 \mathrm{ddH}_{2} 0$ and $50 \mu \mathrm{l}$ precipitation mix was added.
4. The plate was centrifuged at $4^{\circ} \mathrm{C}, 4000 \mathrm{rpm}$ for 25 minutes, and the ethanol was decanted.
5. $100 \mu \mathrm{l}$ of ice-cold $70 \%$ ethanol was added, and the plate was centrifuged for 23 minutes at $4^{\circ} \mathrm{C}, 4000 \mathrm{rpm}$. This step was repeated.
6. The ethanol was removed and the plate inverted on a tissue and centrifuged at 250 rpm to remove all traces of ethanol. The plate was dried at $90^{\circ} \mathrm{C}$ for 10 minutes in the dark. Plates were stored at $-20^{\circ} \mathrm{C}$ until loaded onto the sequencer.

### 2.7.3 Sequencing instrumentation

DNA sequenced by me was loaded on either an ABI PRISM® 373 DNA sequencer or an ABI PRISM® 377 DNA sequencer and generated by the Sanger Sequencing Centre on an ABI PRISM® 3100 DNA analyser (Applied Biosystems).

### 2.7.3.1 ABI PRISM® 373 DNA sequencer set-up:

1. The sequencing gel plate (see section 2.3 for preparation) was inserted into the ABI cassette of the ABI PRISM® 373 DNA sequencer and secured using clips; ensuring that the gel plates were flat in the cassette.
2. The plates were cleaned using a lint free tissue and the plates-checked by scanning the glass plates. If 4 flat coloured lines appeared in the scan window the upper buffer chamber was put in place and both upper and lower chambers were filled with $1 \times$ TBE buffer before pre-running the machine for 30 minutes. If there were peaks in the trace the plate was removed from the cassette and cleaned before repeating the plate-checking process.
3. $3 \mu \mathrm{l}$ of sequencer loading dye was added to each sequencing reaction, briefly centrifuged then denatured by heating at $80^{\circ} \mathrm{C}$ for 10 minutes before loading.
4. The comb was removed from the gel and wells were rinsed using 1 x TBE to
ensure that there were no air bubbles before $3 \mu \mathrm{l}$ of sample was loaded to each well (36 maximum) using a Gilson pipette.
5. Data was collected over a run-time of 8 hours.

### 2.7.3.2 ABI PRISM® 377 DNA sequencer set-up:

1. The sequencing gel plate (see section 2.3 for preparation) was inserted into the ABI cassette of the ABI PRISM® 377 DNA sequencer and secured using clips; ensuring that the gel plates were flat in the cassette.
2. The plates were cleaned using a lint free tissue and the plates-checked by scanning the glass plates. If 4 flat coloured lines appeared in the scan window the upper buffer chamber and heat plate that clipped in front of the gel plate were put in place. If there were peaks in the trace the plate was removed from the cassette and cleaned before repeating the plate-checking process.
3. The upper and lower buffer chambers were filled with $1 \times$ TBE buffer before pre-running the machine for 30 minutes.
4. $2 \mu \mathrm{l}$ of loading dye was added to each dried sequencing reaction and the samples were then briefly centrifuged.
5. The comb was removed from the gel and wells were rinsed using 1 x TBE to ensure that there were no air bubbles before $2 \mu 1$ of sample was loaded to each well (48-60) using a Gilson pipette.
6. Data was collected over a run-time of 4 hours.

### 2.7.4 Data analysis of shotgun sequencing reactions and clone assembly

The data produced from the ABI sequencers was transferred to the UNIX system
where a number of Sanger Institute in house software programs have been developed for the analysis of this data. The first procedure involved in analysing an ABIPRISM® 373 or ABI-PRISM® 377 sequencing gel is to establish the position of each sample on a gel. This lane tracking is automatically performed by the program 'Gelminder' (Platt and Mullikin, unpublished) but manual checking and in some cases, repositioning is required. After manual checking of the lane tracking, the individual bases are called by 'Gelminder' using the program 'Phred'. The sequencing data produced by the capillary sequencer ABI-PRISM® 3100 is automatically uploaded into 'Capminder' and the bases are identified using the program 'Phred'.

Data from each sequencing reaction is then passed into the 'Automated Sequence Preprocessor (ASP)' program (Hodgson, unpublished) which cuts off sequence according to whether it is cloning or sequencing vector, E.coli contamination and sequence of an unacceptably poor quality. Clipped good quality sequences are then passed into the 'Phrap2Gap' program (Mott and Dear, unpublished), a modification of 'Phred' (a base-calling program) and 'Phrap' (a sequence assembly program; Gordon et al, 1998). 'Phrap2Gap' allows phrap-assembled reads to be transferred into the 'GAP' editing package. The 'GAP' sequence assembly program was developed as part of the Staden package (Bonfield et al, 1995; Staden, 1980; Staden et al, 2000); over the years versions have been updated from 'xGAP' to 'GAP' to 'GAP4' to 'GAP4.new'. Clones assembled as part of this project were largely assembled using 'GAP4.new' packages.

### 2.7.5 Contiguation or 'finishing' of a clone

Generally, a clone is not a contiguous piece of DNA sequence upon transfer into a
'GAP' package. The clones, bA544A12 and bA18B16, were not contiguous and a number of steps were required in order to produce a 'finished' clone (defined as a contiguous piece of sequence with both cloning vector arms present). A 'finished' clone also required that all the sequence was 'double stranded', which refers to the idea that the entire clone should be covered by at least two individual reads. Assembling a clone, therefore, required the use of a number of pieces of software, resequencing certain subclones and generating specific segments of DNA using the PCR reaction with the addition of reaction additives (section 2.7.5.1).

After a clone was contiguous and double stranded, the virtual restriction digest of the clone was checked against fragments generated by 3 actual restriction digests. This involved generating the real digests (described in section 2.4) and generating the virtual digests. Virtual digests were generated by the program 'Confirm' (Production Software Group, Sanger Institute, unpublished) which also has a graphical display showing the real and virtual digests alongside each other.

### 2.7.5.1 'Finishing' PCR reaction

The additives A, E and F (Invitrogen) are used to sequence 'difficult' regions. Additive A is the 'universal additive' and is designed to generally aid the sequencing reactions on problematic areas. Additive E is used to sequence regions with high GA composition and additive F for high AT composition. The dGTP BigDye ${ }^{\text {TM }}$ terminator mix (Applied Biosciences) is used for regions of high GC content.

1. $2 \mu \mathrm{l}(40 \mathrm{nM})$ of forward primer and $2 \mu \mathrm{l}(40 \mathrm{nM})$ reverse primer were dispensed into a 96 well plate (Costar), spun briefly and dried down in a $90^{\circ} \mathrm{C}$
oven for 10 minutes.
2. To $3 \mu \mathrm{l}$ DNA template, $4 \mu \mathrm{l}$ BigDye ${ }^{\mathrm{TM}}$ Terminator mix (Applied Biosystems) or dGTP BigDye ${ }^{\mathrm{TM}}$ Terminator Ready Reaction mix (Applied Biosystems), 2 $\mu 1$ additive A , E or F (Invitrogen) and $4 \mu 1 \mathrm{ddH}_{2} 0$ was added.
3. Samples were placed on the PTD-225 Peltier Thermocycler (MJ Research) with the following program: (i) $95^{\circ} \mathrm{C}$ for 15 seconds, (ii) $45^{\circ} \mathrm{C}$ for 5 seconds, (iii) $60^{\circ} \mathrm{C}$ for 2 minutes, (iv) steps (i)-(iii) repeated 25 times, (v) $4^{\circ} \mathrm{C}$ until program stopped.
4. Sequencing protocols were performed as described in section 2.7.2, using the appropriate primer(s).

## Expression profile analysis

### 2.8 Design of paralogue specific primers

Primers were designed manually and using the Primer3 program (Rozen and Skaletsky, 2000) for each paralogue ${ }^{1}$ to ensure that the primers and product were 'paralogue specific' ${ }^{2}$. Primer sequences, $18-25 \mathrm{bp}$ in length with an average GCcontent of $40-60 \%$ and melting temperature of $55^{\circ} \mathrm{C}-65^{\circ} \mathrm{C}$, were designed, in most cases, in the $3^{\prime}$ UTR of the paralogue mRNA to generate a PCR product between 250500 bp . The primer sequences used are given in Appendix 3 and 4.

Sequences were chosen:
(i) to avoid areas of simple sequence showing non-representative use of the bases and obvious repetitive sequence i.e. runs of single nucleotides (e.g. TTTT) or double nucleotides (e.g. CGCGCG) motifs.
(ii) to avoid complementarity between primer pairs as this would result in primers annealing to each other and forming primer dimers.
(iii) to exclude palindromes which will form inhibitory secondary structure (e.g. GACGTC)

Each primer was also designed with the universal 5' adaptor sequence ' 5 '-TGACCATG-3" necessary for attaching the paralogue specific amplicon to the

[^0]surface of the microarray (as per section 2.13.2).

The specificity of each primer and product was determined by BLAST searching the sequence against the ENSEMBL human genome build (UCSC (ENSEMBL 1.1.0). Each PCR product was also verified by sequencing (section 2.7 using appropriate primer).

### 2.9 PCR amplification of paralogue specific PCR products

The primers used to amplify the paralogue specific PCR products for the Southern, Northern and dot-blot experiments are summarised in Appendix 3 and the primers used in the RT-PCR and microarray experiments are summarised in Appendix 4.

1. To $5 \mu \mathrm{l}$ human genomic DNA $(1 \mu \mathrm{~g} / \mu \mathrm{l}), 2 \mu \mathrm{l} 10 \mathrm{x}$ PCR Buffer, 10 mM dNTPs , $0.5 \mu \mathrm{l}$ of $\operatorname{primer} 1(200 \mathrm{ng} / \mu \mathrm{l}), 0.5 \mu \mathrm{l}$ primer $2(200 \mathrm{ng} / \mu \mathrm{l}), 0.125 \mu \mathrm{l}$ Taq Polymerase and $10.875 \mu \mathrm{l}$ of $\mathrm{ddH}_{2} 0$ was added.
2. The paralogue-specific PCR products were amplified using a PTD-225 Peltier Thermocycler (MJ Research) with the following program: (i) $95^{\circ} \mathrm{C}$ for 5 minutes, (ii) $95^{\circ} \mathrm{C}$ for 1 minute (iii) [annealing temperature] ${ }^{\circ} \mathrm{C}$ for 1 minute 30 seconds (iv) $72^{\circ} \mathrm{C}$ for 1 minute 30 seconds (v) repeat (ii)-(iv) 35 times (vi) $72^{\circ} \mathrm{C}$ for 5 minutes.
3. $5 \mu \mathrm{l}$ of PCR product with $10 \mu \mathrm{l}$ loading buffer were separated on a $2.5 \%$ agarose gel made up with 1x TBE and visualised with ethidium bromide.

### 2.10 Total RNA extraction from mammalian cell-lines

The 5 cell-lines growth medium (with serum and antibiotics): RPMI 1640 Medium
(GIBCO) supplemented with $10 \%$ fetal calf serum (FCS, GIBCO) and 5 ml penicillin/streptomycin $\left(10,000 \mathrm{U} / \mathrm{ml}\right.$; GIBCO BRL). Stored at $4^{\circ} \mathrm{C}$.

1. The cell-line liquid nitrogen stocks were first thawed then washed by adding 25 ml of the tissue-culture medium and gently mixed.
2. The cell pellet was collected by centrifugation at 1500 rpm for 5 minutes and the supernatant discarded.
3. The cell pellet was resuspended in 15 ml of growth medium and grown in suspension at $37^{\circ} \mathrm{C}$ in $5 \% \mathrm{CO}_{2} / 95 \%$ air in $75 \mathrm{~cm}^{2}$ filter capped flasks.
4. A cell culture with $70-80 \%$ confluence ( $\sim 10^{7}$ cells) was taken and centrifuged to pellet the cells at 1500 rpm
5. The medium was removed with a pasteur pipette and the cells washed twice with 50 ml PBS and the cell pellet collected by centrifugation at 1000 rpm for 5 minutes.
6. 1 ml TRIZOL reagent (GIBCO BRL) was added to each pellet and mixed well by pipetting until the pellet was completely resuspended (TRIZOL is a clear red liquid which will become cloudy once pellet is resuspended). An additional 1 ml TRIZOL was added if pellet did not resuspend completely.
7. The samples were dispensed into 1 ml aliquots in 2 ml round-bottom tubes and incubated at $60^{\circ} \mathrm{C}$ (heating block) for 10 mins to fully resuspend the pellet.
8. $200 \mu \mathrm{l}$ chloroform was added to each 1 ml aliquot and mixed vigorously by shaking for $\sim 15$ seconds then incubated at room temperature for 2-3mins.
9. The samples were centrifuged at $14,000 \mathrm{rpm}$ for 15 mins at $4^{\circ} \mathrm{C}$.
10. The aqueous upper phase (clear, colourless) was dispensed into a new 2 ml tube without disturbing the other layers and the remaining layers were discarded.
11. 0.5 ml isopropanol was added to the aqueous layer and mixed by inversion then incubated at room temperature for 10 mins .
12. The RNA pellet was collected by centrifugation at $14,000 \mathrm{rpm}$ for 15 mins at $4^{\circ} \mathrm{C}$ (the RNA was visible as a white pellet at the bottom of the tube).
13. The supernatant was removed and discarded and the pellet washed once with 1 $\mathrm{ml} 75 \%$ ethanol. Vortexed to mix and centrifuged at $7,500 \mathrm{rpm}$ for 5 mins at room temperature
14. The supernatant was removed and the pellet was centrifuged at $7,500 \mathrm{rpm}$ for 2 minutes and the remaining supernatant carefully removed.
15. The pellet was air dried for $\sim 30 \mathrm{mins}$.
16. The pellet was re-suspended in $100 \mu \mathrm{l}$ DEPC and incubated at $60^{\circ} \mathrm{C}$ (heating block) to ensure the pellet was completely resuspended.
17. The total RNA was quantitated using a spectrophotometer and qualitated by assessing $2 \mu \mathrm{~g}$ RNA by electrophoresis on a $1 \%$ agarose gel made with DEPC/ $1 \times$ TBE (not exceeding 80 mA as RNA will smear).
18. 3 x volume $75 \%$ ethanol was added to the RNA sample. Stored at $-70^{\circ} \mathrm{C}$.

### 2.11 DNase treatment of RNA

Prior to use the total cell-line RNA was treated with DNase to remove any DNA contamination using the Ambion DNA-free ${ }^{\mathrm{TM}}$ kit.

1. $1 \mu \mathrm{~g}$ of RNA was incubated with 0.1 volumes 10 x DNase I Buffer (provided with kit) and $1 \mu \mathrm{l}$ DNase I (2 units) at $37^{\circ} \mathrm{C}$ for 30 minutes.
2. $5 \mu \mathrm{l}$ of DNase Inactivation Reagent (provided with kit) was added to the reaction mix and incubated at room temperature for 2 minutes.
3. The DNase Inactivation Reagent pellet was collected by centrifugation at $13,000 \mathrm{rpm}$ for 1 minute and the supernatant containing the DNA free RNA removed into a fresh tube.

### 2.12 First strand cDNA synthesis and amplification of target cDNA using paralogue specific primers

The cDNA was synthesised using Superscript ${ }^{\text {TM }}$ First-Strand Synthesis System for RT-PCR (Invitrogen). All reagents were provided with the kit.

1. To $1 \mu \mathrm{~g}$ DNA free total RNA 10 mM dNTP mix, $1 \mu \mathrm{l}$ Oligo(dT) $)_{12-18}(0.5$ $\mu \mathrm{g} / \mu \mathrm{l}$ ) was added and made-up to $10 \mu \mathrm{l}$ with DEPC-treated water.
2. The reaction mix was incubated at $65^{\circ} \mathrm{C}$ for 5 minutes, then snap chilled on ice for 1 minute.
3. To the reaction mix, $2 \mu \mathrm{l} 10 \mathrm{x}$ RT buffer, $25 \mathrm{mM} \mathrm{MgCl}_{2}, 0.1 \mathrm{M}$ DTT and $1 \mu \mathrm{l}$ RNaseOUT ${ }^{\text {TM }}$ Recombinant RNase Inhibitor was added then incubated at $42^{\circ} \mathrm{C}$ for 2 minutes.
4. $1 \mu 1$ of SuperScript ${ }^{\mathrm{TM}}$ II RT ( 50 units) was added to the reaction, mixed and incubated at $42^{\circ} \mathrm{C}$ for 50 minutes.
5. The reaction was terminated by incubating at $70^{\circ} \mathrm{C}$ for 15 minutes then chilled on ice.
6. The reaction was collected by centrifugation and $1 \mu 1 \mathrm{RNase} \mathrm{H}$ was added. The reaction was incubated at $37^{\circ} \mathrm{C}$ for 20 minutes.
7. Amplification of target cDNA was carried out according to section 2.9 substituting $5 \mu \mathrm{l}$ genomic DNA with $2 \mu \mathrm{l}$ first-strand synthesised cDNA and increasing $\mathrm{ddH}_{2} 0$ from $10.375 \mu \mathrm{l}$ to $13.375 \mu$ l.

### 2.13 Overview of microarray experiments

Design of paralogue specific primers


Manufacture of Microarrays by Sanger Institute Microarray Facility


Fluorescent labelling of PCR product (2.13.3.1)


10K/Paralogue Microarray


Fluorescent labelling of RNA (2.13.3.2)


Spot identification and analysis


### 2.13.1 Description of microarrays used

Two different microarrays were produced by the Sanger Institute Microarray Facility;
(i) The 'Paralogue Microarray' has 40 paralogue-specific PCR products arrayed in triplicate. This microarray was used to ensure that the amplified PCR products do not cross-hybridise with any of the other paralogue-specific PCR products.
(ii) The ' $10 \mathrm{~K} /$ Paralogue Microarray' is a modification of the Sanger Institute human 10K microarray (Hver1.2.1). Further information can be found at http://www.sanger.ac.uk/Projects/Microarrays. The 10K array consists of 12 x 4 super-arrays corresponding to 48 sub-arrays each containing 224 DNA elements arranged as 14 rows and 16 columns (figure 2.1). There are currently 9932 DNA elements corresponding to human genes on the 10 K microarray. The first row of each sub-array is generally reserved for duplicate sets of positive and negative controls consisting of. Cy 3 positive control (a spot of Cy3), a negative control (empty spot) and 5 bacterial controls representing Bacillus subtilis trp, lysA, thrB, dapB and pheB genes. The duplicate set of controls has been substituted on the $10 \mathrm{~K} /$ Paralogue Microarray by 2 of the 40 paralogue-specific PCR products arrayed in quadruplicate. The quadruplicate sets of the 40 paralogues are represented in 2 different locations on the microarray; once in super-array rows 1-6 and again in super-array rows 7-12. Therefore, each paralogue specific PCR product appears 8 times on the microarray. The $10 \mathrm{~K} /$ Paralogue Microarrays were used to determine the expression profiles of the paralogues and the standard 10 K DNA elements in

10 human RNAs.


Figure 2.1 The $10 \mathrm{~K} /$ Paralogue Microarray. The layout of the 48 sub-arrays in $12 \times 4$ super-arrays is shown and the sub-array coloured blue is expanded. The first row of the sub-array is boxed in orange. Columns 1 to 8 of row 1 contain the controls described in the text. The paralogue specific PCR products of one paralogue are arrayed in rows 9 to 12 (shown as 4 green spots) and a second paralogue in rows 13 to 16 (shown as 4 blue spots). The paralogue specific PCR products are represented in two different locations on the microarray and the super-array containing the same paralogue specific PCR products is coloured red.

### 2.13.2 Generation of paralogue specific PCR products with a Universal

## Adaptor for use on microarrays

The paralogue specific PCR products generated as described in section 2.9 were subjected to a second round of PCR in which a universal primer (5, GCTGAACAGCTATGACCATG- $3^{\prime}$ ) was used to attach an aminolinker to the $5^{\prime}$ of the PCR product. The aminolinker enables the attachment of the PCR product to the microarray surface.

1. The paralogue specific PCR products were amplified according to section 2.9. The bands corresponding to the required PCR products were excised from the gel and transferred into $1 \mathrm{ml} \mathrm{T}_{0.1} \mathrm{E}$ and placed at $4^{\circ} \mathrm{C}$ for 18 hours, then stored
at $-20^{\circ} \mathrm{C}$.
2. To $15 \mu$ l of paralogue specific $P C R$ product in $T_{0.1} \mathrm{E}, 6 \mu 110 \mathrm{x}$ PCR buffer, $3 \mu \mathrm{l}$ $10 \mathrm{mM} \mathrm{dNTPs}, 1.5 \mu \mathrm{l}$ universal primer, $1.5 \mu \mathrm{l}$ paralogue specific reverse primer, $0.375 \mu \mathrm{l}$ Taq polymerase and $32.625 \mu \mathrm{ddH}_{2} 0$ was added.
3. The thermocycler program was as follows (i) $95^{\circ} \mathrm{C}$ for 5 minutes, (ii) $95^{\circ} \mathrm{C}$ for 1 minute (iii) [Annealing temperature] ${ }^{\circ} \mathrm{C}$ for 1 minute 30 seconds (iv) $72^{\circ} \mathrm{C}$ for 1 minute 30 seconds (v) repeat (ii)-(iv) 35 times (vi) $72^{\circ} \mathrm{C}$ for 5 minutes.
4. $2 \mu \mathrm{l}$ PCR was analysed by electrophoresis on a $2.5 \%$ agarose $/ 1 \times \mathrm{TBE}$ gel.
5. $15 \mu \mathrm{l}$ spotting buffer was added to each PCR product and this was arrayed onto the Microarrays.

### 2.13.3 Generation of fluorescently labelled DNA

### 2.13.3.1 Generation of fluorescently labelled paralogue-specific PCR products using the Cyanine 3-dCTP dye for hybridisation onto the 'Paralogue Microarray'

In order to ensure the specific PCR products do not cross-hybridise to the other paralogues the paralogue-specific PCR products generated in section 2.9 were labelled with a fluorescent dye and hybridised to the Paralogue Microarray.

1. To $5 \mu \mathrm{l} \mathrm{T}_{0.1}$ E DNA stocks of the paralogue specific PCR products $2 \mu \mathrm{l} 10 \mathrm{x}$ PCR buffer, $1 \mu \mathrm{l} 10 \mathrm{mM} \mathrm{dA}, \mathrm{T}, \mathrm{GTP} / 5 \mathrm{mM}$ dCTP mix, $0.5 \mu \mathrm{l}$ primer $1,0.5 \mu \mathrm{l}$ primer $2,0.125 \mu \mathrm{l}$ Taq polymerase, $2 \mu \mathrm{ldCTP}-\mathrm{Cy} 3$ and $8.875 \mu \mathrm{ddH} \mathrm{H}_{2} 0$.
2. The thermocycler program was as follows (i) $95^{\circ} \mathrm{C}$ for 5 minutes, (ii) $95^{\circ} \mathrm{C}$ for

1 minute (iii) [Annealing temperature] ${ }^{\circ} \mathrm{C}$ for 1 minute 30 seconds (iv) $72^{\circ} \mathrm{C}$ for 1 minute 30 seconds (v) repeat (ii)-(iv) 35 times (vi) $72^{\circ} \mathrm{C}$ for 5 minutes.
3. Excess nucleotides were removed from the PCR reaction using QIAquick Nucleotide Removal Kit (Qiagen) according to the manufacturers' instructions and eluted with $40 \mu \mathrm{ldH} \mathrm{H}_{2} 0$.
4. $5 \mu \mathrm{l}$ of product with $5 \mu \mathrm{l}$ loading buffer were analysed on a $1 \%$ agarose 0.5 x TBE gel.
5. Depending on how successful the labelling reactions was, between $3-10 \mu 1$ of fluorescently labelled paralogue specific PCR product was denatured at $100^{\circ} \mathrm{C}$ for 5 minutes then snap chilled on ice and mixed with $38 \mu l$ hybridisation buffer.

### 2.13.3.2 Generation of fluorescently labelled single-stranded cDNA target using direct incorporation of Cyanine dyes for hybridisation onto the '10K/Paralogue Microarray'

The Bacterial mRNA "cocktail" was provided by Sanger Institute Microarray Facility.

1. $1 \mu \mathrm{l}$ of bacterial "cocktail" ( 1 x stock in $75 \%$ ethanol) was added to $40 \mu \mathrm{~g}$ of total RNA (in $75 \%$ ethanol) and precipitated by adding $1 / 40^{\text {th }}$ volume of 3 M sodium acetate at $-70^{\circ} \mathrm{C}$ for 30 minutes.
2. The RNA pellet was collected by centrifugation at $13,000 \mathrm{rpm}$ and washed briefly in $100 \mu 170 \%$ ethanol and air-dried for 30 minutes.
3. The RNA pellet was resuspended in $12.9 \mu \mathrm{l}$ DEPC and $2.5 \mu \mathrm{l}$ anchored oligo$\mathrm{dT}\left(2 \mu \mathrm{~g} / \mu \mathrm{l}\right.$ final concentration; mixture of $\mathrm{T}_{17} \mathrm{~A}, \mathrm{~T}_{17} \mathrm{G}$ and $\mathrm{T}_{17} \mathrm{C}$ primers $)$.
4. The RNA/oligo mixture was heated to $70^{\circ} \mathrm{C}$ for 10 minutes and then snap
chilled on ice.
5. To $15.4 \mu \mathrm{l}$ RNA/oligo mixture, $6 \mu \mathrm{l} 5 \mathrm{x}$ first strand buffer (Invitrogen), $3 \mu \mathrm{l}$ 0.1 M DTT (Invitrogen), $0.6 \mu 10 \mathrm{mM} \mathrm{dA}, \mathrm{T}, \mathrm{GTP} / 5 \mathrm{mM}$ dCTP mix dNTPs, $3 \mu \mathrm{l}$ dCTP-Cy 3 or dCTP-Cy5 and $2 \mu \mathrm{l}$ Superscript II (Invitrogen) was added.
6. The reaction was incubated at $42^{\circ} \mathrm{C}$ for 2 hours.
7. $1.5 \mu 11 \mathrm{M} \mathrm{NaOH}$ was added to the reaction and incubated at $70^{\circ} \mathrm{C}$ for 20 minutes to hydrolyse the RNA.
8. $1.5 \mu \mathrm{l} 1 \mathrm{M} \mathrm{HCl}$ was added to neutralise the reaction.
9. The nucleotides and short oligomers were removed using the Autoseq G-50 columns (Amersham Biosciences) according to the manufacturers' instructions resulting in $\sim 33 \mu$ l of labelled cDNA sample.
10. $33 \mu 1$ of test cDNA sample was combined with $33 \mu 1$ of control cDNA and $4 \mu 1$ polyA DNA (Sigma), $8 \mu \mathrm{l} \mathrm{C}_{\mathrm{o}} \mathrm{t} 1 \mathrm{DNA}$ (Gibco BRL) and precipitated with $7.8 \mu \mathrm{l}$ 3 M sodium acetate pH 5.2 and $260 \mu \mathrm{l} 100 \%$ ethanol at $-70^{\circ} \mathrm{C}$ for 25 minutes.
11. The pellet was collected by centrifugation at $13,000 \mathrm{rpm}$ and washed briefly in $70 \%$ ethanol. All traces of ethanol were carefully removed and the pellet airdried.
12. The pellet was resuspended in $40 \mu \mathrm{l}$ microarray hybridisation buffer and $8 \mu \mathrm{l}$ $\mathrm{ddH}_{2} \mathrm{O}$.

### 2.13.4 Hybridisation, washing and scanning of microarrays

1. $46 \mu \mathrm{l}$ of hybridisation mixture was spotted onto the microarray cover slip ( 25 x 60 mm ) and the microarray was inverted and lowered onto it.
2. The microarray was placed in a humid chamber ( $2 \mathrm{~cm} \times 7 \mathrm{~cm} 3 \mathrm{MM}$ paper
moistened with $2 \mathrm{ml} 40 \%$ formamide, $2 \times \mathrm{xSC}$ in a Petri dish) and incubated for $12-24$ hours at $47^{\circ} \mathrm{C}$.
3. The cover slip was carefully removed from the microarray by rinsing in microarray wash solution 1 for $10-15$ seconds.
4. The microarray was first washed in microarray wash solution 1 for 5 minutes at room temperature with gentle shaking. Followed by 2 washes in microarray wash solution 2 for 30 minutes at room temperature with vigorous shaking and, finally, in microarray wash solution 3 for 5 minutes with vigorous shaking at room temperature.
5. The microarray was dried by centrifugation at 1000 rpm for $1-2$ minutes.
6. Using a laser-based scanner (GSI Lumonics ScanArray® 5000) the microarray was scanned at the two wavelengths compatible with efficient excitation for Cy 3 and Cy 5 ( 550 nm and 650 nm respectively) at $10 \mu \mathrm{~m}$ scanning resolution.

### 2.13.5 Analysis of microarrays

GSI Lumonics Quantarray® microarray analysis application software was used to determine the fluorescence intensity of spots in microarray images produced by ScanArray®. A three stage protocol was observed: (i) spot finding, (ii) spot quantitation; (iii) data export and visualisation. Once the spots have been identified and quantitated the standard deviation between the spot intensity and background intensity was calculated. In most cases, if a spot was present the standard deviation was greater than 2 . To verify these results each spot was also assessed by-eye for each experiment using Quantarray®. The microarray data was clustered using the program EPCLUST at EMBL-EBI as described in section 2.18.

### 2.14 Overview of blot expression analysis



### 2.14.1 Radioactive labelling of DNA

### 2.14.1.1 Radioactive labelling of paralogue-specific PCR products

1. In a $0.5 \mu 1$ microcentrifuge tube, $2 \mu 110 \mathrm{x}$ PCR buffer, $1 \mu 110 \mathrm{mM}$ dNTPs mix, $0.5 \mu 1$ primer $1,0.5 \mu 1$ primer $2,0.125 \mu \mathrm{l}$ Taq polymerase, $4 \mu 1\left[\alpha-{ }^{32} \mathrm{P}\right]$-dCTP and $6.875 \mu \mathrm{lddH} 20$ was added to $5 \mu \mathrm{l}$ of the $\mathrm{T}_{0.1} \mathrm{E}$ DNA stocks of the paralogue specific PCR products generated as described in section 2.9.
2. The reaction was overlaid with mineral oil to prevent evaporation and subjected to PCR in a DNA thermal cycler (Perkin Elmer, USA). PCR cycling conditions were as follows (i) $95^{\circ} \mathrm{C}$ for 5 minutes, (ii) $95^{\circ} \mathrm{C}$ for 1 minute (iii) [Annealing temperature] ${ }^{\circ} \mathrm{C}$ for 1 minute 30 seconds (iv) $72^{\circ} \mathrm{C}$ for 1 minute 30 seconds (v) repeat (ii)-(iv) 35 times (vi) $72^{\circ} \mathrm{C}$ for 5 minutes.
3. Excess nucleotides were removed using QIAquick Nucleotide Removal Kit (QIAGEN) according to manufacturers' instructions and the labelled PCR product was eluted in $50 \mu 1 \mathrm{ddH}_{2} 0$.

### 2.14.1.2 Radioactive labelling of DNA using MegaPrime ${ }^{\text {TM }}$ DNA labelling system (Amersham)

1. To 25 ng DNA template, $5 \mu \mathrm{l}$ of primers was added and the final volume made up to $50 \mu \mathrm{l}$ with $\mathrm{ddH}_{2} 0$.
2. The reaction mix was denatured at $95^{\circ} \mathrm{C}$ for 5 minutes.
3. The reaction was collected by centrifugation at $13,000 \mathrm{rpm}$.
4. $10 \mu 1$ labelling buffer, $5 \mu 1\left[\alpha-{ }^{32} \mathrm{P}\right]$-dCTP and $2 \mu 1$ enzyme was added to the reaction mix. Mixed then centrifuged.
5. The reaction was incubated at $37^{\circ} \mathrm{C}$ for 1 hour and the reaction stopped by the addition of $5 \mu \mathrm{l} 0.2 \mathrm{M}$ EDTA.

### 2.14.2 Probe verification

### 2.14.2.1 Assessment of radiolabel incorporation using thin-layer chromatography

1. $1 \mu \mathrm{l}$ of PCR product was spotted onto a $5 \times 10 \mathrm{~cm}$ Polygram CEL $300 \mathrm{PEI} / \mathrm{UV}$ thin-layer chromatography sheet (Macherey-Nagel, GmbH \& Co) approximately 1.5 cm from the bottom edge.
2. This was placed in a beaker containing $0.75 \mathrm{M} \mathrm{KH}_{2} \mathrm{PO}_{4}(\mathrm{pH} 3.5) 1 \mathrm{~cm}$ in depth and left for 30 minutes.
3. The chromatogram was subjected to autoradiography for 30 minutes.
4. Incorporated isotope remains at the spotting position, whereas unincorporated migrates with the buffer front.

### 2.14.2.2 Measurement of radioactively labelled PCR product concentration

The optimal concentration of radioactively labelled PCR product (or probe) is 1-2 x $10^{7} \mathrm{cpm} / \mathrm{ml}$. This was calculated using either a mini Geiger counter or a Scintillation counter (Easicount 4000, Scotlab, UK).

### 2.14.3 Manufacture of Southern Blots

### 2.14.3.1 Restriction digest of human genomic DNA

1. To $10 \mu \mathrm{~g}$ human genomic DNA, 1 mM Spermidine, 1 mM DTT, $1.5 \mu \mathrm{l}$ restriction enzyme (either PstI, EcoRI and HindIII), $5 \mu \mathrm{l}$ appropriate NEBuffer were added and the total reaction volume made up to $50 \mu 1$ with $\mathrm{T}_{0.1} \mathrm{E}$.
2. The reaction was incubated at $37^{\circ} \mathrm{C}$ for several hours (time optimised for each enzyme). After 1 hour another $1 \mu 1$ enzyme was added.
3. $3 \mu \mathrm{l}$ of digest was analysed on a $0.8 \%$ agarose $0.1 \times$ TAE gel with a 100 bp ladder. If digestion was not occurring after 24 hours more enzyme was added and the reaction incubated at $37^{\circ} \mathrm{C}$ until genomic DNA was completely digested and a further $3 \mu 1$ analysed by electrophoresis.
4. Once the genomic DNA had completely digested all 3 digests were loaded on a $0.8 \%$ agarose, $1 \times$ TAE gel ( 2.4 g agarose, $300 \mathrm{ml} 1 \times$ TAE, $10 \mu \mathrm{l}$ Ethidium Bromide) with a lambda Hind III ladder (100ng) and run at 50 v for $\sim 16$ hours.

### 2.14.3.2 Transfer of digested genomic DNA onto filter

1. Excess gel was cut away and the gel was denatured in 1 x denaturation solution for 30 minutes with gentle shaking.
2. The gel was rinsed twice in $\mathrm{ddH}_{2} 0$ then washed twice in 1 x neutralisation solution for 30 minutes each with gentle shaking.
3. Gels were blotted for 24 hours in $10 \times$ SSC onto hybridisation transfer membrane (Hybond ${ }^{\mathrm{TM}}-\mathrm{N}$; Amersham) with frequent changing of towels.
4. The membranes were rinsed in $2 \times \mathrm{SSC}$, dries on Whatman paper and the

DNA cross-linked on a UV transilluminator ( 320 nm ) for 2.5 minutes.

### 2.14.4 Hybridisation of radiolabelled PCR product to blots

1. The blots were prehybridised in ExpressHyb ${ }^{\mathrm{TM}}$ Hybridisation Solution (Clontech) containing 1.5 mg sheared salmon testes DNA (Stratagene) at $65^{\circ} \mathrm{C}$ for 1-4 hours.
2. In the case of the Human Multiple Tissue Northern (MTN®) blots (Clontech) and the Southern blots, the radiolabelled DNA were denatured at $95-100^{\circ} \mathrm{C}$ for 10 minutes then snap chilled on ice for 10 minutes before being added to appropriate volume fresh ExpressHyb ${ }^{\mathrm{TM}}$ solution.
3. In the case of the Human Multiple Tissue Expression (MTE ${ }^{\mathrm{TM}}$ ) Arrays (Clontech) $30 \mu \mathrm{~g}$ of $\mathrm{C}_{\mathrm{o}} \mathrm{t}-1$ DNA, $150 \mu \mathrm{~g}$ of sheared salmon testes DNA (Stratagene) and $50 \mu \mathrm{~L} 20 \mathrm{x}$ SSC were added. The reaction volume was made up to $200 \mu \mathrm{l}$ with $\mathrm{ddH}_{2} 0$ then heated to $95-100^{\circ} \mathrm{C}$ for 5 minutes then incubated at $68^{\circ} \mathrm{C}$ for 30 minutes.
4. The pre-hybridising solution was discarded and replaced with fresh ExpressHyb ${ }^{\mathrm{TM}}$ solution containing 1.5 mg sheared salmon testes DNA and the denatured radiolabelled PCR product. All the blots were hybridised at $65^{\circ} \mathrm{C}$ for 16-18 hours.

### 2.14.5 Washing

1. The hybridisation solution was discarded and replaced with the appropriate wash solution I. The blots were rinsed 5 times with wash solution I before being washed in fresh wash solution I for 30-40 minutes (the wash solution
was replaced several times) at room temperature for MTN and Southern blots and $65^{\circ} \mathrm{C}$ for MTE Arrays.
2. Wash solution I was discarded and the MTN and Southern blots washed at room temperature in wash solution II and MTE array washed at $65^{\circ} \mathrm{C}$ until the background signal was significantly reduced and activity detected with a Geiger counter more specific ( $\sim 5 \mathrm{cpm}$ ).
3. Excess liquid was removed and from the filters by laying them briefly onto Whatman 3MM paper. The filters were then subjected to autoradiography using pre-flashed film and intensifier screens at $-70^{\circ} \mathrm{C}$ for 24 hours, 3 days in all cases, and longer if necessary.

### 2.15 Computational analysis

A multitude of bioinformatics programs were used in this thesis in order to identify and characterise genes; both in the annotation of genomic clones and the identification and characterisation of MHC paralogues. The individual tools are discussed in section 2.15.1 and the methods in which they were used for a particular analysis are discussed in later sections.

### 2.15.1 General programs used in this thesis

'BLAST' is an acronym for the basic alignment search tool (Altschul et al, 1990). The program has become widely used in DNA and protein database searches. It is based on measuring local similarity between sequences, calculated by the maximal segment pair (MSP) score. There are several types of BLAST searches available for both nucleotide and protein sequences. In general, 'tblastn' was used to search the protein sequence against the selected nucleotide database translated in all six reading frames. In addition, PSI-BLAST (Position Specific Iterated BLAST) was used in the identification of paralogues. This uses an iterative search in which sequences found in one round of searching are used to build a score model for the next round of searching thus identifying paralogues sharing weak sequence homology. The databases searched using BLAST were either stored at EMBL-EBI or the NCBI.
'NIX' is a tool at the HGMP used to view the results of running many DNA analysis programs on a DNA sequence. In the initial step the sequence is masked for repeats using 'RepeatMasker' (Smit and Green, unpublished). This program screens against a library of interspersed repeats and low complexity DNA sequence called 'Repbase'
(Jurka, 2000). BLAST searches are started using the masked sequence against a number of databases, including Swissprot, TrEMBL, EMBL, EST, HTG, Unigene, Ecoli and Vector. The DNA sequence is also run through a number of gene finding programs, including 'Grail', 'Genefinder', 'Hexon' and 'Fgene'. The results from so many different programs are presented in a graphical interface and the features in the DNA sequence identified. By viewing all the results side-by-side it makes it easier to see when many programs have a consensus about a feature.
'Electronic PCR' (e-PCR) is a tool used to identify molecular markers, such as STSs, in a query sequence. In order to determine the true locations of known genes on chromosome 9, e-PCR was performed using the cDNA sequences of the genes as the query sequences. The STSs matching the cDNA sequence of the gene were identified and used to determine which genomic clone the genes were located within the chromosome 9 database, '9ace'.

The 'ENSEMBL' genome browser was used extensively throughout this project. The 'ENSEMBL' genome browser is a joint project between EMBL-EBI and the Sanger Institute and provides a bioinformatics framework to organise biology around the sequences of large genomes (Hubbard et al, 2002). ENSEMBL provides a fully annotated human genome incorporating the data from existing biological databases and as $a b$ initio gene predictions. Other genome browsers were also used to view the genomic sequence and annotation; the UCSC genome browser based at UC Santa Cruz (Kent and Haussler, 2001; Kent et al, unpublished) and the NCBI Map Viewer. All three genome browsers are now built using the same reference sequence constructed directly from the physical maps representing the minimum clone tiling path being finished by the genome centres. All analyses for this thesis were performed
using NCBI31 genome data freeze (November 2002).

EMBOSS (Rice et al, 2000) is the 'European Molecular Biology Open Software Suite' which provides a comprehensive suite of sequence analysis programs ( $\sim 100$ ). Programs such as 'water' and 'needle' were used to generate local and global sequence alignments, respectively. Several other programs were used to manipulate both DNA and protein sequences.

### 2.16 Identification of extended MHC paralogous genes in the human genome

Chapter 4 summarises the results of a search to identify the extended MHC genes in the human genome. Several methods and programs have been developed to facilitate the identification of the paralogues but only the final method used to generate the results presented in chapter 4 is described here. The paralogues were identified with increasing levels of confidence using a number of criteria; the method used is described in sections 2.16.1 and 2.16.2.

### 2.16.1 Identification of extended MHC paralogues based on protein sequence homology

The extended MHC protein sequences were BLAST searched against the ENSEMBL human genome build NCBI31 using the 'tblastn' executable. The BLAST program used in this analysis was Washington University BLAST version 2.0 (WUBLAST2.0) which is capable of detecting relationships between proteins with low
sequence identities (Brenner et al, 1998). The BLAST search parameters have been optimised to identify the paralogues based on sequence homology and to eliminate false-positives and reduce background noise as much as possible without losing the sensitivity of the analysis. The 2 critical parameters optimised were; (i) the substitution matrix and (ii) the Expected (E) value.
i. The substitution matrix is a key element in evaluating the quality of an alignment and assigns a score for aligning any possible pair of residues. The BLOSUM62 (Henikoff and Henikoff, 1992) matrix was used in this analysis as it is one of the best for detecting weak sequence similarities of query length greater than 85 amino acids/nucleotides.
ii. The Expect value (E) is a parameter that describes the number of hits one can "expect" to see just by chance when searching a database of a particular size (Karlin and Altschul, 1990). Essentially, the E value describes the random background noise that exists for matches between sequences and the E value is used as a convenient way to create a significance threshold for reporting results. The E-value used in this analysis was 10 . Using a set of protein sequences I found that by increasing the E value from 10 a larger list with more low-scoring hits was reported and no new paralogues were identified. By decreasing the E-value the number of hits was reduced and the low-scoring hits were practically eliminated but known paralogues were also not identified.

The resulting BLAST hits were then filtered according to the P -value and results with a $P$-value $\geq \mathrm{E}^{-5}$ removed from the analysis. The P value is the probability of finding such a hit by chance. In short, small P values are considered to be good and very unlikely to be random, therefore meaningful, but P values become unreliable above
$10^{-5}$ (Lesk, 2002). This filtering value was selected in order to maintain both sensitivity and specificity of the experiment.

### 2.16.2 Identification of extended MHC paralogues with increasing levels of confidence

The initial BLAST search identified 1000's of BLAST hits. Using knowledge of the protein sequence and the gene structure these BLAST hits were filtered to identify the extended MHC paralogues with the highest level of confidence.

### 2.16.2.1 Filter 1: Domain-masking

The protein domains were identified by searching the protein sequence against the 'PFAM' database of protein domain families using the perl script 'pfam_scan.pl' (written by the PFAM Software Group and kindly provided by K.Howe). The domains were masked using another perl script 'x_out_domains.pl' (written by K.Howe). The domain-masked protein sequences were then BLAST searched against the human genome as described in section 2.16.1 and the results sorted according to the P value. By masking the protein domains a large number of BLAST hits were identified that were just to a particular protein domain. More significantly, it also identified the extended MHC paralogues which still share good sequence homology outside the domains.

### 2.16.2.2 Filter 2: FINEX

Putative paralogues were initially identified by sequence homology using similarity searching to find relationships. However, genomic sequence data provides gene architecture information not used by conventional search methods. In particular, intron positions and phases are expected to be relatively conserved features, because mis-splicing and reading frame shifts should be selected against. 'FINEX' (Fingerprinting of INtron EXon boundaries) is an alignment technique which exploits the gene structure information provided by a genomic sequence (Brown et al, 1995). A single exon fingerprint can be compared rapidly against all the entries in a library of fingerprints which is generated using the CDS (coding sequence information) features in the annotated EMBL entry (EMBL release 73). The phases of the exon fingerprints are classified according to their position relative to the reading frame of the gene: introns lying between two codons (phase 0 ); introns interrupting a codon between the first and second base (phase 1); and, introns interrupting a codon between the second and third base (phase 2). These intron positions and phases are expected to be relatively conserved features, because mis-splicing and reading frame shifts should be selected against.

The FINEX database relies on coding sequence (CDS feature) information available in annotated EMBL entries for genomic clones. Only a small percentage of genomic clones are annotated therefore the FINEX database does not contain the fingerprint for every gene in the genome. As the MHC region is one of the best characterised regions and the majority of clones covering the region are annotated all the MHC gene fingerprints are present in the FINEX database compiled using EMBL release version 73. Therefore, the FINEX fingerprint was generated for all putative paralogues and
used to search the FINEX fingerprint database using the optimised parameters: weight $=0.5$, power $=4.0$ and gap penalty $=0.5$.

A number of scores were generated for each alignment to add statistical significance. The important scores to consider when determining a cut-off threshold are the $\mathrm{D}_{\text {avg }}$ score, which is the alignment length normalised score used to rank the alignments, the $\mathrm{D}_{\text {mat }}$ score, which is the global alignment score that measures the quality of the alignment and the z-score, which is the significance of the $\mathrm{D}_{\text {mat }}$ score for a given query/hit. The best alignment attainable is with self and, by definition, the dissimilarity scores $\mathrm{D}_{\mathrm{mat}}$ and $\mathrm{D}_{\text {avg }}$ are zero and has the highest z-score (Brown et al, 1995). With this in mind the putative paralogues were used to search the FINEX fingerprint database and it was generally observed that the highest $z$-score obtained corresponded to the MHC gene it is paralogous to, or to another paralogue. Analysis of the paralogues identified ambiguous matches with a z-score less than 3.00 therefore a $z$-score greater than 3.00 was taken as significant. This is in agreement with significant z-score values for conventional sequence comparison (Dayhoff et al, 1978; Feng et al, 1984).

### 2.17 In-silico expression analysis

The 'UNIGENE' database at the NCBI automatically clusters the 'GenBank' sequences into a non-redundant set of gene-oriented clusters. Each UniGene cluster contains sequences that represent a unique gene, as well as related information including the tissue types in which the gene has been expressed. This information, in the form of expressed sequence tags (EST) was downloaded into a text file <gene_name>_unigene.txt for each gene. In addition to ensure no ESTs had been
omitted the gene mRNA or cDNA was used to BLAST search the database 'dbEST'; a division of GenBank that contains sequence data and other information on 'singlepass' cDNA sequences.

The 'BLAST' results were then filtered to remove insignificant hits (generally $<90 \%$ sequence identity) and the results saved in a text file <gene_name>_dbest.txt. The 2 text files were then parsed to produce a list of EST accession numbers using 'parse.pl' and the 2 lists were compared to identify 'unique' and 'not-unique' ESTs for a particular gene using the perl script 'check_unique.pl'. The 'not-unique' ESTs were removed from the list and the non-redundant EST lists for each paralogue were compared against each other and 'not-unique' ESTs removed resulting in a paralogue specific list of ESTs.

The DNA sequence for each paralogue specific EST was extracted using 'sequence_retrieval.pl' and aligned against the gene cDNA using the program 'b2b' (written by R.Horton) and any false positive ESTs removed from the analysis. A database containing the full database entry for each paralogue specific EST list was produced using 'db_extract.pl' and the tissue information extracted using 'tissue.pl'. As the annotation within EST database entries is not consistent several versions of 'tissue.pl' exist to extract the tissue information. Finally, the EST data was inputted into Excel and sorted by tissue and system. All perl scripts used in this section were written by K.Crum and modified by myself, unless stated otherwise.

### 2.18 Clustering methods

The data presented in this thesis was clustered using the unsupervised clustering methods, hierarchical clustering (clustering methods are reviewed by Brazma and Vilo, 2001) using using EPCLUST (Expression Profile Data CLUSTering and Analysis) at the EBI. Hierarchical clustering arranges the data in a tree-like structure (similar to phylogenetic trees), where genes with similar expression patterns occupy neighbouring 'leaves' of the tree. The algorithms used for hierarchical clustering are largely the same as used for distance-based phylogenetic reconstruction from sequence data, but restricted to those methods that are fast enough to deal with large numbers of nodes. Hierarchical clustering works by iteratively partitioning clusters starting with the complete set. After the joining of two clusters, the distances between all other clusters and a new joined cluster are recalculated. The complete linkage method used in this analysis uses the maximum distances between the members of two clusters to cluster the data.

Expression data was also clustered using the perl script 'exprofile' (written by R.Younger), or modifications of this script. The input file consists of a tab delimited table containing the expression data. The cells contain values 0 and 100 which correspond to whether the gene is expressed in the corresponding tissue or not, respectively. Alternatively, the cells may contain a value between 0 and 100 , which is the percentage of genes expressed in a particular tissue. The output of the program is a postscript file containing the image corresponding to the input data, i.e. where a gene is expressed there is a black bar and when there is no expression it is white. The thickness of the black bar corresponds to the percentage of genes expressed in a particular tissue. This is described in more detail in chapter 6.

### 2.19 Phylogenetic analysis

The consensus phylogenetic trees presented in Chapter 5 were produced by merging the trees generated by 3 different software packages; PHYLIP, TREE-PUZZLE and MEGA2. The PHYLIP (Phylogeny Interface Program version 3.6; Felsenstein, 1989) package is a public domain package that provides a wide range of programs for constructing phylogenetic trees from molecular and other types of data. TREEPUZZLE version 5.0 (Schmidt et al, 2002) is a computer program to reconstruct phylogenetic trees from molecular sequence data by maximum likelihood using the quartet-puzzling algorithm and MEGA2 (Molecular Evolutionary Genetics Analysis) software (Kumar et al, 1994; Kumar et al, 2001) is a software package for exploring and analysing aligned DNA or protein sequences from an evolutionary prospective and offers useful and easy-to-use methods of comparative sequence analysis.

### 2.19.1 Protein sequence alignments

Protein sequences were aligned using the 'ClustalW' program (Thompson et al, 1994). This is a progressive multiple sequence alignment method which, firstly, assigns individual weights to each sequence in a partial alignment in order to downweight near-duplicate sequences and up-weight the most divergent ones. Secondly, it varies amino acid substitution matrices at different alignment stages according to the divergence of the sequences to be aligned. Thirdly, residue-specific gap penalties and locally reduced gap penalties in hydrophilic regions encourage new gaps in potential loop regions rather than regular secondary structure. After a gap has been opened, locally reduced gap penalties are applied to positions around this gap. The alignments
produces by 'ClustalW' were viewed in 'belvu' (Sonnhammer, unpublished) and edited using 'Jalview' (Clamp, unpublished).

### 2.19.2 Estimation of the gamma distribution

Evolutionary analysis of DNA and protein sequences is typically performed by either assuming that all evolutionary lineages evolve at the same rate or by avoiding any attempt to directly consider the fact that the rate of evolution changes over time. The default parameters for the 3 programs used assume that the rate of evolution is constant. However, there are several factors that affect the rate of molecular evolution (e.g., mutation, population size, selection) and therefore the rate of molecular evolution is extremely unlikely to be identical for different evolutionary lineages or individual amino acids or nucleotides. This was taken into account in this analysis and the rate of variation (or rate of heterogeneity) between sites was calculated using the gamma distribution. The shape of this distribution is determined by the value of a parameter known as the gamma distribution parameter alpha and was calculated using TREE-PUZZLE.

### 2.19.3 Bootstrapping and tree-puzzling steps

The aligned sequences were bootstrapped using the program SEQBOOT in PHYLIP and by selecting the bootstrapping option in MEGA2. Bootstrapping (Felsenstein, 1985) involves taking each site within a protein and rearranging sites to create a number of 'pseudoalignments'. These 'pseudoalignments' are then used to recreate a number of trees which are compared to the original tree. Groupings obtained in the
original tree are then given a percentage expressing how many times they are recreated in the 'pseudoalignment' trees.

The 'puzzling-step' parameter was selected in TREE-PUZZLE which is similar to bootstrapping and trees are composed into so-called intermediate trees. This step results in many intermediate trees (default 1000) and from these a majority rule consensus tree is built and the number of intermediate trees lending support for the consensus topology is displayed at each node. Bootstrap or puzzling-step values of over $50 \%$ were considered to represent reliable groupings those below were considered to show little or no support. However, low values at branches are not considered worthless as every phylogenetic tree is the best tree obtainable using a specific method and sequences. Computer simulations have shown that the branching patterns of an inferred tree may be correct even if they are not supported by high bootstrap values (Nei and Kumar, 2000).

### 2.19.4 Phylogenetic analysis using distance methods

Trees were generated using the Neighbour-Joining method (Saitou and Nei, 1987). This method uses an algorithm to convert pairwise distances between sequences into a matrix, from which branching order and branch lengths are computed. The Jones, Taylor and Thornton, or JTT, (Jones et al, 1992) model of amino acid change was used. This model is very similar to another model, the PAM Dayhoff (Dayhoff et al, 1978) model, which provides a measure of probability calculating how likely the amino acid in one sequence is likely to change the amino acid in the other sequence. These probabilities were based on a subset of closely related proteins that were organised into a phylogenetic tree and the frequency of change from each amino acid
to another was determined by adding up the changes at each evolutionary step. The JTT model is based on a recounting of the number of observed changes in amino acids of a much larger set of proteins therefore this model is to be preferred over the original Dayhoff PAM model. Using this model the Neighbour-Joining method constructed trees from the matrices of the multiple data sets from bootstrapping by the successive clustering of lineages and the setting of branch lengths as the lineages join.

### 2.19.4.1 PHYLIP

The output of the SEQBOOT program in PHYLIP was used as the input into the distance program PROTDIST. The program corrects distances for unequal rates of change at different amino acid positions using the coefficient of variation (CV) which was calculated using the gamma distribution alpha parameter from TREE-PUZZLE. The square of the CV is the value of the alpha parameter. The PROTDIST output was used as an input file to the program NEIGHBOR. The consensus tree is produced by using the output of the NEIGHBOR program as the input of the CONSENSE program.

### 2.19.4.2 MEGA2

MEGA2 is an easy to use software package and phylogenetic trees are generated quickly and in one simple step. First, the protein alignments were converted into MEGA2 format (.meg file) within the software package then the trees were generated using the neighbour-joining method (Saitou and Nei, 1987) under the JTT (Jones et al, 1992) model with 1000 bootstraps. Two additional parameters were selected; the
pairwise deletion comparison option and the Gamma distance option. The former removes sites containing missing data or alignment gaps from the analysis as they arise. This is in contrast to the complete-deletion option which removes all such sites prior to analysis. Both options were initially used but no significant difference was observed. The Gamma distance was used to take care of the inequality of the substitution rates among sites and the gamma shape parameter, or alpha parameter, calculated using TREE-PUZZLE was used in this analysis.

### 2.19.5 Phylogenetic analysis using the maximum likelihood method

The maximum likelihood (ML) method allows the inference of evolutionary trees from nucleotide or amino acid sequences under a probabilistic model of nucleotide/amino acid evolution (Felsenstein, 1981). The ML method looks for all possible tree topologies between the sequences by initially constructing an unrooted tree using three sequences then the $4^{\text {th }}$ is added to the tree and the 'best' tree topology for the four sequences chosen under likelihood criterion. This is repeated for the $5^{\text {th }}$, $6^{\text {th }}, 7^{\text {th }}$ etc sequences until the final tree is produced. The log likelihood value is calculated and the best tree is the one with the most positive log likelihood value.

### 2.19.5.1 PHYLIP

The PHYLIP program PROML implements the maximum likelihood method for protein amino acid sequences using the JTT model of changes between amino acids. The model assumes that each position and each lineage have evolved independently and the different rates of evolution were determined using the Gamma distribution. As
previously the gamma distribution alpha parameter was calculated using TREEPUZZLE and the Coefficient of Variation used as input into PROML. PROML is CPU intensive and, for this reason, data analysed was not bootstrapped.

### 2.19.5.2 TREE-PUZZLE

TREE-PUZZLE (TREE-PUZZLE version 5.0) constructs phylogenetic trees using maximum likelihood by implementing the fast tree search algorithm, quartet-puzzling. The protein alignment was used as input into the program and the 1000 'puzzlingstep' option selected. Trees were generated using the JTT model and the rate of heterogeneity was set as Gamma distance. The 'outfile' generated contained information regarding the calculation of the gamma distribution alpha parameter and the consensus tree.

### 2.20 Useful web-sites

BLAST http://www.ncbi.nlm.nih.gov/BLAST/
Chromosome 6 http://www.sanger.ac.uk/HGP/Chr6/

Chromosome 9 http://www.sanger.ac.uk/HGP/Chr9/
ClustalW http://www.ebi.ac.uk/clustalw/index.html
Electronic PCR http://www.ncbi.nlm.nih.gov/genome/sts/epcr.cgi
EMBL-EBI http://www.ebi.ac.uk
EMBOSS http://www.hgmp.mrc.ac.uk/Software/EMBOSS/overview.html
ENSEMBL http://www.ensembl.org/Homo_sapiens
EPCLUST http://www.ebi.ac.uk/microarray/ExpressionProfiler/ep.html

| FINEX | http://www.sanger.ac.uk/cgi-bin/finex/finex_search.pl |
| :---: | :---: |
| GeneMap99 | http://www.ncbi.nlm.nih.gov/genemap99/ |
| HGMP | http://www.hgmp.mrc.ac.uk |
| HUGO | http://www.gene.ucl.ac.uk/hugo/ |
| LocusLink | http://www.ncbi.nlm.nih.gov/LocusLink |
| MEGA2 | http://www.megasoftware.net |
| MIPS | http://mips.gsf.de |
| NCBI | http://www.ncbi.nlm.nih.gov |
| NIX | http://www.hgmp.mrc.ac.uk/Registered/Webapp/nix/ |
| PFAM | http://www.sanger.ac.uk/Software/pfamservice.shtml |
| Primer3 | http://www.genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi |
| Repbase | http://www.geospiza.com/products/tools/repbase.htm |
| RepeatMasker | $\mathrm{http}: / / \mathrm{ftp} . \mathrm{genome.washington.edu/cgi-bin/RepeatMasker}$ |
| PHYLIP | http://evolution.genetics.washington.edu/phylip.html |
| Sanger Institute | http://www.sanger.ac.uk |
| TREE-PUZZLE | http://www.tree-puzzle.de |
| UniGene | http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=unigene |

## Chapter 3

## Characterisation of 9q32-q34.3

### 3.1 Introduction

The extended Major Histocompatibility Complex (MHC), on 6p22.2-p21.3, is a gene rich region that has taught us a great deal about the evolutionary dynamics of a chromosomal segment (The MHC Sequencing Consortium, 1999; Beck and Trowsdale, 2000). It has been proposed that the three chromosomal regions 1q21-q25, 9q33-q34 and 19p13.3-p13.1 in the human genome are paralogous to the MHC region (Sugaya et al, 1994; Kasahara et al, 1996a; Katsanis et al, 1996; Sugaya et al, 1997; Kasahara, 1999a; Kasahara, 1999b; Kasahara et al, 2000; Flajnik and Kasahara, 2001).

MHC paralogy was first observed by Sugaya and co-workers in 1994 during the analysis of three MHC class III genes in the human genome. Two years later, in 1996, the proteasome Z subunit (PSMB7), a paralogue of the PSMB8 and PSMB9 genes, was mapped to mouse chromosome 2, which is syntenic to 9 q 34 in humans (Kasahara et al, 1996a). PSMB7 is involved in the generation of cytosolic peptides by MHC class I molecules and, on closer inspection of the mouse loci adjacent to the region containing this gene, ten more paralogues representing MHC gene families were identified; including ABCA2, a putative paralogue of the TAP1 and TAP2 genes that are also involved in MHC class I peptide processing. Independently, Katsanis and colleagues (1996) found that the MHC and 9q33-q34 regions are paralogous and also identified two additional regions in the human genome, 1q21-q25 and 19p13.3-p13.1,
containing clusters of genes with related copies in the MHC.

The combined list of genes from both studies indicates that there are ten MHC genes with paralogues in one, two or three of the proposed paralogous regions on chromosomes 1, 9 and 19 (table 3.1).

Table 3.1 Summary of the first MHC paralogues identified in three other regions of the genome

| Chromosome 6 | Chromosome 9 | Chromosome 1 | Chromosome 19 |
| :---: | :---: | :---: | :---: |
| BAT2 | BAT2 exon | - | - |
| COL11A2 | - | COL11A1 | - |
| HSPA1A/B/L | - | HSPA6/HSPA7 | - |
| NOTCH4 | NOTCH1 | NOTCH2 | NOTCH3 |
| PBX2 | PBX3 | PBX1 | - |
| RXRB | RXRA | RXRG | - |
| TNX | TBC | TNR | - |
| C4 | C5 | C3 | - |
| TAP1/2 | ABC2 | - | - |
| LMP2/7 | PSMB7 | - | - |

The paralogues of MHC genes and their genomic locations were initially identified using mapping data and it was important to clarify these findings using sequence data. Compared with the MHC region the proposed regions on chromosomes 1, 9 and 19 containing the MHC paralogues are much less characterised and, in order to truly understand the evolution of these proposed paralogous regions and the human genome, it is important to have finished, contiguous genomic sequence. With this in mind, and the progress of the mapping and sequencing of chromosome 9 , the initial focus of the project was on the characterisation of the proposed paralogous region on 9q32-q34.3. This chapter describes my contribution to the mapping, sequencing and characterisation of 9q32-q34.3 and compares this chromosomal region with the extended MHC region.

### 3.2 Results

### 3.2.1 Identification of genes on 9q32-q34.3

The localisation of the MHC paralogues and other genes to 9q32-q34.3 was initially determined using the physical and genetic mapping data available for chromosome 9 . The mapping and sequencing of chromosome 9 was carried out by the Chromosome 9 Mapping and Sequencing groups at the Wellcome Trust Sanger Institute in collaboration with the chromosome 9 community. The chromosome 9 project followed the clone-by-clone approach where bacterial clones were initially isolated by screening the human BAC libraries RPCI 11 and 13. The clones were mapped to this region using a landmark map consisting of approximately 15 markers per Mb , first constructed using whole genome radiation hybrid mapping (Walter et al, 1994; Hudson et al, 1995), incorporating available markers, including STSs (sequence tagged sites), ESTs (expressed sequence tags), polymorphic microsatellites and gene based markers from GeneMap99 (Deloukas et al, 1998).

At the start of this project, in October 1999, the sequencing of the human genome was still in its early stages and less than $5 \%$ of the genomic sequence was available. The region 9 q 32 to 9 q 34.3 , at the telomere of chromosome 9 , had less than $2 \%$ draft sequence coverage and was split into 13 contigs of various sizes. As the region was largely unfinished, the chromosome 9 mapping data available in the Sanger in-house ACE database '9ace' was interrogated using 103 genes, identified in LocusLink, HUGO and GeneMap99, known to map to this region. Initial searches anchored $60 \%$ of known genes, including all 10 proposed paralogues to chromosome 9q32-q34.3 clones and contigs. This was done using electronic PCR (as described in section
2.15.1) on available cDNA sequences and BLAST sequence similarity searches against the genomic databases. In addition, several genes had previously been mapped to this region and were already incorporated into the chromosome 9 database and were therefore identified by querying ' 9 ace'.

### 3.2.2 Mapping of the Olfactory Receptor gene cluster to 9q33.1-q34.12

Sequence similarity search identified the BAC clone, bA465F21 (AC006313), as containing several olfactory receptor genes (ORs). The clone was being sequenced by another sequencing centre, the Whitehead Institute, and draft sequence was publicly available. Initial mapping information mapped this clone to 9 q 34 according to sequence similarity with three STS markers (stSG69605, stSHGC-9207 and stAFMa239xe9). As an olfactory receptor gene cluster is located in the most telomeric region of the MHC, the MHC extended class I region, but no cluster had previously been identified in the paralogous regions it was important to determine the exact location of this clone. In addition, identification of an OR cluster within this region may help determine the boundaries of the paralogous region.

There are clusters of olfactory receptor genes located throughout the genome (Rouquier et al, 1998), therefore, it was important to confirm that bA465F21 mapped to 9 q 34 and determine the precise chromosomal location. Using fluorescent in situ hybridisation (FISH) of metaphase chromosomes, low resolution mapping of bA465F21 chromosome 9 was achieved. The genomic clone was fluorescently labelled and hybridised to metaphase chromosomes revealing the approximate location of this fragment of genomic sequence as shown on figure 3.1.


Figure 3.1 FISH analysis of bA465F21. Arrows indicate the location of the clone on the two copies of chromosome 9 .

Upon comparison of the clone position with standard chromosome bands the clone was anchored to $9 \mathrm{q} 33.1-\mathrm{q} 34.12$. However, the precise location within the clone-contig map could not be determined. This was achieved using Hind III restriction digest fingerprinting (as described in section 2.4). The restriction pattern of bA465F21 was created (figure 3.2A), compared against other 9q33.1-q34.12 clones, and the degree of overlap between clones calculated according to shared restriction sites (figure 3.2B). Based on the comparison of restriction patterns, clone bA465F21 was localised to contig 100 on 9q33.2 overlapping clones bA64P14 and bA163B6 (figure 3.2C).
A.

B. bA314N24|| \|| \| \||||||||| bA465F21 ||| | || || |||||||||||||||||||||

C.


Figure 3.2 Localisation of the clone bA465F21 to the chromosome 9 tiling path. The gel image and the computationally determined fingerprint generated by Hind III restriction digest (A) was compared with the fingerprints of other chromosome 9 clones (B). Overlapping bands with clones bA314N24 and bA373D18 localised the clone to contig 100 of chromosome 9 (C). The screen shot of the chromosome 9 FPC database (C) shows the marker information; those highlighted in green correspond to markers present in the clone bA465F21, which is highlighted in blue. Other clones involved in the tiling path across the contig are highlighted in red, and corresponding marker data is highlighted yellow. Useful information regarding bA465F21 is highlighted pink.

With confirmation that bA465F21 was located within 9q32-q34.3 it was placed in the minimum tiling path covering the region. The 186555 bp sequence of the clone was completely sequenced and finished at the Whitehead Institute. NIX analysis identified seven olfactory receptor genes and, upon investigation of sequences corresponding to the overlapping clones, a further nine olfactory receptor genes were identified. This gene cluster was found to be uninterrupted by any other genes thus forms a novel olfactory receptor gene cluster on 9 q32 spanning 324109 bp .

Further analysis of chromosome 9 identified a single olfactory receptor (OR) gene approximately 3.2 Mb centromeric of the $9 \mathrm{q} 32-\mathrm{q} 34.3$ paralogous region boundary (on clone bA386D8). The existence of the single OR gene and a cluster in the paralogous region resembled the arrangement of the two OR gene clusters (a major and a minor one) in the extended class I MHC region. As the extended class I region is one of the flanking regions of the MHC, this arrangement suggested that this could be the boundary of the chromosome 9 paralogous region. However, the identification of an additional cluster of approximately 10 OR genes on 9 q 31.1 , approximately 6.6 Mb centromeric of the single OR gene, revealed that the olfactory receptor genes could not be used as a reliable source when defining the boundaries.

### 3.2.3 Identification of the Allograft Inflammatory Factor 1 (AIF1) paralogue

Ab initio analysis of the sequence available in draft format for clone bA544A12 identified a putative paralogue of the allograft inflammatory factor 1 (AIF1) gene (figure 3.3).

C.

D.


Figure 3.3 Computational identification of the AIF1 paralogue. The six exons of the AIF1 paralogue on chromosome 9, as shown in (A) were determined during sequence assembly (B) and NIX analysis (C). The gene structure has since been confirmed in ENSEMBL (D).

The genomic structure of the AIF1 paralogue (figure 3.3.A) was determined and confirmed using a number of bioinformatics tools (figure 3.3). During sequence assembly the exons and CpG islands (associated with the start of a gene) were predicted within the GAP4 database (figure 3.3.B). In total, six exons were predicted (shown in purple in figure 3.3.B) by the GAP4 software with the start of the gene (characterised by 'ATG') located adjacent to a predicted CpG island (shown in green in figure 3.3B). NIX analysis (figure 3.3.C) determined the coding region, spanning from the start to the stop of the gene, and detected protein sequence identity of $64 \%$ to the human (P55008), $61.3 \%$ to mouse (O70200), and $62 \%$ to rat (P55009) AIF1 genes.

The AIF1 transcript located on 6p22.2-p21.3 has a length of 661 bp , spans 1.79 kb , and encodes for a 147 amino acid protein. In contrast, the AIF1 paralogue located on 9q32-q34.3 encodes for a 150 amino acid protein and has a transcript length of 3381 bp spanning 26.62 kb of the genome. Both paralogues have conserved gene structure with similar exon sizes, but the intron sizes vary greatly with the average intron length of the chromosome 6 paralogue being 0.2 kb compared to 4.6 kb on chromosome 9 . The exon and intron sizes are summarised in table 3.2.

Table 3.2 Summary of exon and intron sizes and comparison of splicing phases of the two AIF1 paralogues. The exon and intron sizes are shown in nucleotides.

| EXON | 6p22.2-p21.3 AIF1 |  |  | 9q32-q34.3 AIF1 |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Exon | Intron | Phase | Exon | Intron | Phase |
| 1 | 25 | 166 | 1 | 31 | 141 | 1 |
| 2 | 62 | 87 | 0 | 62 | 14733 | 0 |
| 3 | 67 | 367 | 1 | 67 | 2913 | 1 |
| 4 | 42 | 198 | 1 | 42 | 3137 | 1 |
| 5 | 163 | 309 | 2 | 163 | 2316 | 2 |
| 6 | 85 |  |  | 88 |  |  |

The exon and intron boundaries and splice phases were determined by aligning the cDNA sequence with the genomic sequence and were annotated using the GT/AG rule (summarised in table 3.2; Padgett et al, 1986). Both genes have identical exon splice phases indicating the importance of conservation of the gene structure. Conservation at the protein level has also been maintained as they share $64 \%$ sequence identity and both contain the sequence encoding for an EF-hand domain, which is involved in calcium binding (figure 3.4).

```
                        X
AIF1 MS--QTRDLQGGKAFGLLKAQQEERLDEINKQFLDDPKYSSDEDLPSKLEGFKEKYMEFD
AIF1L MSGELSNRFQGGKAFGLLKARQERRLAEINREFLCDQKYSDEENLPEKLTAFKEKYMEFD
    ** :. :***********:**.** ***::** * ***.:*:**.** .*********
        Y Z-Y-X -Z
AIF1 LNGNGDIDIMSLKRMLEKLGVPKTHLELKKLIGEVSSGSGETFSYPDFLRMMLGKRSAILK
AIF1L LNNEGEIDLMSLKRMMEKLGVPKTHLEMKKMISEVTGGVSDTISYRDFVNMMLGKRSAVLK
    ** : :* :**:******:***********:** :* .** :.* .:*:** ** :.********:**
AIF1 MILMYEEKAREKE-KPTGPPAKKAISELP
AIF1L LVMMFEGKANESSPKPVGPPPERDIASLP
    :::*:* **.*... **.***.:: * :.**
```

Figure 3.4 ClustalX sequence alignment of the two AIF1 paralogues. The protein sequence encoded by the six exons are alternatively coloured red and blue. The asterix symbol '*' indicates identical residues, ' $\because$ ' shows highly conserved residues, '. ' is used for weakly conserved residues and no symbol indicates no conservation (Chenna et al, 2003). The residues corresponding to the EF-hand domain are shown in bold and labeled $\mathrm{X}, \mathrm{Y}, \mathrm{Z},-\mathrm{Y},-\mathrm{X}$ and -Z .

Whole-genome assembly of the human genome sequence in the ENSEMBL genome browser subsequently confirmed the structure of the AIF1 paralogue (figure 3.3.D) and also enabled the annotation of the surrounding genes. The genomic clone bA544A12 was sequenced and finished in its entirety to identify adjacent genes. In
total, 5079 reads, of which $72.8 \%$ were of good quality, were used to assemble the 238131 bp sequence of the clone, which was submitted to the EMBL database under accession number AF157938. The clone bA544A12 had previously been mapped to 9 q 34.12 and was anchored within a contig containing the BAT2 paralogue, which is a neighbouring gene of AIF1 in the MHC class III region. Therefore, it was essential to identify adjacent genes which might be putative paralogues and further examine the degree of shared synteny between these two chromosome regions (6p22.2-p21.3 and 9q32-q34.3).

NIX analysis did not identify any further paralogues on this genomic clone but did identify a 36 exon gene encoding a nuclear pore complex protein (NUP214). The nuclear pore is a large structure that extends across the nuclear envelope and the protein encoded by NUP214 is required for cell cycle progression and nucleocytoplasmic transport. The 3-prime portion of the gene forms a fusion gene with the DEK gene located on chromosome 6 (6p22.3) in a $t(6,9)$ translocation associated with myeloid leukaemia, providing evidence of the fragile nature of this paralogous region. In addition, the most 3-prime exon (approximately 3 kb ) of the 28 exon laminin gamma-3 precursor, LAMC3, was identified on this clone. Laminin is a complex glycoprotein consisting of three different polypeptide chains (alpha, beta and gamma) that bind cells via a high affinity receptor and it is thought to mediate the attachment, migration and organisation of cells into tissues during embryonic development.

### 3.2.4 Problems associated with using mapping data and draft sequence

Investigation of the shared synteny between the MHC region and 9q32-q34.3 using
the available mapping and sequencing data revealed a number of paralogues previously not cited in the literature. For example, a putative paralogue of the extended class I MHC gene GPX5 was localised to clone bA18B16 using mapping data. This clone had been mapped to a contig on chromosome 9 q 33 centromeric to the olfactory receptor gene cluster on 9q33.2. Therefore, the identification of another extended class I gene paralogue would enable the boundaries of $9 \mathrm{q} 32-\mathrm{q} 34.3$ to be clarified. In order to confirm this prediction, the clone was successfully sub-cloned into pUC vectors and the inserts were sequenced.

In total, 5225 reads were generated and used in the assembly of the genomic clone (AL157702). NIX analysis of the finished sequence to identify genes on this clone did not identify a GPX5 paralogue but did reveal a 'Novel' gene ( 0.4 kb transcript) with homology to a cDNA clone in mouse (Q921Q2) of unknown function, which did not share significant sequence similarity with GPX5. These findings were also confirmed in the assembly of the whole genome in the ENSEMBL genome browser thus demonstrating the importance of having finished sequence. As sequence became available, computational analysis of the surrounding region did not identify the paralogue on the overlapping clones (figure 3.5).


Figure 3.5 Overview of the gene content of region analysed to identify a putative GPX5 paralogue. The two known genes are labeled RG3 (red) and AMBP (blue) and novel genes are shown in grey and genes with no assigned name are shown in yellow (the latter refer to database entries NM_152575, Q8TF49 and NM_18424 from left to right). No GPX5 paralogue was identified.

### 3.2.5 Orientation of contigs containing putative paralogues

Conservation of gene order provides an insight into the evolution of the identified paralogous genes. If the genes had evolved by whole-genome duplication, or as part of a block duplication event, the overall gene order may still be visibly conserved. The determination of gene order on chromosome 9q32-q34.3 was hindered by the number of gaps in the physical map. For example, two putative paralogues, BRD3 and RALGDS, were identified on separate contigs on 9 q 34.2 but the orientation and order of the contigs in this region had not been confirmed. It was therefore necessary to determine the order of the contigs to ultimately determine the order of these two paralogues. This was achieved using interphase and fibre fluorescent in-situ hybridisation.

During interphase chromosomes are at their most unpacked allowing higher resolution mapping of clones to be achieved compared with metaphase chromosomes. In order to orientate the contigs containing the two paralogues of interest three clones were selected: one from the contig containing BRD3 (bA317B10), one from the contig containing RALGDS (bA244N20) and another neighbouring contig (bB97D14). Each clone was fluorescently labelled using two different dyes, Texas Red (red) and FITC (green), and hybridised in different combinations to interphase chromosomes. The resulting combinations of clones labelled in the different dyes enabled the exact order of the clones to be determined (figure 3.6.A and B).

In order to clarify the order of the clones and determine the distance between them, the labelled clones were hybridised against extended DNA fibres (figure 3.6.C). The precise order and distance between the clones and contigs was determined and the precise location of the clones clarified. The resulting order of the genes was, from
centromere to telomere, RALGDS-BRD3 separated by one contig and two 100 kb gaps (figure 3.6.D).


Figure 3.6 Overview of methods used to order and orientate the contigs containing RALGDS and BRD3 putative paralogues. Three clones representing three different contigs were labelled using fluorescent dyes then hybridised in different combinations to interphase chromosomes (A and B). By analysing the order of the labelled clones in the different combinations the contig order could be determined. The clones were then used to hybridise against chromosome fibres which revealed the distance between the clones (C). The clone bB97D14 had previously been anchored to a contig centromeric of this region and using this information the precise order, orientation and gap sizes were determined (D).

### 3.2.6 Current status of 9q32-q34.3

The putative MHC paralogous region in August 2003 is in six contigs with gap sizes ranging from less than 5 kb to 200 kb (the latter is approximately the size of a BAC clone insert). The current status is summarised in figure 3.7.


Figure 3.7 Schematic representation of the status (August 2003) of the MHC paralogous region on 9q32-q34.3.

### 3.2.7 Comparison of the MHC paralogous region on 9q32-q34.3 and the MHC region on 6p22.2-p21.3

### 3.2.7.1 Gene and paralogue content

The region 9q32-q34.3 contains 198 fully sequenced clones that have all been individually analysed using NIX and ENSEMBL to identify known genes and paralogues (summarised in Appendix 1). Now that the human genome sequence has been assembled using the official minimum tile-path clones (previous human genome assemblies did not use the tile-path clones being sequenced and finished by the various genome centres), the locations of genes identified in NIX and early ENSEMBL freezes, based on sequence similarity and gene prediction programs, could finally be confirmed and integrated into the 9q32-q34.3 gene list. In total, 322 genes have been identified, of which 178 are known genes, 44 are 'Novel' genes characterised by the ENSEMBL genome browser, 24 have no assigned name, 36 are hypothetical proteins and 40 are putative MHC paralogues (see Flajnik and Kasahara, 2001 for most recent paralogue list).

The proposed paralogous region on chromosome 9 is gene rich (one gene per 73 kb ) compared with the rest of the chromosome (one gene per 129 kb ) (summarised in table 3.3). The gene dense nature of $9 \mathrm{q} 32-\mathrm{q} 34.3$ is comparable to the MHC region on 6p22.2-p21.3 that has approximately one gene per 33 kb , which is high when compared to the chromosome 6 average of one gene per 132 kb . Overall, $9 \mathrm{q} 32-\mathrm{q} 34.3$ is a less gene dense region as opposed to the MHC region on 6p22.2-6p21.3; however, the gene density is still greater than the genome average of approximately one gene per 100 kb (table 3.3).

Table 3.3 Summary of the gene content and sizes of chromosomes 6 and 9 and the paralogous regions compared with genome average.

| Chromosome or <br> region | Number of <br> genes | Size (Mb) | Approximate gene density |
| :---: | :---: | :---: | :---: |
| Chromosome 6 | 1296 | 170.67 | 1 gene per 132 kb |
| 6p22.2-p21.3 | 222 | 7.22 | 1 gene per 32 kb |
| Chromosome 9 | 1031 | 132.88 | 1 gene per 129 kb |
| 9q31.2-q34.3 | 322 | 23.78 | 1 gene per 73 kb |
| Human genome | $\sim 30,000$ | 3,000 | $\sim 1$ gene per 100 kb |

The distribution of the paralogues, including distances between proposed paralogues and the number of interspersed genes, has been summarised in figure 3.8. Identification of the MHC paralogous genes has determined that the proposed paralogous region spans approximately 24 Mb from 9 q 32 through to 9 q 34.3 . Within this region, paralogues represent $12.4 \%$ of the total gene repertoire (39/322). In comparison, the MHC region spans approximately 7.2 Mb of which the cited paralogues represent almost $18 \%$ of the total gene repertoire (40/222).

It has been noted that the order of genes within some paralogous regions has been conserved, namely in the case of the Hox gene clusters (Garcia-Fernandez and Holland, 1994). Initial analysis of the proposed MHC paralogous regions indicated that the gene order of the paralogues located using mapping data was not conserved (Katsanis et al, 1996). Now that the precise locations of the putative paralogues have been determined, a full comparison of the gene order is possible (figure 3.8).


Figure 3.8 Comparison of the order of paralogues between the MHC region on $6 \mathrm{p} 22.2-\mathrm{p} 21.3$ and the paralogous region on $9 \mathrm{q} 32-\mathrm{q} 34.3$. The numbers in red indicate the distances between paralogues and the number in blue shown in parentheses corresponds to the number of coding genes interspersed between the paralogues. The extended class I genes and corresponding chromosome 9 paralogues are shaded green, class I in yellow, class III in red, the class II in blue and the extended class II in pink. The tubulin paralogue is a pseudogene, indicated by the letter ' p ' in parentheses.

It appears that the overall gene order is poorly conserved between the two regions but small blocks of conservation can be seen, namely between gene pairs such as AIF1/AIF1-L and BAT2/BAT2-L. There are several examples of gene pairs that are located in the reverse orientation, including RXRB/A and COL11A2/COL5A1, as well as TNXB/TNC and C4/C5. Endo and co-workers (1997) identified five paralogues with conserved gene order, namely C4/C5-PBX2/PBX3-BRD2/BRD3-COL11A2/COL1A5-RXRB/RXRA, which all appeared to have arisen at the origins of vertebrate emergence. Upon identification of the precise location of the paralogues, this gene order is essentially conserved, albeit with the reverse orientation of RXRB/A and COL11A2/COL1A5. More recently, Flajnik and Kasahara (2001) analysed the gene order of all four proposed paralogous regions and identified six paralogues which have remained in the same order on $6 \mathrm{p} 22.2-\mathrm{p} 21.3$, $9 \mathrm{q} 32-\mathrm{q} 34.3$ and 19p13.3p13.1 but not on chromosome 1 . These include only two of the genes proposed by Endo and colleagues (1997). This will be discussed in more detail in chapter 4 upon full analysis of the MHC paralogues in the human genome.

The number of genes separating the MHC paralogues on 9q32-q34.3 range from zero to over 80 and are, in general, structurally and functionally unrelated, which is reminiscent of the MHC region. A number of transcription factors, solute carriers, homeobox proteins, lipocalins and kinases have been identified in the region but no HLA class I or class II genes have been found. An HLA-DR associated protein (also known as SET) and a hypothetical protein containing an Ig_MHC domain have been anchored to clones located on 9 q 34 , but the association of the genes within this paralogous region with the immune system is not as prevalent as genes located within the MHC region. The extended MHC region is characterised by multigene families, in particular the HLA class I and class II families, histones, olfactory receptor genes and
zinc finger genes. The region on $9 \mathrm{q} 32-\mathrm{q} 34.3$ does not contain such a repertoire of multigene families but a number of zinc-finger proteins (six) and ribosomal proteins (four) have been identified along with the Surfeit locus. The Surfeit locus is not associated with the MHC region, but like many gene families located in the MHC region, is of biological interest.

The Surfeit locus contains an unusually tight cluster of six housekeeping genes, designated SURF1 to SURF6, which are unrelated by sequence similarity (Yon et al, 1993). The cluster exhibits alternation of transcription, bi-directional promoters and produce overlapping transcripts that has led to the proposition that these genes form a locus with potential regulatory and/or functional significance (Huxley and Fried, 1990; Gaston and Fried, 1994; Lennard et al, 1994). Colomobo and co-workers (1992) found that this cluster along with associated CpG rich islands have remained tightly clustered over 600 million years of divergent evolution that separate birds and mammals. However, it has been shown that in the teleost fish Fugu the five SURF genes are located in separate locations on two different chromosomes (Bouchireb et $a l, 2001)$. Thus, indicating that this tightly organised functional unit does not need to be next to each other in this organism. Nevertheless, the Surfeit cluster represents a gene cluster in which the gene organisation has biological significance in mammals, which is reminiscent of gene families located within the MHC region.

### 3.2.7.2 Genomic landscape

Surveys of genomic landscapes have noted the non-random distribution of particular sequence features, namely GC content and repeat elements. The assessment of these features is essential when characterising a genomic landscape (table 3.4). The overall

GC content of the $7.2 \mathrm{Mb} 6 \mathrm{p} 22.2-6 \mathrm{p} 21.3$ and the $24 \mathrm{Mb} 9 \mathrm{q} 32-\mathrm{q} 34.3$ regions was calculated using Repeatmasker (http://repeatmasker.genome.washington.edu). The GC content in both regions ( $44 \%$ and $47 \%$, respectively) was higher than the genome average of $41 \%$. High GC content is associated with high gene density (IHGSC, 2001), which is a feature of both regions.

It is estimated that repeat sequences account for approximately $45 \%$ of the human genome (IHGSC, 2001). Although repeat elements are quite recent additions to the genome compared to the ancient duplication events proposed by Ohno (1970), it is interesting to compare the overall repeat content between regions as they shed light on chromosome structure and dynamics. Over time, these repeats reshape the genome by rearranging it, thereby creating entirely new genes or modifying and reshuffling existing genes.

Most human repeat sequences are derived from transposable elements and are made up of four major classes of repetitive elements (Smit, 1999): (1) short interspersed elements (SINEs), (2) long interspersed elements (LINEs), (3) elements possessing long terminal repeats (LTR elements) and (4) DNA transposons. The repeat content of the four main classes was calculated for the paralogous regions 6 p22.2-p21.3 and 9q32-q34.3 using Repeatmasker and compared against the averages in the human genome (summarised in table 3.4).

The Alu content of both regions is higher than the genome average, which is interesting because Alu elements are associated with gene-rich regions of the genome (Smit, 1999; IHGSC, 2001). They are also associated with some chromosomal translocation breakpoint regions that suggest that these sequences could provide hot spots for homologous recombination, and could mediate the translocation process and
elevate the likelihood of other types of chromosomal rearrangements taking place.

Table 3.4 Comparison of the repeat content of the $6 \mathrm{p} 22.2-\mathrm{p} 21.3$ and $9 \mathrm{q} 32-\mathrm{q} 34.3$

| Repeat <br> element | 6p22.2-p21.3 <br> (\% of <br> sequence) | 9q32-q34.3 <br> (\% of <br> sequence) | Genome <br> average (\% of <br> sequence) |
| :--- | :---: | :---: | :---: |
| Alu | 14.83 | 14.42 | 10.60 |
| MIR | 1.06 | 3.45 | 2.20 |
| Total SINE | $\mathbf{1 5 . 8 9}$ | $\mathbf{1 7 . 8 7}$ | $\mathbf{1 2 . 8 0}$ |
| L1 | 14.29 | 10.02 | 16.89 |
| L2 | 2.21 | 2.86 | 3.22 |
| L3 | 0.11 | 0.25 | 0.31 |
| Total LINE | $\mathbf{1 6 . 6 1}$ | $\mathbf{1 3 . 1 3}$ | $\mathbf{2 0 . 4 2}$ |
| Total LTR | $\mathbf{1 0 . 4 7}$ | $\mathbf{5 . 2 6}$ | $\mathbf{8 . 2 9}$ |
| Total DNA | $\mathbf{2 . 3 5}$ | $\mathbf{2 . 0 2}$ | $\mathbf{2 . 8 4}$ |
| Unclassified | $\mathbf{0 . 6 5}$ | $\mathbf{0 . 1 7}$ | $\mathbf{0 . 1 2}$ |
| Total (\%) | $\mathbf{4 5 . 9 7}$ | $\mathbf{3 8 . 4 4}$ | $\mathbf{4 4 . 8 3}$ |
| \%GC (\%) | $\mathbf{4 4}$ | $\mathbf{4 7}$ | $\mathbf{4 1}$ |

### 3.2.7.3 Evidence of gene and segmental duplication

Gene and segmental duplications have shaped the MHC region (reviewed by Beck and Trowsdale, 2000) and there is strong evidence of such duplication events on 9q32-q34.3. Recent evidence indicates that duplication played a central role in the emergence of the two regions from a common ancestral region (Abi-Rached et al, 2002). It had previously been proposed that the MHC and 9q32-q34.3 regions, along with the proposed MHC paralogous regions on 1q21-q25 and 19p13.3-p13.1, had emerged via a series of large-genome duplication events prior to vertebrate emergence (Kasahara, 1999a). In order to test this hypothesis, Abi-Rached and colleagues (2002)
characterised the corresponding region in the cephalochordate amphioxus by identifying nine anchor genes and sequencing both the anchor genes and the regions that flank them. Analysis of the distribution of the human and amphioxus orthologues in their respective genomes revealed that they arose from a common ancestral region by block duplication events. The phylogenetic relationships determined that the duplications occurred after the divergence of cephalochordates (i.e. amphioxus) and vertebrates but before the gnathostomata (jawed vertebrates) radiation. Thus, showing the important role duplication has played in the origins of these two chromosomal segments.

Duplications have also played a major role in moulding the present-day arrangement of the 9q32-q34.3 region. For example, Lacazette and co-workers (2000) identified a new paralogous gene family on human chromosome 9 q 34 which they deduced were created by genomic duplications. They detected, in addition to the known, LCN1 (tear lipocalin) gene, two LCN1 pseudogenes and two OBPii genes (odorant binding proteins) paralogous to LCN1. Phylogenetic analyses indicated that the LCN1 and OBPii genes correspond to a subfamily of lipocalin genes that have arisen from a common ancestor by duplication. Figure 3.9 summarises the mechanisms involved in the emergence of the OBPii-LCN1 family.

Evidence suggests that a tandem duplication event of a seven exon lipocalin ancestor gave rise to two lipocalin paralogous genes. Following the differentiation of these two paralogues there were three complete, or partial, duplications of this 50 kb region on human chromosome 9 q 34 . Analysis of the present day gene structures of the LCN1 and the OBPiiA and OBPiiB implied that the OBPii genes have evolved by integrating additional surrounding intronic DNA and recruiting an additional exon.


Present day arrangement

Figure 3.9 Evolution of the lipocalin paralogous gene family on 9 q 34 . Gene differentiation is demonstrated by the change in colour of the boxes (genes) during evolution.

Recently, a 76 kb duplicon has been identified on chromosome 9 q 34 that is believed to mediate recombination leading to the Philadelphia chromosome ( Ph ) associated with leukaemia (Saglio et al, 2002). Segmental duplications, or duplicons, are segments of DNA with near-identical sequence. They are believed to be 'hotspots', or predisposition sites, for the occurrence of non-allelic homologous recombination or unequal crossing-over leading to genomic mutations such as inversions (Giglio et al, 2001), translocations (Giglio et al, 2002; Saglio et al, 2002), deletions and duplications (Reiter et al, 1996). The Ph chromosome is the most frequent cytogenetic abnormality present in human leukaemias and is a derivative chromosome 22 arising as a consequence of a reciprocal translocation between the long arms of chromosomes

9 and 22 (Saglio et al, 2002 and references therein). During the study of a patient with chronic myeloid leukeamia a large deletion on chromosome 9 q 32 and an unusual BCR-ABL transcript was observed. The unusual transcript was characterised by the insertion, between BCR exon 14 located on 22q11.2 and ABL exon 2 located on 9 q 34 , of 126 bp derived from a region located on chromosome $9,1.4 \mathrm{Mb} 5$-prime to ABL. This sequence is located in the clone bA65J3 which I have confirmed to be located approximately 1.4 Mb centromeric to the start of the ABL gene.

Fluorescence in situ hybridisation experiments on normal metaphase chromosomes detected two signals; a clear signal at 9 q 34 and a faint but distinct signal at 22q11.2. Sequence similarity search using BLAST determined that there was a large stretch of sequence similarity of 76 kb between 9 q 34 and a region approximately 150 kb 3 prime of the BCR gene on 22q11.2. Evolutionary studies using fluorescent in-situ hybridisation identified the region as a duplicon, which transposed from the region orthologous to human 9 q 34 to chromosome 22 after the divergence of orang-utan from the human-chimpanzee-gorilla common ancestor about 14 million years ago. The discovery of a large duplicon relatively close to the ABL and BCR genes, and the finding that the 126 bp insertion is very close to the duplicon at 9 q 34 , opens the question of the possible involvement of the duplicon in the formation of the Philadelphia chromosome translocation as well as providing further evidence of the dynamic nature of this premier paralogous region.

### 3.2.7.4 Diseases associated with 9q32-q34.3

Several diseases and disorders are associated with the 322 identified genes and putative paralogues on 9q32-q34.3 (table 3.5), which is reminiscent of the MHC
region. For example, the truncation of the putative paralogue NOTCH1 is believed to play a role in human pre-T-cell acute leukeamias (T-ALL), which involves the chromosomal translocation between 7 q 34 and 9q34.3 (Ellisen et al, 1991). The association between NOTCH1 and 9q34.3 was first observed during the study of three cases of acute T-cell lymphoblastic leukaemia demonstrating the $\mathrm{t}(79)(\mathrm{q} 34 ; \mathrm{q} 34.3)$ (Ellisen et al, 1991). Ellisen and colleagues (1991) identified breakpoints within 100 bp of an intron in NOTCH1, resulting in the truncation of NOTCH1 transcripts. They suggested that the alteration of the NOTCH1 gene may play a role in the pathogenesis of some neoplasms. In addition, putative NOTCH1 paralogues have been identified at positions 1p13-p11 (NOTCH2) and 19p13.2-p13.1 (NOTCH3), which are also regions of neoplasia-associated translocation. The association of a variety of diseases and disorders with genes located within the paralogous region on $9 \mathrm{q} 32-\mathrm{q} 34.3$ is one of the similarities between this region and the MHC region.

Table 3.5 Summary of some of the disorders associated with 9q32-q34.3

| Gene | Disorder | Reference |
| :--- | :--- | :--- |
| SURF1 | Leigh's Disease | Zhu et al, 1998 |
| TSC1 | Tuberous sclerosis | van Slegtenhorst et al, 1997 |
| COL5A1 | Ehlers-Danlos syndrome | Nicholls et al, 1994 |
| TAL2 | T cell acute leukeamia | Xia et al, 1991 |
| SET | Leukaemia | von Lindern et al, 1992 |
| FCMD | Fukayama muscular dystrophy | Kobayashi et al, 1998 |
| NR5A1 | XY sex reversal | Achermann et al, 1999 |
| DBCCR1 | Bladder cancer | Habuchi et al, 1998 |

### 3.3 Discussion

This chapter presents the findings from the characterisation of one of the chromosomal regions proposed to be paralogous to the MHC. The region spans from 9 q 32 to 9 q 34.3 encompassing approximately 24 Mb of genomic sequence and represents the largest chromosomal region containing MHC paralogues to be mapped, sequenced and analysed to-date. Analysis of 9q32-q34.3 has not only provided insight into its genomic organisation but it has revealed a number of features that are shared with the MHC.

One of the main features common to both regions is that they are gene rich. Overall, the density of genes located within the MHC region is higher compared with the proposed paralogous region on 9q32-q34.3, but both contain a higher density of genes when compared with the rest of the genome. The gene-rich nature of both regions is also associated with a high GC content, which is a feature of both 6 p22.2-p21.3 and 9q32-q34.3. High GC content may also explain why gaps still remain in the region 9q32-q34.3. At the time of writing (August 2003), the minimum tiling-path of 9q32q34.3 has 198 fully sequenced clones but still contains five gaps ranging in size from approximately 5 kb to 200 kb . High GC content is believed to cause the region to be deletion-prone through frameshift mutagenesis or other unknown cellular mechanisms (Bichara et al, 1995; 2000) and thus making it difficult to clone and sequence.

In total, 322 genes were identified within the region $9 \mathrm{q} 32-\mathrm{q} 34.3$. These genes are both structurally and functionally unrelated, which is a feature of the genes located within the MHC class III region but is not mirrored by the extended MHC region as a whole. All of the 40 paralogues cited in the literature, corresponding to 25 MHC gene families, were identified within 9q32-q34.3 (Kasahara, 1999a; 1999b; Flajnik and

Kasahara, 2001). It is important to note that the paralogues discussed in this chapter are termed 'putative paralogues' as they have only been identified based on previously published data and have not been characterised within this chapter; this will be addressed in chapter 4.

One of the main differences between the extended MHC region and 9q32-q34.3 is that the prior is characterised by the human leukocyte antigen (HLA) genes located in the class I and class II regions, which are involved in antigen presentation, whereas the latter does not contain any of these genes. In contrast, it has been shown that the proposed paralogous region on 1 q 22 has a cluster of class I-like HLA genes, termed the CD1 gene cluster (Shiina et al, 2001). From this analysis it is not possible to determine whether 9q32-q34.3 once contained HLA class I-like genes and they have since been lost or whether they have never been part of the $9 \mathrm{q} 32-\mathrm{q} 34.3$ gene repertoire.

The linkage of the putative MHC paralogues on 9q32-q34.3 is associated with a common origin of the two regions by large-scale duplication; either as a block or the entire genome. If they did have a common origin it is expected that the regions are syntenic. However, analysis of the overall gene order of the paralogues between the MHC and 9q32-q34.3 is not strictly conserved, but there is evidence of conservation in the order of some paralogues. My findings are consistent with those of Endo and colleagues (1997) who deduced the gene order on chromosome 9 using cytogenetic and genetic maps in mouse, although two paralogues are actually in the reverse order than they proposed. The likelihood of synteny between the MHC region and 9q32q34.3 may well be related to the time that has elapsed since their emergence. If they did emerge at the time of vertebrate emergence as proposed by Endo and co-workers
(1997), as well as others including Kasahara (1997; 1999a; 1999b), then approximately 500 million years of evolution have passed. It is also associated to the amount of rearrangement of the genomic sequence by evolutionary mechanisms, including inversions, translocations and duplications. The dynamic nature of the region 9q32-q34.3 is evident by the presence of duplicons and repetitive elements known to be involved in chromosomal rearrangements. There is also further evidence of local duplication events within both regions.

If the paralogues did not emerge simultaneously by block duplication they must have duplicated independently. Hughes (1998) proposed two hypotheses as to why these paralogues have come together; they are (1) that the cluster of paralogues is a result of chance and (2) that it is selectively advantageous for these paralogues to be together. Such a large number of independent translocations are unlikely to have occurred by chance and it has been suggested that there are selective advantages as to why the MHC paralogues are clustered on 9q32-q34.3, namely a functional reason. Analysis of the genes located within 9q32-q34.3 does not support this hypothesis as they appear to have diverse functions. However, this will be discussed in more detail in chapter 6.

## Chapter 4

# Identification of the extended MHC paralogues in the 

human genome

### 4.1 Introduction

Following the analysis of the proposed paralogous region on chromosome 9 and the release of the first assembled draft human genome sequence it became possible to search for MHC paralogues genome-wide. Previous studies had been criticised for being misleading as they concentrated only on the MHC paralogous genes located in the clusters on 1, 9 and 19 but did not consider paralogues elsewhere in the genome in as much detail. In the words of Hughes and Pontarotti (2000) 'there is no reason to believe that genes in the MHC region are any more likely to have paralogues on these three chromosomes than on any three chromosomes chosen at random from the genome'.

With the increasing amount of genomic sequence data putative MHC paralogues have been identified outside the proposed paralogous regions on 1,9 and 19 ; including 12p11-p13, 5q13.1, and 21q22.3 (reviewed by Flajnik and Kasahara, 2001). However, no comprehensive study of the entire genome has been published and the location of the majority of loci cited are based on mapping information available in UNIGENE or generated using cytogenetic mapping techniques, which are not precise. With the advent of the human genome sequence it was now possible to determine the exact location of the proposed MHC paralogues as well as identify novel paralogues which were previously not detected. The purpose of this chapter is to present the findings of
a comprehensive and unbiased survey of the human genome with the aim to identify all the MHC paralogous genes and determine their exact location.

### 4.2 Strategy used to identify MHC paralogues

Previous studies investigating the paralogous gene clusters on chromosomes 1,9 and 19 identified the putative paralogues using BLAST sequence similarity searches of each available MHC gene (for an example refer to Kasahara, 1999a). Conserved sequence similarity is a feature of homologous gene families and is a good indicator for paralogous genes. In this analysis I use sequence similarity as the initial criterion to identify paralogues but add confidence by using additional sequence features, such as conserved gene structure (intron/exon boundary phases). The approach taken to identify MHC paralogues with increasing levels of confidence in this chapter is outlined in figure 4.1 and discussed in more detail in sections 4.2.1-4.2.2.

### 4.2.1 MHC genes used in whole-genome survey

The extended MHC is defined as the sequence on chromosome 6 between HFE (the hereditary haemochromatosis locus), in the extended class I region, and KIFC1 (formerly KNSL2) in the extended class II region (The MHC Sequencing Consortium, 1999).


Figure 4.1 (A) Overview of the strategy used to identify MHC paralogues with increasing levels (L0 to L3) of confidence and definitions (B).

In total, 222 protein-coding gene loci were identified in the region by amalgamating the information published by The MHC Sequencing Consortium (1999) and the up-todate annotated sequence data available in the Chromosome 6 database, '6ace' (table 4.1). Of the 222 protein-coding genetic loci, 128 were used in the whole-genome survey (table 4.1).

Table 4.1 Distribution of genes in the extended MHC region

|  | Number <br> of gene <br> loci | Number <br> of genes** | Number of <br> genes used <br> in the <br> analysis | Size <br> (Mb) | $\sim$ Gene <br> loci density |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Extended class I | 151 | 93 | 15 | $\sim 3.6$ | 1 gene per 24 kb |
| Class I | 111 | 36 | 23 | 1.8 | 1 gene per 16 kb |
| Class III | 58 | 58 | 56 | 0.7 | 1 gene per 12 kb |
| Class II | 35 | 18 | 18 | 0.8 | 1 gene per 23 kb |
| Extended class II | 23 | 17 | 16 | 0.3 | 1 gene per 13 kb |
| Total | $\mathbf{3 7 8}$ | $\mathbf{2 2 2}$ | $\mathbf{1 2 8}$ | $\sim \mathbf{7 . 2}$ | $\mathbf{1}$ gene per 19 kb |

* Genes known, or predicted, to encode a protein.

The 128 genes were selected in order to represent each gene family found within the MHC region. In the case of the gene families found within the extended MHC generally only one of the genes was chosen to represent the family. For example, only one of the three Heat Shock Proteins was used in the analysis as they all have one coding exon and share very high sequence similarity. In other cases more than one member of the family was used to attain a full representation of the MHC genes. To date no HLA class II paralogues have been identified in the human genome, therefore in order to ensure any paralogues were detected, all the expressed HLA class II genes
were included in the analysis.

Some multigene families that are known to have undergone large-scale expansion have been excluded from the detailed analysis. For example, the extended class I region contains multiple members of the zinc finger, ribosomal and olfactory receptor multigene families that each have up to 1000 paralogues throughout the genome.

### 4.2.2 Identification of MHC paralogues with increasing levels of confidence

The protein sequences encoded by the 128 MHC gene loci were extracted from either the annotated EMBL database entry of the genomic clone or retrieved from the SWISSPROT or SPTREMBL databases (Bairoch and Apweiler, 1997) and used to identify its paralogues in the human genome (as described in section 2.16). The protein sequence was preferred over the DNA sequence as protein sequence similarity searches increase the likelihood of identifying paralogues which have diverged. DNA sequences are far less conserved particularly as many changes in DNA sequences (third-base changes) do not alter the encoded protein but do change the level of DNA sequence conservation, therefore, lowering the chances of detection by sequence similarity searches. It is generally accepted that if the biological sequence of interest encodes a protein, protein sequence comparison is always the method of choice.

Two sequence features were used to filter the BLAST search results in order to identify paralogues with increasing levels of confidence: these were (1) the exon fingerprints and (2) known protein domains. As described in section 2.16.2, the exon fingerprints of the MHC genes were generated using the CDS features of the annotated genomic clones in the EMBL database and used to search the FINEX
database. In addition, the exon fingerprints were deduced for all putative paralogues identified by the initial BLAST similarity search and used to search the FINEX database (summarised in figure 4.2).

| RXRB | 6p21.32 | AL031228.12 | 10 | 3:1:235 1:0:248 0:1:157 1:1:180 1:0:173 0:1:130 |
| :---: | :---: | :---: | :---: | :---: |
| RXRG | 1 q 23.3 | AL160058.2 | 10 | 3:1:49 1:0:248 0:1:145 1:1:180 1:0:161 0:1:130 |
| RXRA | 9q34.2 | AL669970.50 | 10 | 3:1:103 1:0:251 0:1:151 1:1:180 1:0:170 0:1:130 |
|  |  |  | * | * * * * * * * * * * * * |

```
RXRB 6p21.32 1:2:133 2:1:92 1:2:106 2:3:145
RXRG 1q23.3 1:2:133 2:1:92 1:2:106 2:3:145
RXRA 9q34.2 1:2:133 2:1:92 1:2:106 2:3:145
    * * * ** * * * * * * *
```

Figure 4.2 Alignment of the exon fingerprints of the extended MHC class I gene RXRB (in red) and its paralogues, RXRA and RXRG, identified in the genome survey (discussed in section 4.4.1). The gene names corresponding to the exon fingerprints are boxed in purple and the genomic location in blue. The genomic clone, in which the gene is located, is boxed in orange. In the case of RXRB, the gene is located in the genomic clone, RP5-1033B10, with the EMBL accession number AL031228, and it is the $12^{\text {th }}$ annotated gene with more than one exon within the EMBL entry (hence ' $.12^{\prime}$ ). The number boxed in green corresponds to the numbers of coding exons of the gene. The fingerprint of each of the 10 exons follows the same pattern and is represented by a set of three numbers separated by two colons. For example, in the case of the RXRB gene, the first number ' 3 ' indicates that this is the start of the gene, characterised by the start codon 'ATG'. The second number ' 1 ' indicates that the first intron interrupts a codon and lies between the first and second base. The third number corresponds to the size of the exon, thus, the first exon of RXRB has 235 nucleotides. The asterix indicate whether the phases or exons aligned are identical (black) or different (red).

The known protein domains were identified by searching the PFAM database as described in section 2.16.2. The protein domains of the MHC extended class II encoded protein RXRB and the corresponding regions in the two paralogues, RXRG and RXRA, are shown in figure 4.3.

Exon 1
MSWAARPPFLPQRHAAGQCGPVGVRKEMHCGVASRWRRRRPWLDPAAAAAAAVAGGEQQT

Exon 2

RXRB
RXRG
RXRA

RXRB
RXRG
RXRA

RXRB
RXRG
RXRA
KPP--VLGVRGLHCPPPPGGPGAGKRLCAICGDRSSGKHYGVYSCEGCKGFFKRTIRKDL KPLPGLPGIGNMN-YPSTSPGSLVKHICAICGDRSSGKHYGVYSCEGCKGFFKRTIRKDL KPPLGLNGVLKVPAHPSGNMASFTKHICAICGDRSSGKHYGVYSCEGCKGFFKRTVRKDL ** * * * *******************************

Exon 4
RXRB TYSCRDNKDCTVDKRQRNRCQYCRYQKCLATGMKREAVQEERQRGKDK-DGDGEGAGGAP RXRG IYTCRDNKDCLIDKRQRNRCQYCRYQKCLVMGMKREAVQEERQRSRERAESEAECATSGH RXRA TYTCRDNKDCLIDKRQRNRCQYCRYQKCLAMGMKREAVQEERQRGKDRNENEVESTSSAN * ******* ***************** *************

Exon 5
EEMPVDRILEAELAVEQKSDQGVEGPGGTGGSGSSPNDPVTNICQAADKQLFTLVEWAKR EDMPVERILEAELAVEPKTESYGDMN--MEN---STNDPVTNICHAADKQLFTLVEWAKR EDMPVERILEAELAVEPKTETYVEAN--MGLNPSSPNDPVTNICQAADKQLFTLVEWAKR
$* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *)$

Exon 6
Exon 7
RXRB IPHFSSLPLDDQVILLRAGWNELLIASFSHRSIDVRDGILLATGLHVHRNSAHSAGVGAI RXRG IPHFSDLTLEDQVILLRAGWNELLIASFSHRSVSVQDGILLATGLHVHRSSAHSAGVGSI RXRA IPHFSELPLDDQVILLRAGWNELLIASFSHRSIAVKDGILLATGLHVHRNSAHSAGVGAI $\star * * * * * * * * * * * * * * * * * * * * * * * * * * * * \quad * * * * * * * * * * * * * * * * * * * * * * *$

## Exon 8

Exon 9
FDRVLTELVSKMRDMRMDKTELGCLRAIILFNPDAKGLSNPSEVEVLREKVYASLETYCK FDRVLTELVSKMKDMQMDKSELGCLRAIVLFNPDAKGLSNPSEVETLREKVYATLEAYTK FDRVLTELVSKMRDMQMDKTELGCLRAIVLFNPDSKGLSNPAEVEALREKVYASLEAYCK ************ ** *** ******** ***** ****** ***

Exon 10
RXRB
RXRG
RXRA
QKYPEQQGRFAKLLLRLPALRSIGLKCLEHLFFFKLIGDTPIDTFLMEMLEAPHQLA QKYPEQPGRFAKLLLRLPALRSIGLKCLEHLFFFKLIGDTPIDTFLMEMLETPLQIT HKYPEQPGRFAKLLLRLPALRSIGLKCLEHLFFFKLIGDTPIDTFLMEMLEAPHQMT


Figure 4.3 Protein sequence alignment of the extended MHC class II encoded protein, RXRB, and its two paralogues, RXRA and RXRG. The amino acid residues encoded by the 10 exons are shown in red and blue alternatively. The regions indicated by the orange and green arrows correspond to the zinc-finger and ligand binding domains respectively predicted by PFAM, which were masked as described in section 2.16.2. The asterix indicate whether the aligned amino acid residues are identical (black).

### 4.3 Definitions

The MHC paralogues were identified using the method described in chapter 2 and summarised in section 4.2, and have been defined according to the level of confidence determined by the filtering methods. The terminology used to define the paralogues in this analysis is described in the sections below.

### 4.3.1 L0-paralogues

L0-paralogues are paralogues that have the lowest level of support. They have been identified by the BLAST similarity search of the ENSEMBL human genome assembly (Hubbard et al, 2002) using the TBLASTN executable. They correspond to the BLAST matches with a P-value of less than $10^{-5}$ and have no other levels of support. A TBLASTN, or translated database search against the human genome is a very productive way to identify paralogous proteins. It is especially suited to working with error prone data like draft genomic sequence because it combines BLAST statistics for hits to multiple reading frames and thus is robust to frame shifts introduced by sequencing or assembly error, which were prevalent in the early genome assemblies.

### 4.3.2 L1-paralogues

L1-paralogues are paralogues with a moderate level of confidence and level 1 support. They were initially detected by the TBLASTN search of the human genome sequence and have a P -value less than $10^{-5}$. In addition, they also have sequence similarity
outside the protein domains detected by a TBLASTN search of the domain-masked protein sequence using an expected (E) value of 10 (as described in section 2.16.2.1). In brief, the domains for each protein were identified using the PFAM database and the corresponding residues masked with X's. This method is similar in principle to Repeatmasker which identifies a repeat sequence and substitutes the corresponding nucleotide with either an X or an N (Smit and Green, unpublished). The domainmasked protein sequences were then BLAST searched against the ENSEMBL human genome sequence assembly using the TBLASTN executable.

### 4.3.3 L2-paralogues

L2-paralogues are paralogues with a higher level of confidence and level 2 support. They were initially detected by the TBLASTN search of the human genome sequence and have a P-value less than $10^{-5}$ but also have conserved gene structure (FINEX zvalue greater than 3.0; as described in section 2.16). In this analysis the FINEX alignment tool was used to compare the exon fingerprints of the MHC encoded gene and the L0-paralogues against the FINEX database (Brown et al, 1995). It has been shown for the HLA class II and other gene families that similarities in intron phases and exon fingerprints can be used to define a paralogous gene family (Beck et al, 1992a; Radley et al, 1994). In addition, MHC proteins encoded by a single exon (for which an exon fingerprint can not be generated) with BLAST similarity matches to paralogues with only one coding exon are also termed L2-paralogues.

### 4.3.4 L3-paralogues

L3-paralogues are paralogues with the highest level of confidence and level 3 support. They were initially detected by the TBLASTN sequence similarity search of the human genome sequence and have a P-value less than $10^{-5}$. They also have conserved sequence identity outside the protein domains and conserved gene structure determined by the two filtering steps.

In summary, the paralogues were identified with varying levels of confidence in order to gain better understanding of the true relationship between the MHC genes and their paralogues. The two filtering methods used to classify the paralogues, detected by the initial sequence similarity search, give an indication of this relationship. The domainmasking filter identifies the paralogues with sequence similarity beyond the domain regions. This filtering step also identifies the paralogues that could be false positives and have only been detected because of a shared domain. These are likely to be members of the same superfamily and are more distantly related. By independently generating the exon fingerprint of the MHC genes, and the paralogues identified in the initial TBLASTN search, the paralogues with conserved gene structures, regardless of sequence similarity, can be distinguished. In addition, the level of conservation of the exons and introns can be determined. Conservation of gene structure and protein sequence indicates that these features are likely to be important for its current day function.

### 4.4 Results

### 4.4.1 Identification of MHC paralogues: RXRB as an example

The RXRB gene, also known as retinoic acid receptor beta, is located within the MHC extended class II region on chromosome 6. This gene belongs to the nuclear hormone receptor superfamily and two putative paralogues have previously been identified in the paralogous regions on chromosomes 1 and 9 based on sequence similarity alone. This gene was selected as one of the first genes to be used to identify the paralogues with increasing levels of confidence. The superfamily the gene belongs to is large and includes a number of types of receptors. The receptors share known protein domains and, therefore, sequence identity with RXRB and by applying the filtering steps the paralogues with the highest level of confidence were identified.

The initial TBLASTN sequence similarity search using the RXRB protein sequence identified a total of 48 BLAST sequence similarity matches in the human genome (figure 4.4), of which 27 had a P-value less than $10^{-5}$. The 27 BLAST matches, termed paralogues, were then classified (as defined in section 4.3) according to the level of confidence based on the results of two separate filtering steps. One filtering step involved the identification and masking of the protein domains. The RXRB protein contains two PFAM predicted domains; a zinc finger, C4 type spanning from amino acid residue 203 to 278, which is the DNA binding domain of a nuclear receptor (PF00105) and a ligand binding domain spanning from residue 344 to 526 , involved in binding the hormone (PF00104). The amino acid residues of the two domains were masked with a series of X's and the masked protein sequence used to BLAST search the human genome using the TBLASTN executable. Two paralogues were identified
by this filtering step. They corresponded to two of the 27 paralogues identified by the initial TBLASTN search; the RXRA gene on chromosome 1 and the RXRG gene on chromosome 19 (figure 4.4).


Figure 4.4 Summary of the results of the initial (A) and domain-masked (B) TBLASTN search of the human genome using the RXRB protein sequence. The coloured arrows correspond to the ENSEMBL BLAST score which roughly corresponds to the P -value. In short, a green arrow implies low score and high P value, a blue arrow indicates moderate score and P -value and a red arrow indicates a high score and low P-value. The location of the RXRB gene and its paralogues RXRA and RXRG are indicated in B.

The second filtering step used gene architectural information to identify paralogues with a higher level of confidence. The intron positions and phases were determined and used to search the FINEX database (described in section 4.2.2 and 2.16). As the FINEX database derived from the EMBL database release 73 contains only 12,282 fingerprints and is not non-redundant the database does not contain the fingerprints for all 30,000 genes in the human genome. This is because the fingerprint database is
compiled using annotated coding sequence (CDS feature) information of the EMBL database entry and not all the tiling path clones of the human genome are yet annotated. In order to counteract this, the fingerprints of all 27 paralogues identified by the initial TBLASTN search of the human genome were manually derived and used to search the FINEX database. The paralogues identified the corresponding MHC locus (figure 4.5), and the paralogues were classified based on all three lines of evidence.

```
FINEX Results
Hit 1 :AL031228.12 (RXRB)
Scores :Davg= 0.061 Dmat= 0.611 z= +9.67 al=10 af=100% l=10,10
m,i,t=10,0,0
AL669970.50 3:1:103 1:0:251 0:1:151 1:1:180 1:0:170 0:1:130 1:2:133
AL031228.12 3:1:235 1:0:248 0:1:157 1:1:180
AL669970.50 2:1:92 1:2:106 2:0:148
    | | | | | | : |
AL031228.12 2:1:92 1:2:106 2:3:148
Hit 2 :AL160058.2 (RXRG)
Scores :Davg= 0.067 Dmat= 0.670 z= +9.43 al=10 af=100% l=10,10
m,i,t=10,0,0
AL669970.50 3:1:103 1:0:251 0:1:151 1:1:180 1:0:170 0:1:130 1:2:133
AL160058.2 3:1:49 1:0:248 0:1:145 1:1:180 1:0:161 0:1:130 1:2:133
AL669970.50 2:1:92 1:2:106 2:0:148
AL160058.2 2:1:92 1:2:106 2:3:148
--------------------------------------------------------------------------------
Hit 3 :AL390195.3 (Novel)
Scores :Davg= 0.357 Dmat= 4.998 z= +2.64 al=14 af= 60% l=10,10 m,i,t=
6,8,0
\begin{tabular}{|c|c|c|c|c|c|c|c|}
\hline AL669970.50 & 3:1:103 & 1:0:251 & \(0: 1: 151\) & 1:1:180 & 1:0:170 & \(0: 1: 130\) & 1:2:133 \\
\hline & | | * & & & | | * & & & | | \\
\hline AL390195.3 & 3:1:115 & & & 1:1:186 & & & 1:2:142 \\
\hline AL669970.50 & 2:1:92 & & & & 1:2:106 & & 2:0:148 \\
\hline & | | * & & & & | | * & & | : \\
\hline 90195.3 & 2:1:50 & 0:7 & 0:1:55 & :1:72 & 1:2:109 & 2:2:69 & 2:3:16 \\
\hline
\end{tabular}
```

Figure 4.5 Summary of the FINEX search using the RXRA fingerprint (AL669970.50). The RXRA gene identified the RXRB and RXRG genes (in bold) with a $z$-score greater than 3.0 (as described in section 2.16.2.2; highlighted in red).

To summarise, by combining all three sets of results, or lines of evidence, it was found that, of the 27 paralogues identified by the initial sequence similarity search the RXRB gene has 25 L0-paralogues, no L1-paralogues, no L2-paralogues and two L3paralogues. The two L3-paralogues, or paralogues with the highest level of confidence, are the RXRG and RXRA genes located on 1 q 23.3 and 9 q 34.2 , respectively.

### 4.4.2 Identification of all the MHC paralogues in the human genome

Over two-thirds of the 128 MHC genes investigated in the genome survey have paralogues in the human genome with, at least, the lowest level of support (88/128); the remaining third have no paralogues detectable by this method. In summary, 30\% of the MHC genes with identified paralogues have L3-paralogues (26/88), 16\% have L2- paralogues (14/88), 18\% have L1-paralogues (16/88) and the remaining $36 \%$ have L0-paralogues (32/88). The results are summarised in table 4.2 and figure 4.6.

Table 4.2 Summary of the MHC genes with paralogues of increasing levels with support

| MHC Region | L0- <br> paralogues | L1- <br> Paralogues | L2- <br> Paralogues | L3- <br> Paralogues | Total |
| :--- | :---: | :---: | :---: | :---: | :---: |
| Extended class I | 3 | 5 | 4 | 3 | 15 |
| Class I | 5 | 4 | 2 | 4 | 15 |
| Class III | 6 | 4 | 5 | 13 | 28 |
| Class II | 11 | 2 | 2 | 3 | 18 |
| Extended class | 7 | 1 | 1 | 3 | 12 |
| II |  |  |  |  |  |
| Total | $\mathbf{3 2}$ | $\mathbf{1 6}$ | $\mathbf{1 4}$ | $\mathbf{2 6}$ | $\mathbf{8 8}$ |


$\mathrm{C}_{0}^{\mathrm{O}} \mathrm{F}$

 $\square \square \square \square \square \square \square \square \square \square \square \square \square \square \square \square \square \square \square \square \square \square \square \square \square \square \square \square \square \square \square \square \square \square \square \square \square \square \square \square \square \square \square \square \square \square \square \square \square \square \square \square \square \square \square \square$



Figure 4.6 Summary of the results of the whole-genome survey using 128 MHC genes. The MHC region is divided into five classes and the genes within each class are represented by coloured boxes; extended class I are cerise, class I yellow, class III orange, class II blue and extended class II are pink. Green filled boxes in row 2 indicate that paralogues were detected by the initial BLAST similarity search, turquoise filled boxes in row 3 indicate that paralogues were detected by the domain-masked BLAST search, purple filled boxes in row 4 indicate that paralogues were detected by FINEX and red filled boxes in row 5 represent genes that have paralogues with the highest level of confidence (L3-paralogues) in the human genome. Grey filled boxes indicate that no results were obtained by the corresponding analysis.

A total of 1057 BLAST similarity matches to the 128 MHC genes were identified with a P-value less than $10^{-5}$. Of the 1057 BLAST matches, 128 correspond to the MHC genes used in the analysis and a further 138 loci are located within the MHC region. The 138 loci represent the paralogous genes within the MHC region itself, for example the HIST1H2AC, HLA-A and HLA-E genes are all members of multigene families that share high sequence similarity and, therefore, BLAST sequence similarity search detected the other family members. These 138 loci have been removed from the analysis.

In total, 791 MHC paralogues have been identified outside the MHC region, of which 618 are L0-paralogues, 91 are L1-paralogues, 38 are L2-paralogues and 44 are L3paralogues (summarised in figure 4.7).


Figure 4.7 Summary of the proportion (\%) of BLAST hits corresponding to the paralogues with different levels of confidence.

The paralogues classified as either L2- or L3-paralogues have conserved gene structure, whereas the L0- and L1-paralogues have been identified by sequence similarity alone and may represent distantly related genes rather than paralogues, this will be discussed in section 4.4.6. In total, 44 L3-paralogues have been identified in
this analysis. Figure 4.8 summarises the number of paralogues with the different levels of confidence for each MHC gene used in the genome survey.


Figure 4.8 Summary of the MHC genes with L0- to L3-paralogues. The L0paralogues are shown in green, the L1-paralogues are in turquoise, the L2-paralogues are shown in purple and the L3-paralogues are in red. The y-axis on each graph represent the number of paralogues identified with each level of confidence (note scales differ) and the x -axis represent the MHC genes used in the analysis plotted (from left to right) in order from the most telomeric in the extended class I region (xI) to the most centromeric in the extended class II region (xII).

The MHC genes with L3-paralogues are not restricted to one region of the MHC and span almost the entire length of the region, including genes within the telomeric extended MHC class I region and the centromeric extended MHC class II region. Analysis of the distribution of the genes within the MHC region with L3-paralogues reveal 'hotspots' of genes with paralogues; one in particular is located towards the centromeric end of the class III region bordering the class II region. The genes located within this 'hotspot' include EGFL8, TNXB and NOTCH4 which have two, one and three paralogues in the human genome, respectively. There are also 'cold-spots' of MHC genes with no paralogues; namely surrounding the Ly6 gene family in the MHC class III region.

Figure 4.9 summarises the percentage of MHC genes with different numbers of L0-, L1-, L2- and L3-paralogues in the human genome. In general, the MHC genes do not have paralogues with the highest level of confidence; however, there are gene families with two or more L3-paralogues. For example, the C6orf29 gene has two L3paralogues and the BRD2 gene has three. In the extreme, the TUBB gene has seven L3-paralogues located in the human genome and the CLIC1 gene has five.


Figure 4.9 Summary of the percentage (\%) of MHC genes with no, 1, 2, 3, 4 or more L0, L1, L2 and L3-paralogues in the human genome

### 4.4.3 Distribution of MHC paralogues in the human genome

In order to determine the distribution of the MHC paralogues in the human genome the L0- to L3-paralogues were plotted on an ideogram of all 24 chromosomes (figure 4.10). The frequency of the paralogues per chromosome is summarised in table 4.3. Interestingly, the chromosomes with the highest number of L3-paralogues correspond to the chromosomes proposed to contain paralogous gene clusters. In contrast, chromosomes 2, 3, 4, 8 and Y do not contain any L2- or L3- paralogues, but do harbour paralogues with lower levels of support.

Table 4.3 Summary of the distribution of MHC paralogues in the human genome.

| Chromosome | L3- <br> paralogue | L2- <br> paralogue | L1- <br> paralogue | L0- <br> paralogue | Total |
| :---: | :---: | :---: | :---: | :---: | :---: |
| $\mathbf{1}$ | $\mathbf{1 2}$ | $\mathbf{1 0}$ | 11 | 62 | 95 |
| $\mathbf{2}$ | 0 | 0 | 6 | 37 | 43 |
| $\mathbf{3}$ | 0 | 0 | 2 | 36 | 38 |
| $\mathbf{4}$ | 0 | 0 | 7 | 22 | 29 |
| $\mathbf{5}$ | $\mathbf{2}$ | $\mathbf{1}$ | 15 | 28 | 46 |
| $\mathbf{6}$ | $\mathbf{3}$ | $\mathbf{1}$ | 2 | 29 | 35 |
| $\mathbf{7}$ | $\mathbf{0}$ | $\mathbf{2}$ | 8 | 31 | 41 |
| $\mathbf{8}$ | 0 | 0 | 2 | 23 | 25 |
| $\mathbf{9}$ | $\mathbf{1 2}$ | $\mathbf{5}$ | 5 | 33 | 55 |
| $\mathbf{1 0}$ | $\mathbf{1}$ | $\mathbf{0}$ | 1 | 27 | 29 |
| $\mathbf{1 1}$ | $\mathbf{0}$ | $\mathbf{8}$ | 10 | 34 | 52 |
| $\mathbf{1 2}$ | $\mathbf{1}$ | $\mathbf{1}$ | 3 | 25 | 30 |
| $\mathbf{1 3}$ | $\mathbf{0}$ | $\mathbf{1}$ | 3 | 19 | 23 |
| $\mathbf{1 4}$ | $\mathbf{0}$ | $\mathbf{1}$ | 1 | 13 | 15 |
| $\mathbf{1 5}$ | $\mathbf{0}$ | $\mathbf{1}$ | 3 | 26 | 30 |
| $\mathbf{1 6}$ | $\mathbf{1}$ | $\mathbf{0}$ | 1 | 21 | 23 |
| $\mathbf{1 7}$ | $\mathbf{1}$ | $\mathbf{1}$ | 0 | 31 | 33 |
| $\mathbf{1 8}$ | $\mathbf{1}$ | $\mathbf{0}$ | 1 | 2 | 4 |
| $\mathbf{1 9}$ | $\mathbf{6}$ | $\mathbf{5}$ | 0 | 48 | 59 |
| $\mathbf{2 0}$ | $\mathbf{1}$ | $\mathbf{0}$ | 2 | 17 | 20 |
| $\mathbf{2 1}$ | $\mathbf{1}$ | $\mathbf{0}$ | 0 | 10 | 11 |
| $\mathbf{2 2}$ | $\mathbf{1}$ | $\mathbf{0}$ | 8 | 12 | 21 |
| $\mathbf{X}$ | $\mathbf{1}$ | $\mathbf{1}$ | 0 | 30 | 32 |
| $\mathbf{Y}$ | 0 | 0 | 0 | 2 | 2 |
| Total | $\mathbf{4 4}$ | $\mathbf{3 8}$ | $\mathbf{9 1}$ | $\mathbf{6 1 8}$ | $\mathbf{7 9 1}$ |



Figure 4.10 Distribution of MHC paralogues in the human genome. Column A represents all BLAST similarity matches with a P-value less than $10^{-5}$. Column B represents the BLAST matches still detected after the domain-masking filtering step, column C represents BLAST matches still detected after the FINEX filtering step. The final column (D) represents the BLAST matches which passed both filtering steps and represent the L3 paralogues. The lines correspond to the paralogues and are colour-coded according to type: black represent L0-paralogues, green L1paralogues, blue L2-Paralogues and red L3-paralogues. The data used to generate this figure is summarised in Appendix 2.

In total, 82 L2- and L3-paralogues of genes located within the MHC region have been identified elsewhere in the genome, and correspond to 29 MHC gene families. Almost $50 \%(40 / 82)$ of these paralogues are confined to the paralogous regions on 1 q21.2q25.3, $9 \mathrm{q} 32-\mathrm{q} 34.3$ and 19 p 13.3 -p13.11 and the remaining $51 \%$ are scattered throughout the genome. In total, 38 of the 82 L2- and L3-paralogues are novel findings.

### 4.4.4 MHC paralogues located on chromosomes 1, 9 and 19

The whole genome survey has confirmed that there are clusters of paralogues on chromosomes 1, 9 and 19. The distribution of the L2- and L3-paralogues on these three chromosomes and the corresponding MHC genes is summarised in figure 4.11. Each of the 29 MHC genes and their respective paralogue(s) are represented by coloured symbols and the distance separating the genes along each chromosome is given. In order to compare the findings of the whole genome survey with previous publications, a comprehensive list of the 78 putative paralogues already described in the literature was obtained by combining the gene lists published by Kasahara (1999a; 1999b) and Flajnik and Kasahara (2001). Each of the chromosomes will be discussed individually in the following sections.

Figure 4.11 Summary of MHC paralogues on chromosomes 1, 9 and 19. The MHC genes on chromosome 6 and corresponding paralogues are represented by coloured symbols. The distance, in kilobases, between paralogues is shown below the gene track. The cytogenetic loci are given in blue text below the gene track for some paralogues for orientation purposes. The paralogous regions are boxed and shaded peach 1q21.2-q25.3, blue for 9q32-q34.3 and yellow corresponds to 19p13.3-p13.11.


### 4.4.4.1 Chromosome 1 paralogues

There are a total of 49 putative paralogues located on the long arm of chromosome 1 spanning from 1q21.1 to 1 q 44 , of which, 28 are L0-paralogues, five are L1paralogues, eight are L2-paralogues and eight are L3-paralogues. The L2- and L3paralogues are summarised in table 4.4.

Table 4.4 Summary of the L2- and L3-paralogues on chromosome 1. The paralogues shown in red are novel and the paralogous region is shaded orange.

|  | MHC gene | MHC Region | Paralogue | Locus | Confidence |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  | CLIC1 | III | CLIC4 | 1 p 35.3 | 3 |
|  | C6orf29 | III | NM_152697 | 1 p 31.1 |  |
|  | DDAH2 | III | DDĀH1 | 1 p 22.3 | 2 |
|  | BRD2 | II | BRDT | 1 p 22.1 | 3 |
|  | COL11A2 | xII | COL11A1 | 1 p 21.1 | 2 |
|  | NOTCH4 | III | NOTCH2 | 1 p 11.2 | 3 |
|  | Histone cluster | xI | Histone cluster | 1 q 21.2 | 2 |
|  | POU5F1 | I | Q9BZW0 | 1 q 22 | 3 |
|  | HFE | xI | CD1A | 1 q 23.1 | 2 |
|  | HSPA1L | III | HSPA6 | 1 q 23.3 | 2 |
|  | CREBL1 | III | ATF6 | 1 q 23.3 | 3 |
|  | DDR1 | I | DDR2 | 1 q 23.3 | 3 |
|  | PBX2 | III | PBX1 | 1 q 23.3 | 3 |
|  | RXRB | xII | RXRG | 1 q 23.3 | 3 |
|  | BAT2 | III | BAT2-ISO | 1 q 24.3 | 3 |
|  | TNF | III | TNFSF6 | 1 q 24.3 | 2 |
|  | TNXB | III | TNR | 1 q 25.1 | 3 |
|  | HLA Class I/II | I/II | HLALS | 1 q 25.3 | 2 |
|  | RAB2L | xII | RGL1 | 1 q 25.3 | 2 |
|  | RING1 | xII | RNF2 | 1 q 25.3 | 3 |
|  | ATP6V1G2 | III | ATP6V1G3 | 1 q 31.3 | 2 |
|  | Histone cluster | xI | H2-like | 1 q 4.13 | 2 |

The chromosome 1 paralogous region is defined by a histone cluster at the most centromeric end (1q21.2) and the RNF2 paralogue of RING1, spanning approximately 35 Mb (summarised in figure 4.11). The centromeric histone cluster is reminiscent of the histone cluster located in the extended MHC class I region. In addition to the
histone gene cluster (considered here as a single entity), there are eight L3-paralogues six L2- paralogues, one L1-paralogue and 11 L0-paralogues located within this region. Within the paralogous region there is a small cluster of L2- and L3-paralogues spanning from the CREBL1 paralogue, ATF6 (most centromeric), located on 1q23.3 to the TNXB paralogue, TNR, located on 1q25.1 (telomeric). This cluster contains seven MHC paralogues with level 2 or 3 confidences encompassing 13.4 Mb .

In addition to the paralogues located within the region on the q -arm of chromosome 1 , there are six L2- and L3-paralogues located on the short arm of chromosome 1, of which some have previously been cited as being part of the paralogous region on chromosome 1 (reviewed by Kasahara, 1999b). It is believed that the paralogous gene cluster was split onto both arms as a result of the insertion of the centromere or by a perincentromeric inversion of chromosome 1 (reviewed by Kasahara, 1999b). Thus, the four L3-paralogues may have been part of the original paralogous gene cluster on the q -arm and have since been separated.

In total, three new paralogues have been identified in the genome survey, which have previously not been cited in the literature. The three novel paralogues are a C6orf29like gene (NM_152697) on 1p31.1, a POU5F1-like gene (Q9BZW0) and the ATP6V1G3 gene, which is a paralogue of the MHC class III gene ATP6V1G2. A paralogue of the MHC class I gene, POU5F1, has previously been cited in the literature on 1p34.1 (POU3F1) but this was not the paralogue identified in this analysis.

The L2- and L3-paralogues located on both arms of chromosome 1 correspond to 21 MHC gene families. However, 31 paralogues corresponding to 26 MHC gene families have previously been identified on chromosome 1 (see Flajnik and Kasahara (2001)
for most recent gene list). In this analysis 18 have been identified as L2- and L3paralogues, three were identified with the lowest level of support and nine were not identified at all. Of the ten paralogues not identified, four are paralogues of MHC genes that were excluded from the analysis for reasons given in section 4.2. The remaining five paralogues were not detected in the genome survey because of low protein sequence identity and is discussed in more detail in section 4.4.4.4.

The NTRK1 gene, located on 1q23.1, has been cited as a paralogue of the MHC class I gene DDR1 (Flajnik and Kasahara, 2001) and, in this survey of the human genome, was identified as a paralogue with the lowest level of support (L0-paralogue). The NTRK1 gene was identified by the BLAST sequence similarity search but, once the known domains were masked, it did not have conserved sequence identity beyond these regions. The gene structure is also very different to that of the DDR1 gene and shows high conservation with the NTRK2 gene located on 9q21.33. The NTRK2 gene has also been cited as a paralogue of DDR1 but was only identified as an L0paralogue in this analysis. Evidence, based on gene structure and protein sequence similarity, indicates that NTRK1 is paralogous to NTRK2 but is more distantly related to DDR1. Therefore, the DDR2 gene located on 1q23.3 (an L3-paralogue) represents the only true paralogue of DDR1 in the human genome. Thus demonstrating how the genome-wide survey presented in this chapter has enabled errors to be corrected.

### 4.4.4.2 Chromosome 9 paralogues

Chromosome 9 harbours 55 paralogues, of which 17 are L2- and L3-paralogues (summarised in table 4.5).

Table 4.5 Summary of the L2- and L3-paralogues on chromosome 9. The paralogues shown in red text are novel and the paralogous region is shaded blue.

|  | MHC gene | MHC Region | Paralogue | Locus | Confidence |
| :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{aligned} & \text { Q } \\ & \text { © } \\ & 0 \\ & 0 \\ & 0 \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ | NOL5B | xI | NOL5B-L | 9p21.3 | 3 |
|  | GABBR1 | xI | GPR51 | 9q22.33 | 2 |
|  | ATP6V1G2 | III | ATP6V1G1 | 9 q 32 | 2 |
|  | TNF | III | TNFSF15 | 9 q 32 | 2 |
|  | TNXB | III | TNC | 9 q 33.1 | 3 |
|  | C4 | III | C5 | 9 q 33.2 | 2 |
|  | PBX2 | III | PBX3 | 9 q 33.3 | 3 |
|  | AIF1 | III | NM_031426 | 9 q 34.12 | 3 |
|  | RAB2L | xII | RALGDS | 9 q 34.2 | 3 |
|  | BRD2 | II | BRD3 | 9 q 34.2 | 3 |
|  | RXRB | xII | RXRA | 9 q 34.2 | 3 |
|  | COL11A2 | xII | COL5A1 | 9 q 34.3 | 2 |
|  | NOTCH4 | III | NOTCH1 | 9 q 34.3 | 3 |
|  | EGFL8 | III | ZNEU1 | 9 q 34.3 | 3 |
|  | AGPAT1 | III | AGPAT2 | 9 q 34.3 | 3 |
|  | CLIC1 | III | CLIC3 | 9 q 34.3 | 3 |
|  | BAT8 | III | HMT1 | 9 q 34.3 | 3 |

There is only one L3-paralogue located on the p-arm of chromosome 9, NOL5B-L, which is a novel finding. To-date, no paralogues of the extended MHC class I encoded gene, NOL5B, have been discussed in the literature. The L3-paralogue is actually a 'Novel' protein and, has been termed NOL5B-L in this thesis. The paralogous region encompasses the regions 9 q 32 to 9 q 34.3 (refer to chapter 3 for more detail; also see figure 4.11) spanning from the ATP6V1G2 paralogue, ATP6V1G1, to the BAT8 paralogue, HMT1 (approximately 24 Mb ). Within this region there are 28 putative paralogues; 15 L2- and L3-paralogues, one L1- paralogue and 12 L0-paralogues. There are two small clusters located within the defined boundaries; cluster 1 spans from the AIF1-L paralogue (9q34.12) to COL5A1 (9q43.3) encompassing approximately 4 Mb and the second cluster spans approximately 14.8 Mb from NOTCH1 (9q34.3) to HMT1 (9q34.3). There is an additional L3-paralogue located on 9q22.33, almost 16 megabases centromeric of the

ATP6V1G2 gene defining the paralogous gene cluster on $9 \mathrm{q} 32-\mathrm{q} 34.3$. This is the previously published GPR51 gene, which is paralogous to the GABBR1 gene.

In total, 30 putative paralogues have been identified in the literature, corresponding to 27 MHC gene families, and are cited as being located within the paralogous region on chromosome 9. The whole genome survey has identified 15 as L2- and L3paralogues, 1 as a pseudogene (TUBB2) and two as L0-paralogues. In total, nine of the 31 putative paralogues were not identified in the genome survey presented in this chapter. Two of these putative paralogues are paralogous to MHC genes not used in the genome survey, for reasons discussed in section 4.2, and the remaining five were not identified because they share low sequence similarity with the corresponding MHC encoded protein (discussed in more detail in section 4.4.4.4).

One gene of interest is the BAT2 gene located within the MHC class III region. The KIAA0515 gene located on chromosome 9 has been cited as a putative paralogue of BAT2, but it was not identified as a paralogue in my analysis. However, an L1paralogue has been identified, which is the neighbouring gene of KIAA0515 in the genome. In addition to the new NOL5B paralogue identified on the p-arm of chromosome 9, a novel paralogue of the EGFL8 gene, ZNEU1, has been discovered on 9 q 34.3 . This MHC gene was previously not identified as being part of the published MHC paralogous group.

### 4.4.4.3 Chromosome 19 paralogues

Sixteen putative paralogues have previously been identified on the short arm of chromosome 19. The genome-wide survey presented in this chapter identified nine of
these as L2- or L3-paralogues (table 4.6). The seven remaining putative paralogues were not identified at all; three were not identified because they are paralogous to MHC genes not used in this analysis (for the reasons given in section 4.2), and four share low sequence similarity with the corresponding MHC encoded protein (discussed in section 4.4.4.4).

Table 4.6 Summary of the L2- and L3-paralogues on chromosome 19. The paralogues shown in red text are novel and the paralogous region is shaded yellow.

|  | MHC gene | MHC Region | Paralogue | Locus | Confidence |
| :---: | :---: | :---: | :---: | :---: | :---: |
| O00000000 | TUBB | I | TUBB5 | 19p13.3 | 3 |
|  | TNF | III | TNFSF14 | 19p13.3 | 2 |
|  | C4B | III | C3 | 19p13.3 | 2 |
|  | COL11A2 | xII | COL5A3 | 19p13.2 | 2 |
|  | C6orf29 | III | CTL2 | 19p13.2 | 3 |
|  | RAB2L | xII | Q8TEP0 | 19p13.2 | 2 |
|  | BAT1 | III | DDX39 | 19p13.13 | 3 |
|  | NOTCH4 | III | NOTCH3 | 19p13.12 | 3 |
|  | BRD2 | II | BRD4 | 19p13.12 | 3 |
|  | PBX2 | III | PBX4 | 19p13.11 | 3 |
|  | HLA Class I | I | FCGRT | 19q13.33 | 2 |

The paralogous region spans approximately 13.6 Mb (figure 4.11 ) from the TUBB5 gene at the telomere to the PBX4 gene towards the centromere. In total, 25 paralogues are located within this region, of which, six are L3-paralogues, four are L2-paralogues and 15 are L0-paralogues. Within this region there is a smaller cluster of paralogues spanning almost 9.9 Mb from the COL5A3 gene (19p13.2) to the PBX4 (19p13.11) gene encompassing seven L2- and L3-paralogues. In addition there is an HLA class I like gene, FCGRT, located on the q -arm of chromosome 19.

Two new paralogues were identified within the paralogous region on 19p13.3-p13.11. The TNFSF14 gene is paralogous to the tumour necrosis factor (TNF) gene located
within the MHC class III region. Although, other members of the TNF family have been identified in the literature as putative TNF paralogues, this paralogue is a novel finding. The second new paralogue extends the RAB2L paralogous gene family from two to three members, and the family now has members located in the MHC extended class II region, on 1q25.3 (RGL1) and 19p13.2 (Q8TEP0).

### 4.4.4.4 Putative paralogues not identified in the genome-wide survey

Of the 78 putative paralogues presented in the literature, $32 \%$ were not identified in the whole genome survey presented in this thesis (summarised in table 4.7). The strategy I used to identify paralogues relies on sequence similarity (as described in section 4.2). Therefore, if the protein sequence similarity is too low it is either not detected by a BLAST similarity search using the parameters described in section 2.16 or has a P -value greater than $10^{-5}$ and is filtered from the BLAST results because it is regarded as either insignificant or a distant relative (Lesk, 2002). This is exemplified by the tumour necrosis factor genes, LTA, TNF and LTB, located in the MHC class III region. In total, seven putative paralogues of these three genes have been discussed in the literature; however, only two were identified in my genome-wide analysis. This is because they share less than $20 \%$ protein sequence identity which will probably not be detectable by the BLAST algorithm used in this analysis, WU-BLAST2 (discussed in more detail in section 4.4.7; Brenner et al, 1998).

Table 4.7 Summary of the putative MHC paralogues not identified in my genomewide survey. The putative paralogues of MHC genes not used in the analysis are shaded in lilac and are in italics.

| $\begin{array}{\|l} \hline \text { MHC } \\ \text { region } \\ \hline \end{array}$ | MHC Gene | Published paralogue | Published locus |
| :---: | :---: | :---: | :---: |
| xI | HMG17L3 | HMG17 | 1p36.5-p35 |
| xI | PRSS16 | DPP7 | 9 q 34 |
| $x I$ | ZNF184 | ZNF85 | 19p12-p13.1 |
| xI | ZNF184 | ZNF91 | 19p12-p13.1 |
| xI | GPX5 | GPX4 | 19p13.1 |
| xI | OR cluster | OR cluster | 9q21-q22, 9q34 |
| $x I$ | OR cluster | OR cluster | 19p13.1 |
| $I$ | KIAA0170 | PRG4 | 1q25-q31 |
| III | TNF/LTA/LTB | TNFSF18 | 1q23 |
| III | TNF/LTA/LTB | TNFSF4 | 1 q 25 |
| III | TNF/LTA/LTB | TNFSF8 | 9 q 33 |
| III | TNF/LTA/LTB | TNFSF9 | 19p13 |
| III | TNF/LTA/LTB | TNFSF7 | 19p13 |
| III | AIF1 | AIF 1-L | 1p33-p34 |
| III | HSPA1L | HSPA5 | 1 q 23.3 |
| III | C6orf29 | CTL1 | 9 q 31.1 |
| III | C6orf46 | KIAA1572 | 9 q 33.3 |
| III | C6orf46 | KIAA0414 | 9 q 33.3 |
| III | C6orf46 | ZNF91 | 19p13.1 |
| III | PPT2 | PPT1 | 1 p 32 |
| II | TAP2/1 | ABCA2 | 9 q 34 |
| II | PSMB8/9 | PSMB7 | 9q34.11-q34.12 |
| xII | RPS18 | RPS18-like | 1q22-q23 |
| xII | LYPLA2L | LYPLA2 | 1p36.12-p35.1 |
| xII | RPL12L | RPL12 | 9 934 |

### 4.4.4.5 Comparison of the order of L2- and L3-paralogues located on

 chromosomes 1, 9 and 19Now that the MHC paralogues have been identified in the proposed paralogous regions on chromosomes 1,9 and 19 it is interesting to compare the gene order between chromosomes (summarised in figure 4.12).


Figure 4.12 Comparison of the order of L2- and L3-paralogues on chromosomes 1, 9 and 19. The gene names in red represent L3-paralogues and the L2-paralogues are shown in black. Continued on next page.


Figure 4.12 Continued. See previous page for legend.

If the four regions did arise by block duplication events, they would be expected to have detectable conservation of gene order (Endo et al, 1997). In general, the order of paralogues is not conserved. However, this is not surprising if hundreds of millions of years have passed since their emergence by duplication. The most interesting group of paralogues in this context are the paralogues with copies on all four chromosomes. In total, there are five MHC genes with paralogues that have been conserved on all four paralogous regions; they are NOTCH4, PBX2, COL11A2, BRD2 and RAB2L. Comparison of the gene order of the five genes in each region reveals that they are not strictly conserved (summarised in figure 4.13).

Chromosome 6 TNF-PBX2-NOTCH4-BRD2-COL11A2-RAB2L

Chromosome 1
BRDT-COL11A1-NOTCH2-PBX1-TNFSF6-RGL1

Chromosome 9

Chromosome 19
TNFSF14-COL5A3-RAB2L-L-NOTCH3-BRD4-PBX4

Figure 4.13 Comparison of the MHC paralogues with copies on all four paralogous regions. The MHC genes and corresponding paralogues are represented by the same coloured text.

However, there are pairs of genes that are in the same order on two or more of the chromosomes, such as the paralogues of the chromosomes 6 genes BRD2 and COL11A2 are in the same order on chromosomes 1 and 9. The TNF and PBX2 paralogues on chromosome 9 are also in the same order, whereas the paralogues of PBX2 and NOTCH4 on chromosome 1 are in the reverse orientation. Thus, showing
that if the genes did emerge together as part of a series of block duplication events the regions have been subjected to extensive chromosomal rearrangements.

As mentioned in chapter 3, Flajnik and Kasahara (2001) analysed the gene order of all four proposed paralogous regions in the most recent analysis of the MHC paralogues. One of the examples of gene order conservation mentioned in this study involved six paralogues on chromosomes 9 and 19; they are (using chromosome 9 gene symbols) CTL1 (not identified as a true paralogue in this genome survey), TNFSF15, C5, DNM1 (does not have a paralogue in the MHC region therefore not identified in this analysis), BRD3 and NOTCH1. The genome survey presented in this chapter reveals that the order is not conserved overall and that the paralogues of BRD3 and NOTCH1 on chromosome 19 are actually in the reverse order. Therefore, the gene order of the chromosome 19 paralogues (TNFSF14-C3-NOTCH3-BRD4) is identical to the order on chromosome 6 (TNF-C4-NOTCH4-BRD2) rather than chromosome 9 (TNFSF15-C5-BRD3-NOTCH1). In comparison, the order of the equivalent paralogues identified on chromosome 1 (BRDT-NOTCH2-TNFSF6) is actually the reverse order of chromosomes 6 and 19.

### 4.4.5 Paralogues located outside the paralogous regions

One of the most interesting and novel findings of the whole-genome survey was that not all paralogues are confined to the paralogous regions on chromosomes 1, 9 and 19 but others are scattered throughout the genome (table 4.8).

Table 4.8 Summary of the MHC paralogues located outside the paralogous regions on chromosomes 1, 9 and 19. Cells shaded grey represent paralogues discussed in previous sections.

|  | MHC gene | MHC Region | Paralogue | Locus | Confidence |
| :---: | :---: | :---: | :---: | :---: | :---: |
| 1 | CLIC1 | III | CLIC4 | 1 p 35.3 | 3 |
|  | C6orf29 | III | NM 152697 | 1 p 31.1 | 3 |
|  | DDAH2 | III | DDĀH1 | 1 p 22.3 | 2 |
|  | BRD2 | II | BRDT | 1 p 22.1 | 3 |
|  | COL11A2 | xII | COL11A1 | 1 p 21.1 | 2 |
|  | NOTCH4 | III | NOTCH2 | 1 p 11.2 | 3 |
|  | ATP6V1G2 | III | ATP6V1G3 | 1 q 31.3 | 2 |
|  | Histone cluster | xI | H2-like | 1 q 42.13 | 2 |
| 2 | No L2 or L3 paralogues |  |  |  |  |
| 3 | No L2 or L3 paralogues |  |  |  |  |
| 4 | No L2 or L3 paralogues |  |  |  |  |
| 5 | SMA3LHistoneGPX5 | xI | Novel | 5p13.3 | 3 |
|  |  | xI | H2AFY | 5q31.1 | 2 |
|  |  | xI | GPX3 | 5q33.1 | 3 |
| 6 | TUBB | I | TUBBL | 6p25.2 | 3 |
|  | TUBB | I | TUBBL2 | 6p25.2 | 3 |
|  | CLIC1 | III | CLIC5 | 6 p 21.1 | 3 |
|  | MAS1L | xI | MAS1 | 6 q 25.3 | 2 |
|  | HSPA1L | III | Genscan prediction | 7 p 21.3 | 2 |
| 7 | HLA Class I | xI | AZGP1 | 7 q 22.1 | 2 |
| 8 | No L2 or L3 paralogues |  |  |  |  |
|  | NOL5B | xI | Genscan | 9 p 21.3 | 3 |
| 9 | GABBR1 | xI | GPR51 | 9 q 22.33 | 2 |
| 10 | TUBB | I | Q8WZ78 | 10p15.3 | 3 |
| 11 | MAS1L | xI | Novel | 11p15.4 | 2 |
|  | MAS1L | xI | MRGX3 | 11p15.1 | 2 |
|  | MAS1L | xI | MRGX4 | 11p15.1 | 2 |
|  | MAS1L | xI | MRGX1 | 11p15.1 | 2 |
|  | MAS1L | xI | Novel | 11p15.1 | 2 |
|  | MAS1L | xI | MRGX2 | 11p15.1 | 2 |
|  | MAS1L | xI | Q8TDS 7 | 11q13.3 | 2 |
|  | Histone | xI | H2AFX | 11q23.3 | 2 |
| 12 | Histone | xI | H2AFJ | 12p12.3 | 2 |
|  | TAP2/1 | II | ABCB9 | 12 q 24.31 | 3 |
| 13 | Histones | xI | H2A-like | $13 q 32.3$ | 2 |
| 14 | HSPA1L | III | HSPA2 | 14 q 23.3 | 2 |
| 15 | Histones | xI | H2 -like | 15 q 26.1 | 2 |
| 16 | TUBB | I | TUBB4 | 16 q 24.3 | 3 |
| 17 | PSMB9 | II | PSMB6 | 17p13.2 | 2 |
|  | FLOT1 | I | FLOT2 | 17 q 11.2 | 3 |
| 18 | TUBB | I | TUBBL | 18p11.32 | 3 |
| 19 | HLA Class I | 1 | FCGRT | 19 q 13.33 | 2 |
| 20 | TUBB | I | TUBB1 | 20q13.32 | 3 |
| 21 | CLIC1 | III | CLIC6 | 21q22.12 | 3 |
| 22 | RNF5 | III | Q96GF1 | 22q12.2 | 3 |
| X | CLIC1 | III | CLIC2 | Xq28 | 3 |
|  | Histones | xI | H2AFB | Xq28 | 2 |

In total, there are 43 L2- and L3-paralogues located outside the paralogous regions on 1q21.2-q25, 9 q32-q34.3 and 19p13.3-p13.11; corresponding to over $50 \%$ of the total number of L2- and L3-paralogues identified. The paralogues located outside the paralogous regions predominately exist as singletons. Singletons are paralogues which are not in clusters or pairs with other paralogues and exist as a single entity in the genome. Nevertheless, there are paralogues located within clusters, for example there is a cluster of paralogues of the MAS1L gene located on chromosome 11 p15.1. In addition, another MAS1L paralogue is located on 11q13.3. Chromosome 6 contains four paralogues, of which two are TUBB paralogues located within 70 kb of each other. There is also a CLIC1 paralogue (CLIC4) and a MAS1L paralogue (MAS1) located on the p -arm and q -arm, respectively.

Of the 44 L2- and L3-paralogues located outside the paralogous regions, 32 are novel findings. This corresponds to $89 \%(32 / 36)$ of all the new paralogues identified in this analysis. The chromosome harbouring the largest number of paralogues is chromosome 11 with a total of 8 , including the MAS1L paralogue gene cluster. The majority of chromosomes only have one L2- or L3-paralogue; however, chromosomes 5, 7, 12 and 17 contain two to three paralogues. Chromosomes 2, 3, 8 and 12 do not contain any L2- or L3-paralogues.

### 4.4.6 L0- and L1-paralogues

The L0- and L1-paralogues were identified in the genome survey based on sequence similarity alone. Analysis of the 709 paralogues has revealed that they largely represent homologues with shared domains and are members of a protein superfamily.

For example, the DHX6 gene has 19 L0-paralogues and no paralogues have been identified with higher levels of support. The DHX6 gene is a member of the DEAD box helicase protein superfamily, which is a very large family of proteins with over 60 members identified in the human genome (ENSEMBL NCBI 31). Of the 709 paralogues with the lowest level of support it is expected that only the minority will represent paralogues and the majority will be homologues that share similar domains and are distantly related. For examples, the NR5A2 gene on 1q32.1 was detected as an L0-paralogue of the RXRB gene but it is actually a distant relative. Both the RXRB and NR5A2 genes belong to the nuclear receptor gene superfamily and have the same domains. Therefore, the NR5A2 gene was identified as a paralogue because of sequence similarity to the domain regions, but it is actually a more distant relative.

### 4.4.7 Caveats associated with my strategy

Paralogues are genes that are found within the same genome and have originated through duplication of an ancestral gene. Immediately after duplication the paralogous genes will be identical; they will have the same exon fingerprint, DNA sequence and code for the same protein. These features have been used in my strategy to identify paralogues in the human genome. However, this type of analysis has its limitations. Over time a number of evolutionary processes may act upon the genomic sequence that will result in changes to the DNA, gene structure and, consequently, the encoded protein. Such processes include exon shuffling and mutations that will render the genes undetectable as paralogues by my strategy. Therefore, paralogues do not necessarily have any sequence similarity at all. This is one of the inherent difficulties of this type of research and the main caveat associated with the strategy I have used to
identify paralogous genes, exemplified by the HLA class I-like genes.

There are several HLA class I-like genes located outside the extended MHC region in the human genome; the CD1A-E genes (1q22-q23), AZGP1 (7q22.1), FCGRT (19q13.33) and HLALS (1q25.3) and RAET1E-N genes ( $6 \mathrm{q} 24.2-\mathrm{q} 25.3$ ). The CD1 genes, AZGP1, FCGRT and HLALS have previously been cited as putative paralogues. However, they were not all identified in the genome survey because they share low sequence similarity with the five HLA class I and class I-like genes, HFE, HLA-A, HLA-E, MICA and MICB, used in the genome survey (summarised in table 4.9).

Table 4.9 Summary of the P-values obtained for the HLA class I-like genes (column 1) from the BLAST similarity search using HFE, HLA-A, HLA-E, MICA and MICB, and the percentage sequence identities (\%ID) determined from a global sequence alignment. The four HLA class I-like genes identified as paralogues in the genome survey, and the corresponding P-values and \% IDs, are in red. The shaded boxes denote that the HLA class I-like gene was not detected by BLAST search using the MHC encoded protein sequence, therefore no P-values was obtained.

| HLA class <br> I-like gene | HFE |  | HLA-A |  | HLA-E |  | MICA |  | MICB |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | $P$-value | \%ID | $P$-value | \%ID | $P$-value | \%ID | $P$-value | \%ID | $P$-value | \%ID |
| CD1A | 2.6e-05 | 23.9 |  | 25.10 | 0.014 | 24.70 | 0.054 | 24.1 | 0.58 | 23.0 |
| CD1B |  | 20.8 |  | 23.80 |  | 25.40 |  | 23.8 |  | 22.4 |
| CD1C |  | 22.3 |  | 23.70 |  | 22.40 |  | 23.4 |  | 22.9 |
| CD1D | 0.012 | 25.6 | 0.013 | 23.90 | 0.12 | 24.80 | 0.097 | 24.5 | 0.98 | 22.2 |
| CD1E |  | 22.1 |  | 25.80 |  | 22.40 |  | 24.3 |  | 21.2 |
| HLALS | 3.5e-31 | 38.8 | 5.8e-38 | 37.20 | 3.3e-38 | 39.10 | 1.1e-18 | 30.4 | 3.2e-15 | 27.0 |
| RAET1E |  | 23.6 |  | 22.70 |  | 18.80 | 0.039 | 27.7 |  | 28.9 |
| ULBP2 | 0.013 | 26.4 |  | 24.60 | 0.999950 | 28.00 |  | 26.9 |  | 22.9 |
| ULBP1 |  | 24.2 |  | 24.70 |  | 26.10 |  | 22.5 |  | 23.0 |
| RAET1L |  | 27.7 |  | 24.10 |  | 26.90 |  | 26.7 |  | 24.1 |
| ULBP3 |  | 24.7 | 0.47 | 26.60 | 0.31 | 26.00 |  | 26.5 |  | 25.9 |
| AZGP1 | 8.3e-29 | 37.5 | 1.9e-34 | 38.80 | 3.8e-29 | 35.70 | 5.4e-08 | 30.0 | 2.5e-07 | 29.2 |
| FCGRT | 8.6e-10 | 29.4 | 2.1e-09 | 31.20 | 1.3e-13 | 31.30 | 7.9e-06 | 27.2 | 0.00059 | 24.3 |

The percentage amino acid sequence identities between the class I like protein sequence and the protein sequences used in the analysis (HFE, HLA-A, HLA-E, MICA and MICB) are within the 'Twilight Zone' of homology; described as between $15 \%$ and $25 \%$ amino acid identity (Doolittle et al, 1986). The BLAST algorithm used in this analysis, WU-BLAST2, is capable of detecting almost all relationships between proteins whose sequence identities are greater than $30 \%$ but is only $50 \%$ effective when the proteins have sequence identities between 20 and $30 \%$ (Brenner et $a l, 1998)$. Thus, it is not unexpected that the HLA class I like genes were not detected at all or only detected with a low P-value (summarised in table 4.9). In cases like these, with low sequence similarity, the Position-Specific Iterated BLAST (or PSIBLAST) program could have been used. This is the most sensitive BLAST program and is designed to detect more distantly related proteins. However, at this time it was not possible to use this program to search the assembled human genome sequence in ENSEMBL.

To summarise, HLALS, AZGP1, FCGRT and CD1A were the only HLA class I-like genes identified as paralogues in this genome survey. Interestingly, other members of the CD1 cluster and members of the RAET1/ULBP gene cluster were found by the BLAST similarity search, although the P-values for members of this gene cluster were more than the designated BLAST cut-off, $10^{-5}$, and were therefore eliminated from the analysis. Thus, indicating that, in this case, the search criteria were too strict to detect this family of HLA class I-like genes. Using the gene architectural information the HLALS, AZGP1, FCGRT and CD1A genes were classified as L2-paralogues. No HLA class I-like genes were classified as L3-paralogues as the detectable homology is restricted to the shared immunoglobulin domain only.

The RAET1/ULBP genes are a novel family of HLA class I-like genes located outside the MHC region (Radosavljevic et al, 2002). Although they are recognised as being related to the HLA class I genes they have not been identified as paralogues in this, or any other analysis performed to-date. In order to determine the relationship between the HLA class I genes and the RAET1-N genes an independent FINEX analysis was performed using RAET1N (alias ULBP3) which was detected by BLAST analysis of HFE, HLA-A and HLA-E protein sequences, albeit with very high P-values. The highest $z$-scores, not exceeding 4.5, were to the PROCR gene, located on 20q11.2, and to the HLA class II genes located within the MHC region. The PROCR gene is an endothelial protein involved in the blood coagulation pathway which shares the same tridomain backbone as the HLA class I and class I-like genes. The HLA class II genes are believed to have arisen from the same ancestral gene but have since undergone significant expansion by gene duplication (reviewed by Beck and Trowsdale, 2000), thus the original HLA class I and class II genes are paralogous. In addition, gene structure homology was also detected for members of the CD1 gene cluster with zscores approximately 3.5 , to FCGRT with a z-score of approximately 3.2 and to HLAA with a z-score of 3.4. Thus, showing that the relationship of this complex family of HLA class I genes and HLA class I-like genes cannot be determined using sequence similarity alone and demonstrates the importance of using additional criteria to detect paralogous relationships, such as exon fingerprints.

### 4.5 Discussion

The genome-wide survey presented in this chapter shows the true distribution of MHC paralogues in the human genome. Not only has this piece of research confirmed that there are regions on chromosomes 1, 9 and 19 that contain clusters of MHC paralogues but I have also shown that there are paralogues located throughout the human genome. Furthermore, I have also presented a novel method to identify and classify the MHC paralogues, in which the paralogues are initially identified based on sequence similarity, but, by applying additional knowledge of gene structure and domain content, paralogues with increasing levels of confidence ( $\mathrm{L} 0>\mathrm{L} 1>\mathrm{L} 2>\mathrm{L} 3$ ) are identified.

In total, 82 L2- and L3-paralogues of genes located within the MHC region were identified in the genome, corresponding to 29 MHC gene families. Almost $50 \%$ are located within the paralogous gene clusters on 1q21.2-q25.3, 9q32-q34.3 and 19p13.3-p13.1. Analysis of the paralogous genes within the clusters on 1,9 and 19 defined the boundaries of these paralogous gene clusters as $1 \mathrm{q} 21.2-\mathrm{q} 25.3,9 \mathrm{q} 32-\mathrm{q} 34.3$ and 19p13.3-p13.1. As discussed in the literature (such as Kasahara 1999a) there is also a smaller cluster of six paralogues located on the short arm of chromosome 1 , which span over 95 Mb of genomic sequence. The paralogous gene cluster on the qarm spans from 1q21.2 to 1 q 25.3 and contains one histone cluster, the CD1 gene cluster and 12 single MHC paralogues and encompasses approximately 35 Mb of genomic sequence. The region 9q32-q34.3 spans approximately 24 Mb and 19p13.3p13.1 encompasses almost 14 Mb , each cluster contains 15 and 10 MHC L2- or L3paralogues, respectively. In concordance with my results, McLysaght and co-workers (2002) conducted an analysis of the entire draft human genome sequence in order to
identify paralogons, or pairs of regions containing duplicated genes. The most extensive region paired 41 Mb of chromosome 1 q , including the tenascin paralogue TNR, with a 20 Mb region of chromosome 9 q , including the TNC gene.

The existence of four paralogous gene clusters suggests that they have a common origin by either two rounds of large-scale block duplication or even as part of the whole-genome duplication events originally proposed by Ohno (1970). Interestingly, a single related cluster of genes orthologous to the MHC paralogues located in two or more of the clusters on 1, 6, 9 and 19 has been identified in amphioxus (reviewed by Flajnik and Kasahara, 2001) and linkage between orthologues of MHC region genes has also been observed in Drosophila (Danchin et al, 2003). The region in amphioxus is believed to be the closest living example of the ancestral region of 1q21.2-q25.3, $6 \mathrm{p} 22.2-\mathrm{p} 21.3,9 \mathrm{q} 32-\mathrm{q} 34.3$ and $19 \mathrm{p} 13.3-\mathrm{p} 13.1$, as this organism is ideally situated at the base of the vertebrate lineage and predates the duplication events proposed by the 2 R hypothesis. Therefore, once the complete amphioxus genome sequence is available it will be of interest to determine which genes were involved in the genomeduplication events.

If the MHC paralogues within the regions on chromosomes 1,9 and 19 did have a common origin there should be detectable synteny between them. However, comparison of gene order within the paralogous regions revealed that the order is not strictly conserved. The lack of synteny between the paralogous regions raises a counterpoint to the hypothesis that these four regions arose simultaneously as part of a block or whole-genome duplication event: it may be that they have duplicated individually and are clustered because of a selective reason (Hughes, 1998) or that there has been extensive chromosomal rearrangement since the block/whole-genome
duplication events. There is strong evidence to support the latter explanation. For example, duplicons have been identified in both the MHC and 9q32-q34.3, and there is also evidence of a recent pericentromeric inversion on chromosome 1 resulting in the rearrangement of the genes on the chromosome.

One of the most interesting and novel findings of the whole-genome survey was that over $50 \%$ of the MHC paralogues are not located within clusters but are scattered throughout the genome, largely as singletons. No further clusters of genes paralogous to different MHC genes were identified, but small clusters of members of the same MHC paralogous gene family were identified, for example there is a cluster of six MAS1L paralogues on the short arm of chromosome 11 suggesting that this gene family has expanded by local duplication events. Of the 44 L2- and L3-paralogues located outside the paralogous regions, 32 are novel findings. This corresponds to $89 \%(32 / 36)$ of all the new paralogues identified in this analysis.

The existence of paralogues located outside the regions on chromosome 1, 9 and 19 suggests a more complex history than that previously proposed - the origin of the paralogues will be addressed in more detail in chapter 5 . One thing that is clear is that not all MHC genes have paralogues in the human genome; this corresponds to approximately one-third of the genes used in the analysis (40/128). There are two hypotheses to explain why some genes do not have paralogues, these are; (1) there has been extensive gene loss or silencing since the large-scale duplication of the ancestral region or (2) not all MHC genes were involved in the proposed large-scale duplication events. This issue should be resolved upon analysis of the gene contents of 'key' organisms in the vertebrate lineage, such as amphioxus, hagfish and lamprey once the complete genomic sequence is available.

## Chapter 5

# Phylogenetic analysis of extended MHC paralogous gene <br> families 

### 5.1 Introduction

The genome-wide survey presented in chapter 4 identified over 700 MHC paralogues with varying levels of confidence. Analysis of the distribution of the 82 L2- and L3paralogues confirmed that there were paralogous regions on chromosomes 1q21.2q25.3, $9 \mathrm{q} 32-\mathrm{q} 34.3$ and 19p13.3-p13.11. One of the most interesting and novel findings was that there are also paralogues scattered throughout the genome. However, the origin of these paralogues is not known. By definition paralogues have arisen by duplication of an ancestral gene, which can involve a chromosomal segment containing one or more genes (block duplication), an entire chromosome or the whole genome. One of the most useful approaches to study the history of paralogues is to reconstruct the evolutionary relationships using orthologous sequences.

These relationships are commonly represented by means of a phylogenetic tree using sequence data from a range of evolutionary distant organisms. A phylogenetic tree is simply a branching diagram in which each terminal element (e.g. a protein sequence) is linked only once to one or more other protein sequences, thus specifying a hierarchy. Trees can be rooted using a distantly related sequence, such as the Drosophila or amphioxus orthologue, and corresponds to a point at the base of a tree indicating the evolutionary direction. Internal branch points, or 'nodes', represent putative ancestors and are connected by 'branches'. Two sequences that are very
much alike will be located as neighbouring outside branches and will be joined to a common branch beneath them. Evolutionary trees can be constructed such that the length of a branch connecting two proteins is proportional to the number of residue differences in the sequences. Thus, the object of phylogenetic analysis is to discover all of the branching relationships in the tree and the branch lengths.

The paralogues located in the paralogous regions on chromosomes 1, 9 and 19 are believed to be remnants of two rounds of large-scale duplication events involving the whole genome early in vertebrate history. This phenomenon is referred to as the 2 R hypothesis (Sidow, 1996). The first whole-genome duplication event occurred after an 'amphioxus stage' prior to the divergence of Agnatha (jawless vertebrates, represented by lamprey and hagfish) and Gnathostomata (jawed vertebrates), while a second occurred after the divergence of Agnatha but before the divergence of cartilagenous fish (represented by sharks) (summarised in figure 5.1).


Figure 5.1 Summary of the 2R hypothesis. The first round of genome duplication (1R) occurred after the emergence of amphioxus (yellow), prior to agnatha divergence (green) and the second occurred after the divergence of agnatha but before the divergence of cartilagenous fish (pink). The two duplication events are represented by red circles.

If two or more genes have been duplicated simultaneously as the result of a block duplication event, this should be revealed by phylogenetic analysis. If the $2 R$ hypothesis is correct (assuming no genes have been lost since duplication) four paralogous genes should be found in humans and other jawed vertebrates, such as mice and chickens. Jawless fish, such as hagfish, should only have two paralogous genes, which are considered orthologous to the four paralogues in jawed vertebrates and the cephalochordate will have only one; corresponding to the closest relative of the 'ancestral gene' (figure 5.2). The branching pattern of the phylogenetic tree should be representative of the duplication events showing the double-forked tree topology, or the so-called $2+2$ or $(\mathrm{A}, \mathrm{B})(\mathrm{C}, \mathrm{D})$ topology. The age of the split of AB and CD is the same thus showing the history of successive rounds of duplication (summarised in figure 5.2).


Figure 5.2 Schematic representation of the effects of two rounds of gene, or genome, duplication on the topology of the phylogenetic tree (A1,A2)(B1,B2) and the resulting number of ( $\mathrm{N}=$ ) paralogues in 'key' species (1:2:4 ratio between amphioxus:hagfish:humans).

In this chapter, I present the phylogenetic analyses of ten paralogous gene families in order to determine the mechanism(s) by which they arose. Figure 5.3 summarises the topology of the phylogenetic tree expected if the paralogues arose from a common ancestor via two rounds of genome duplication (i.e. support the 2 R hypothesis).


Figure 5.3 Schematic representation of the 'ideal' phylogenetic tree in support of the 2R hypothesis. The species are colour coded according to the number of expected paralogues; species with one copy are highlighted in yellow, two copies (P1-2) in green and four paralogues (P1-4) in pink. It is important to note that in the phylogenetic trees presented in this chapter the species zebrafish, Fugu and Xenopus are highlighted pink, since they are jawed vertebrates, but they are expected to have more than four paralogues as an additional genome duplication event has occurred in their lineage.

### 5.2 MHC paralogous gene families used in phylogenetic analysis

In order to understand the evolutionary history of the MHC paralogues, 10 MHC genes and their paralogues (termed paralogous gene families) were selected for further analysis (summarised in figure 5.4).

Chromosome 6


## Chromosome 1



## Chromosome 9



Chromosome 19


## Elsewhere



Figure 5.4 Summary of the MHC genes and paralogues selected for further investigation. The MHC genes and corresponding paralogues are represented by a shaded symbol. The cytogenetic locus for each gene on chromosomes 1,9 and 19 is shown in blue text. 'CEN' corresponds to the centromere. The shaded areas correspond to the paralogous regions as defined in chapter 4.

The 10 paralogous gene families presented in this chapter were selected in order to satisfy a number of criteria. Firstly, the families were chosen to ensure that each of the five classes of the MHC region were represented by at least one paralogous gene family. Secondly, there were families with L2- and L3-paralogues located within the gene clusters on 1q21-q25, 9q32-q34.3 and 19p13.3-p31.3 only and, finally, there were also families with paralogues located elsewhere in the human genome.

### 5.3 Results

The protein sequences corresponding to the orthologues and paralogues of the 10 MHC genes were identified by searching the annotated protein databases and literature. The protein sequences were aligned with the ClustalW program using default parameters, and edited in Jalview. The sequence similarity between the MHC paralogues showed varying levels of divergence and, it was found that, the sequence alignments were often only reliable for conserved regions of the proteins. Therefore, in most circumstances, only these conserved regions were used to generate the trees. However, in cases, such as the TUBB family, where the sequence identity is very high (between 72.9 and $99.6 \%$ ), the full length protein sequences were used. The number of sequences and protein regions used to produce the trees is summarised in table 5.1.

Table 5.1 Summary of the MHC paralogous gene families used to generate phylogenetic trees. The first three columns show the MHC gene locus, the location within the MHC region and the location of their paralogues, respectively. The remaining four columns, from left to right, show the number of sequences, the gamma-distribution alphaparameter ( $\alpha$ ), number of amino acid (aa) residues and a description of the protein region used to generate the trees. The alpha-parameter is a measure of the rate of heterogeneity or change between amino acid sites (as described in 2.19.2). PR stands for paralogous region.

| MHC <br> Locus | MHC <br> class | Location of paralogues | No. of sequences used | $\alpha$ | a a residues used/length | Description of protein region used |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| GPX5 | xI | Outside PRs | 22 | 1.09 | 221/221 | Complete sequence |
| TUBB | I | Inside and outside PRs | 27 | 0.29 | 444/444 | Complete sequence |
| AIF1 | III | In PR | 11 | 1.21 | 92/147 | Includes EF-hand domain |
| CLIC1 | III | Inside and outside PRs | 13 | 1.82 | 232/241 | Most of sequence |
| C4 | III | In PRs | 27 | 1.42 | 1275/1744 | Includes anaphylatoxin and macroglobulin domains |
| TNXB | III | In PRs | 14 | 1.28 | 309/4289 | Includes a fibronectin III domain and the fibrinogen c-terminal. |
| PBX2 | III | In PRs | 13 | 0.33 | 180/430 | Includes homebox |
| NOTCH4 | III | In PRs | 17 | 0.97 | 385/2003 | Includes 11 EGF-like domains |
| BRD2 | II | In PRs | 14 | 0.74 | 113/801 | Includes a bromodomain |
| RXRB | xII | In PRs | 20 | 0.23 | 313/533 | Includes the DNA binding domain. |

The phylogenetic trees presented in this chapter, unless otherwise stated, are a consensus of four trees generated using the three software packages: PHYLIP, MEGA2 and PUZZLE (as described in section 2.19). In each tree, the number on the branches of the tree correspond to the average percentage bootstrap or puzzling-step confidences from the three software packages. It should be noted that the protein names for all species, apart from human, are given in lower case.

### 5.3.1 Phylogenetic analysis of the BRD paralogous gene family

The BRD2, or the bromodomain containing 2, gene is located in the MHC class II region (Beck et al, 1992b). Denis and Green (1996) discovered that the RING3 product is a mitogen-activated nuclear kinase involved in signal transduction and that it is upregulated in certain types of leukeamia. In total, three paralogues of the BRD2 gene have been identified in the human genome with the highest level of confidence; these are BRDT on 1p22.3, BRD3 on 9q34.2 and BRD4 on 19p13.12. They all belong to the BET subgroup of bromodomain proteins and contain two bromodomains and an ET (or extraterminal) motif, which is a protein-protein interactive surface. The precise function of the bromodomains is unclear but it may be involved in protein-protein interactions and may play a role in assembly or activity of multi-component complexes involved in transcriptional activation (Tamkun, 1995).

The topology of the phylogenetic tree of the BRD paralogous gene family is (BRD2,BRD3)(BRD4,BRDT), thus supporting the 2R hypothesis (figure 5.5). Phylogenetic analysis shows that the timings of the two duplication events occurred after the divergence of cephalochordates and prior to the emergence of jawless fish. This is indicated by the positions of the amphioxus and hagfish orthologues on the
tree. Overall, the phylogenetic analysis of the BRD2 paralogues and othologues shows that the BRD paralogous gene family arose by two rounds of duplication, but it should be noted that some branches show low levels of support.


Figure 5.5 Phylogenetic tree of the BRD paralogous and orthologous family. The accession numbers are: P25440 (human BRD2), Q15059 (human BRD3), O14789 (human BRDT), O60885 (human BRD4), O54795 (mouse brd2), Q8K2F0 (mouse brd3), Q9ESU6 (mouse brd4), Q90971 (chicken brd2), Q8QFT7 (Fugu brd3), Q8T775 (amphioxus brd), P13709 (Drosophila fsh) and Q20948 (C.elegans brd2).

### 5.3.2 Phylogenetic analysis of the PBX paralogous gene family

The PBX2 (pre-B-cell leukaemia 2) gene encodes a homeodomain-containing protein. It was first identified on the basis of the extensive homology to the PBX1 gene involved in $\mathrm{t}(1 ; 19)(\mathrm{q} 23 ; \mathrm{p} 13.3)$ translocation in acute pre-B-cell leukaemias (Monica et al, 1991). The genome survey identified three paralogues located within the paralogous regions on 1q23.3, 9q33.3 and 19p13.11, named PBX1, PBX3 and PBX4, respectively. Phylogenetic analysis shows that the PBX paralogous gene family arose by two rounds of duplication (figure 5.6). The topology of the tree is (PBX2,

PBX4)(PBX1, PBX3), which supports the 2R hypothesis. The timings of the two duplication events can be determined as occurring after the divergence of cephalochordates and prior to the emergence of jawed fish, indicated by the positions of the amphioxus and zebrafish orthologues on the tree.


Figure 5.6 Phylogenetic analysis of the PBX paralogous gene family. The accession numbers of the vertebrate protein sequences used are: P40425 (human PBX2), P40424 (human PBX1), P40426 (human PBX3), Q9BYU1 (human PBX4), O35984 (mouse pbx2), P41778 (mouse pbx1), O35317 (mouse pbx3), Q99NE9 (mouse pbx4), Q9IB15 (chicken pbx1a), Q9I9B7 (zebrafish pbx1a), Q9I9B5 (zebrafish pbx3), AF39192_1 (amphioxus pbx) and P41779 (C.elegans pbx).

### 5.3.3 Phylogenetic analysis of the NOTCH paralogous gene family

The Notch gene was first identified in Drosophila as a regulator of cell fate determination and has been implicated in a large number of developmental processes in Drosophila and vertebrate systems (reviewed by Bray, 1998; Lewis, 1998). The phylogenetic tree using 14 vertebrate protein sequences and three invertebrate protein sequences is presented in figure 5.7.


Figure 5.7 Phylogenetic analysis of the NOTCH paralogous gene family. The protein sequences, with the accession numbers given in parentheses, are: human NOTCH4 (O00306), human NOTCH1 (P46531), human NOTCH2 (Q04721), human NOTCH3 (Q9UM47), mouse notch4 (P31695), mouse notch1 (Q01705), mouse notch2 (O35516), mouse notch3 (Q61982), rat notch1 (O07008), rat notch2 (Q9QW30), rat notch3 (Q9R172), Xenopus xotch (P21783), zebrafish notch1 (P46530), Fugu notch2 (O13149), amphioxus notch (Q9GPA5), sea urchin notch (O16004) and Drosophila notch (P07207).

In Drosophila and lower deuterostomes (such as sea urchins) there is a single Notch gene, while in vertebrates there are multiple Notch genes (four in humans and mouse). Phylogenetic analysis of the NOTCH4 paralogues and orthologues supports the hypothesis that NOTCH1-4 arose from a common ancestor via two duplication events. The single amphioxus notch protein branches at the base of the four vertebrate Notch proteins. Together with the presence of single Notch gene in the sea urchin it suggests that Notch duplicated within the vertebrate lineage. Thus, both duplications occurred after the divergence of amphioxus and prior to the divergence of bony fish and tetrapods.

### 5.3.4 Phylogenetic analysis of the complement paralogous gene family

The C4 gene is located in the MHC class III region and encodes the complement factor 4 protein. C4 plays a central role in the activation of the classical pathway of the complement system. The complement system is the principle effector mechanism of humoral immunity and consists of at least 24 serum proteins and 11 membranebound proteins. The interaction of these proteins leads to a complement cascade and results in a number of responses, including cell lysis, opsonisation of targets for phagocytosis by macrophages, regulation of B cell responses and the generation of potent anaphylatoxins (for review see Reid and Porter, 1981). Two paralogues of the C 4 gene have been identified in the human genome; these are C 5 located on 9 q 33.2 and C3 located on 19p13.3.

Phylogenetic analysis of the full length C3, C4 and C5 protein sequences (figure 5.8) supports the view that C 5 diverged first with C 3 and C 4 subsequently diverging before the separation of jawed and jawless fishes (Hughes, 1994). The presence of C3 in jawless deuterostomes, such as sea urchin (Smith et al, 1999), hagfish (Ishiguro et $a l, 1992$ ) and lamprey (Nonaka and Takashii, 1992) enables the divergence times of the complement genes to be determined and establishes the ancient origin of the complement system. The clustering of the lamprey and hagfish C3 with the other vertebrate C 3 proteins clearly indicates that the duplication of the C 3 and C 4 genes from the ancestral gene occurred after the divergence of jawless vertebrates and prior to the divergence of jawed vertebrates. One would expect the orthologue of C 4 to be revealed upon full sequencing of the hagfish and lamprey genomes. The divergence of C5 occurred after the cephalocordate split prior to the divergence of jawless fish. Phylogenetic analysis shows a ratio of 1:2:2:3 Amphioxus:Hagfish:Lamprey:Human.

Thus, supporting the 2 R hypothesis, accompanied with the loss of one of the C 4 duplicate giving the topology $(\mathrm{C} 5(\mathrm{C} 4, \mathrm{C} 3))$ rather than the predicted $(\mathrm{A}, \mathrm{B})(\mathrm{C}, \mathrm{D})$.


Figure 5.8 Phylogenetic analyses showing the relationship of the C4 paralogues and orthologues. The accession numbers of the proteins used to generate the trees are: human C4 (P01028), mouse c4 (P01029), chicken c4 (O73905), Xenopus c4 (Q91741), Medaka c4 (Q9IBG9), carp c4 (Q91933), human C5 (P01031), mouse c5 (P06684), trout c5 (Q90XS7), human C3 (P01024), mouse c3 (P01027), chicken c3 (Q90633), Xenopus c3 (Q91588), rat c3 (P01026), guinea pig c3 (P12387), pig c3 (Q9GKP1), cobra c3 (Q01833), lungfish c3 (Q9W6G1), carp c3 (Q9YIB0), trout c3 (P98093), Medaka c3 (Q9IBH1), wolffish c3 (Q98TS6), flounder c3 (Q9PTY1), lamprey c3 (Q00685), hagfish c3 (P98094), amphioxus c3 (Q969A4) and sea urchin c3 (O44344).

### 5.3.5 Phylogenetic analysis of the RXR paralogous gene family

The retinoid X receptor beta, or RXRB, protein is a retinoid receptor and belongs to the steroid/thyroid hormone receptor superfamily of transcriptional regulators (Mangelsdorf et al, 1992). Retinoid receptors are soluble nuclear proteins that fall into
two classes: retinoic acid receptors (RAR) and retinoid X receptors (RXR). The RXR subfamily consists of three polypeptide chains, namely alpha, beta and gamma, encoded by separate loci. The three loci encoding the alpha (RXRA), beta (RXRB) and gamma (RXRG) proteins are located on chromosomes 9, 6 and 1, respectively.

The RXR phylogenetic tree was rooted with the Drosophila orthologue, usp (figure
5.9).


Figure 5.9 Phylogenetic tree showing the evolutionary relationship between the RXRB paralogues and orthologues. The accession numbers are: X52773 (human RXRA), X63522 (human RXRB), U38480 (human RXRG), M84817 (mouse rxra), M84818 (mouse rxrb), M84819 (mouse rxrg), L06482 (rat rxra), M81766 (rat rxrb), X58997 (chicken rxrb), L11446 (Xenopus rxra), X87366 (Xenopus rxrb2), S73269 (Xenopus rxrb1), L11443 (Xenopus rxrg), U29940 (zebrafish rxra), U29894 (zebrafish rxrg), U29941 (zebrafish rxrd), U29942 (zebrafish rxre), AF316878 (lamprey rxr), AF391296/5 (amphioxus rxr) and P20153 (Drosophila usp).

The results show that the human paralogues cluster, as expected, with equivalent orthologues. The RXR orthologues of the invertebrate species, Drosophila and
amphioxus, both fall outside all of the vertebrate genes. However, the RXR orthologue of the invertebrate lamprey clusters with vertebrate RXRB. This indicates that RXRB diverged first, after the cephalochordate split prior to the divergence of jawless fish. This was followed by a duplication event between RXRA and RXRG after the divergence of jawless fish. The zebrafish RXRD and RXRE genes resulted from a duplication occurring around the time of teleost/mammalian divergence. The topology of the tree, (RXRB(RXRA, RXRG)), clearly supports at least one round of large-scale duplication but it is possible that the RXR family arose by two-rounds of large-scale duplication events and one paralogue has been lost over time. Thus, the present day topology is (RXRB (RXRA, RXRG)).

### 5.3.6 Phylogenetic analysis of the tenascin paralogous gene family

The tenascin proteins are a family of extracellular matrix proteins (ECM) (for a review see Erickson, 1993). The Tenascin X (TNX) gene is located within the MHC class III region overlapping the CYP21A2 and C4 genes. Two paralogues, tenascin C (TNC, cytoactin, hexabrachion) and tenascin R (TNR, restrictin) have been identified in the paralogous regions on chromosomes 9 q 33.1 and 1 q 24.1 , respectively. Tenascin orthologues have been identified in a range of vertebrates but only one invertebrate (summarised in the legend of figure 5.10). The Drosophila protein, ten ${ }^{m}$, contains the EGF-like and FN-III domains and is believed to be the closest relative of the vertebrate tenascins (Baumgartner et al, 1994). This has been used as the outgroup to root the phylogenetic tree presented in figure 5.10.


Figure 5.10 Phylogenetic analyses of the TNXB paralogues and orthologues. The accession numbers of the protein sequences used to generate this tree are as follows; P22105 (human TNXB), P24821 (human TNC), Q15568 (human TNR), O35452 (mouse tnxb), Q64706 (mouse tnc), Q05546 (rat tnr), P10039 (chicken tnc), Q00546 (chicken tnr), Q91008 (chicken tny), Q29038 (pig tnxb), Q29116 (pig tnc), O18977 (bovine tnxb) and Q24551 (Drosophila ten ${ }^{\mathrm{m}}$ ).

The topology of the tree strongly supports that TNXB diverged prior to the divergence of TNR and TNC as suggested by Katsanis and co-workers (1996) and Hughes (1998). Phylogenetic analysis shows that the TNC and TNR paralogues are most closely related and have arisen from a common ancestor. The clustering of the zebrafish TNC orthologue with the other TNC orthologous sequences indicates that the duplication which gave rise to the TNC and TNR paralogues occurred prior to the divergence of bony fish and tetrapods, approximately 450 million years ago. However, without the orthologous protein sequences of the key species (amphioxus, hagfish and lamprey) it cannot be determine whether the tenascin $X$ gene supports the 2R hypothesis. Compelling evidence from the five other MHC paralogous gene families presented in sections 5.3.1-5.3.6 implies that these genes may have arisen via the same mechanism.

### 5.3.7 Phylogenetic analysis of the AIF paralogous gene family

The Allograft inflammatory factor 1 (AIF-1) gene was first isolated from activated macrophages in rat atherosclerotic allogenic heart grafts undergoing chronic transplant rejection (Utans et al, 1995). In humans, the full-length clone has been isolated and characterised (Autieri, 1996). Only one AIF-1 paralogue (AIF1-L) has been identified in the human genome (discussed in chapters 3 and 4) and is located in the chromosome 9 paralogous region.

The AIF1 encoded protein is evolutionarily well conserved within vertebrate species (Utans et al, 1996). To-date, it has been identified in seven vertebrates: humans, pig, rat, macaque, mouse, bovine, red sea bream and carp. It has only been identified in two invertebrates, the sea sponge and amphioxus. Phylogenetic analysis of the AIF1 paralogues and orthologues was carried out using the distantly related amino acid sequence from sea sponge as the outgroup (figure 5.11).


Figure 5.11 Phylogenetic tree of the AIF1 paralogues and orthologues. The species, and corresponding accession numbers given in parentheses, used to generate the tree are as follows: human AIF1 (P55008), human AIF1-L (Q9BQI0), pig aif1 (P81076), rat (P55009), Rhesus macaque aif1 (Q9GMH2), mouse aif1 (070200), bovine aif1 (Q9BDK2), red sea bream aif1 (Q9YI94), carp aif1 (O93246), sea sponge aif1 (Q966Y8) and aif1 amphioxus (translated from EMBL entry AU234552).

Evidence provided by the phylogenetic tree indicates that the duplication event involving the ancestral gene of the two AIF1 paralogues occurred prior to divergence of bony fish and post-dates the divergence of Amphioxus. Thus, this analysis supports at least one round of duplication prior to vertebrate emergence, or the 1 R hypothesis. Interestingly, the AIF1 protein in carp clusters with AIF1-L in the phylogenetic tree suggesting that the carp AIF1 protein may actually be the orthologue of the human AIF1-L gene on chromosome 9. A sequence similarity search using the AIF1-L protein did not identify any orthologous sequences previously not identified for AIF1. To-date, a second AIF1 orthologue has not been identified in the carp genome to confirm that this is the true AIF 1L orthologue. In summary, the AIF1 paralogous gene family have occurred via a large-scale duplication after the divergence of the cephalochordate lineage prior to the emergence of bony fish. Thus, supporting one round of large-scale duplication, or the 1 R hypothesis.

### 5.3.8 Phylogenetic analysis of the $\beta$-tubulin paralogous gene family

The $\beta$-tubulins form the basic building blocks of the microtubulins when they form heterodimers with $\alpha$-tubulins (reviewed by McKean et al, 2001). Microtubulins constitute a major component of the cytoskeleton in eukaryotic cells and are involved in essential processes, including cell division and intracellular transport. The survey of the human genome revealed seven paralogues of the TUBB gene scattered throughout the genome. The paralogues share very high sequence similarity, ranging from $72.9 \%$ to $99.6 \%$ at the protein level. The high level of similarity has resulted in the misannotation of these genes, i.e. the same SWISSPROT or SPTREMBL accession number has been given as the encoded protein sequence for multiple genes. In order to
prevent confusion, the corresponding ENSEMBL accession numbers is given in table 5.2 that was identified in the genome survey.

Table 5.2 Summary of the TUBB paralogues in the human genome

| Gene | Locus | Genomic clone <br> accession <br> number | ENSEMBL <br> gene ID | No. of <br> amino <br> acids |
| :--- | :--- | :---: | :---: | :---: |
| TUBB | 6 p 21.3 | AB023051 | ENSG00000137379 | 444 |
| TUBBL1 | 6 p 25.2 | AL031963 | ENSG00000137267 | 445 |
| TUBBL2 | 6 p 25.2 | AL445309 | ENSG00000137285 | 445 |
| TUBB4QL | 10 p 15.3 | AL713922 | ENSG00000173876 | 444 |
| TUBB4 | 16 q 24.3 | AC0092143 | ENSG00000141037 | 442 |
| TUBBL | 18 p 11.3 | AP001005 | ENSG00000173213 | 433 |
| TUBB5 | 19 p 13.3 | AC010503 | ENSG00000104833 | 444 |
| TUBB1 | 20 q 13.3 | AC109840 | ENSG00000101162 | 451 |

The $\beta$-tubulin genes are extensively conserved evolutionarily, but the number of encoding genes varies dramatically among species (Lewis and Cowan, 1990). A search of the protein databases, SWISSPROT and SPTREMBL, revealed several vertebrate $\beta$-tubulin proteins; one chimpanzee, one squirrel monkey, one rhesus macaque, one baboon, two mouse, one rat, two chicken and three Xenopus $\beta$-tubulin proteins. In addition, seven invertebrate $\beta$-tubulin proteins were extracted from the database; two sea squirt, one sea urchin, two Drosophila, one C.elegans and one

## C.briggsae.

Phylogenetic analysis using the protein sequences encoded by the TUBB paralogues reveals evidence in support of a number of duplication events (figures 5.12 and 5.13). The phylogenetic tree presented in figure 5.12 reveals two main gene clusters; one including only new world monkey and human sequences and the other, also containing human sequences, including a number of more 'ancient' species, namely the sea squirt and sea urchin clustered with vertebrates.


Figure 5.12 Phylogenetic analysis of the $\beta$-tubulin paralogues and orthologues. The two major species clusters corresponding to ancient duplication events (surrounded by a dashed red line) and more recent duplications (black dashed line). The accession numbers of the protein sequences used to generate this tree are: Q8WP14 (tubb4q, chimpanzee), Q8WP12 (tubb4q, squirrel monkey), AAD33992 (tubb4q, Rhesus macaque), Q8WP13 (tubb4q, baboon), Q9D6F9 (tubb4, mouse), P05218 (tubb5, mouse), P04691 (tubb1, rat), P32882 (tubb2, chicken) P09244 (tubb7, chicken), P13602 (tubb2, Xenopus), P30883 (tubb4, Xenopus), Q91575 (tubb5, Xenopus), O18343 (hrtbb2, sea squirt), O18342 (hrtbb1, sea squirt), P11833 (tubb, sea urchin), Q24560 (tubb56d, Drosophila), P08840 (tubb85d, Drosophila), P12456 (mec-7, C.elegans) and Q17299 (mec-7, C.briggsae).

The cluster containing the new world monkey $\beta$-tubulin proteins indicates that some of the tubulin paralogues in the human genome are the result of recent duplication events. This is supported by the analysis of the TUBB4Q pseudogene on 4 q 35.2 and related paralogues and orthologues by van Geel and co-workers (2002). Analysis of the human chromosomal segment, 4 q 35 , containing the TUBB4Q pseudogene has indicated a substantial amount of duplication throughout the genome (Grewal et al, 1999; van Geel et al, 1999). Van Geel and colleagues (2002) revealed that this segment has undergone a number of duplications at different time points within the last 25 million years of catarrhine (New World Monkeys and humans) evolution.

The phylogenetic tree presented in figure 5.13 reveals evidence of ancient duplication events which occurred earlier than those proposed by the 2R hypothesis. The timings of the two rounds of duplication are proposed as follows; the first round of duplication occurred prior to the divergence of sea squirt and sea urchin and the second, after their divergence, prior to vertebrate emergence. The $\beta$-tubulin paralogues have been involved in a much earlier round of duplication followed by further duplications; this is supported by the clustering of the sea squirt and sea urchin orthologues with the mammalian counterparts.

There is evidence of a more recent duplication event telomeric to the MHC region on chromosome 6. The two newly identified paralogues, termed TUBBL1 and TUBBL2, on 6 p 25.2 share identical exon fingerprints and have $99.6 \%$ protein sequence similarity. The two paralogues are located within 70 kb of each other and span approximately 3.4 kb . They appear to have arisen by a tandem duplication event after amphibian divergence and prior to the emergence of rodents (the orthologue of TUBBL2 in rat may not be functional or the dataset used to generate the tree may not be complete).


Figure 5.13 Phylogenetic tree showing the ancient duplication events that have shaped the present day $\beta$-tubulin paralogues and orthologues. The three main groups are highlighted in different colours. The protein accession numbers are as described in figure 5.12.

Analysis of the distribution of $\beta$-tubulin paralogues in the human genome (Chapter 4) reveals a strong positional bias towards the pericentromeric and subtelomeric regions of the genome. It is known that frequent exchange of sequences occurs between these dynamic chromosome regions (Eichler et al, 1996; Pryde et al, 1997; Eichler, 1998; IHGSC, 2001), which can result in the acquisition of new genes as well as genetic diversity. There is evidence to suggest that the TUBB4Q pseudogene on 4 q 35.2 was
once a functional gene and, because of its proclivity to duplicate to subtelomeric locations, a novel tubulin member was transposed to 10p15.3 (TUBB4QL) approximately 7.3 MYA (van Geel et al, 2002). It has also been suggested that GCrich repeat elements play a direct role in the pericentromeric localisation of intra- and interchromosomal duplication events (Eichler et al, 1999). It would be interesting to investigate whether there are GC-rich repeat elements bordering the duplicated segments containing the TUBB paralogues but this is beyond the scope of this thesis.

### 5.3.9 Phylogenetic analysis of the GPX paralogous gene family

The glutathione peroxidase proteins (GPX) are enzymes involved in the protection of the cell against oxidative damage. Using glutathione as the reducing agent they metabolise hydroperoxides generated by normal oxidative metabolism which otherwise would have deleterious effects, mainly on cell-wall integrity (Dufaure et al, 1996) phylogenetic relationship of the GPX5 paralogues and orthologues is shown in figure 5.14.

The human GPX protein sequences were aligned with the protein sequences obtained from a range of vertebrates and a single invertebrate species, Suberites domuncula also known as the sea sponge (see legend of figure 5.14). In total, one true paralogue of GPX5, named GPX3, was identified in the genome survey on 5q33.1. Two putative paralogues were also identified on chromosomes 3p21.31, GPX1, and GPX3, 5q33.1 but have a very different exon structure compared with GPX5. In addition, another member of the glutathione peroxidase family, GPX4, has been identified in the paralogous region on 19p13.3 but was not identified as a paralogue in this analysis.


Figure 5.14 Phylogenetic analysis of the GPX family. The protein sequences used, with the corresponding accession numbers given in parentheses, were as follows; human GPX5 (O75715), human GPX3 (P22352), human GPX1 (P18283), human GPX2 (P18283), human GPX4 (P36969), mouse gpx5 (P21765), mouse gpx3 (P46412), mouse gpx1 (P11352), mouse gpx2 (Q9JHC0), mouse gpx4 (O70325), pig gpx5 (O18994), pig gpx4 (P36968), rat gpx5 (P30710), rat gpx3 (P23704), rat gpx1 (P04041), rat gpx4 (P36970), bovine gpx3 (P37141), bovine gpx1 (P00435), bovine gpx4 (Q9N2N2), dog gpx5 (O46607), Rhesus macaque gpx5 (P28714) and sea sponge gpx (Q966Y9).

Phylogenetic analysis shows that GPX4 is the most distantly related member. This is to be expected as it has a very different exon structure than the other GPX family members and shares less than $30 \%$ sequence identity. The GPX genes with identical exon fingerprints and highest protein sequence identity, GPX5-GPX3 and GPX1GPX2, cluster together indicating that the genes have descended from a common ancestor. The duplications occurred after sea sponge divergence but prior to rodent divergence thus could have resulted from two rounds (or more) of whole-genome
duplication. More data is needed to determine the precise times of the duplication events.

### 5.3.10 Phylogenetic analysis of the CLIC paralogous gene family

The chloride intracellular channel (CLIC) paralogous gene family encode for chloride channels, which are involved in chloride ion transport within various subcellular compartments (reviewed by Jentsch et al, 2002). Phylogenetic analysis of the CLIC family suggests a series of successive duplication events including at least 2 rounds of whole-genome duplications (figure 5.15).


Figure 5.15 Phylogenetic analysis of the CLIC family. The protein sequences used, with the corresponding accession numbers given in parentheses, were as follows; human CLIC1 (O00299), human CLIC2 (O15247), human CLIC3 (O95833), human CLIC4 (Q9Y696), human CLIC5 (Q9NZA1), human CLIC6 (Q9NY7), mouse clic1 (Q9Z1Q5), mouse clic3 (Q9D7P7), mouse clic4 (Q9QYB1), mouse clic5 (Q9CYD1), rat clic4 (Q9Z0W7), rat clic5 (Q9EPT8), Drosophila clicL (NM_132700).

The topology of the tree indicates that the Xq28 CLIC2 gene diverged first. Following the divergence of CLIC2 there were two rounds of whole-genome duplication. The first duplication event resulted in the CLIC (MHC,9q34.3) and the CLIC (21q22.12(1p35.3,6p21.1)) gene precursors. This was followed by a second round of whole-genome duplication resulting in CLIC1 (MHC), CLIC3 (9q34.3), CLIC6 (21q22.12) and the CLIC (1p35.3, 6 p 21.1 ) precursor (possibly located on 19p13). A further segmental duplication event occurred resulting in the present day location of the CLIC4 and CLIC5 genes on 1p35.3 and 6p21.1, respectively. The latter segmental duplication is supported by the observation that there has been a large-scale triplication involving the chromosomal regions $1 \mathrm{p} 35,6 \mathrm{p} 21.1$ and 21q22.12 (Strippoli et al, 2002). Strippoli and colleagues (2002) identified a large (approximately 500 kb ) segment on human chromosome 21 q 22 that is triplicated on chromosomes 1 p35 and 6p12-p21. The region on chromosome 21 contains the CLIC6 gene, along with two other genes, DSCR1 and AML1, which have functional copies in the other regions. The gene order within these regions, termed the ACD clusters, is identical and it was suggested that the triplication occurred by segmental duplication as part of the genome-duplication events before the divergence of tetrapods and teleosts. However, more sequence data is needed to confirm this prediction and to fully understand the complex history of this paralogous gene family.

### 5.4 Discussion

The evolutionary histories of 10 MHC paralogous gene families have been reconstructed using phylogenetic trees. Analysis of the topologies of the trees and the arrangement of the paralogues and orthologues has revealed that the evolution of the MHC paralogues is complex. What is evident is that gene duplication has played a major role in the evolution of these gene families. In particular, there is evidence in support of the 2 R hypothesis. The 2 R hypothesis proposes that the genome evolved via two rounds of whole-genome duplication events early in the vertebrate lineage; one occurring after amphioxus divergence, prior to the emergence of hagfish and lamprey and the second just after. In order to support the $2 R$ hypothesis, phylogenetic analyses of gene families should meet the following criteria: (a) the vertebrate members of the gene family can be shown to have duplicated within the vertebrate lineage and (b) the gene family phylogenies show the (A,B)(C,D) topology.

The 2R hypothesis would give rise to four copies of an ancestral gene therefore this is best exemplified by the paralogous gene families with four members in the human genome. The BRD, NOTCH and PBX paralogous gene families all have four paralogues, including the MHC locus, in the human genome. The topology of the three phylogenetic trees support the $2 R$ hypothesis, showing the (A,B)(C,D) topology. Furthermore, some of the orthologous genes have been identified in the three key organisms, amphioxus, lamprey and hagfish, and the positions of these organisms in the phylogenetic trees are in support of the timings of the duplication events proposed by the 2 R hypothesis. Thus, if the sequences are available, a single amphioxus orthologue is positioned at the base of each tree and at least one hagfish or lamprey orthologue clusters with the mammalian counterparts.

The paralogous gene families with three members also support the 2 R hypothesis, albeit accompanied by gene loss. This appears particularly likely as extensive gene loss has been shown to take place after gene duplication events ( Gu and Huang, 2002). Furthermore, the paralogous gene family with only two members is also in support of at least one round of genome duplication in the vertebrate history (the 1R hypothesis). Alternatively, it also supports the 2 R hypothesis accompanied with the loss of two genes. The timings of the duplication events as suggested by the 2 R hypothesis are also supported by the clustering of the 'key' organisms in these phylogenetic trees.

Ideally, if the paralogues emerged simultaneously by block or whole-genome duplication, the genes from the same chromosomal regions should cluster together on the tree. For example, previously published phylogenetic analyses of three paralogous gene families indicated that the paralogous regions on 1q21-q25 and 9q33-q34 were most related (Katsanis et al, 1996; Kasahara, 1997; Hughes, 1998). It would therefore be expected that the paralogues on chromosomes 1 and 9 will cluster and 6 and 19 will also cluster. However, this is not the case. The NOTCH and PBX paralogous gene families support this clustering however the BRD paralogues do not; with the BRD paralogues on chromosomes 6 and 9, and, 1 and 19 clustering. Since the construction of phylogenetic trees utilises sequence information the different rates by which the sequences of the paralogues have evolved since duplication, dictated by the evolutionary pressures acting upon them, may explain why different sets of paralogues cluster.

Phylogenetic analysis of the MHC paralogous gene families with five or more members revealed that the evolution of the MHC paralogues involved more than just
the two rounds of large-scale duplication events proposed by the 2 R hypothesis. This is exemplified by the $\beta$-tubulin family, which shows evidence of both ancient duplication events, dated prior to the divergence of sea squirt and sea urchin prior to the emergence of amphioxus, as well as much more recent duplications. This is in concordance with previously published phylogenetic studies of the MHC paralogous gene families (Endo et al, 1997; Hughes; 1998). These studies revealed that duplication events of multigene families, such as the proteasome component (PSMB) genes, occurred much earlier than those proposed by the 2 R hypothesis.

In conclusion, there is strong evidence that some MHC paralogues evolved via the mechanism proposed by the 2 R hypothesis but that others have emerged by independent means. Therefore, there could still be a selective advantage, potentially related to function, for these genes to have been brought together and remained clustered.

## Chapter 6

# Expression analysis of extended MHC paralogous gene <br> families 

### 6.1 Introduction

The MHC paralogous genes identified in the human genome (presented in chapters 3 and 4) have arisen by duplication (discussed in chapter 5). Duplication results in new genes and, if they are duplicated in their entirety (including the regulatory elements) there will be some inter-gene redundancy, with the two paralogues being able to fulfil the same function. In principle, the genetic redundancy created by duplication will allow evolutionary experimentation; since only one copy is required to maintain the function provided by the single, ancestral gene the other copy is free to diverge. Thus, one of the duplicate genes is left under purifying selection (selection against deleterious alleles) and therefore maintains the original function of the ancestral gene and the other duplicate gene is freed from all functional constraints to diverge.

The classical model, originally proposed by Ohno in 1970, predicts two potential fates for the 'other' duplicate gene. The most likely fate is that it will degenerate into a pseudogene or will be lost from the genome altogether, due to locus deletions or point mutations, by a process called non-functionalisation (figure 6.1.A). The less frequently expected outcome is that the duplicated gene acquires mutations that modify either the expression pattern of the gene or the function of the encoded protein in an advantageous way. The novel allele could then become fixed in the population, exposing the formerly redundant gene to new and distinct selective constraints in a
process known as neo-functionalisation (figure 6.1.B).

It is believed that neo-functionalisation is rare and that few duplicates will be retained in the genome (reviewed by Prince and Pickett, 2002). However, analysis of the human genome has revealed that at least $15 \%$ of human genes are duplicates (Li et al, 2001) and that segmental duplications cover approximately $10 \%$ of the genome (IHGSC, 2001; Bailey et al, 2002). In order to explain the preservation of duplicate genes in the genome, the sub-functionalisation model has been proposed (figure 6.1.C; Force et al, 1999; Lynch and Force, 2000). Sub-functionalisation proposes that, after duplication, the two duplicate gene copies acquire complementary loss-of function mutations. The two genes therefore develop independent functions, and are both required to produce the full complement of functions of the ancestral gene.


Figure 6.1 Fates of duplicated genes (adapted from Mazet and Shimeld, 2002). (A) non-functionalisation, in which one copy degenerates after duplication, (B) neofunctionalisation, when initially identical duplicates with function $A$ diverge by acquiring new functions $B$ and $C$ and (C) sub-functionalisation, in which duplicate genes with multiple functions $A$ and $B$ diverge by reciprocal loss.

The process or mechanism by which the MHC paralogous gene families have evolved since duplication is not known. However, what is clear is that their emergence by gene duplication created genetic redundancy. It is therefore interesting to determine the present-day function(s) of the paralogues in order to gain some understanding of the mechanism(s) by which they have evolved. The first step to understanding the function and phenotype of the genes and the corresponding proteins is to generate the expression profile of the human paralogues in a range of normal human tissues.

Each tissue in the human body is different from another because of the synthesis of a distinct set of RNA molecules. The proportion of the genes expressed as mature messenger RNA (mRNA), collectively known as the transcriptome, represent only a small part of the human genome. Messenger RNA (mRNA) represents approximately $2.5 \%$ of the RNA in a cell, with ribosomal RNA (rRNA) and transfer RNA (tRNA) making up $75 \%$ and $10 \%$ respectively (Jackson et al, 2000). The remainder is made up of RNA molecules such as small nuclear RNAs (snRNAs) and small nucleolar RNAs (snoRNAs). The analysis of the transcriptome can provide many clues to the functional significance of a particular gene. For example, the presence of an RNA transcript in one specific tissue and absence in all others would suggest a specialised function of the gene in that tissue. Therefore, by generating a comprehensive expression profile in a range of human tissues we can discover whether the paralogues have similar or divergent functions to ultimately understand how the paralogues have evolved since their emergence by duplication.

This chapter focuses on the characterisation of 40 MHC paralogues, corresponding to the 10 MHC paralogous gene families discussed in chapter 5 (see section 5.2 for more detail), in a range of normal human tissues and cell-lines using different approaches.

### 6.2 Terminology

In total, five different methods were used in this project to obtain a comprehensive profile of the expression of 40 paralogues in a range of human tissues and cell-lines; these were In-silico, Northern blot, Dot-blot, RT-PCR and microarray analysis. Each method will be discussed individually within the results section. One point to note is the use of the terms 'probe' and 'target' when referring to the hybridisation methods. In this chapter the terms 'probe' and 'target' have been used to describe elements in both the blotting (namely Southern, Northern and Dot blots) and microarray experiments. In the case of the blotting methods the 'target' is referred to as either the DNA or RNA attached to the membrane and the 'probe' is the free nucleic acid which is labelled and used to hybridise to the blot.

The microarray experiments were divided into two phases; I and II. Phase I corresponds to the cross-hybridisation (control) experiments using the 'Paralogue Microarray' (as described in section 2.13.1) and phase II refers to the expression profiling experiments using the ' $10 \mathrm{~K} /$ Paralogue Microarray' (as described in section 2.13.1). In the phase I microarray experiments, the paralogue specific PCR products represent both the 'target' and the 'probe', as they are attached to the surface of the 'Paralogue Microarray' and used to hybridise with the array. In the case of the phase II experiments using the ' $10 \mathrm{~K} /$ Paralogue Microarray', the 'probe' is the free labelled nucleic acid used to hybridise with the array, i.e. the complementary DNA of the RNA either extracted from the cell-line (as described in section 2.10) or purchased from Ambion. The 'target' is the DNA attached to the ' $10 \mathrm{~K} /$ Paralogue Microarray', and corresponds to the paralogue specific PCR products generated for each of the 40 genes and the DNA elements already on the standard Sanger Institute 10K microarray.

### 6.3 Results

### 6.3.1 Cross-hybridisation (control) experiments

The potential for cross-hybridisation needs to be considered when working with paralogous genes and proteins. It has been shown that gene targets with 77-100\% sequence identity cross-hybridise in hybridisation experiments using nylon membranes (Vernier et al, 1996) and over $80 \%$ in glass cDNA microarray experiments (Evertsz et al, 2001). Although the primers for each paralogue were designed to amplify a paralogue specific PCR product it was still essential to ensure that they did not demonstrate any cross-reactivity. Two methods were used to verify that they were paralogue specific.

First, the paralogue specific PCR products were arrayed, or printed, onto the 'Paralogue Microarray' in triplicate (the primers used to amplify the PCR products are summarised in Appendix 4). The same PCR products were also fluorescently labelled (as described in section 2.13.3) and hybridised to the array (as described in section 2.13.4). If the probes were specific to the particular paralogue they did not crosshybridise with other members of the same paralogous gene family. This was detected upon scanning of the array after hybridisation. The probes corresponding to the 10 extended MHC genes were labelled and individually hybridised to the 'Paralogue Microarray'. In addition, the 10 probes were pooled and used to hybridise to the array (this is presented in figure 6.2.A and 6.2.B).

Secondly, the paralogue specific PCR products were hybridised to Southern blots to ensure that there was only a single copy in the genome (the primers used to amplify the PCR products are summarised in Appendix 3). Southern blots were made (as
described in section 2.14.3) by digesting human genomic DNA with three different restriction endonucleases, HINDIII, PstI and BamHI. Restriction endonucleases are enzymes that bind to a DNA molecule at a specific sequence and make a doublestranded cut at or near to that sequence, resulting in restriction fragments of genomic DNA. After treatment with the restriction endonucleases, the resulting fragments were examined by agarose electrophoresis to determine their size. When the digested genomic DNA was run on a gel it appeared as a smear because there were DNA fragments of every possible length merged together (data not shown). The restriction fragments from the agarose gel were then transferred from the agarose gel to a nylon membrane and fixed by UV irradiation. This process resulted in the DNA bands becoming immobilised in the same relative positions on the surface of the membrane, and is referred to as the target.

The hybridisation probe was prepared by radioactively labelling the paralogue specific PCR product as described in section 2.14.1, which was then verified as described in section 2.14.2. The Southern blots were probed using the radioactively labelled paralogue specific PCR products as described in section 2.14.4. The sequence of the labelled DNA molecule was complementary to the target DNA, therefore they hybridised. The position of the hybridised probe on the membrane was identified by detecting the signal given out by the label attached to the probe. The signal was detected by autoradiography. If the probes were specific to a particular paralogue only a single band was seen on the autoradiograph corresponding to the restriction fragment that hybridises to the probe and which contains the paralogue of interest (figure 6.2.C).


Figure 6.2 Verification of probe specificity. (A) represents the results of the 'Paralogue Microarray' hybridisation using the 10 pooled probes. The corresponding probes and targets have hybridised and the spots (in triplicate) are visible (they are boxed and the name of the extended MHC gene given). The area highlighted by the yellow dashed lines is shown in more detail in (B). Within this region there are spots corresponding to the four members of the BRD paralogous gene family. The BRD2 probe was fluorescently labelled and hybridised to the array. The probe only hybridises to the BRD2 target and not to the three paralogues, indicating that the probe is specific to the BRD2 gene. (C) Southern Blot analysis using the BRD2 probe confirms that it is specific to the BRD2 gene. There is only a single band in lanes 1 and 3 (indicated with arrows), which contain genomic DNA digested with the restriction enzymes HINDIII and BamHI, respectively. The smear in lane 2 indicates that the digest with the restriction enzyme PstI was not successful.

### 6.3.2 Expression profiling

There are many ways in which to study the expression pattern of a gene. Classical techniques, such as Northern blotting, can be used to discover the expression profile on a low-throughput scale, while microarrays can be used to give a high-throughput analysis of gene expression. In total, five different methods were used to study the expression profile; In-silico, Dot-blotting, Northern Blotting, RT-PCR and Microarrays.

### 6.3.2.1 In-silico analysis

The aim of the human genome project was to produce a complete and accurate sequence of the entire genetic material. It was realised that the transcriptome was the information of most interest to scientists and this was addressed in part by the EST sequencing project. ESTs are Expressed Sequence Tags, which are short single-pass DNA sequences obtained from either end of complementary DNA (cDNA) clones. These ESTs are derived from a vast number of cDNA libraries obtained from different tissues, and species. Complementary DNA is prepared by converting an mRNA preparation into double-stranded DNA. Because the mRNA in a cell is derived from protein-coding genes, cDNAs and the ESTs obtained from them represent the genes that were being expressed in the cell from which the mRNA was prepared. ESTs are looked upon as a rapid means of gaining access to the sequences of important genes, and they are valuable even if their sequences are incomplete. They are also very useful for the preliminary analysis of gene expression in different tissues or pathological states. As this analysis is performed solely using computational techniques it has been termed 'in-silico'.

In silico analysis of EST data was performed as described in section 2.17. In summary, ESTs were retrieved from the UNIGENE cluster and by BLAST searching the EST database (dbEST) using the protein sequences. UNIGENE is an experimental system which automatically partitions the GENBANK sequences into non-redundant sets of gene-specific clusters. Each cluster contains sequences that represent a unique gene, as well as related information including the EST data. The EST data in the UNIGENE clusters is compiled using the EST database. In order to ensure I had the most comprehensive list of ESTs for each gene, the EST database was independently searched. However, in all cases no additional ESTs were identified. The ESTs were filtered in order to produce a non-redundant, unique set of ESTs for 36 MHC paralogues (summarised in Appendix 5).

Figure 6.3 summarises the results of the in-silico analysis of the BRD2 gene and the three paralogues, BRDT, BRD3 and BRD4. The expression profile of the BRD paralogous gene family was achieved in 59 different tissues corresponding to eight systems of the human body. In addition, the genes were all identified in pools of tissues that were categorised as mixed and in tissues of unknown sources, termed unknown. The transcript patterns of BRD2 and BRD3 have previously been determined in 43 human adult tissues and were found to be ubiquitously expressed (Thorpe et al, 1997). The expression profile using the EST data indicates that they are not ubiquitously expressed and have a more specialised transcript pattern.

One of the main advantages of EST data is that information is freely available for the majority of genes in the human genome in an array of tissues and cell-lines. Therefore, an extensive profile for a particular gene can be obtained relatively quickly. However, EST data has its limitations, including the types and sizes of the libraries available.


Figure 6.3 Summary of the results of the in-silico expression analysis of the BRD2 gene and its three paralogues. The tissues are divided into eight systems of the human body; nervous (red), cardiovascular (yellow), digestive (orange), genitourinary (blue), immune (purple), respiratory (green), secretory (pink) and muscle (grey). A black bar indicates that the gene is expressed in the tissue (i.e. there was one or more EST hits for the gene in the tissue). A white bar indicates that no EST was identified for a particular gene in the corresponding tissue; therefore there is no evidence of expression. Each tissue is separated by a horizontal grey line.

There is also a vast amount of redundancy within the EST libraries, which has been associated with the different rates and levels at which genes are expressed within various tissues, for example, in the UNIGENE dataset for the GPX3 gene there are 1335 ESTs compared with just 3 for the GPX5 gene. This implies that GPX3 is more highly expressed than GPX5, which is correct as GPX5 has a restricted expression Perry et al, 1992; Hall et al, 1998) whereas GPX3 is expressed in a range of tissues (Chu et al, 1992). In this thesis the EST data was used as a preliminary screen in order to determine in which tissues the genes were expressed and all findings were experimentally verified using a number of techniques.

### 6.3.2.2 Dot-blot analysis

The dot-blot, or Multiple Tissue Expression Array (MTE ${ }^{\text {TM }}$ Array), enabled the accurate profile of gene expression over a range of human tissues and cancer cell-lines in one experiment. In total, 76 tissue-specific poly $\mathrm{A}^{+}$RNAs were spotted onto the nylon membrane, including 17 areas of the brain, seven regions of the heart and RNA from other major organs of the body (summarised in figure 6.4.D). The paralogue specific probes were amplified using the primers summarised in Appendix 3 and radioactively labelled as described in section 2.14.1. The activity and the amount of incorporation of radioactivity were verified as described in section 2.14.2. The labelled probes were then hybridised to the dot-blot for 16 hours, washed and exposed for up to 8 days (as described in sections 2.14.4 and 2.14.5). The results for the 37 MHC paralogues analysed are summarised in Appendix 6.

Figure 6.4 summarises the results of the dot-blot analysis of the Allograft inflammatory factor 1 gene (AIF1; figure 6.4.A) and the paralogue on 9q34.12 (AIF1-

L; figure 6.4.B). Both genes show expression in most tissues spotted on the blot, albeit with varying levels of expression. The AIF1 gene was first isolated from activated macrophages in rat atherosclerotic allogenic heart grafts undergoing chronic transplant rejection (Utans et al, 1995). Autieri (1996) showed that AIF1 was a cytokine-inducible, tissue-specific, and highly conserved transcript transiently expressed in response to vascular trauma. AIF1 is also known to be expressed in a variety of human tissues, with highest expression in tissues of lymphoid origin, in particular, spleen and thymus. This has been confirmed by my dot-blot analysis of the gene. Both paralogues, AIF1 and AIF1-L, are highly expressed in adult and foetal spleen suggesting an overlap (or redundancy) in function. However, only AIF1 is expressed in adult and foetal thymus showing functional divergence.

There are other examples of co-expression and divergence of expression. In particular, both are expressed in areas of the brain. AIF1-L is expressed in whole brain as well as the 17 different sections of the brain individually spotted on the blot, whereas AIF1 is more selective and is expressed in 10 areas of the brain but is not detected in whole brain. The overlap in expression suggests that the two paralogues maybe involved in the same pathway and, owing to redundancy, can perform the same function in certain parts or stages of that pathway. One of the other interesting findings of the dot-blot analysis is that AIF1-L is highly expressed in kidney whereas the expression of the AIF1 gene is very weak. This indicates that these paralogues also have divergent functions.

Figure 6.4 Transcription pattern of the AIF1 (A), AIF1L (B) and $\beta$-actin control (C) genes after hybridisation with paralogue-specific probes to the dot blot with RNA from different tissues. (D) Tissue key of the RNA dot-blot as supplied by the manufacturer (Clontech). The tissues shaded red indicate that both AIF1 and AIF1L were expressed in that tissue, blue shows only AIF1 was expressed, yellow indicates only AIF1L was expressed and white shows that neither gene were expressed in that tissue. Blots A and B were exposed for 3 days and blot C for 2 days.
A. AIF1 (6p21.33)

B. AIF1L (9q34.12)

C. Control

D. Template


[^1]
### 6.3.2.3 Northern blot analysis

Northern blotting can be used to determine the expression profile of a gene as well as identify the number of alternative splice variants. Alternative splicing is a widely occurring and important mechanism for controlling differential expression of cellular genes. The process changes the effect of a gene in different tissues and developmental states by generating distinct mRNA isoforms composed of different selections of exons, which produce variant proteins. This phenomenon is widespread in the human genome and it has been predicted that between $40-60 \%$ of human genes are alternatively spliced (Modrek and Lee, 2002).

Whilst studying the expression profile of the MHC paralogous genes it was important to understand how many splice variants that utilise the region amplified by the paralogue specific primers were expressed in a particular tissue. This was achieved using Multiple Tissue Northern (MTN ${ }^{\mathrm{TM}}$ ) blots purchased from Clontech, referred to as Northern blots throughout this chapter. The Northern blots used in this thesis enabled the assessment of the alternative splice forms, sizes (ranging from 0.5 to 10 kb ) and relative abundance of the transcript in eight different normal human tissues (figure 6.5). The Northern blots were made using poly $\mathrm{A}^{+}$RNA extracted from the eight different normal human tissues.

The paralogue specific probes were used to hybridise to the Northern blots in order to assess how many splice variants were present in each tissue for 37 MHC paralogues (the tenascin paralogous gene family has been removed from the analysis, see section 6.3.3.1). The primers used and the results for the paralogues analysed are summarised in Appendix 3 and 7 respectively. The results of the Northern blot analyses for the four members of the BRD paralogous gene family is shown in figure 6.5.


Figure 6.5 Transcription pattern and splice variants of the BRD2 (A), BRD3 (B) BRD4 (C), BRDT (D) and $\beta$-actin control (E) genes after hybridisation with specific probes to a Northern blot with eight different tissues. (F) Tissue/source key of the Northern blot as supplied by the manufacturer (Clontech). The splice variants are indicated with arrows for the BRD paralogous genes. Blots in $\mathrm{A}, \mathrm{B}, \mathrm{C}$ and E were exposed for 3 days whereas the blot in D was exposed for 18 days.

Northern analysis revealed that the BRD2, BRD4 and BRDT genes have multiple transcripts, whereas BRD3 only has one (indicated by arrows in figure 6.5). Two alternative splice variants of 4.6 kb and 3.8 kb were detected in all eight tissues probed using the BRD2 gene (figure 6.5.A). The weakest transcripts were identified in brain, lung and kidney. The strongest signals were for the heart and pancreas. A single transcript of approximately 6.5 kb was observed for BRD3 in the eight tissues on the Northern blot, with the strongest signal in skeletal muscle and the weakest in lung (figure 6.5.B). Two splice variants of the BRD4 gene were identified in all eight tissues of approximately 6.0 kb and 4.4 kb corresponding to the long and short isoforms of the BRD4 gene (French et al, 2003). The weakest expression was in lung and the strongest in skeletal muscle, which is similar to the BRD3 gene.

Weak expression of a single BRDT transcript of approximately 7 kb was detected in heart, brain, placenta, liver, skeletal muscle and kidney. In addition three transcripts were identified in pancreas, corresponding to the 7 kb transcript and two pancreas specific splice variants of approximately 3.5 kb and 4.0 kb . The strongest signal corresponds to the 3.5 kb variant in pancreas and the 7 kb transcript in skeletal muscle. These findings are interesting as the BRDT gene was identified using an EST from a testis-specific library (Diatchenko et al, 1996). Further expression analysis using 16 normal human tissues and eight cancer cell-lines indicated that there were only two BRDT transcripts of 3.5 kb and 4.0 kb which were both specific to testis (hence the gene being named bromodomain, testis-specific or BRDT; Jones et al, 1997). I have shown that this transcript is expressed at very low levels in a number of tissues by using the BRDT paralogue specific probe.

To summarise, Northern analysis shows that the BRD paralogous genes are co-
expressed in most of the tissues tested. In particular, the BRD3 and BRD4 genes both demonstrate elevated expression in skeletal muscle suggesting an important role in this tissue.

### 6.3.2.4 Microarray analysis

Microarrays can be used to simultaneously determine the expression profile of thousands of genes in a particular tissue or cell-line. Each experiment provides static information about gene expression (i.e. in which tissue(s) the gene is expressed) and dynamic information (i.e. how the expression pattern of one gene relates to those of others). In the expression microarray experiments a modified standard Sanger Institute 10 K microarray was used to establish the expression profile of all the DNA elements on the array in ten different RNAs (described in more detail later in this section).

First, the RNAs were extracted from five cell-lines (as described in section 2.10) and five were purchased from Ambion. As a control, a standard RNA was purchased from Stratagene that is routinely used by the Sanger Institute Microarray Facility for the quality control of the microarrays they manufacture. The quality of the RNA was determined by electrophoresis of $2 \mu \mathrm{~g}$ of each of the RNAs on a $1 \%$ agarose gel (figure 6.6.A). The quality of the RNA is indicated by two bands corresponding to 28 S and 18 S ribosomal RNA. Sharp and distinct bands indicate good quality RNA but diffused and smeared are indicative of degradation. The RNA was also checked for DNA contamination using 'no RT-PCR'. The RNA was used as a template in a standard PCR reaction and the paralogue specific primers (summarised in Appendix 4) for the BRD2 gene were used, as described in section 2.9. If the RNA was contaminated a faint band was visible after 35 PCR cycles and the RNA was DNase
treated to remove the DNA in the sample and the quality of the RNA re-checked (as described in section 2.11).
A.

B.

C. Key

| 1. Adrenal gland | 6. 293T (kidney) |
| :--- | :--- |
| 2. Brain | 7. Jurkat (T cell) |
| 3. Skeletal muscle | 8. Raji (B cell) |
| 4. Spleen | 9. THP1 (monocyte) |
| 5. Testis | 10. U937 (lung) |

Figure 6.6 (A) Assessment of the quality of the eleven RNAs used in the expression microarray experiments. The RNA is of good quality and has the two distinct bands corresponding to 28 S and 18 S ribosomal RNA, indicated by arrows. (B) RNA was checked for DNA contamination using 'no RT-PCR'. The primers used were specific for the BRD2 gene which amplifies a 411 bp product in the positive control, where genomic DNA was used as the template, only. (C) is the key to the ten RNAs used in the analysis. RNAs 1 to 5 were purchased from Ambion and RNAs 6 to 10 were extracted from cell-lines as described in section 2.10. Water was used as the template in the negative control.

In the expression microarray experiments presented in this thesis the standard Sanger Institute 10,000 gene (or 10 K ) microarray was modified to accommodate the 40
paralogous genes and is termed the ' $10 \mathrm{~K} /$ Paralogue Microarray' in this thesis (as described in section 2.13.1). In short, the 40 paralogue specific targets were amplified using the PCR specific primers (summarised in Appendix 4) and arrayed in quadruplicate onto the matrix, in this case a glass microscope slide. The mRNA from the tissue or cell-line was reverse-transcribed into cDNA, labelled with a fluorescent dye and hybridised to the '10K/Paralogue Microarray'. After hybridisation, a laser scanner measured the amount of fluorescence at each spot. The results of a hybridisation using the standard RNA purchased from Stratagene is shown in figure

## 6.7.



Figure 6.7 Results of a hybridisation with the standard Stratagene RNA to the ' $10 \mathrm{~K} /$ Paralogue Microarray'. The layout of the 48 sub-arrays in $12 \times 4$ super-arrays is visible after hybridisation and the sub-array boxed in yellow is expanded. The first row of the sub-array is boxed in red. Columns 1 to 8 of row 1 contain the controls described in section 2.13.1. The paralogue specific PCR products of one paralogue are arrayed in rows 9 to 12 (shown as 4 green spots) and of a second paralogue in rows 13 to 16 (shown as 4 blue spots). The level of expression is indicated by the intensity of the spot, which is, in turn, is indicated by the colour of the spot. The colour intensities are, from highest to lowest, white $>$ red $>$ yellow $>$ green $>$ blue $>$ black (i.e. no spot).

In short, when a spot is visible after hybridisation with the labelled cDNA the corresponding DNA element on the array is expressed in that tissue but when the particular transcript is not expressed no spot is visible. This is summarised in figure
6.8.


Figure 6.8 One of the 48 sub-arrays of the ' $10 \mathrm{~K} /$ Paralogue Microarray' after hybridisation using the Stratagene standard RNA. The four spots boxed in red correspond to one paralogue which is expressed in the standard RNA. The area boxed in blue contains four DNA elements corresponding to one paralogue which is not expressed in the standard RNA, indicated by the absence of spots. The level of expression is indicated by the intensity of the spot, which is, in turn, indicated by the colour of the spot. The colour intensities are, from highest to lowest, white $>$ red $>$ yellow $>$ green $>$ blue $>$ black (i.e. no spot).

The intensity of the spot and the background were determined using the fixed circle method in the Quantarray ${ }^{\circledR}$ software package. The highly regular arrangement of the spots in rows and columns resulting from the robotic printing rendered the image data amenable to extraction by highly developed, digital image processing procedures. In order to detect the spots a grid was overlaid on the scanned array image. Firstly, the array pattern was established and the initial definition of the area of the spot (i.e. the spot diameter and the row and column information) determined. In an ideal situation
the spots are perfectly circular, homogenous (i.e. the intensity is the same at each pixel in the spot) and the background signal is well defined. However, the spots on the slide may be somewhat irregular in nature and are not perfectly placed on the slide. Therefore, to counteract this, the precise location of each spot was identified by editing the array pattern and the reading was taken within the region defined as containing the spot. A spot typically consists of a number of pixels and the image analysis algorithms either assign pixels to a spot or not and produces a summary of the intensity of the fluorescence at each spot and the surrounding unspotted area i.e. the background.

In total, three experiments were performed for each of the 10 test RNAs and the Stratagene standard RNA. The outputs of the analysis of each of the 30 arrays were independently analysed. In order to determine whether a spot was present or not, i.e. the gene is expressed in that tissue or not, the standard deviation between the spot intensity and the background intensity was calculated. It was determined that a standard deviation greater than two indicated that a spot was present and the gene therefore expressed. For example, the standard deviation of the BRD2 gene in brain tissue for one experiment across all four spots in the upper section of the array were $7.09,7.09,8.08$ and 8.02 , thus clearly indicating that the BRD2 gene is expressed. This was also confirmed by the in-silico, Dot-blot and Northern blot analyses. In the case of the 40 paralogues each of the corresponding spots were manually analysed.

As a control, the 10 test RNAs were reverse transcribed into complementary DNA and were used as the templates in PCR reactions to amplify the paralogue specific PCR products for the AIF1 gene and its paralogue, AIF1-L. The results of the microarray and RT-PCR experiment performed these two genes shows that the same
expression profile was achieved using both techniques (summarised in figure 6.9A).


Figure 6.9 Microarray results confirmed by RT-PCR. (A) RT-PCR (using the primers AIF1.F1 and AIF1.R1 summarised in appendix 4) and (B) RT-PCR results (using AIF1-L.F and AIF1-L.R see Appendix 4) and microarray results of AIF1-L. The negative (-ve) control used water as a template and the positive (+ve) control used genomic DNA as the template and only apply to RT-PCR. (C) summarises the marker and tissue key.

### 6.3.2.5 Importance of designing specific microarray targets

In addition to the 40 paralogues selected for further analysis there are 9464 other DNA elements spotted onto the standard Sanger Institute 10K array. These DNA
elements correspond to cDNAs derived from direct sequencing of I.M.A.G.E (or Integrated Molecular Analysis of Genomes and their Expression) clones, which are generated as part of the EST project, and 468 chromosome 22 gene-specific PCR products. In total, 15 of the 40 paralogues selected for further analysis are already represented on the standard Sanger Institute 10K microarray and are part of the gene repertoire. The 15 genes correspond to eight of the 10 paralogous gene families. It is, therefore, of interest to compare the expression profiles of the paralogue specific PCR products designed in this thesis and those already on the microarray. Examples of such a comparison are shown in figure 6.10.
A.

C.

1. Adrenal gland
2. 293 T (kidney)
3. Brain
4. Skeletal muscle
5. Jurkat (T cell)
6. Spleen
7. Raji (B cell)
8. Testis
9. THP1 (monocyte)
10. U937 (lung)

Figure 6.10 Comparison of the expression profiles of the paralogue specific PCR products designed in this thesis and those already on the standard Sanger Institute 10K microarray corresponding to (A) GPX4 and (B) BRD3 genes. (C) is the key to the tissues and cell-lines used.

The expression profile of the paralogue specific PCR product designed for GPX4 in this thesis is identical to that of the DNA element (GPX4_743350_A) already spotted onto the standard Sanger Institute 10K array (figure 6.10.A). However, the DNA element BRD3_773539_A is expressed in all of the same tissues as the paralogue
specific PCR product I designed for the BRD3 gene but it is also expressed in two additional tissues (figure 6.10.B). The difference in expression may be due to the DNA element cross-hybridising with another paralogue or may correspond to different splice variants that are not represented by my paralogue specific PCR product. This emphasises the importance of understanding, not only, which gene, but the splice variant a DNA element on a microarray corresponds to when interpreting the results of a hybridisation experiment. It also shows the value of designing a paralogue and splice variant-specific microarray.

### 6.3.3 Interpretation of expression data

In order to interpret the vast amounts of expression data generated in this thesis and determine the relationships between the MHC paralogous genes the data was clustered. Clustering is a technique used in exploratory data analysis and pattern discovery to extract underlying cluster structures. The data presented in this chapter was clustered using the unsupervised clustering methods, hierarchical clustering (clustering methods are reviewed by Brazma and Vilo, 2001) using EPCLUST (Expression Profile Data CLUSTering and Analysis) available from the EBI, unless stated otherwise.

### 6.3.3.1 Tenascin paralogous gene family

The tenascin paralogous gene family was removed from the analysis when it became apparent that I had designed paralogue specific primers to the wrong transcript of Tenascin X. The tenascin proteins are a family of extracellular matrix proteins (ECM) (for a review see Erickson, 1993). The Tenascin X gene was partially duplicated
during the duplication of the region on 6 p , which gave rise to two isoforms, the 65 kb TNXB and 4.5 kb TNXA. A truncated version of the TNXB gene, termed TNXB-S (or TNXB-short) has been identified as an adrenal gland specific transcript (Tee et al, 1995). Evidence from the expression profiling experiments indicated that I had designed TNXB specific primers to the TNXB-S transcript as microarray experiments determined that it was only expressed in adrenal gland (figure 6.11). This was confirmed by Dot-blot analysis.


Key

1. Adrenal gland
2. Brain
3. Skeletal muscle
4. Spleen
5. Testis
6. 293T (kidney)
7. Jurkat (T cell)
8. Raji (B cell)
9. THP1 (monocyte)
10. U937 (lung)

Figure 6.11 Expression profile of the TNXB gene indicates that it is adrenal gland specific. This suggests that the paralogue specific primers were designed for the truncated TNX transcript rather than the full length gene.

### 6.3.3.2 Microarray expression data

The results of the microarray expression experiments and the resulting clustering are summarised in figure 6.12. Each spot is representative of one of the 24 spots corresponding to an individual paralogue ${ }^{1}$. In order to cluster the data it was necessary to assign numerical values to the expression profiles. When the gene was expressed in a particular tissue, indicated by the presence of a spot, it was assigned the number 1 . When no spot was present, 0 was assigned. As the experiments were performed in triplicate, in the case of uncertainty, the majority rule was applied. In other words, if

[^2]two out of the three experiments showed expression the gene in that tissue was assigned the value of 1 .

Analysis of the microarray results presented in figure 6.12.A shows that the members of only one of the ten MHC paralogous gene families have identical expression patterns. This family is the complement paralogous gene family which has three members, C4, C3 and C5. These genes are not expressed in any of the ten tissues used in this analysis. Interestingly, upon clustering the complement genes do cluster together, along with the six other genes also not expressed in any of the tissues tested (figure 6.12.B).

In addition to highlighting the relationships between members of the same paralogous gene families, clustering the data reveals the relationships between all the paralogues used in the expression analysis (summarised in figure 6.12.B). It is interesting to note that the four paralogues that are expressed in all ten tissues are clustered, of which two are members of the GPX paralogous gene family, GPX1 and GPX4, and the other two, BRD2 and CLIC1, are members of different paralogous gene families. As stated earlier, the nine genes not expressed in any of the ten tissues are also clustered. Although it was apparent prior to clustering the data that the members of the same paralogous gene families are differentially expressed there are some members of the $\beta$-tubulin paralogous gene family which do cluster; they are TUBB5 and TUBB4. However, the other four members investigated cluster with members of other paralogous gene families, including the GPX and the CLIC paralogous gene families, which have different functions in the human body.

Figure 6.12 (A) Summary of the microarray expression data and (B) the result of applying Hierarchical clustering methods. Red indicates that the gene is expressed in the corresponding tissue, whereas black shows lack of expression. Members of the same paralogous gene families that cluster together are highlighted by blue box in (B). The raw data is summarised in Appendix 8.
A.

| تِّ | 皆 |  |  | $\begin{aligned} \frac{g}{g_{2}^{2}} \\ \frac{2}{2} \end{aligned}$ | 霽 |  | $\underset{\sim}{2}$ | $\begin{array}{\|l\|l} \stackrel{y}{y} \\ \stackrel{y}{y} \end{array}$ | $\stackrel{\overline{\vec{®}}}{\approx}$ |  |  | - |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| AIF1 |  |  |  | $\cdots$ |  |  |  | 2 |  |  |  | $\square$ |
| AIF1L |  |  |  | 0 |  |  |  |  |  |  |  |  |
| BRD2 |  | P1 |  |  | 0 |  |  | 0 | 3 |  |  | \% |
| BRDT |  |  |  |  |  |  |  |  |  |  |  |  |
| BRD3 |  | 2 |  |  |  |  |  | 3 |  |  |  |  |
| BRD4 |  |  |  |  |  |  |  |  |  |  |  |  |
| C4 |  |  |  |  |  |  |  |  |  |  |  |  |
| C5 |  |  |  |  |  |  |  |  |  |  |  |  |
| C3 |  |  |  |  |  |  |  |  |  |  |  |  |
| CLIC1 | $*$ |  |  | * |  |  |  | 6 | 8 | - |  |  |
| CLIC4 |  | c |  | 2 |  |  |  |  | 5 |  |  |  |
| CLIC3 |  |  |  |  |  |  |  |  |  |  |  |  |
| CLIC5 |  |  | 0 | 0 |  |  |  |  |  |  |  |  |
| CLIC6 |  |  |  |  |  |  |  |  |  |  |  |  |
| CLIC2 |  |  |  |  |  |  |  |  |  |  |  |  |
| GPX5 |  |  |  |  |  |  |  |  |  |  |  |  |
| GPX4 | $\bullet$ | 0 |  | 8 | b |  | - | $\bigcirc$ | 0 |  |  | $\square$ |
| GPX1 |  | 8 | 8 | * | 8 |  | - | 4 | - |  |  | 4 |
| GPX3 | 2 |  | 0 |  |  |  |  |  |  |  |  |  |
| GPX2 |  |  |  |  |  |  |  |  |  |  |  |  |
| NOTCH4 |  |  |  |  |  |  |  |  |  |  |  |  |
| NOTCH2 |  |  |  |  |  |  |  |  |  |  |  |  |
| NOTCH1 |  |  |  |  |  |  |  |  |  |  |  |  |
| NOTCH3 |  |  |  |  |  |  |  |  |  |  |  |  |
| PBX2 |  |  |  |  |  |  |  |  |  |  |  |  |
| PBX1 |  | 8 |  |  |  |  |  |  |  |  |  |  |
| PBX3 |  |  |  |  |  |  |  |  |  |  |  |  |
| PBX4 |  |  |  |  |  |  |  |  |  |  |  |  |
| RXRB |  |  |  |  |  |  |  |  |  |  |  |  |
| RXRG |  |  |  |  |  |  |  |  |  |  |  |  |
| RXRA |  |  |  |  |  |  |  |  |  |  |  |  |
| TUBB |  | 0 | a | 4 | 6 |  | \% | 8 | 8 |  |  | 8 |
| TUBB5 |  | $\square$ |  |  |  |  |  |  |  |  |  |  |
| TUBB4Q |  | * | \% |  | 0 |  |  |  | 8 |  |  |  |
| TUBB4 |  | 8 |  |  |  |  |  |  |  |  |  |  |
| TUBB2 | * | 8 | 6 | * | E |  |  |  | * | 4 |  |  |
| TUBB1 |  |  |  | . |  |  |  |  |  |  |  |  |

B.

Brain
Testis
Raji (B cell)
Skeletal muscle
Spleen
Jurkat (T cell)
U337 (lung)
Adrenal gland
THP1 (monocyte)
293T (kidney)


### 6.3.3.3 In-silico expression data

The in-silico data compiled for nine MHC genes and 27 paralogues was clustered for 61 different tissues and cell-lines (figure 6.13). It is important to note that the TUBB4QL gene located on 10p15.3 did not have a UNIGENE cluster and no unique ESTS were identified, therefore, there is no in-silico data for this gene. However, there is a vast amount of information regarding the remaining 36 paralogues. Clustering has enabled relationships to be discovered between the paralogues which were not apparent upon initial analysis of the raw data (summarised in Appendix 5). It is interesting to see that some members of the same paralogous gene families are clustered. For example, both members of the AIF paralogous gene family are clustered together, which is interesting as they demonstrate both co-expression as well as divergence in their expression patterns. As in the microarray experiments two members of the $\beta$-tubulin paralogous gene family cluster, albeit they are TUBB5 and TUBB1 rather than TUBB5 and TUBB4.

Two members of the RXR family, RXRA and RXRB, are also clustered and demonstrate overlapping expression profiles in a number of tissues. The third member of this group, RXRG, does not cluster with them as it has more specialised expression profile. In addition, both NOTCH1 and NOTCH3 genes cluster and it has previously been proposed that these genes may have an overlapping function (Lardelli et al, 1994). It is interesting to note that all 36 genes were represented in the EST libraries, with the GPX5 gene only represented in testis and epididymis, as previously described by Perry and co-workers (1992) and Hall and colleagues (1998).

Figure 6.13 Clustering of the in-silico expression profile results. Red indicates the gene is expressed in the corresponding tissue and black shows that there is no evidence of expression. The raw data is summarised in Appendix 5.

Tissue



### 6.3.3.4 Dot-blot expression data

Clustering of the dot-blot expression data reveals a number of relationships between the expression profiles of the 37 paralogues investigated (figure 6.14). One of the most interesting findings is that eight of the 37 paralogous genes are ubiquitously expressed and are clustered as one group. Some members within this group, namely BRD2, CLIC1 and GPX4 also demonstrate similar expression profiles in the microarray and in-silico clustering figures. In addition, two members of the NOTCH paralogous gene family cluster, albeit they are NOTCH2 and NOTCH3 rather than NOTCH1 and NOTCH2 which cluster together in the in-silico analyses. The clustering of two members of the PBX paralogous gene family, PBX 1 and PBX 4 , is unique to the dot-blot analysis.

There are two genes that are not expressed in any of the tissues, CLIC2 and GPX5, which are clustered. In addition, both the in-silico and microarray analyses showed a restricted expression pattern for the GPX5 gene in the tissues analysed. The expression profile of the CLIC2 gene generated by the microarray expression experiments showed limited expression whereas in-silico analysis showed expression in a wider range of tissues. This highlights the advantage of using multiple techniques, and RNAs from a range of tissues and sources, to generate expression profiles.

One point to note regarding the clustering of the expression data is that, although the clustering presented in this section reveals relationships between paralogues regarding their expression in various tissues, it should be viewed with caution. Further investigation is required to determine true relationships.

Figure 6.14 Clustering of the dot-blot expression profile results. Red indicates the gene is expressed in the corresponding tissue and black shows that there is no expression. The raw data is summaries in Appendix 6.


### 6.3.3.5 Comparison of the expression profiles of the MHC paralogues

## located in the paralogous regions on chromosomes 1, 9 and 19

In order to understand the relationship between the expression profiles and the location of the paralogous genes the data was clustered as described in section 2.18 (presented in figure 6.15).
A.

| Tissue |
| :--- |
| Brain (whole) |
| Heart |
| Aorta |
| Oesophagus |
| Stomach |
| Liver |
| Pancreas |
| Colon |
| Kidney |
| Bladder |
| Prostate |
| Uterus |
| Ovary |
| Testis |
| Placenta |
| Spleen |
| Thymus |
| Leukocyte |
| Lymph node |
| Bone marrow |
| B cell |
| T cell |
| Trachea |
| Lung |
| Adrenal gland |
| Thyroid gland |
| Salivary gland |
| Muscle |



Figure 6.15 Comparison of the expression profiles of the paralogues located within the paralogous regions on chromosomes 1,9 and 19 with the MHC genes using (A) in-silico and (B) dot blot analysis in 28 normal human tissues. The tissues are divided into eight systems of the human body; nervous (red), cardiovascular (yellow), digestive (orange), genitourinary (blue), immune (purple), respiratory (green), secretory (pink) and muscle (grey). A black bar indicates that genes within that region are expressed; the thickness of the bar is indicative of the percentage of genes expressed (i.e. the thicker the bar the more genes are expressed). Each tissue is separated by a grey horizontal line.

A total of 28 different normal human tissues corresponding to eight different systems of the body were common to both the in-silico and the dot-blot analyses. The results
presented in figure 6.15 correspond to 27 genes; of which nine are located within the MHC region, five are on chromosome 1 , seven on chromosome 9 and six on chromosome 19. Overall, the genes located within the MHC region are expressed in most systems of the body and the profile is most similar to that of chromosome 9. It is apparent from figure 6.15 that the genes located within the region on chromosome 1 have a more specialised expression pattern whereas the chromosome 19 genes are more highly expressed throughout the different systems of the body.

### 6.3.3.6 Comparison of the methods used to generate expression profiles

Nine of the tissues used in the microarray, dot-blot and in-silico analyses are common to all three methods. It is, therefore, of interest to compare the expression profiles of the paralogous genes in these tissues in order to see how expression differs between the techniques used in this thesis (summarised in table 6.1 and Appendix 9). The number of differences between each method was determined and the percentage differences calculated. For example, when comparing the expression profiles of the 36 genes in testis there were four differences between the microarray results, four differences between the dot-blot results and five differences between the in-silico data and the other two methods. These corresponded to $11 \%, 11 \%$ and $14 \%$ differences respectively.

Table 6.1 Comparison of three methods used to generate the expression profiles for nine MHC paralogous gene families. M refers to microarray data, D is dot-blot data and S refers to the in-silico data. Full table can be found in Appendix 9.

|  | Adrenal Gland |  |  | Brain |  |  | Skeletal muscle |  |  | Spleen |  |  | Testis |  |  | Kidney |  |  | $T$ cell |  | B cell |  |  | Lung |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | M | D | S | M | D | S | M | D | S | M | D | S | M | D | S | M | D | S | M | D | M | D | S | M | D | S |
| \% differences between methods | 14 | 8 | 25 | 11 | 3 | 22 | 14 | 11 | 14 | 8 | 14 | 19 | 11 | 11 | 14 | 44 | 3 | 22 | 8 | 61 | 6 | 6 | 14 | 42 | 0 | 28 |

There are some very large differences between the expression profiles of the genes within certain tissues. For example, $44 \%$ of the results obtained in the microarray analysis for the expression profiles of the genes in kidney are different to those determined by dot-blot and in-silico analyses. This is probably due to the sources of the RNA. In the case of the microarray experiments, the RNA was extracted from the human kidney cell-line, 293T, whereas the RNA on the dot-blot is pooled from 14 different individuals and the kidney EST libraries have been generated from a range of different kidney tissues. The age and gender of the individual from which the RNA was extracted may also affect the expression profiles of the genes in a particular tissue. This emphasises the importance of understanding the source of RNA when studying the expression of transcripts in a particular tissue.

### 6.4 Discussion

In order to understand the mechanism(s) by which the MHC paralogues have evolved since their emergence by duplication, the expression profiles of nine MHC paralogous gene families were generated in a range of tissues corresponding to eight different systems of the human body. A lot of information regarding the potential functions of the MHC paralogues can be deduced from the knowledge in which tissues they are expressed, but it is difficult to determine the precise mechanism by which the MHC paralogues have evolved without prior knowledge of the function, or functions, of the ancestral gene.

The function(s) of the ancestral gene can be deduced by analysing the expression profiles of the orthologues in organisms near the origin of the vertebrate lineage. For example, comparison of the expression of the four vertebrate NOTCH genes with that of the single Notch gene in amphioxus during embryogenesis indicates that they have similar roles (Holland et al, 2001). This organism is in a unique phylogenetic position as it is located at the base of the vertebrate lineage and can therefore be used as a 'stand-in' for the ancestral species. However, further investigation of the individual functions of the vertebrate NOTCH genes is necessary to determine the process by which paralogues have evolved. For example, functional comparisons will determine whether just one gene has maintained the functions of the ancestral gene, indicating that the paralogues have evolved via the process of neo-functionalisation, or whether the functions of the ancestral gene have been 'shared' between the four paralogues, thus they have evolved by the process of sub-functionalisation.

The data generated in this chapter has enabled the comparison of members of the same paralogous gene family as well as with members of other families in the same
tissues. In general, the MHC paralogues have distinct overall expression profiles to one another; but, in many cases there is still some level of overlap, or co-expression, in a number of tissues. For example, the expression profiles generated in this thesis for the NOTCH paralogues demonstrate some overlap in expression. One reason to explain why a certain amount of redundancy has been maintained over several hundred million years of evolution is that the paralogues concerned may perform the same functions.

It has been shown that experimental disruption of many individual genes does not exert lethal effects on an organism or even visible changes in phenotype of the organism with the knockout. In the unicellular eukaryote Saccharomyces cerevisiae there are approximately 5350 protein coding genes (Mackiewicz et al, 1999; 2002), of which only 924 are essential and probably unique, since their elimination from the genome has a lethal effect, while for about half of the other genes no changes in phenotype after disruption has been found (MIPS 2002 database (http://mips.gsf.de); Cebrat and Stauffer, 2002). If paralogues can perform the same function they may act as a 'back-up' system, thus if one paralogue is knocked-out, or rendered nonfunctional, another paralogue may be able to act as a substitute to prevent changes in phenotype, especially harmful ones.

To-date, there is little evidence to prove or refute this hypothesis. Experiments involving mice deficient for a member of the BRD paralogous gene family, the BRD4 gene, showed phenotypic changes in heterozygotes and fatality in homozygous mice (Houzelstein et al, 2002). The mice heterozygous for the BRD4 allele displayed pre and postnatal growth defects and exhibited a variety of malformations, including head malformations, absence of subcutaneous fat, cataracts and abnormal liver cells. The

BRD4 homozygous mice died shortly after implantation and were compromised in their ability to maintain an inner cell mass in-vitro. These experiments suggest that BRD4 plays an important role but it can not be substituted by the other three paralogues, or any other gene in the genome.

Comparison of the expression profiles of the BRD4 gene and the three paralogues generated in this thesis shows overlapping expression in a number of tissues. BRD4, BRD2 and BRD3 are expressed in most of the tissues used in the analysis and are expressed in all systems of the body, whereas the BRDT gene demonstrates a more restricted tissue distribution. Co-expression of the BRD genes in the same tissues would indicate that they have a similar function and could act as substitutes for each other if necessary. However, the experiments in mouse discussed above indicate otherwise.

Evidence from other paralogous genes in the mammalian genome has shown that paralogues with similar expression profiles have complementary functions in certain tissues and demonstrate partial redundancy rendering them functionally interchangeable. An example of this is demonstrated by two members of the Hox paralogous gene family, Hoxa3 and Hoxd3 (reviewed by Prince and Pickett, 2002). These genes have virtually identical expression patterns (Greer et al, 2000 and references therein). Intriguingly, mice lacking either a functional Hoxa3 or Hoxd3 gene show no obvious overlap in phenotype thus indicating that they have independent functions. However, the analysis of mice carrying different combinations of the mutant alleles of the Hox3 paralogues suggests that there is also a functional overlap between these genes.

It is apparent that a lot more functional information is needed before we will fully
understand the role of paralogous genes in the human body and just how much genetic redundancy is maintained or lost during evolution. To-date, there is evidence of functional redundancy as well as complementation between members of paralogous gene families. Expression analysis is only the first step in exploring the function of a gene and we are still a long way from having a detailed gene expression profile of every gene and paralogue in the human genome. The transcript patterns of nine MHC paralogous gene families presented in this chapter will therefore act as the basis for future research. The results in this chapter show that, like genome sequencing, systematic gene expression profiling is valuable but is not the end in itself. In order to understand the mechanism(s) by which the MHC paralogues have evolved we need to have a complete understanding of the functions of these genes. Therefore, further genetic analysis combined with biochemical studies are necessary to shed light on the functional evolution of the paralogues.

## Chapter 7

## Conclusions and future work

### 7.1 Conclusions

This thesis presents the first systematic, unbiased survey of the entire human genome sequence to identify MHC paralogous genes with increasing levels of confidence and to determine their distribution. The genome-wide survey identified 791 MHC paralogous genes in the human genome with increasing levels $(\mathrm{L} 0>\mathrm{L} 1>\mathrm{L} 2>\mathrm{L} 3)$ of confidence; of which 618 are L0-paralogues, 91 are L1-paralogues, 38 are L2paralogues and 44 are L3-paralogues. It was found that over two-thirds of the MHC genes used in this study have paralogues located throughout the human genome and a total of one-third have paralogues with the highest level of confidence (L2- and L3paralogues). The MHC genes with L2- and L3-paralogues are not restricted to just one region of the MHC and span almost the entire length of 6p22.2-p21.3, including genes within the most telomeric and centromeric regions; the extended class I and extended class II regions, respectively. Thus, indicating that the entire MHC region has been involved in the events giving rise to paralogous genes.

The study of the distribution of the MHC paralogous genes has confirmed that there are clusters of MHC paralogues located in the previously proposed regions on human chromosomes 1, 9 and 19. Almost $50 \%$ of the L2- and L3-paralogues are located within the regions $1 \mathrm{q} 21.2-\mathrm{q} 25.3,9 \mathrm{q} 32-\mathrm{q} 34.3$ and 19p13.3-p13.11. No further clusters of MHC paralogous genes were identified in the human genome, as postulated by Hughes and Pontarotti (2000). However, one of the most interesting, and novel,
findings of this thesis is that the MHC paralogous genes are not confined just to these regions but there are paralogues scattered throughout the human genome.

In order to understand the relationship between the MHC and the other chromosomal regions containing clusters of MHC paralogues the region 9q32-q34.3 was mapped, sequenced and analysed. The characterisation of 9q32-q34.3 presented in this thesis represents the largest genomic region containing MHC paralogous genes to be characterised to-date. The comparison of 9q32-q34.3 and the MHC region has revealed a number of features common to both chromosomal segments. In total, 322 genes were identified within the $9 \mathrm{q} 32-\mathrm{q} 34.3$ region, which spans almost 24 Mb , corresponding to approximately one gene per 73 kb . The gene dense nature of $9 \mathrm{q} 32-$ q34.3 is comparable to that of the MHC region. But this is just one feature these regions share. Other features shared by both regions include; they are associated with a number of diseases, the presence of structurally and functionally different genes and high GC content. One of the key differences between 9q32-q34.3 and the MHC region is that, although paralogues of 25 gene families located within the MHC region were identified on 9q32-q34.3, no HLA class I or class II-like genes were identified. Characterisation of the 1.7 Mb region of the paralogous region on $1 \mathrm{q} 21-\mathrm{q} 22$ confirmed that there was a cluster of HLA class I-like genes, termed the CD1 gene cluster (Shiina et al, 2001).

The existence of chromosomal regions containing clusters of duplicated genes is indicative of a common origin by large-scale duplication of either the whole-genome or of a block. In this thesis, I have identified three regions containing clusters of genes paralogous to those found within the MHC region, which is indicative of at least two rounds of large-scale duplication events. This is in support of the $2 R$ hypothesis
which, in its simplest form, assumes two rounds of whole-genome duplication early in the vertebrate lineage; the first in the common ancestor of all vertebrates and the second in a common ancestor of jawed vertebrates after its separation from jawless fish (reviewed by Wolfe, 2001). It is also in support of two rounds of duplication of a chromosomal segment, or block duplication. Either way, if they did have a common origin, it is expected that the regions are syntenic, which is not strictly obeyed.

Analysis of the gene order of the 40 MHC genes and the corresponding paralogues on 9q32-q34.3 revealed that the overall gene order is not conserved. Thus, if they did descend from a common ancestral region then they have experienced numerous rearrangements caused by evolutionary mechanisms, such as duplications, inversions, deletions and translocations, after its inception. There is evidence of the dynamic natures of the two regions, particularly of gene and segmental duplications, which would explain the observed differences in gene order. Another factor that would have had an impact on the present-day structure of the paralogous regions is the amount of time which has passed since their emergence. Thus, it is expected that the more time that has elapsed the more time evolution has had to act upon the sequence, which could result in a number of differences between the regions. In order to understand how and when the MHC paralogous genes emerged, the phylogenetic relationships of the MHC paralogues and orthologues were investigated.

Prior to my genome survey, the proposed genomic distribution of the MHC paralogous genes in the regions on 1,9 and 19 was considered as evidence of past large-scale duplication (Kasahara, 1997; 1999a; 1999b). It was presumed that the regions emerged as part of two rounds of whole-genome duplication believed to have occurred early in the history of vertebrates, approximately 500 million years ago. The
results of the phylogenetic studies presented in this thesis indicate that some of the MHC paralogues did emerge via large-scale duplication events early in the vertebrate lineage. This is consistent with the extensive evidence emerging in the literature to show that there was a burst of gene duplication during early chordate evolution (Pépusque et al, 1998; Wang and Gu, 2000; Miyata and Suga, 2001; Escriva et al, 2002; McLysaght et al, 2002; Panopoulou et al, 2003).

The paralogous gene families (BRD, PBX, and NOTCH) with four members all showed the expected $(\mathrm{A}, \mathrm{B})(\mathrm{C}, \mathrm{D})$ tree topology that would be the result of two rounds of duplication, as proposed by the 2 R hypothesis. Three member families (complement, RXR and tenascin) also indicate that there were two rounds of duplication, accompanied by gene loss. The timings of the duplication events as suggested by the 2 R hypothesis are supported by the clustering of ' key ' organisms in the phylogenetic trees. Thus, a single amphioxus orthologue is positioned at the base of each tree and there is at least one hagfish or lamprey orthologue clustered with the mammalian counterparts. Preliminary analysis of the MHC paralogous gene families, including PBX and tenascin, in the hagfish genome suggests that jawless fish have at least two paralogues (Flajnik and Kasahara, 2001). It is therefore expected that, upon complete sequencing of the hagfish genome, two paralogues should be identified for each MHC paralogue, thus supporting the proposed 2R hypothesis.

The only two member family (AIF) studied also shows that there was at least one round of duplication in the vertebrate lineage after the emergence of amphioxus. The existence of only two paralogues indicates that this family was only involved in one round of genome duplication (supporting a 1R hypothesis) or two paralogues have been lost after two genome duplication events (supporting the 2R hypothesis). It has
been calculated that the average time before silencing of one member of a duplicate gene pair is approximately four million years in animals (Lynch and Conery, 2000), therefore the likelihood of these paralogues being lost since their emergence, approximately 500 million years ago, is high.

Phylogenetic studies of paralogous gene families with more than four members have shown the evolution of the MHC paralogous genes is much more complex. The MHC paralogous genes have emerged via recent duplication events that have resulted in the expansion of the paralogous gene families. For example, members of the CLIC paralogous gene family have been involved in a triplication event along with at least two other gene families not associated with the MHC region and a number of duplication events have given rise to members of the $\beta$-tubulin paralogous gene families within the last 25 million years of catarrhine (New World Monkeys and humans) evolution. These events have all resulted in MHC paralogues located outside the chromosome 1,9 and 19 paralogous regions.

Gene and, potentially, genome duplication have played a central role in the evolution of the MHC paralogues. It has been shown that gene duplications are frequent events in the mammalian genome with an average duplication rate of approximately $1 \%$ per gene per million years (Lynch and Conery, 2000). But what happens after gene or genome duplication? The classical model predicts that one copy will be maintained under purifying selection whereas the other will accumulate mutations which will generally lead to the loss of function of that gene copy. In rare cases, new functions will be created and both duplicate genes will be conserved. In contrast, under the subfunctionalisation model both duplicates are preserved due to the partition of different functions between duplicates: the development of new functions is also possible. In
order to understand how the paralogues have evolved since duplication the first step was to determine the function(s) of these genes in humans. This was addressed in this thesis by generating the expression profiles of the members of nine MHC paralogous gene families. The profiles were generated in a range of tissues corresponding to the major systems of the human body using several different approaches.

Comparison of the expression profiles of the MHC paralogous genes revealed that, in most cases, the paralogues have distinct expression profiles. However, there is still some overlap in the expression patterns of some members of the same paralogous gene family indicating levels of genetic redundancy. The absence of a modified or 'scoreable' phenotype following gene knock-out studies has alerted biologists to the presence of genes with overlapping, or redundant, functions. As paralogues have arisen from the same ancestral gene, and therefore may still have conserved gene structure, sequence, protein structure etc., they may act as a 'back-up' system in order to protect an organism against phenotypic changes and any deleterious effects of gene loss. However, further functional studies are necessary to confirm this prediction.

Analysis of the expression profiles revealed evidence of functional divergence. In particular, paralogues located on chromosome 1 appear to have a more specialised expression profile, for example BRDT and RXRG are restricted to expression in only a few tissues. Further investigation of genes on this chromosome is necessary before any conclusions can be made but data presented in this thesis indicates that genes on chromosomes 1 may have a more specialised function compared with genes elsewhere in the genome. It is apparent from this study that the precise mechanism by which they have evolved could not be determined based on the comparison of expression profiles alone. It is essential that we understand the function(s) of the
ancestral genes as well as the functions of the human genes.

In conclusion, the paralogous genes on human chromosomes 1, 6, 9 and 19 emerged together as part of two large-scale duplication events early in the vertebrate lineage. From the emerging evidence in the literature and the findings of this thesis it can be argued that they were part of the two rounds of whole-genome duplication proposed by the 2 R hypothesis. Further gene duplication events have also occurred resulting in the present-day genome organisation. The precise mechanism by which the MHC paralogues have functionally evolved is unclear. Overall, the MHC region has offered a unique opportunity for scrutinising genome evolution in vertebrates and, one thing that is clear from this thesis is that, the investigation of gene duplication events remains an exciting field of research. Further investigation of genes, genomes and the encoded proteins are necessary before we have a true understanding of the biological processes that shaped evolution and the complexity of our own species at the molecular level.

### 7.2 Future work

I would suggest that future work involving the MHC paralogous genes should follow a number of lines:

## 1. Comparative studies

The MHC paralogous genes have provided an exciting model to study genome evolution. It is also of particular interest regarding the origin of adaptive immunity. The rapidly accumulating information on the genomic organisations of the MHC regions in various model organisms is already providing insights into the long-term dynamics and evolution which have moulded the present day MHC and human genome (reviewed by Flajnik and Kasahara, 2001). Therefore, complete sequencing of the genomes of key species in the vertebrate lineage, namely amphioxus, hagfish and lamprey, will be invaluable for deciphering the evolution of the MHC paralogues and the genome as a whole.
2. Further analysis of the human genome

Initial analysis of the human genome identified significantly less genes than expected and it has been proposed that differential splicing of genes and the different encoded proteins play a crucial role in humans. The analysis of the splice variants identified in this thesis will help understand the role paralogues play and it will also be of interest to determine whether the same splice variants are maintained and used by the different paralogues. It will also be of interest to
determine whether the functions of the ancestral genes have been split between the different splice variants of the paralogues and whether they have specific functions. The study of the regulatory features of the paralogues will also provide insight to both the evolution and control of the paralogues.

## 3. Improved strategy to identify paralogues

It is apparent from this thesis that a number of sequence features can be used to identify paralogous genes. The program, FINEX, used to search for paralogues with conserved gene structures will be invaluable once the EMBL genomic clones are fully annotated. An additional dimension that should be added to the strategy I have employed in this thesis is the emerging 3-dimensional protein structures. It will then be possible to identify novel paralogues that no longer share detectable sequence identity.

## 4. Functional studies

The determination of the function(s) of the ancestral genes is crucial to understanding the mechanism(s) by which the paralogues have evolved. Functional studies of orthologues in key organisms, such as amphioxus and hagfish, as well as in higher organisms will also shed light on the present day role of the paralogues in our own genome. Genetic redundancy is evident between paralogues and it will be of interest to understand why redundancy has been maintained.

## 5. Paralogue-specific microarrays

The expression profile analysis using microarrays has highlighted the value of developing genome-wide paralogue-specific microarrays. Furthermore, in order to truly understand the expression pattern of a particular transcript it is important to develop microarrays that are also splice-variant and allele specific.

## Final conclusion

The evidence presented in this thesis is concordant with the 2 R hypothesis. Phylogenetic analysis showed that the MHC paralogues located in the paralogous regions on human chromosomes 1, 9 and 19 emerged as part of two large-scale, whole-genome duplication events early in the vertebrate lineage; the first prior to the emergence of jawless fish and one shortly after. Furthermore, investigation of MHC paralogues located outside these regions showed that small-scale duplications, both prior to and after the two whole-genome duplication events, have also moulded the present-day human genome. In total, 791 MHC paralogues were identified in the human genome and were classified as L0, L1, L2 or L3-paralogues by applying a number of criteria. I am confident that the majority of MHC paralogues were identified using my method. However, the addition of further information, such as protein structure data, will enable the detection of any MHC paralogues that have significantly diverged in both sequence and structure since their emergence and were undetected in this thesis. In conclusion, if this project were to be repeated I believe that the approach I took is still viable but I would consider modifying my identification method to include other criteria and I would select more MHC paralogous gene families for further investigation to confirm my thesis findings.

## Bibliography

Abi Rached L., McDermott M. F., and Pontarotti P. (1999). The MHC big bang. Immunol Rev 167: 33-44.

Abi-Rached L., Gilles A., Shiina T., Pontarotti P., and Inoko H. (2002). Evidence of en bloc duplication in vertebrate genomes. Nat Genet 31: 100-5.

Achermann J. C., Ito M., Hindmarsh P. C., and Jameson J. L. (1999). A mutation in the gene encoding steroidogenic factor-1 causes XY sex reversal and adrenal failure in humans. Nat Genet 22: 125-6.

Adams M. D., Celniker S. E., Holt R. A., Evans C. A., Gocayne J. D., Amanatides P. G., Scherer S. E., Li P. W., Hoskins R. A., Galle R. F., George R. A., Lewis S. E., Richards S., Ashburner M., Henderson S. N., Sutton G. G., Wortman J. R., Yandell M. D., Zhang Q., Chen L. X., Brandon R. C., Rogers Y. H., Blazej R. G., Champe M., Pfeiffer B. D., Wan K. H., Doyle C., Baxter E. G., Helt G., Nelson C. R., Gabor G. L., Abril J. F., Agbayani A., An H. J., Andrews-Pfannkoch C., Baldwin D., Ballew R. M., Basu A., Baxendale J., Bayraktaroglu L., Beasley E. M., Beeson K. Y., Benos P. V., Berman B. P., Bhandari D., Bolshakov S., Borkova D., Botchan M. R., Bouck J., Brokstein P., Brottier P., Burtis K. C., Busam D. A., Butler H., Cadieu E., Center A., Chandra I., Cherry J. M., Cawley S., Dahlke C., Davenport L. B., Davies P., de Pablos B., Delcher A., Deng Z., Mays A. D., Dew I., Dietz S. M., Dodson K., Doup L. E., Downes M., Dugan-Rocha S., Dunkov B. C., Dunn P., Durbin K. J., Evangelista C. C., Ferraz C., Ferriera S., Fleischmann W., Fosler C., Gabrielian A. E., Garg N. S., Gelbart W. M., Glasser K., Glodek A., Gong F., Gorrell J. H., Gu Z., Guan P., Harris M., Harris N. L., Harvey D., Heiman T. J., Hernandez J. R., Houck J., Hostin D., Houston K. A., Howland T. J., Wei M. H., Ibegwam C., et al. (2000). The genome sequence of Drosophila melanogaster. Science 287: 2185-95.

Altschul S. F., Gish W., Miller W., Myers E. W., and Lipman D. J. (1990). Basic local alignment search tool. J Mol Biol 215: 403-10.

Amores A., Force A., Yan Y. L., Joly L., Amemiya C., Fritz A., Ho R. K., Langeland J., Prince V., Wang Y. L., Westerfield M., Ekker M., and Postlethwait J. H. (1998). Zebrafish hox clusters and vertebrate genome evolution. Science 282: 1711-4.

Anderson S., Bankier A. T., Barrell B. G., de Bruijn M. H., Coulson A. R., Drouin J., Eperon I. C., Nierlich D. P., Roe B. A., Sanger F., Schreier P. H., Smith A. J., Staden R., and Young I. G. (1981). Sequence and organization of the human mitochondrial genome. Nature 290: 457-65.

Aparicio S., Chapman J., Stupka E., Putnam N., Chia J. M., Dehal P., Christoffels A., Rash S., Hoon S., Smit A., Gelpke M. D., Roach J., Oh T., Ho I. Y., Wong M., Detter C., Verhoef F., Predki P., Tay A., Lucas S., Richardson P., Smith S. F., Clark M. S., Edwards Y. J., Doggett N., Zharkikh A., Tavtigian S. V., Pruss D., Barnstead M., Evans C., Baden H., Powell J., Glusman G., Rowen L., Hood L., Tan Y. H., Elgar G.,

Hawkins T., Venkatesh B., Rokhsar D., and Brenner S. (2002). Whole-genome shotgun assembly and analysis of the genome of Fugu rubripes. Science 297: 1301-10.

Autieri M. V. (1996). cDNA cloning of human allograft inflammatory factor-1: tissue distribution, cytokine induction, and mRNA expression in injured rat carotid arteries. Biochem Biophys Res Commun 228: 29-37.

Bailey J. A., Gu Z., Clark R. A., Reinert K., Samonte R. V., Schwartz S., Adams M. D., Myers E. W., Li P. W., and Eichler E. E. (2002). Recent segmental duplications in the human genome. Science 297: 1003-7.

Bairoch A., and Apweiler R. (1997). The SWISS-PROT protein sequence data bank and its supplement TrEMBL. Nucleic Acids Res 25: 31-6.

Bankier A. T., Weston K. M., and Barrell B. G. (1987). Random cloning and sequencing by the M13/dideoxynucleotide chain termination method. Methods Enzymol 155: 51-93.

Baumgartner S., Martin D., Hagios C., and Chiquet-Ehrismann R. (1994). Tenm, a Drosophila gene related to tenascin, is a new pair-rule gene. Embo $J$ 13: 3728-40.

Beck S., Kelly A., Radley E., Khurshid F., Alderton R. P., and Trowsdale J. (1992a). DNA sequence analysis of 66 kb of the human MHC class II region encoding a cluster of genes for antigen processing. $J$ Mol Biol 228: 433-41.

Beck S., Hanson I., Kelly A., Pappin D. J., and Trowsdale J. (1992b). A homologue of the Drosophila female sterile homeotic (fsh) gene in the class II region of the human MHC. DNA Seq 2: 203-10.

Beck S., and Trowsdale J. (2000). The human major histocompatability complex: lessons from the DNA sequence. Annu Rev Genomics Hum Genet 1: 117-37.

Bernstein R. M., Schluter S. F., Bernstein H., and Marchalonis J. J. (1996). Primordial emergence of the recombination activating gene 1 (RAG1): sequence of the complete shark gene indicates homology to microbial integrases. Proc Natl Acad Sci U S A 93: 9454-9.

Bichara M., Schumacher S., and Fuchs R. P. (1995). Genetic instability within monotonous runs of CpG sequences in Escherichia coli. Genetics 140: 897-907.

Bichara M., Pinet I., Schumacher S., and Fuchs R. P. (2000). Mechanisms of dinucleotide repeat instability in Escherichia coli. Genetics 154: 533-42.

Blattner F. R., Plunkett G., 3rd, Bloch C. A., Perna N. T., Burland V., Riley M., Collado-Vides J., Glasner J. D., Rode C. K., Mayhew G. F., Gregor J., Davis N. W., Kirkpatrick H. A., Goeden M. A., Rose D. J., Mau B., and Shao Y. (1997). The complete genome sequence of Escherichia coli K-12. Science 277: 1453-74.

Bogart J. P. (1980). Evolutionary implications of polyploidy in amphibians and reptiles. In "Polyploidy: Biological Relevance" (W. H. Lewis, Ed.), Plenum, New York.

Bonfield J. K., Smith K., and Staden R. (1995). A new DNA sequence assembly program. Nucleic Acids Res 23: 4992-9.

Bouchireb N., Grutzner F., Haaf T., Stephens R. J., Elgar G., Green A. J., and Clark M. S. (2001). Comparative mapping of the human 9 q 34 region in Fugu rubripes. Cytogenet Cell Genet 94: 173-9.

Bray S. (1998). Notch signalling in Drosophila: three ways to use a pathway. Semin Cell Dev Biol 9: 591-7.

Brazma A., and Vilo J. (2001). Gene expression data analysis. Microbes Infect 3: 8239.

Brenner S. E., Chothia C., and Hubbard T. J. (1998). Assessing sequence comparison methods with reliable structurally identified distant evolutionary relationships. Proc Natl Acad Sci U S A 95: 6073-8.

Bristow J., Tee M. K., Gitelman S. E., Mellon S. H., and Miller W. L. (1993). Tenascin-X: a novel extracellular matrix protein encoded by the human XB gene overlapping P450c21B. J Cell Biol 122: 265-78.

Brown N. P., Whittaker A. J., Newell W. R., Rawlings C. J., and Beck S. (1995). Identification and analysis of multigene families by comparison of exon fingerprints. J Mol Biol 249: 342-59.
C. elegans Sequencing Consortium (1998). Genome sequence of the nematode C. elegans: a platform for investigating biology. Science 282: 2012-8.

Cebrat S., and Stauffer D. (2002). Monte Carlo simulation of genome viability with paralog replacement. $J$ Appl Genet 43: 391-5.

Chenna R., Sugawara H., Koike T., Lopez R., Gibson T. J., Higgins D. G., and Thompson J. D. (2003). Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Res 31:3497-500.

Chu F. F., Esworthy R. S., Doroshow J. H., Doan K., and Liu X. F. (1992). Expression of plasma glutathione peroxidase in human liver in addition to kidney, heart, lung, and breast in humans and rodents. Blood 79: 3233-8.

Colombo P., Yon J., Garson K., and Fried M. (1992). Conservation of the organization of five tightly clustered genes over 600 million years of divergent evolution. Proc Natl Acad Sci U S A 89: 6358-62.

Danchin E. G., Abi-Rached L., Gilles A., and Pontarotti P. (2003). Conservation of the MHC-like region throughout evolution. Immunogenetics.

Dausset J. (1958). Iso-leuco-anticorps. Acta Haem 20: 156-166.
Dayhoff M. O., Schwartz R. M., and Orcutt B. C. (1978). "A model of evolutionary change in proteins," National Biomedical Research Foundation, Washington D.C.

Deloukas P., Schuler G. D., Gyapay G., Beasley E. M., Soderlund C., RodriguezTome P., Hui L., Matise T. C., McKusick K. B., Beckmann J. S., Bentolila S., Bihoreau M., Birren B. B., Browne J., Butler A., Castle A. B., Chiannilkulchai N., Clee C., Day P. J., Dehejia A., Dibling T., Drouot N., Duprat S., Fizames C., Bentley D. R., and et al. (1998). A physical map of 30,000 human genes. Science 282: 744-6.

Denis G. V., and Green M. R. (1996). A novel, mitogen-activated nuclear kinase is related to a Drosophila developmental regulator. Genes Dev 10: 261-71.

Diatchenko L., Lau Y. F., Campbell A. P., Chenchik A., Moqadam F., Huang B., Lukyanov S., Lukyanov K., Gurskaya N., Sverdlov E. D., and Siebert P. D. (1996). Suppression subtractive hybridization: a method for generating differentially regulated or tissue-specific cDNA probes and libraries. Proc Natl Acad Sci U S A 93: 6025-30.

Doolittle R. F., Feng D. F., Johnson M. S., and McClure M. A. (1986). Relationships of human protein sequences to those of other organisms. Cold Spring Harb Symp Quant Biol 51 Pt 1: 447-55.

Driscoll J., Brown M. G., Finley D., and Monaco J. J. (1993). MHC-linked LMP gene products specifically alter peptidase activities of the proteasome. Nature 365: 262-4.

Dufaure J. P., Lareyre J. J., Schwaab V., Mattei M. G., and Drevet J. R. (1996). Structural organization, chromosomal localization, expression and phylogenetic evaluation of mouse glutathione peroxidase encoding genes. C R Acad Sci III 319: 559-68.

Eichler E. E. (1998). Masquerading repeats: paralogous pitfalls of the human genome. Genome Res 8: 758-62.

Eichler E. E., Archidiacono N., and Rocchi M. (1999). CAGGG repeats and the pericentromeric duplication of the hominoid genome. Genome Res 9: 1048-58.

Eichler E. E., Lu F., Shen Y., Antonacci R., Jurecic V., Doggett N. A., Moyzis R. K., Baldini A., Gibbs R. A., and Nelson D. L. (1996). Duplication of a gene-rich cluster between 16 p11.1 and Xq28: a novel pericentromeric-directed mechanism for paralogous genome evolution. Hum Mol Genet 5: 899-912.

Ellisen L. W., Bird J., West D. C., Soreng A. L., Reynolds T. C., Smith S. D., and Sklar J. (1991). TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 66: 649-61.

Endo T., Imanishi T., Gojobori T., and Inoko H. (1997). Evolutionary significance of intra-genome duplications on human chromosomes. Gene 205: 19-27.

Erickson H. P. (1993). Tenascin-C, tenascin-R and tenascin-X: a family of talented proteins in search of functions. Curr Opin Cell Biol 5: 869-76.

Escriva H., Manzon L., Youson J., and Laudet V. (2002). Analysis of lamprey and hagfish genes reveals a complex history of gene duplications during early vertebrate evolution. Mol Biol Evol 19: 1440-50.

Evertsz E. M., Au-Young J., Ruvolo M. V., Lim A. C., and Reynolds M. A. (2001). Hybridization cross-reactivity within homologous gene families on glass cDNA microarrays. Biotechniques 31: 1182-1192.

Felsenstein J. (1981). Evolutionary trees from DNA sequences: a maximum likelihood approach. J Mol Evol 17: 368-76.

Felsenstein J. (1985). Confidence-Limits On Phylogenies - an Approach Using the Bootstrap. Evolution 39: 783-791.

Felsenstein J. (1989). PHYLIP -- Phylogeny Inference Package (Version 3.2). Cladistics 5: 164-166.

Feng D. F., Johnson M. S., and Doolittle R. F. (1984). Aligning amino acid sequences: comparison of commonly used methods. J Mol Evol 21: 112-25.

Fiers W., Contreras R., Haegemann G., Rogiers R., Van de Voorde A., Van Heuverswyn H., Van Herreweghe J., Volckaert G., and Ysebaert M. (1978). Complete nucleotide sequence of SV40 DNA. Nature 273: 113-20.

Flajnik M. F., Canel C., Kramer J., and Kasahara M. (1991). Which came first, MHC class I or class II? Immunogenetics 33: 295-300.

Flajnik M. F., and Kasahara M. (2001). Comparative genomics of the MHC: glimpses into the evolution of the adaptive immune system. Immunity 15: 351-62.

Flajnik M. F., Ohta Y., Namikawa-Yamada C., and Nonaka M. (1999). Insight into the primordial MHC from studies in ectothermic vertebrates. Immunol Rev 167: 5967.

Force A., Lynch M., Pickett F. B., Amores A., Yan Y. L., and Postlethwait J. (1999). Preservation of duplicate genes by complementary, degenerative mutations. Genetics 151: 1531-45.

French C. A., Miyoshi I., Kubonishi I., Grier H. E., Perez-Atayde A. R., and Fletcher J. A. (2003). BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. Cancer Res 63: 304-7.

Friedman R., and Hughes A. L. (2001). Pattern and timing of gene duplication in animal genomes. Genome Res 11: 1842-7.

Gallardo M. H., Bickham J. W., Honeycutt R. L., Ojeda R. A., and Kohler N. (1999). Discovery of tetraploidy in a mammal. Nature 401: 341.

Garcia-Fernandez J., and Holland P. (1994). Archetypal organisation of the amphioxus Hox gene cluster. Nature 370: 563-6.

Gaston K., and Fried M. (1994). YY1 is involved in the regulation of the bidirectional promoter of the Surf-1 and Surf-2 genes. FEBS Lett 347: 289-94.

Giglio S., Broman K. W., Matsumoto N., Calvari V., Gimelli G., Neumann T., Ohashi H., Voullaire L., Larizza D., Giorda R., Weber J. L., Ledbetter D. H., and Zuffardi O. (2001). Olfactory receptor-gene clusters, genomic-inversion polymorphisms, and common chromosome rearrangements. Am J Hum Genet 68: 874-83.

Giglio S., Calvari V., Gregato G., Gimelli G., Camanini S., Giorda R., Ragusa A., Guerneri S., Selicorni A., Stumm M., Tonnies H., Ventura M., Zollino M., Neri G., Barber J., Wieczorek D., Rocchi M., and Zuffardi O. (2002). Heterozygous submicroscopic inversions involving olfactory receptor-gene clusters mediate the recurrent $\mathrm{t}(4 ; 8)(\mathrm{p} 16 ; \mathrm{p} 23)$ translocation. Am J Hum Genet 71: 276-85.

Gordon, D., Abajian, C. and Green, P. (1998) Consed: a graphical tool for sequence finishing Genome Res 8 (3): 195-202

Greer J. M., Puetz J., Thomas K. R., and Capecchi M. R. (2000). Maintenance of functional equivalence during paralogous Hox gene evolution. Nature 403: 661-5.

Grewal P. K., van Geel M., Frants R. R., de Jong P., and Hewitt J. E. (1999). Recent amplification of the human FRG1 gene during primate evolution. Gene 227: 79-88.

Gruen J. R., and Weissman S. M. (2001). Human MHC class III and IV genes and disease associations. Front Biosci 6: D960-72.

Gu X., and Huang W. (2002). Testing the parsimony test of genome duplications: a counterexample. Genome Res 12: 1-2.

Habuchi T., Luscombe M., Elder P. A., and Knowles M. A. (1998). Structure and methylation-based silencing of a gene (DBCCR1) within a candidate bladder cancer tumor suppressor region at 9q32-q33. Genomics 48: 277-88.

Hall L., Williams K., Perry A. C., Frayne J., and Jury J. A. (1998). The majority of human glutathione peroxidase type 5 (GPX5) transcripts are incorrectly spliced: implications for the role of GPX5 in the male reproductive tract. Biochem J 333 ( Pt 1): 5-9.

Heiskanen M., Karhu R., Hellsten E., Peltonen L., Kallioniemi O. P., and Palotie A. (1994). High resolution mapping using fluorescence in situ hybridization to extended DNA fibers prepared from agarose-embedded cells. Biotechniques 17: 928-9, 932-3.

Henikoff S., and Henikoff J. G. (1992). Amino acid substitution matrices from protein blocks. Proc Natl Acad Sci U S A 89: 10915-9.

Herberg J. A., Beck S., and Trowsdale J. (1998a). TAPASIN, DAXX, RGL2, HKE2 and four new genes (BING 1, 3 to 5) form a dense cluster at the centromeric end of the MHC. J Mol Biol 277: 839-57.

Herberg J. A., Sgouros J., Jones T., Copeman J., Humphray S. J., Sheer D., Cresswell P., Beck S., and Trowsdale J. (1998b). Genomic analysis of the Tapasin gene, located close to the TAP loci in the MHC. Eur J Immunol 28: 459-67.

Holland L. Z., Rached L. A., Tamme R., Holland N. D., Kortschak D., Inoko H., Shiina T., Burgtorf C., and Lardelli M. (2001). Characterization and developmental expression of the amphioxus homolog of Notch (AmphiNotch): evolutionary conservation of multiple expression domains in amphioxus and vertebrates. Dev Biol 232: 493-507.

Holland P. W. (2003). More genes in vertebrates? J Struct Funct Genomics 3: 75-84.
Holland P. W., Garcia-Fernandez J., Williams N. A., and Sidow A. (1994). Gene duplications and the origins of vertebrate development. Dev Suppl: 125-33.

Holzinger I., de Baey A., Messer G., Kick G., Zwierzina H., and Weiss E. H. (1995). Cloning and genomic characterization of LST1: a new gene in the human TNF region. Immunogenetics 42: 315-22.

Houzelstein D., Bullock S. L., Lynch D. E., Grigorieva E. F., Wilson V. A., and Beddington R. S. (2002). Growth and early postimplantation defects in mice deficient for the bromodomain-containing protein Brd4. Mol Cell Biol 22: 3794-802.

Hubbard T., Barker D., Birney E., Cameron G., Chen Y., Clark L., Cox T., Cuff J., Curwen V., Down T., Durbin R., Eyras E., Gilbert J., Hammond M., Huminiecki L., Kasprzyk A., Lehvaslaiho H., Lijnzaad P., Melsopp C., Mongin E., Pettett R., Pocock M., Potter S., Rust A., Schmidt E., Searle S., Slater G., Smith J., Spooner W., Stabenau A., Stalker J., Stupka E., Ureta-Vidal A., Vastrik I., and Clamp M. (2002). The Ensembl genome database project. Nucleic Acids Res 30: 38-41.

Hudson T. J., Stein L. D., Gerety S. S., Ma J., Castle A. B., Silva J., Slonim D. K., Baptista R., Kruglyak L., Xu S. H., and et al. (1995). An STS-based map of the human genome. Science 270: 1945-54.

Hughes A. L., and Nei M. (1993). Evolutionary relationships of the classes of major histocompatibility complex genes. Immunogenetics 37: 337-46.

Hughes A. L. (1994). Phylogeny of the C3/C4/C5 complement-component gene family indicates that C5 diverged first. Mol Biol Evol 11: 417-25.

Hughes A. L., and Yeager M. (1997). Molecular evolution of the vertebrate immune system. Bioessays 19: 777-86.

Hughes A. L. (1998). Phylogenetic tests of the hypothesis of block duplication of homologous genes on human chromosomes 6, 9, and 1. Mol Biol Evol 15: 854-70.

Hughes A. L., and Pontarotti P. (2000). Gene duplication and MHC origins. Immunogenetics 51: 982-3.

Hughes A. L., and Friedman R. (2003). 2R or not 2R: testing hypotheses of genome duplication in early vertebrates. $J$ Struct Funct Genomics 3: 85-93.

Huxley C., and Fried M. (1990). The mouse surfeit locus contains a cluster of six genes associated with four CpG-rich islands in 32 kilobases of genomic DNA. Mol Cell Biol 10: 605-14.

International Human Genome Sequencing Consortium (IHGSC) (2001). Initial sequencing and analysis of the human genome. Nature 409: 860-921.

Ishiguro H., Kobayashi K., Suzuki M., Titani K., Tomonaga S., and Kurosawa Y. (1992). Isolation of a hagfish gene that encodes a complement component. Embo $J$ 11: 829-37.

Jackson D. A., Pombo A., and Iborra F. (2000). The balance sheet for transcription: an analysis of nuclear RNA metabolism in mammalian cells. Faseb $J$ 14: 242-54.

Jentsch T. J., Stein V., Weinreich F., and Zdebik A. A. (2002). Molecular structure and physiological function of chloride channels. Physiol Rev 82: 503-68.

Jones D. T., Taylor W. R., and Thornton J. M. (1992). The rapid generation of mutation data matrices from protein sequences. Comput Appl Biosci 8: 275-82.

Jones M. H., Numata M., and Shimane M. (1997). Identification and characterisation of BRDT: A testis-specific gene related to the bromodomain genes RING3 and Drosophila fsh. Genomics 45: 529-34.

Jurka J. (2000). Repbase update: a database and an electronic journal of repetitive elements. Trends Genet 16: 418-20.

Karlin S., and Altschul S. F. (1990). Methods for assessing the statistical significance of molecular sequence features by using general scoring schemes. Proc Natl Acad Sci U S A 87: 2264-8.

Kasahara M., Hayashi M., Tanaka K., Inoko H., Sugaya K., Ikemura T., and Ishibashi T. (1996a). Chromosomal localization of the proteasome Z subunit gene reveals an ancient chromosomal duplication involving the major histocompatibility complex. Proc Natl Acad Sci U S A 93: 9096-101.

Kasahara M., Kandil E., Salter-Cid L., and Flajnik M. F. (1996b). Origin and evolution of the class I gene family: why are some of the mammalian class I genes encoded outside the major histocompatibility complex? Res Immunol 147: 278-84; discussion 284-5.

Kasahara M. (1997). New insights into the genomic organization and origin of the major histocompatibility complex: role of chromosomal (genome) duplication in the emergence of the adaptive immune system. Hereditas 127: 59-65.

Kasahara M. (1999a). The chromosomal duplication model of the major histocompatibility complex. Immunol Rev 167: 17-32.

Kasahara M. (1999b). Genome dynamics of the major histocompatibility complex: insights from genome paralogy. Immunogenetics 50: 134-45.

Kasahara M., Yawata M., and Suzuki T. (2000). "The MHC paralogous group: Listing of members and a brief overview," Springer-Verlag,, Tokyo-Berlin-Heidelberg-New York.

Katsanis N., Fitzgibbon J., and Fisher E. M. (1996). Paralogy mapping: identification of a region in the human MHC triplicated onto human chromosomes 1 and 9 allows the prediction and isolation of novel PBX and NOTCH loci. Genomics 35: 101-8.

Kent W. J., and Haussler D. (2001). Assembly of the working draft of the human genome with GigAssembler. Genome Res 11: 1541-8.

Klein J., and Sato A. (1998). Birth of the major histocompatibility complex. Scand $J$ Immunol 47: 199-209.

Kobayashi K., Nakahori Y., Miyake M., Matsumura K., Kondo-Iida E., Nomura Y., Segawa M., Yoshioka M., Saito K., Osawa M., Hamano K., Sakakihara Y., Nonaka I., Nakagome Y., Kanazawa I., Nakamura Y., Tokunaga K., and Toda T. (1998). An ancient retrotransposal insertion causes Fukuyama-type congenital muscular dystrophy. Nature 394: 388-92.

Kumar S., Tamura K., and Nei M. (1994). MEGA: Molecular Evolutionary Genetics Analysis software for microcomputers. Comput Appl Biosci 10: 189-91.

Kumar S., Tamura K., Jakobsen I. B., and Nei M. (2001). MEGA2: molecular evolutionary genetics analysis software. Bioinformatics 17: 1244-5.

Lacazette E., Gachon A. M., and Pitiot G. (2000). A novel human odorant-binding protein gene family resulting from genomic duplicons at 9 q 34 : differential expression in the oral and genital spheres. Hum Mol Genet 9: 289-301.

Lardelli M., Dahlstrand J., and Lendahl U. (1994). The novel Notch homologue mouse Notch 3 lacks specific epidermal growth factor-repeats and is expressed in proliferating neuroepithelium. Mech Dev 46: 123-36.

Larhammar D., Lundin L. G., and Hallbook F. (2002). The Human Hox-bearing Chromosome Regions Did Arise by Block or Chromosome (or Even Genome) Duplications. Genome Res 12: 1910-20.

Lennard A., Gaston K., and Fried M. (1994). The Surf-1 and Surf-2 genes and their essential bidirectional promoter elements are conserved between mouse and human. DNA Cell Biol 13: 1117-26.

Lesk A. (2002). "Introduction to bioinformatics," Oxford University Press, Oxford.

Lewis J. (1998). Notch signalling and the control of cell fate choices in vertebrates. Semin Cell Dev Biol 9: 583-9.

Lewis S. A., and Cowan N. J. (1990). Tubulin genes: structure, expression, and regulation. In "Microtubule proteins" (J. Avila, Ed.), pp. 37-66, CRC Press, Inc, Boca Raton.

Li W.-H. (1997). "Molecular Evolution," Sunderland Sinauer.
Li W. H., Gu Z., Wang H., and Nekrutenko A. (2001). Evolutionary analyses of the human genome. Nature 409: 847-9.

Lundin L. G. (1993). Evolution of the vertebrate genome as reflected in paralogous chromosomal regions in man and the house mouse. Genomics 16: 1-19.

Lundin L. G., and Larhammar D. (1998). "Paralogous genes and nervous systems," Oxford, UK.

Lundin L. G., Larhammar D., and Hallbook F. (2003). Numerous groups of chromosomal regional paralogies strongly indicate two genome doublings at the root of the vertebrates. J Struct Funct Genomics 3: 53-63.

Lynch M., and Conery J. S. (2000). The evolutionary fate and consequences of duplicate genes. Science 290: 1151-5.

Lynch M., and Force A. (2000). The probability of duplicate gene preservation by subfunctionalization. Genetics 154: 459-73.

Mackiewicz P., Kowalczuk M., Gierlik A., Dudek M. R., and Cebrat S. (1999). Origin and properties of non-coding ORFs in the yeast genome. Nucleic Acids Res 27: 35039.

Mackiewicz P., Kowalczuk M., Mackiewicz D., Nowicka A., Dudkiewicz M., Laszkiewicz A., Dudek M. R., and Cebrat S. (2002). How many protein-coding genes are there in the Saccharomyces cerevisiae genome? Yeast 19: 619-29.

Makalowski W. (2001). Are we polyploids? A brief history of one hypothesis. Genome Res 11: 667-70.

Mangelsdorf D. J., Borgmeyer U., Heyman R. A., Zhou J. Y., Ong E. S., Oro A. E., Kakizuka A., and Evans R. M. (1992). Characterisation of three RXR genes that mediate the action of 9-cis retinoic acid. Genes Dev 6: 329-44.

Maresco D. L., Chang E., Theil K. S., Francke U., and Anderson C. L. (1996). The three genes of the human FCGR1 gene family encoding Fc gamma RI flank the centromere of chromosome 1 at 1p12 and 1q21. Cytogenet Cell Genet 73: 157-63.

Marshall E. (2001). Genome sequencing. Celera assembles mouse genome; public labs plan new strategy. Science 292: 822.

Marzluff W. F., Gongidi P., Woods K. R., Jin J., and Maltais L. J. (2002). The human and mouse replication-dependent histone genes. Genomics 80: 487-98.

Mazet F., and Shimeld S. M. (2002). Gene duplication and divergence in the early evolution of vertebrates. Curr Opin Genet Dev 12: 393-6.

McKean P. G., Vaughan S., and Gull K. (2001). The extended tubulin superfamily. $J$ Cell Sci 114: 2723-33.

McLysaght A., Hokamp K., and Wolfe K. H. (2002). Extensive genomic duplication during early chordate evolution. Nat Genet 31: 200-4.

Mewes H. W., Albermann K., Bahr M., Frishman D., Gleissner A., Hani J., Heumann K., Kleine K., Maierl A., Oliver S. G., Pfeiffer F., and Zollner A. (1997). Overview of the yeast genome. Nature 387: 7-65.

Miyata T., and Suga H. (2001). Divergence pattern of animal gene families and relationship with the Cambrian explosion. Bioessays 23: 1018-27.

Modrek B., and Lee C. (2002). A genomic view of alternative splicing. Nat Genet 30: 13-9.

Monaco J. J. (1992). A molecular model of MHC class-I-restricted antigen processing. Immunol Today 13: 173-9.

Monica K., Galili N., Nourse J., Saltman D., and Cleary M. L. (1991). PBX2 and PBX3, new homeobox genes with extensive homology to the human proto-oncogene PBX1. Mol Cell Biol 11: 6149-57.

Muller H. J. (1925). Why polyploidy is rarer in animals than in plants. American Naturalist 59: 346-353.

Nadeau J. H., and Sankoff D. (1997). Comparable rates of gene loss and functional divergence after genome duplications early in vertebrate evolution. Genetics 147: 1259-66.

Nagata T., Weiss E. H., Abe K., Kitagawa K., Ando A., Yara-Kikuti Y., Seldin M. F., Ozato K., Inoko H., and Taketo M. (1995). Physical mapping of the retinoid X receptor B gene in mouse and human. Immunogenetics 41: 83-90.

Neefjes J. J., and Ploegh H. L. (1992). Intracellular transport of MHC class II molecules. Immunol Today 13: 179-84.

Nei M., and Kumar S. (2000). "Molecular Evolution and Phylogenetics," Oxford University Press, New York.

Nicholls A. C., McCarron S., Narcisi P., and Pope F. M. (1994). Molecular abnormalities of type V collagen in Ehlers Danlos syndrome. Am. J. Hum. Genet 55: A233.

Nonaka M., and Takahashi M. (1992). Complete complementary DNA sequence of the third component of complement of lamprey. Implication for the evolution of thioester containing proteins. J Immunol 148: 3290-5.

Ohno S. (1970). "Evolution by Gene Duplication," Springer-Verlag, New York.
Ohno S. (1973). Ancient linkage groups and frozen accidents. Nature 244: 259-62.
Oliver S. G., van der Aart Q. J., Agostoni-Carbone M. L., Aigle M., Alberghina L., Alexandraki D., Antoine G., Anwar R., Ballesta J. P., Benit P., and et al. (1992). The complete DNA sequence of yeast chromosome III. Nature 357: 38-46.

Olson M. V., Dutchik J. E., Graham M. Y., Brodeur G. M., Helms C., Frank M., MacCollin M., Scheinman R., and Frank T. (1986). Random-clone strategy for genomic restriction mapping in yeast. Proc Natl Acad Sci U S A 83: 7826-30.

Ortmann B., Androlewicz M. J., and Cresswell P. (1994). MHC class I/beta 2microglobulin complexes associate with TAP transporters before peptide binding. Nature 368: 864-7.

Padgett R. A., Grabowski P. J., Konarska M. M., Seiler S., and Sharp P. A. (1986). Splicing of messenger RNA precursors. Annu Rev Biochem 55: 1119-50.

Panopoulou G., Hennig S., Groth D., Krause A., Poustka A. J., Herwig R., Vingron M., and Lehrach H. (2003). New evidence for genome-wide duplications at the origin of vertebrates using an amphioxus gene set and completed animal genomes. Genome Res 13: 1056-66.

Pébusque M. J., Coulier F., Birnbaum D., and Pontarotti P. (1998). Ancient largescale genome duplications: phylogenetic and linkage analyses shed light on chordate genome evolution. Mol Biol Evol 15: 1145-59.

Perry A. C., Jones R., Niang L. S., Jackson R. M., and Hall L. (1992). Genetic evidence for an androgen-regulated epididymal secretory glutathione peroxidase whose transcript does not contain a selenocysteine codon. Biochem J 285 (Pt 3): 86370.

Pieters J. (1997). MHC class II restricted antigen presentation. Curr Opin Immunol 9: 89-96.

Pinkel D., Gray J. W., Trask B., van den Engh G., Fuscoe J., and van Dekken H. (1986). Cytogenetic analysis by in situ hybridization with fluorescently labeled nucleic acid probes. Cold Spring Harb Symp Quant Biol 51 Pt 1: 151-7.

Pollard S. L., and Holland P. W. (2000). Evidence for 14 homeobox gene clusters in human genome ancestry. Curr Biol 10: 1059-62.

Postlethwait J. H., Yan Y. L., Gates M. A., Horne S., Amores A., Brownlie A., Donovan A., Egan E. S., Force A., Gong Z., Goutel C., Fritz A., Kelsh R., Knapik E.,

Liao E., Paw B., Ransom D., Singer A., Thomson M., Abduljabbar T. S., Yelick P., Beier D., Joly J. S., Larhammar D., Rosa F., and et al. (1998). Vertebrate genome evolution and the zebrafish gene map. Nat Genet 18: 345-9.

Price P., Witt C., Allcock R., Sayer D., Garlepp M., Kok C. C., French M., Mallal S., and Christiansen F. (1999). The genetic basis for the association of the 8.1 ancestral haplotype (A1, B8, DR3) with multiple immunopathological diseases. Immunol Rev 167: 257-74.

Prince V. E., and Pickett F. B. (2002). Splitting pairs: the diverging fates of duplicated genes. Nat Rev Genet 3: 827-37.

Pryde F. E., Gorham H. C., and Louis E. J. (1997). Chromosome ends: all the same under their caps. Curr Opin Genet Dev 7: 822-8.

Radley E., Alderton R. P., Kelly A., Trowsdale J., and Beck S. (1994). Genomic organization of HLA-DMA and HLA-DMB. Comparison of the gene organization of all six class II families in the human major histocompatibility complex. J Biol Chem 269: 18834-8.

Radosavljevic M., Cuillerier B., Wilson M. J., Clement O., Wicker S., Gilfillan S., Beck S., Trowsdale J., and Bahram S. (2002). A cluster of ten novel MHC class I related genes on human chromosome 6q24.2-q25.3. Genomics 79: 114-23.

Reid K. B., and Porter R. R. (1981). The proteolytic activation systems of complement. Аппи Rev Biochem 50: 433-64.

Reiter L. T., Murakami T., Koeuth T., Pentao L., Muzny D. M., Gibbs R. A., and Lupski J. R. (1996). A recombination hotspot responsible for two inherited peripheral neuropathies is located near a mariner transposon-like element. Nat Genet 12: 288-97.

Rice P., Longden I., and Bleasby A. (2000). EMBOSS: the European Molecular Biology Open Software Suite. Trends Genet 16: 276-7.

Rouquier S., Taviaux S., Trask B. J., Brand-Arpon V., van den Engh G., Demaille J., and Giorgi D. (1998). Distribution of olfactory receptor genes in the human genome. Nat Genet 18: 243-50.

Rozen S., and Skaletsky H. (2000). Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 132: 365-86.

Saglio G., Storlazzi C. T., Giugliano E., Surace C., Anelli L., Rege-Cambrin G., Zagaria A., Jimenez Velasco A., Heiniger A., Scaravaglio P., Torres Gomez A., Roman Gomez J., Archidiacono N., Banfi S., and Rocchi M. (2002). A 76-kb duplicon maps close to the BCR gene on chromosome 22 and the ABL gene on chromosome 9: possible involvement in the genesis of the Philadelphia chromosome translocation. Proc Natl Acad Sci U S A 99: 9882-7.

Saitou N., and Nei M. (1987). The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol 4: 406-25.

Sanger F., Air G. M., Barrell B. G., Brown N. L., Coulson A. R., Fiddes C. A., Hutchison C. A., Slocombe P. M., and Smith M. (1977a). Nucleotide sequence of bacteriophage phi X174 DNA. Nature 265: 687-95.

Sanger F., Nicklen S., and Coulson A. R. (1977b). DNA sequencing with chainterminating inhibitors. Proc Natl Acad Sci U S A 74: 5463-7.

Sanger F., Coulson A. R., Friedmann T., Air G. M., Barrell B. G., Brown N. L., Fiddes J. C., Hutchison C. A., 3rd, Slocombe P. M., and Smith M. (1978). The nucleotide sequence of bacteriophage phiX174. J Mol Biol 125: 225-46.

Sanger F., Coulson A. R., Hong G. F., Hill D. F., and Petersen G. B. (1982). Nucleotide sequence of bacteriophage lambda DNA. J Mol Biol 162: 729-73.

Schmidt H. A., Strimmer K., Vingron M., and von Haeseler A. (2002). TREEPUZZLE: maximum likelihood phylogenetic analysis using quartets and parallel computing. Bioinformatics 18: 502-4.

Schughart K., Kappen C., and Ruddle F. H. (1988). Mammalian homeoboxcontaining genes: genome organization, structure, expression and evolution. $\mathrm{Br} J$ Cancer Suppl 9: 9-13.

Schultz R. J. (1980). Role of polyploidy in the evolution of fishes. In "Polyploidy: Biological Relevance" (W. H. Lewis, Ed.), Plenum, New York.

Sharman A. C. (1999). Some new terms for duplicated genes. Semin Cell Dev Biol 10: 561-3.

Shiina T., Tamiya G., Oka A., Takishima N., Yamagata T., Kikkawa E., Iwata K., Tomizawa M., Okuaki N., Kuwano Y., Watanabe K., Fukuzumi Y., Itakura S., Sugawara C., Ono A., Yamazaki M., Tashiro H., Ando A., Ikemura T., Soeda E., Kimura M., Bahram S., and Inoko H. (1999). Molecular dynamics of MHC genesis unraveled by sequence analysis of the $1,796,938$-bp HLA class I region. Proc Natl Acad Sci U S A 96: 13282-7.

Shiina T., Ando A., Suto Y., Kasai F., Shigenari A., Takishima N., Kikkawa E., Iwata K., Kuwano Y., Kitamura Y., Matsuzawa Y., Sano K., Nogami M., Kawata H., Li S., Fukuzumi Y., Yamazaki M., Tashiro H., Tamiya G., Kohda A., Okumura K., Ikemura T., Soeda E., Mizuki N., Kimura M., Bahram S., and Inoko H. (2001). Genomic anatomy of a premier major histocompatibility complex paralogous region on chromosome 1q21-q22. Genome Res 11: 789-802.

Sidow A. (1996). Gen(om)e duplications in the evolution of early vertebrates. Curr Opin Genet Dev 6: 715-22.

Skrabanek L., and Wolfe K. H. (1998). Eukaryote genome duplication - where's the evidence? Curr Opin Genet Dev 8: 694-700.

Smit A. F. (1999). Interspersed repeats and other mementos of transposable elements in mammalian genomes. Curr Opin Genet Dev 9: 657-63.

Smith L. C., Azumi K., and Nonaka M. (1999). Complement systems in invertebrates. The ancient alternative and lectin pathways. Immunopharmacology 42: 107-20.

Soderlund C., Longden I., and Mott R. (1997). FPC: a system for building contigs from restriction fingerprinted clones. Comput Appl Biosci 13: 523-35.

Spring J., Goldberger O. A., Jenkins N. A., Gilbert D. J., Copeland N. G., and Bernfield M. (1994). Mapping of the syndecan genes in the mouse: linkage with members of the myc gene family. Genomics 21: 597-601.

Spring J. (1997). Vertebrate evolution by interspecific hybridisation--are we polyploid? FEBS Lett 400: 2-8.

Staden R. (1980). A new computer method for the storage and manipulation of DNA gel reading data. Nucleic Acids Res 8: 3673-94.

Staden R., Beal K. F., and Bonfield J. K. (2000). The Staden package, 1998. Methods Mol Biol 132: 115-30.

Stephens R., Horton R., Humphray S., Rowen L., Trowsdale J., and Beck S. (1999). Gene organisation, sequence variation and isochore structure at the centromeric boundary of the human MHC. J Mol Biol 291: 789-99.

Strippoli P., D'Addabbo P., Lenzi L., Giannone S., Canaider S., Casadei R., Vitale L., Carinci P., and Zannotti M. (2002). Segmental paralogy in the human genome: a large-scale triplication on 1p, 6p, and 21q. Mamm Genome 13: 456-62.

Sugaya K., Fukagawa T., Matsumoto K., Mita K., Takahashi E., Ando A., Inoko H., and Ikemura T. (1994). Three genes in the human MHC class III region near the junction with the class II: gene for receptor of advanced glycosylation end products, PBX2 homeobox gene and a notch homolog, human counterpart of mouse mammary tumor gene int-3. Genomics 23: 408-19.

Sugaya K., Sasanuma S., Nohata J., Kimura T., Fukagawa T., Nakamura Y., Ando A., Inoko H., Ikemura T., and Mita K. (1997). Gene organization of human NOTCH4 and (CTG)n polymorphism in this human counterpart gene of mouse proto-oncogene Int3. Gene 189: 235-44.

Tamkun J. W. (1995). The role of brahma and related proteins in transcription and development. Curr Opin Genet Dev 5: 473-7.

Tee M. K., Thomson A. A., Bristow J., and Miller W. L. (1995). Sequences promoting the transcription of the human XA gene overlapping P450c21A correctly predict the presence of a novel, adrenal-specific, truncated form of tenascin-X. Genomics 28: 171-8.

The MHC Sequencing Consortium (1999). Complete sequence and gene map of a human major histocompatibility complex. The MHC sequencing consortium. Nature 401 (6756): 921-3.

Thompson J. D., Higgins D. G., and Gibson T. J. (1994). CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22: 4673-80.

Thomson G. (1995). HLA disease associations: models for the study of complex human genetic disorders. Crit Rev Clin Lab Sci 32: 183-219.

Thorpe K. L., Gorman P., Thomas C., Sheer D., Trowsdale J., and Beck S. (1997). Chromosomal localization, gene structure and transcription pattern of the ORFX gene, a homologue of the MHC-linked RING3 gene. Gene 200: 177-83.

Utans U., Arceci R. J., Yamashita Y., and Russell M. E. (1995). Cloning and characterization of allograft inflammatory factor-1: a novel macrophage factor identified in rat cardiac allografts with chronic rejection. J Clin Invest 95: 2954-62.

Utans U., Quist W. C., McManus B. M., Wilson J. E., Arceci R. J., Wallace A. F., and Russell M. E. (1996). Allograft inflammatory factory-1. A cytokine-responsive macrophage molecule expressed in transplanted human hearts. Transplantation 61: 1387-92.
van Geel M., Heather L. J., Lyle R., Hewitt J. E., Frants R. R., and de Jong P. J. (1999). The FSHD region on human chromosome $4 q 35$ contains potential coding regions among pseudogenes and a high density of repeat elements. Genomics 61: 5565.
van Geel M., Eichler E. E., Beck A. F., Shan Z., Haaf T., van der Maarel S. M., Frants R. R., and de Jong P. J. (2002). A cascade of complex subtelomeric duplications during the evolution of the hominoid and Old World monkey genomes. Am J Hum Genet 70: 269-78.
van Slegtenhorst M., de Hoogt R., Hermans C., Nellist M., Janssen B., Verhoef S., Lindhout D., van den Ouweland A., Halley D., Young J., Burley M., Jeremiah S., Woodward K., Nahmias J., Fox M., Ekong R., Osborne J., Wolfe J., Povey S., Snell R. G., Cheadle J. P., Jones A. C., Tachataki M., Ravine D., Kwiatkowski D. J., and et al. (1997). Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 277: 805-8.

Venter J. C., Adams M. D., Myers E. W., Li P. W., Mural R. J., Sutton G. G., Smith H. O., Yandell M., Evans C. A., Holt R. A., Gocayne J. D., Amanatides P., Ballew R. M., Huson D. H., Wortman J. R., Zhang Q., Kodira C. D., Zheng X. H., Chen L., Skupski M., Subramanian G., Thomas P. D., Zhang J., Gabor Miklos G. L., Nelson C., Broder S., Clark A. G., Nadeau J., McKusick V. A., Zinder N., Levine A. J., Roberts R. J., Simon M., Slayman C., Hunkapiller M., Bolanos R., Delcher A., Dew I., Fasulo D., Flanigan M., Florea L., Halpern A., Hannenhalli S., Kravitz S., Levy S., Mobarry C., Reinert K., Remington K., Abu-Threideh J., Beasley E., Biddick K.,

Bonazzi V., Brandon R., Cargill M., Chandramouliswaran I., Charlab R., Chaturvedi K., Deng Z., Di Francesco V., Dunn P., Eilbeck K., Evangelista C., Gabrielian A. E., Gan W., Ge W., Gong F., Gu Z., Guan P., Heiman T. J., Higgins M. E., Ji R. R., Ke Z., Ketchum K. A., Lai Z., Lei Y., Li Z., Li J., Liang Y., Lin X., Lu F., Merkulov G. V., Milshina N., Moore H. M., Naik A. K., Narayan V. A., Neelam B., Nusskern D., Rusch D. B., Salzberg S., Shao W., Shue B., Sun J., Wang Z., Wang A., Wang X., Wang J., Wei M., Wides R., Xiao C., Yan C., et al. (2001). The sequence of the human genome. Science 291: 1304-51.

Vernier P., Mastrippolito R., Helin C., Bendali M., Mallet J., and Tricoire H. (1996). Radioimager quantification of oligonucleotide hybridization with DNA immobilized on transfer membrane: application to the identification of related sequences. Anal Biochem 235: 11-9.
von Lindern M., van Baal S., Wiegant J., Raap A., Hagemeijer A., and Grosveld G. (1992). Can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3-prime half to different genes: characterization of the 'set' gene. Mol. Cell. Biol. 12: 3346-3355.

Wagner A. (2001). Birth and death of duplicated genes in completely sequenced eukaryotes. Trends Genet 17: 237-9.

Walter M. A., Spillett D. J., Thomas P., Weissenbach J., and Goodfellow P. N. (1994). A method for constructing radiation hybrid maps of whole genomes. Nat Genet 7: 22-8.

Wang Y., and Gu X. (2000). Evolutionary patterns of gene families generated in the early stage of vertebrates. J Mol Evol 51: 88-96.

Wendel J. F. (2000). Genome evolution in polyploids. Plant Mol Biol 42: 225-49.
Wilke C. M., Guo S. W., Hall B. K., Boldog F., Gemmill R. M., Chandrasekharappa S. C., Barcroft C. L., Drabkin H. A., and Glover T. W. (1994). Multicolor FISH mapping of YAC clones in 3p14 and identification of a YAC spanning both FRA3B and the $\mathrm{t}(3 ; 8)$ associated with hereditary renal cell carcinoma. Genomics 22: 319-26.

Wilson R., Ainscough R., Anderson K., Baynes C., Berks M., Bonfield J., Burton J., Connell M., Copsey T., Cooper J., and et al. (1994). 2.2 Mb of contiguous nucleotide sequence from chromosome III of C. elegans. Nature 368: 32-8.

Wittbrodt J., Meyer A., and Schartl M. (1998). More genes in fish? Bioessays 20: 511-515.

Wolfe K. H. (2001). Yesterday's polyploids and the mystery of diploidization. Nat Rev Genet 2: 333-41.

Xia Y., Brown L., Yang C. Y., Tsan J. T., Siciliano M. J., Espinosa R., III, Le Beau M. M., and Baer R. J. (1991). TAL2, a helix-loop-helix gene activated by the (7;9)(q34;q32) translocation in human T-cell leukemia. Proc Natl Acad Sci U S A 88: 11416-20.

Yon J., Jones T., Garson K., Sheer D., and Fried M. (1993). The organization and conservation of the human Surfeit gene cluster and its localization telomeric to the cabl and can proto-oncogenes at chromosome band 9q34.1. Hum Mol Genet 2: 237-40.

Zhu Z., Yao J., Johns T., Fu K., De Bie I., Macmillan C., Cuthbert A. P., Newbold R. F., Wang J., Chevrette M., Brown G. K., Brown R. M., and Shoubridge E. A. (1998). SURF1, encoding a factor involved in the biogenesis of cytochrome c oxidase, is mutated in Leigh syndrome. Nat Genet 20: 337-43.

## Appendix 1

Summary of the annotation of the chromosomal region 9 q 32 to 9 q 34.3 . Putative paralogues are in bold text.

| $\underset{U}{0}$ |  | $\begin{aligned} & \overline{0} \\ & 0 \\ & \text { N } \\ & 0 \\ & \text { B } \\ & 0 \end{aligned}$ | Кииа Iquasuজ ıo basłay ‘yLdS |  | $\begin{aligned} & \text { I } \\ & \text { I } \\ & \text { E } \\ & 0 \\ & E \\ & E \end{aligned}$ |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| AL160275 | q32 | ATP6V1G1 | 075348 | 109082196 | 109092823 | 118 | Vacuolar ATP synthase subunit |
|  | q32 | NM_153045 | Q8ND43 | 109118880 | 109140873 | 281 | Unknown |
| AL390240 | q32 | TNFSF15 | 095150 | 109283763 | 109300582 | 251 | Tumor necrosis factor ligand |
| AL133412 | q32 | TNFSF8 | P32971 | 109398384 | 109424753 | 234 | Tumor necrosis factor ligand |
| AL162425 | q33.1 | TNC | P24821 | 109514975 | 109612609 | 2201 | Tenascin precursor |
| AL355601 | q33.1 | NM_017418 | O17418 | 109636267 | 109897093 | 95 | Deleted in esophageal cancer 1 |
| AL731824 | q33.1 | No genes |  |  |  |  |  |
| AL714001 | q33.1 | No genes |  |  |  |  |  |
| AL691420 | q33.1 | No genes |  |  |  |  |  |
| AL731897 | q33.1 | No genes |  |  |  |  |  |
| AL731813 | q33.1 | No genes |  |  |  |  |  |
| AL732367 | q33.1 | EST-YD1 | Q9P2X8 | 110398837 | 110399090 | 84 | EST-YD1 protein |
| AL691426 | q33.1 | No genes |  |  |  |  |  |
| AL353141 | q33.1 | No genes |  |  |  |  |  |
| AL137024 | q33.1 | PAPPA | Q13219 | 110677328 | 110808083 | 716 | Pregnancy associated plasma protein A |
| AL669963 | q33.1 | No genes |  |  |  |  |  |
| AL133282 | q33.1 | ASTN2 | O75129 | 110836698 | 111823883 | 1321 | Astrotactin 1 |
|  | q33.1 | Novel | ENSG00000179990 | 110963536 | 110981401 | 73 | Unknown |
| AL133284 | q33.1 | TRIM32 | Q13049 | 111098800 | 111112220 | 653 | Zing finger protein HT2A |
| AL157829 | q33.1 | Novel | ENSG00000136913 | 111196159 | 111196227 | 23 | Unknown |
|  | q33.1 | FLJ20958 | Q9BQ00 | 111205755 | 111205826 | 24 | Unknown |
| AL392085 | q33.1 | No genes |  |  |  |  |  |
| AL354981 | q33.1 | No genes |  |  |  |  |  |
| AL355608 | q33.1 | No genes |  |  |  |  |  |
| AL358792 | q33.1 | No genes |  |  |  |  |  |
| AL445644 | q33.1 | No genes |  |  |  |  |  |
| AL161630 | q33.1 | Novel | ENSG00000179956 | 112057445 | 112065871 | 72 | Unknown |
| AL160272 | q33.1 | TLR4 | O00206 | 112113140 | 112124614 | 839 | TOLL-like receptor 4 precursor |
| AL354754 | q33.1 | No genes |  |  |  |  |  |
| AL445663 | q33.1 | No genes |  |  |  |  |  |
| AL158831 | q33.1 | No genes |  |  |  |  |  |
| AL365195 | q33.1 | No genes |  |  |  |  |  |
| AL445440 | q33.1 | No genes |  |  |  |  |  |
| AL355592 | q33.1 | No genes |  |  |  |  |  |
| AL589703 | q33.1 | No genes |  |  |  |  |  |


| AL157780 | q33.1 | No genes |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| AL512602 | q33.1 | No genes |  |  |  |  |  |
| AL445310 | q33.1 | No genes |  |  |  |  |  |
| AL353773 | q33.1 | DCBBR1 | O14618 | 113575169 | 113778264 | 761 | Deleted in bladder cancer chromosome region |
| AL138894 | q33.1 | No genes |  |  |  |  |  |
| AL353630 | q33.1 | No genes |  |  |  |  |  |
| AC006288 | q33.1 | No genes |  |  |  |  |  |
| AL445683 | q33.1 | No genes |  |  |  |  |  |
| AL354931 | q33.1 | No genes |  |  |  |  |  |
| AL441989 | q33.1 | No genes |  |  |  |  |  |
| AL355589 | q33.1 | No genes |  |  |  |  |  |
| AL592549 | q33.1 | No genes |  |  |  |  |  |
| AL353736 | q33.1 | No genes |  |  |  |  |  |
| AL391870 | q33.2 | CDK5RAP2 | Q9NV90 | 114797706 | 114988994 | 943 | CDK5 regulatory subunit associated protein 2 |
| AL590642 | q33.2 | No genes |  |  |  |  |  |
| AL138836 | q33.2 | EGFL5 | Q9H1U4 | 115009649 | 115068409 | 401 | EGF like domain multiple 5 protein |
|  | q33.2 | Novel | ENSG00000176341 | 115098762 | 115122988 | 236 | Unknown |
| AL161911 | q33.2 | FBXW2 | Q9UKT8 | 115160814 | 115202253 | 454 | F-BOX/WD-repeat protein 2 |
|  | q33.2 | PSMD5 | Q16401 | 115224889 | 115251748 | 504 | 26S proteasome non-ATPase regulatory subunit 5 |
|  | q33.2 | Novel | ENSG00000180095 | 115251902 | 115263209 | 105 | Unknown |
| AL354792 | q33.2 | Q9UFS9 | Q9UFS9 | 115264535 | 115286029 | 473 | Transcription factor |
| AC006430 | q33.2 | PRO1995 | Q9P1F7 | 115299108 | 115300075 | 105 | Unknown |
|  | q33.2 | TRAF1 | EBI6 | 115311227 | 115337603 | 350 | TNF receptor associated factor 1 |
|  | q33.2 | C5 | P01031 | 115361172 | 11549110 | 1676 | Complement C5 precursor |
| AL137068 | q33.2 | Novel | ENSG00000171635 | 115499108 | 115516745 | 219 | Testis specfic |
|  | q33.2 | CEP1 | O07018 | 115521379 | 115586444 | 1800 | Centrosomal protein 1 |
|  | q33.2 | RAB14 | P35287 | 115586971 | 115610724 | 215 | Ras-related protein |
| AL513122 | q33.2 | Novel | ENSG00000180552 | 115647510 | 115648753 | 409 | Unknown |
|  | q33.2 | MOST2 | Q9NRJ2 | 115689602 | 115694364 | 209 | MOST2 protein |
|  | q33.2 | GSN | O06396 | 115708681 | 115741676 | 782 | Gelosin precursor, plasma |
| AL161784 | q33.2 | EPB72 | P27105 | 115747913 | 115779060 | 288 | Erythrocyte band 7 integral membrane protein |
| AL359644 | q33.2 | Novel | ENSG00000165196 | 115868813 | 115888025 | 174 | Unknown |
| AL357936 | q33.2 | No genes |  |  |  |  |  |
| AL365274 | q33.2 | DAP2IP | Q8TDL2 | 115974718 | 116194365 | 964 | DOC-2/DAB2 interactive protein |
| AL450285 | q33.2 | Novel |  |  |  |  |  |
| AL596244 | q33.2 | Novel |  |  |  |  |  |
| AL445587 | q33.2 | Novel | ENSG00000171539 | 116362696 | 116383814 | 140 | Unknown |
| AL442634 | q33.2 | Q8NHH0 | Q8NHH0 | 116397745 | 116502441 | 538 | Unknown |
| AL162423 | q33.2 | NDUFA8 | P51970 | 116552893 | 116568579 | 172 | NADH-Ubiquinone oxidoreductase subunit |
| AL162424 | q33.2 | LHX6 | Q9UPM6 | 116611414 | 11667540 | 363 | LIM/Homeobox protein |
|  | q33.2 | NM_033117 | Q96H35 | 116648845 | 11667367 | 190 | Unknown |
|  | q33.2 | NM_138777 | Q9BU92 | 116679683 | 116732299 | 262 | RIKEN cDNA D02 |
|  | q33.2 | PTGS1 | P23219 | 116779785 | 116804538 | 596 | Prostaglandin G/H synthase 1 precursor |
| AL359636 | q33.2 | OR | Q8NGS3 | 116885796 | 116886761 | 322 | Olfactory receptor |
|  |  | OR | OR1J5 | 116919637 | 116920575 | 313 | Olfactory receptor |
|  |  | OR | Q8NGS1 | 116927976 | 116928914 | 313 | Olfactory receptor |
|  |  | OR | OR1N1 | 116935199 | 116936125 | 309 | Olfactory receptor |
|  |  | OR | Q8NGR9 | 116960247 | 116962994 | 316 | Olfactory receptor |
|  |  | OR | Q8NGR8 | 116976386 | 116977312 | 309 | Olfactory receptor |
| Al162254 | q33.2 | OR | Q9UDD7 | 117016871 | 117017632 | 254 | Olfactory receptor |
|  |  | OR | OR1Q1 | 117023573 | 117024514 | 314 | Olfactory receptor |
| AC006313 | q33.2 | OR | Q8NGR6 | 117037417 | 117038367 | 295 | Olfactory receptor |
|  |  | OR | Q8NH94 | 117070551 | 117071480 | 317 | Olfactory receptor |
|  |  | OR | Q8NH93 | 117083965 | 117084936 | 324 | Olfactory receptor |
|  |  | OR | Q8NGR5 | 117132825 | 117133757 | 311 | Olfactory receptor |


|  |  | OR | Q96R80 | 1171588887 | 117159534 | 216 | Olfactory receptor |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | OR | Q8WVK7 | 117170703 | 117171065 | 121 | Olfactory receptor |
| AL359512 | q33.2 | OR | Q8NGR3 | 117208958 | 117209905 | 316 | Olfactory receptor |
|  | q33.2 | PDCL | Q13371 | 117226985 | 117237466 | 301 | Phosdusin-like protein |
|  | q33.2 | MNAB | O18835 | 117253391 | 117314050 | 1191 | Membrane associated binding protein |
| AL731645 | q33.2 | ZID | Q15916 | 117317457 | 117320910 | 424 | Zinc finger protein |
|  | q33.2 | BIOR | Q9HCK0 | 117326928 | 117340094 | 441 | Zinc finger protein |
|  | q33.2 | GAPCenA | Q9Y3P9 | 117349852 | 117513707 | 997 | RAB6 GTPase activating protein |
| AL358946 | q33.3 | No genes |  |  |  |  |  |
| AL365338 | q33.2 | NM_030814 | Q9H2N8 | 117518337 | 117522309 | 167 | Unknown |
|  | q33.2 | STRBP | Q96S19 | 117533552 | 117593141 | 658 | RNA binding protein |
| AL365504 | q33.3 | PRO226 | Q9P180 | 117674928 | 117675167 | 80 | Unknown |
| AL445489 | q33.3 | FLJ38464 | Q8N930 | 117782642 | 117787587 | 215 | Unknown |
|  | q33.3 | FLJ00224 | Q8TEH3 | 117788495 | 118338969 | 896 | Unknown |
| AL161790 | q33.3 | No genes |  |  |  |  |  |
| AL390774 | q33.3 | No genes |  |  |  |  |  |
| AL158208 | q33.3 | No genes |  |  |  |  |  |
| AC006450 | q33.3 | LHX2 | P50458 | 118420439 | 118441992 | 406 | LIM/Homeobox protein |
| AL158052 | q33.3 | No genes |  |  |  |  |  |
| Al445284 | q33.3 | No genes |  |  |  |  |  |
| AL162724 | q33.3 | NEK6 | Q9HC98 | 118666435 | 118761271 | 338 | Serine-threonine protein kinase |
| AL137846 | q33.3 | PSMB7 | Q99436 | 118762294 | 118824271 | 277 | Proteasome subunit beta type 7 |
|  | q33.3 | Q8NH12 | Q8NH12 | 118874053 | 118892161 | 984 | Seven transmembrane helix receptor |
| AL354979 | q33.3 | NR5A1 | Q13285 | 118890062 | 118916249 | 461 | Steroidogenic factor 1 |
|  | q33.3 | NR6A1 | Q15406 | 118928956 | 119180139 | 476 | Orphan nuclear receptor |
| AL669818 | q33.3 | No genes |  |  |  |  |  |
| AL158075 | q33.3 | No genes |  |  |  |  |  |
| AL354928 | q33.3 | FLJ90228 | Q8NCI9 | 119186100 | 119223707 | 318 | Unknown |
|  | q33.3 | Novel | ENSG00000136918 | 119263034 | 119266399 | 233 | Unknown |
|  | q33.3 | RPL35 | P42766 | 119266713 | 119270796 | 141 | 60S ribosomal protein L35 |
|  | q33.3 | NM_030978 | Q9BPX5 | 119278120 | 119286561 | 159 | Actin related protein |
|  | q33.3 | GOLGA1 | Q92805 | 119287196 | 119349928 | 767 | Golgin 97,gap junction protein |
| AL451125 | q33.3 | FLJ40705 | Q8N1I4 | 119360938 | 119552351 | 629 | Unknown |
| AL445930 | q33.3 | PPP6C | O00743 | 119557957 | 119598620 | 305 | Serine/threonine protein phospatase 6 |
|  | q33.3 | Novel | ENSG00000173602 | 119603477 | 119604650 | 282 | 40S ribosomal protein |
| AL354710 | q33.3 | P40 | O00568 | 119609374 | 119642831 | 372 | RAB9 effector P40 |
|  | q33.3 | HSPA5 | P11021 | 119643682 | 119650159 | 654 | 78 KDA Glucose regulated protein |
|  | q33.3 | Novel | ENSG00000176094 | 119672414 | 119672919 | 158 | 40S ribosomal protein |
| AL627223 | q33.3 | FLJ20119 | Q9NXQ1 | 119670661 | 119773833 | 833 | Unknown |
| AL359632 | q33.3 | MAPKAP1 | Q9BPZ7 | 119846225 | 120116031 | 486 | MAP kinase interacting protein 1 |
| AL162584 | q33.3 | Novel | ENSG00000178022 | 120004502 | 120005454 | 316 | Unknown |
| AL358074 | q33.3 | SIN1 |  | 119846225 | 120116031 | 522 | SAPK interacting protein 1 |
|  | q33.3 | NM_016158 | Q9UN39 | 120153187 | 120155380 | 129 | Erythrocyte transmembrane protein |
| AL627303 | q33.3 | No genes |  |  |  |  |  |
| AL445186 | q33.3 | PBX3 | P40426 | 120156161 | 120376205 | 434 | Pre-B-cell leukaemia transcription factor 3 |
| AL589923 | q33.3 | No genes |  |  |  |  |  |
| AL445664 | q33.3 | No genes |  |  |  |  |  |
| AL162391 | q33.3 | No genes |  |  |  |  |  |
| AC006443 | q33.3 | FLJ00022 | Q9H7P6 | 120735668 | 120915859 | 344 | Unknown |
| AL356309 | q33.3 | No genes |  |  |  |  |  |
| AL161908 | q33.3 | No genes |  |  |  |  |  |
| AL161731 | q33.3 | LMX1B | O60663 | 121023337 | 121105270 | 379 | LIM/Homeobox protein |
|  | q33.3 | Q8N243 | Q8N243 | 121212014 | 121214492 | 115 | Unknown |
|  | q33.3 | ZNF297B | 043298 | 121213845 | 121244041 | 467 | Zinc finger 297B |
| AL354944 | q33.3 | KIAA1993 | Q8NCN2 | 121269484 | 121289729 | 532 | Unknown |


| AL160169 | q33.3 | No genes |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| AL356862 | q33.3 | RalGPS1A | Q8WUV7 | 121323592 | 121631982 | 590 | Ral guanine nuceotide factor |
|  | q33.3 | ANGPTL2 | Q9UKU9 | 121496150 | 121531456 | 493 | Angiopoietin-related protein 2 |
| AL357623 | q33.3 | No genes |  |  |  |  |  |
| AL450263 | q33.3 | Novel | ENSG00000176889 | 121633429 | 121650133 | 78 | Unknown |
|  | q33.3 | NM_032293 | Q9BQH6 | 121673400 | 121802357 | 802 | Unknown |
| AL445222 | q33.3 | SLC2A8 | Q9NY64 | 121806004 | 121816716 | 477 | Solute carrier family 2 |
|  | q33.3 | RPL12 | P30050 | 128564940 | 121860226 | 164 | 60S ribosomal protein L12 |
|  | q33.3 | FLJ31641 | Q96MZ7 | 121860323 | 121912317 | 696 | Unknown |
|  | q33.3 | Novel | ENSG00000176217 | 121901370 | 121904622 | 109 | Unknown |
|  | q33.3 | $\begin{array}{\|c\|} \hline \text { NBL_HUMA } \\ \mathrm{N} \end{array}$ | Q96TA1 | 121914157 | 121987798 | 733 | Niban-like protein. |
| AL390116 | q33.3 | No genes |  |  |  |  |  |
| AL162426 | q34.11 | STXBP1 | Q64320 | 122021098 | 122101525 | 594 | Syntaxin binding protein 1 |
|  | q34.11 | Novel | ENSG00000160401 | 122108029 | 122124506 | 785 | Unknown |
|  | q34.11 | FLJ00176 | Q8TEL7 | 122124875 | 122140409 | 867 | Unknown |
|  | q34.11 | TOR2A | Q96LSL7 | 122140333 | 122144087 | 253 | Torsin family 2 , member A |
|  | q34.11 | SH2D3C | Q9Y2X5 | 122147126 | 122187504 | 703 | SH2 Domain containing protein 3 |
| AL162586 | q34.11 | CDK9 | P50750 | 122194861 | 122198896 | 372 | Cell division protein kinase 9 |
|  | q34.11 | Novel | ENSG00000177953 | 122199888 | 122201861 | 85 | Unknown |
|  | q34.11 | FPGS | Q05932 | 122211733 | 122222873 | 587 | Folypolyglutamate synthase |
|  | q34.11 | FLJ33157 | Q96LW6 | 122225388 | 122225972 | 195 | Unknown |
|  | q34.11 | ENG | P17813 | 122224494 | 122263514 | 658 | Endoglin procursor |
| AL157935 | q34.11 | AK1 | P00568 | 122275199 | 122286472 | 194 | Adenylate kinase isoenzyme 1 |
|  | q34.11 | FLJ13838 | Q9H8A2 | 122294130 | 122308407 | 352 | Beta-N-Acetylgalactosaminide |
|  | q34.11 | SIAT7D | Q9H4F1 | 122316695 | 122325831 | 298 | Sialyltransferase |
|  | q34.11 | Novel | ENSG00000167103 | 122330677 | 122339810 | 471 | Kinase |
|  | q34.11 | Novel | ENSG00000136908 | 122343908 | 122347297 | 162 | Unknown |
|  | q34.11 | FLJ00179 | Q8TEL4 | 122349392 | 122356974 | 194 | Unknown |
|  | q34.11 | NM_018033 | Q9NW83 | 122374689 | 122375144 | 152 | Unknown |
| AL360268 | q34.11 | Q8WU12 | Q8WU12 | 122472894 | 122475975 | 172 | Unknown |
| AL590708 | q34.11 | KIAA1896 | Q96PZ1 | 122500273 | 122518054 | 568 | Mitochondrial solute carrier |
|  | q34.11 | PTGES2 | Q9H7Z7 | 122529502 | 122537271 | 379 | Prostaglandin E synthase 2 |
|  | q34.11 | Q9N1Y9 | Q9N1Y9 | 122537454 | 122538008 | 185 | Unknown |
|  | q34.11 | LCN2 | P80188 | 122558275 | 122562260 | 192 | Lipocalin |
|  | q34.11 | C9orf16 | Q9BUW7 | 122569160 | 122572735 | 83 | Unknown |
|  | q34.11 | CIZ1 | Q9ULV3 | 122574874 | 122613197 | 967 | Zinc finger protein |
|  | q34.11 | DNM1 | Q05193 | 122612217 | 122664055 | 864 | Dynamin-1 |
|  | q34.11 | GOLGA2 | Q08379 | 122665504 | 122684750 | 1008 | Golgin-95 |
| AL590722 | q34.11 | Q8N2W6 | Q8N2W6 | 122685026 | 122697798 | 209 | Unknown |
|  | q34.11 | FLJ21673 | Q9H6Y8 | 122709723 | 122710145 | 423 | Unknown |
| AL359091 | q34.11 | FLJ11094 | O95900 | 122717908 | 122731245 | 331 | Unknown |
|  | q34.11 | C0Q4 | Q9Y3A0 | 122731344 | 122742880 | 265 | Coenzyme Q biosynthesis protein 4 |
|  | q34.11 | SLC27A4 | O95186 | 122749454 | 122770025 | 640 | Fatty acid transport protein 4 |
|  | q34.11 | NM_030914 | Q9BTM9 | 122780169 | 122799542 | 101 | Unknown |
|  | q34.11 | KIAA1502 | Q9P226 | 122820574 | 122846159 | 560 | Cerebral cell adhesion molecule |
|  | q34.11 | ODF2 | O14721 | 122864961 | 122909768 | 638 | Outer dense fibre of sperm tails 2 |
| AL445287 | q34.11 | GLE1L | O75458 | 122913513 | 122951096 | 698 | Gle-1 like RNA export mediator |
| AL356481 | q34.11 | SPTAN1 | Q13813 | 122961411 | 123042401 | 2474 | Spectrin alpha chain |
|  | q34.11 | NM_052844 | Q9BV46 | 123042469 | 123065595 | 522 | Unknown |
|  | q34.11 | SET | Q01105 | 123092703 | 123105196 | 290 | SET (HLA-DR associated protein II) |
| AL359678 | q34.11 | No genes |  |  |  |  |  |
| AL441992 | q34.11 | PKNbeta | O13355 | 123111331 | 123129414 | 889 | Protein kinase |
|  | q34.11 | ZDHHC12 | O32799 | 123129677 | 123132930 | 267 | Zinc finger protein |
|  | q34.11 | ZYG | O00156 | 123138594 | 123180701 | 766 | ZYG homologue |
|  | q34.11 | FLJ10743 | Q9NVG8 | 123196140 | 123219240 | 275 | Unknown |


|  | q34.11 | ENDOG | Q14249 | 123227276 | 123231484 | 297 | Endonuclease G |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | q34.11 | HSPC109 | Q9P041 | 123228459 | 123238629 | 384 | Unknown |
|  | q34.11 | CCBL1 | Q16773 | 123241750 | 123290846 | 422 | Cyoplasmic cysteine |
| AL672142 | q34.11 | KIAA1437 | Q9P2B1 | 123294854 | 12336844 | 811 | Unknown |
|  | q34.11 | Q96GM4 | Q96GM4 | 123329703 | 123351210 | 206 | Unknown |
|  | q34.11 | KIAA1094 | Q9UPQ8 | 123354339 | 123356427 | 538 | Unknown |
| AL592211 | q34.11 | KIAA0169 | Q14675 | 123357991 | 123415903 | 1739 | Unknown |
|  | q34.11 | SH3GLB2 | Q9BRZ5 | 123416600 | 123437108 | 130 | SH3-containing protein |
|  | q34.11 | FLJ00199 | Q9TEJ6 | 123445452 | 123480880 | 383 | Unknown |
|  | q34.11 | Q96GF8 | Q96GF8 | 123489937 | 123499243 | 237 | Unknown |
| AL158151 | q34.11 | CRAT | P43155 | 123503602 | 123519612 | 626 | Cartinine o-acetyltransferase |
|  | q34.11 | PPP2R4 | Q15257 | 123519773 | 123557754 | 358 | Protein phosphatase 2A |
|  | q34.11 | Novel | ENSG00000167133 | 123585649 | 123586860 | 290 | Unknown |
| AL161785 | q34.11 | FLJ35269 | Q8NAJ2 | 123729824 | 123733713 | 232 | Unknown |
| AL353803 | q34.11 | FLJ34873 | Q8NAS2 | 123745332 | 123747103 | 144 | Unknown |
| AL391056 | q34.11 | Novel | ENSG00000179068 | 123897948 | 123913240 | 98 | Unknown |
|  | q34.11 | FLJ35803 | Q8NA65 | 124021035 | 124029584 | 377 | Unknown |
| AL590369 | q34.11 | AD003 | Q9UI28 | 124034981 | 124044744 | 223 | Adrenal gland protein |
|  | q34.11 | ASB6 | Q9NWX5 | 124043412 | 124050973 | 421 | Ankyrin repeat containing protein |
|  | q34.11 | PMX2 | Q99811 | 12074444 | 124131482 | 253 | Paired mesoderm protein |
|  | q34.11 | PTGES | O14684 | 124147139 | 124161855 | 152 | Prostaglandin E synthase |
| AL592219 | q34.11 | No genes |  |  |  |  |  |
| AL158207 | q34.11 | TOR1B | O14657 | 124211961 | 124220092 | 336 | Torsin B precursor |
|  | q34.11 | DYT1 | Q96CA0 | 124221751 | 124232942 | 336 | Torsin A precursor |
|  | q34.11 | HSPC220 | Q9NZ63 | 124236100 | 124244083 | 289 | Unknown |
|  | q34.11 | USP20 | Q9Y2K6 | 124244254 | 12490636 | 914 | Ubiquitin carboxyl-terminal hydrolase |
|  | q34.11 | FNBP1 | Q96RU3 | 124295995 | 124451976 | 672 | Thyroid receptor interacting protein |
| AL136141 | q34.11 | GPR107 | Q96T26 | 124462729 | 124548972 | 416 | G Protein-coupled receptor |
| AL392105 | q34.11 | No genes |  |  |  |  |  |
| AL360004 | q34.11 | FREQ | P36610 | 124581381 | 124645435 | 190 | Neuronal calcium sensor 1 |
|  | q34.11 | Novel | ENSG00000178890 | 124674690 | 124718869 | 822 | Unknown |
| 50 kb Gap |  |  |  |  |  |  |  |
| AL354898 | q34.11 | Q8NDA2 | Q8NDA2 | 124808356 | 124841498 | 1187 | Unknown |
|  | q34.11 | FLJ23816 | Q8TCI8 | 124852198 | 124856039 | 220 | Unknown |
|  | q34.11 | ASS | P00966 | 124866845 | 124923190 | 412 | Argininosuccinate synthase |
| AL353695 | q34.11 | No genes |  |  |  |  |  |
| AL359092 | q34.11 | FUBP3 | Q92946 | 125001544 | 125060268 | 542 | Fuse binding protein 3 |
|  | q34.12 | PRDM12 | Q9H4Q4 | 125086510 | 125104913 | 367 | PR domain containing protein 12 |
|  | q34.12 | RRP4 | Q13868 | 125115687 | 125126785 | 293 | Exosome complex exonuclease RRP4 |
| AL161733 | q34.12 | ABL1 | P00519 | 125136236 | 125309589 | 1130 | Abelson murine leukaemia viral oncogene |
|  | q34.12 | FLJ14810 | Q96SJ7 | 125324358 | 125360767 | 198 | Unknown |
| AL583807 | q34.12 | LAMC3 | Q9Y6N6 | 125431028 | 125516389 | 1575 | Laminin gamma-3 chain precursor |
| AL355872 | q34.12 | No genes |  |  |  |  |  |
| AL157938 | q34.12 | AIF1L | Q9BQI0 | 125518441 | 125545061 | 150 | Ionised cacium binding adaptor molecule 2 |
|  | q34.13 | NUP214 | P35658 | 125547506 | 125656586 | 2140 | Nuclear pore complex protein |
|  | q34.13 | Q8N2W3 | Q8N2W3 | 125679994 | 125698463 | 191 | Unknown |
| AL354855 | q34.13 | FLJ90726 | Q8NBV4 | 125711653 | 12731177 | 271 | Unknown |
|  | q34.13 | Novel | ENSG00000130710 | 125729227 | 125729298 | 24 | Unknown |
| AL358781 | q34.13 | BAT2L | Q9BU62 | 125852061 | 125869120 | 325 | HLA-B associated transcript |
|  | q34.13 | LQFBS-1 | O95209 | 125921328 | 125922066 | 245 | Unknown |
|  | q34.13 | POMT1 | Q9UNT2 | 125924841 | 125945722 | 747 | Protein-o-mannosyltransferase 1 |
|  | q34.13 | $\begin{gathered} \hline \text { UCK1_HUM } \\ \text { AN } \\ \hline \end{gathered}$ | Q9HA47 | 125945717 | 125953181 | 201 | Uridine cytidine kinase 1 |
| AL160276 | q34.13 | GRF2 | Q13905 | 126000707 | 126159454 | 1077 | Guanine nucleotide releasing factor 2 |
| AL160271 | q34.13 | CRSP8 | O95401 | 126282028 | 126512112 | 273 | Cofactor required transcriptional activation |
| AL603649 | q34.13 | No genes |  |  |  |  |  |


| AL713892 | q34.13 | No genes |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| AL691506 | q34.13 | No genes |  |  |  |  |  |
| AL513102 | q34.13 | No genes |  |  |  |  |  |
| AL353631 | q34.13 | No genes |  |  |  |  |  |
| AL159997 | q34.13 | KIAA1857 | Q96JH0 | 126594193 | 126675069 | 541 | Netrin G2 |
|  | q34.13 | KIAA0625 | Q8WX33 | 126693686 | 126761056 | 915 | Unknown |
| AL353701 | q34.13 | TTF1 | Q15361 | 126808230 | 126835074 | 882 | Transcription termination factor |
| AL354735 | q34.13 | Novel | ENSG00000178595 | 126930940 | 126975292 | 179 | Unknown |
|  | q34.13 | BARHL1 | Q9BZE3 | 127014851 | 127022519 | 327 | BARH (Drosophila)-like 1 |
| AL160165 | q34.13 | DDX31 | Q96NY2 | 127026534 | 127102646 | 851 | DEAD/H Box Helicase |
|  | q34.13 | GTF3C4 | Q9UKN8 | 127102586 | 127122695 | 822 | General transcription factor |
| AL445645 | q34.13 | FLJ32704 | Q96MA6 | 127157823 | 127310564 | 479 | Unknown |
|  | q34.13 | C9orf9 | Q96E40 | 127310608 | 127322275 | 222 | Unknown |
|  | q34.13 | TSC1 | Q92574 | 127323595 | 127376866 | 1164 | Tuberous sclerosis 1 gene |
|  | q34.13 | Novel | ENSG00000176140 | 127379314 | 127383801 | 47 | Unknown |
| AL593851 | q34.13 | GFI1B | O95270 | 127418923 | 127426295 | 330 | Growth factor independent 1B |
| AL162417 | q34.2 | GTF3C5 | Q9H4P2 | 127462958 | 12790748 | 528 | General transcription factor |
|  | q34.2 | CEL | P19835 | 127494229 | 127504006 | 756 | Carboxyl ester lipase |
|  | q34.2 | NM_173692 |  | 127513557 | 127514144 | 196 | Unknown |
|  | q34.2 | CELL | Q14018 | 127514780 | 127519600 | 59 | Carboxyl ester lipase-like |
|  | q34.2 | RALGDS | Q12967 | 127529965 | 127553410 | 914 | Ral Guanine nucleotide |
|  | q34.2 | FRS | Q9UKI5 | 127585198 | 127596144 | 347 | Forssman synthetase |
| AL732364 | q34.2 | OBPIIB | Q9NPH6 | 127637537 | 127641486 | 170 | Odorant binding protein 2B |
| AL158826 | q34.2 | ABO | P16442 | 127687850 | 127694413 | 287 | ABO blood group system |
|  | q34.2 | SURF6 | 075683 | 127754393 | 127759885 | 361 | SURFEIT locus protein 6 |
|  | q34.2 | SURF5 | Q15528 | 127764596 | 127771813 | 200 | SURFEIT locus protein 5 |
|  | q34.2 | SURF3 | P11518 | 127771906 | 127775122 | 265 | SURFEIT locus protein 3 |
|  | q34.2 | Q9H3B2 | Q9H3B2 | 127774377 | 127775089 | 101 | Unknown |
|  | q34.2 | SURF1 | Q15526 | 127775504 | 127780202 | 300 | SURFEIT locus protein 1 |
|  | q34.2 | SURF2 | Q15527 | 127780269 | 127784875 | 256 | SURFEIT locus protein 2 |
|  | q34.2 | SURF4 | O15260 | 127785181 | 127799817 | 269 | SURFEIT locus protein 4 |
|  | q34.2 | Q8NE28 | Q8NE28 | 127800125 | 127828061 | 651 | Unknown |
|  | q34.2 | Novel | ENSG00000175977 | 127821374 | 127824619 | 97 | Unknown |
|  | q34.2 | XPMC2H | Q9GZR2 | 127828027 | 127840010 | 422 | Prevents mitotic catastrophe 2 |
|  | q34.2 | ADAMTS13 | Q96L37 | 127843961 | 127881349 | 1427 | Von Willebrand factor-cleaving protease |
| AL593848 | q34.2 | C9orf7 | Q9UGQ2 | 127881962 | 127892726 | 172 | Unknown |
|  | q34.2 | SLC2A6 | Q8NCC2 | 127893058 | 127901068 | 515 | Solute carrier family 2 |
| BX324209 | q34.2 | No genes |  |  |  |  |  |
| AC002321 | q34.2 | No genes |  |  |  |  |  |
| <5 kb Gap |  |  |  |  |  |  |  |
| AC002101 | q34.2 | No genes |  |  |  |  |  |
| AL365494 | q34.2 | DBH | P09172 | 128007020 | 128030001 | 603 | Dopamine beta-monooxygenase precursor |
|  | q34.2 | SARDH | Q9UL10 | 128056341 | 128124046 | 832 | Sarcosine dehydrogenase |
|  | q34.2 | PP3781 | Q8WY83 | 123131956 | 128132329 | 124 | Unknown |
| AL590710 | q34.2 | Novel | ENSG00000176983 | 128211430 | 128251481 | 432 | Unknown |
|  | q34.2 | SARDH | Q9UL10 | 128252348 | 128272381 | 396 | Unknown |
| AL357934 | q34.2 | VAV2 | P52735 | 128297977 | 12826304 | 878 | Oncogene VAV-2 protein |
| AL445931 | q34.2 | Novel | ENSG00000179483 | 128559910 | 128562122 | 119 | Unknown |
|  | q34.2 | BRD3 | Q15059 | 128566862 | 128602533 | 726 | Bromodomain containing protein3 |
|  | q34.2 | Novel | ENSG00000179457 | 128588311 | 128592826 | 216 | Unknown |
| AL591386 | q34.2 | No genes |  |  |  |  |  |
| 200kb Gap |  |  |  |  |  |  |  |
| AL354796 | q34.2 | No genes |  |  |  |  |  |
| AL683798 | q34.2 | No genes |  |  |  |  |  |
| 13 kb Gap |  |  |  |  |  |  |  |


| AL669970 | q34.2 | RXRA | P19793 | 129062693 | 129101647 | 453 | Retinoid X receptor, alpha |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| AL591890 | q34.3 | COL5A1 | Q96HC0 | 129302868 | 129503955 | 590 | Collagen alpha 1 (V) chain precursor |
| AL603650 | q34.3 | FCN2 | Q15485 | 129541874 | 129548582 | 313 | Ficolin 2 precursor |
| AL353611 | q34.3 | FCN1 | O00602 | 129570647 | 129579025 | 326 | Ficolin 1 precursor |
| AL159992 | q34.3 | No genes |  |  |  |  |  |
| AL390778 | q34.3 | OLFM1 | Q9BWJ9 | 129736484 | 129782241 | 467 | Olfactomedin related ER localised protein |
| AL353615 | q34.3 | NM_173520 | Q8N4C0 | 130006614 | 130009927 | 152 | Unknown |
| AL161452 | q34.3 | Novel | ENSG00000178197 | 130131516 | 130144083 | 96 | Unknown |
|  | q34.3 | NM_014811 | Q9Y4D3 | 130146060 | 130152258 | 1209 | Unknown |
|  | q34.3 | NM_144654 | Q8WU44 | 130158546 | 130165104 | 92 | Unknown |
|  | q34.3 | MRPS2 | Q9Y399 | 130164060 | 130168038 | 296 | Mitochondrial ribosomal protein S2 |
|  | q34.3 | LCN1 | P31025 | 130184820 | 130189897 | 176 | Lipocalin 1 |
|  | q34.3 | OBPIIA | Q9NY56 | 130209504 | 130213321 | 170 | Odorant-binding protein 2A |
| AL354761 | q34.3 | PAEP | P09466 | 130225123 | 130230141 | 157 | Progestagen associated endometrial |
|  | q34.3 | Novel | ENSG00000176541 | 130238316 | 130250477 | 104 | Unknown |
| AL158822 | q34.3 | MUPL | Q8WX39 | 130326687 | 130329116 | 172 | Putative MUP-like lipocalin |
|  | q34.3 | Q8NEE3 | Q8NEE3 | 130356772 | 130362893 | 348 | Unknown |
|  | q34.3 | KCNT1 | Q9WX41 | 130365551 | 130455523 | 1151 | Unknown |
| AL353636 | q34.3 | NM_018627 | Q9WX42 | 130472946 | 130570503 | 1298 | Unknown |
| AL355574 | q34.3 | GPDR1 | Q9BSL1 | 130596334 | 130624745 | 405 | Glialblastoma related protein |
|  | q34.3 | NM_144653 | Q96BF6 | 130674721 | 130713948 | 587 | Unknown |
| AL591038 | q34.3 | Novel | ENSG00000180858 | 130715097 | 130738981 | 273 | Unknown |
| AL138781 | q34.3 | Q96GU2 | Q96GU2 | 130777953 | 130782228 | 29 | Unknown |
|  | q34.3 | Q8N3G2 | Q8N3G2 | 130869698 | 130887479 | 541 | Unknown |
|  | q34.3 | LHX3 | Q9UBR4 | 130859621 | 130868480 | 397 | LIM Homeobox gene 3 |
| 30 kb Gap |  |  |  |  |  |  |  |
| AL603784 | q34.3 | AGS3 | Q9UFS8 | 130939617 | 130943166 | 530 | Unknown |
| AL592301 | q34.3 | CARD9 | Q9H257 | 130947895 | 130957602 | 536 | Caspase recruitment protein |
|  | q34.3 | SNAPC4 | Q9Y6P7 | 130959516 | 130982736 | 1469 | Small nuclear RNA activating complex |
|  | q34.3 | SDCCAG3 | 060525 | 130985862 | 130994412 | 192 | Serologically defined colon cancer antigen |
|  | q34.3 | INPP5E | Q10713 | 130994603 | 131007700 | 525 | Mitochondrial processing peptidase subunit |
|  | q34.3 | PPI5PIV | Q9NRR6 | 131012558 | 131023761 | 644 | Phosphatidylinositol (4,5) bisphosphate 5- phophatase |
|  | q34.3 | KIAA0310 | Q96HP1 | 131024036 | 131059908 | 1433 | Unknown |
|  | q34.3 | NM_152571 | Q8N9P6 | 131067482 | 131070005 | 203 | Unknown |
|  | q34.3 | NOTCH1 | P46531 | 131078383 | 131129726 | 2559 | Neurogenic locus NOTCH homologue protein |
| AL590226 | q34.3 | Novel | ENSG00000180360 | 131211094 | 131230721 | 251 | Unknown |
|  | q34.3 | Q9P058 | Q9P058 | 131232664 | 131244366 | 146 | Unknown |
|  | q34.3 | ZNEU1 | Q9UHF1 | 131242795 | 131256617 | 273 | ZNEU1/NEU1 protein |
|  | q34.3 | AGPAT2 | 015120 | 131257082 | 131271362 | 278 | Acylglycerol-phophate-acyltransferase 2 |
|  | q34.3 | NM_152421 | Q8WYU5 | 131296511 | 131307989 | 431 | Unknown |
| AL355987 | q34.3 | NM_032887 | Q96IC0 | 131309173 | 131312123 | 37 | Unknown |
|  | q34.3 | Novel | ENSG00000169672 | 131313093 | 131332422 | 726 | Unknown |
|  | q34.3 | FLJ33328 | Q8NBE9 | 131338327 | 131341477 | 333 | Unknown, has IG_MHC domain |
|  | q34.3 | FLJ10101 | Q96BU21 | 131383198 | 131425126 | 307 | Unknown |
|  | q34.3 | FLJ30985 | Q96NE7 | 131387866 | 131392787 | 197 | Unknown |
|  | q34.3 | Nov-01 | ENSG00000054148 | 131433033 | 131434977 | 186 | Unknown |
|  | q34.3 | Novel | ENSG00000148406 | 131436356 | 131438789 | 350 | Unknown |
|  | q34.3 | Novel | ENSG00000179285 | 131439193 | 131440765 | 264 | Unknown |
|  | q34.3 | Q8NCX7 | Q8NCX7 | 131440944 | 131444739 | 236 | Unknown |
|  | q34.3 | EDF1 | O60869 | 131446058 | 131450225 | 148 | Endothelial differentiation-related factor 1 |
| AL449425 | q34.3 | TRAF2 | TRA2_HUMAN | 131482651 | 131510546 | 501 | TNF receptor associated factor 2 |
| AL807752 | q34.3 | NM_018998 | Q969U6 | 131524374 | 131528545 | 566 | Unknown |
|  | q34.3 | C8G | P07360 | 131529200 | 131530906 | 198 | Complement component 8, gamma subunit |
|  | q34.3 | PTGDS | P41222 | 131561509 | 131565680 | 190 | Prostaglandin D2 synthase |
|  | q34.3 | Novel | ENSG00000176785 | 131567941 | 131570349 | 137 | Unknown |


|  | q34.3 | CLIC3 | 095833 | 131578574 | 131580807 | 207 | Chloride intracellular channel protein 3 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | q34.3 | ABCA2 | Q9BZC7 | 131591173 | 131612250 | 2440 | ATP-binding cassette, subfamily A, member 2 |
|  | q34.3 | Q9BUH6 | Q9BUH6 | 131576357 | 131577915 | 212 | Unknown |
|  | q34.3 | FUT7 | Q11130 | 131614669 | 131615685 | 339 | Fucosyltransferase 7 |
| AL929554 | q34.3 | Q8N224 | Q8N224 | 131618602 | 131619006 | 135 | Unknown |
|  | q34.3 | NPDC1 | Q9NQX5 | 131623413 | 131630157 | 325 | Neuronal proliferation protein 1 |
|  | q34.3 | ENTPD2 | Q9Y5L3 | 131632616 | 131638290 | 494 | Ectonucleoside triphosphate diphosphydrolase 2 |
|  | q34.3 | Q8TEI1 | Q8TEI1 | 131662043 | 131670905 | 270 | Unknown |
|  | q34.3 | Q8WUC7 | Q8WUC7 | 131669250 | 131671114 | 104 | Unknown |
|  | q34.3 | MAN1B1 | Q9UKM7 | 131671245 | 131695076 | 699 | Endoplasmic reticulum mannosidase |
|  | q34.3 | Novel | ENSG00000179395 | 131687948 | 131691411 | 989 | Unknown |
|  | q34.3 | DPP7 | Q9UHL4 | 131696546 | 131699393 | 331 | Dipeptidyl-peptidase |
|  | q34.3 | GRIN1 | Q05586 | 131724505 | 131753424 | 928 | Glutamate receptor subunit zeta 1 |
|  | q34.3 | NM_013366 | Q9UJX6 | 131759296 | 131773049 | 822 | Anaphase-promoting complex subunit 2 |
|  | q34.3 | SSNA1 | O43805 | 131773159 | 131774882 | 119 | Sjorgen's syndrome nuclear autoantigen 1 |
|  | q34.3 | FLJ90254 | Q8NCH2 | 131776627 | 131784420 | 433 | Unknown |
|  | q34.3 | NM_053045 | Q969S6 | 131788473 | 131790029 | 136 | Unknown |
| BX255925 | q34.3 | Unfinished |  |  |  |  |  |
| BX322799 | q34.3 | Unfinished |  |  |  |  |  |
| AL365502 | q34.3 | AD038 | Q96F01 | 132035782 | 132039264 | 205 | AD038 protein, function unknown |
|  | q34.3 | NM_152285 | Q8N5I2 | 132039236 | 132048941 | 433 | Unknown |
|  | q34.3 | MZIP | Q96E35 | 132064147 | 132072376 | 227 | Melanin-concentrating hormone receptor 1 |
|  | q34.3 | NM_138778 | Q9BTV6 | 132075663 | 132096389 | 484 | Unknown |
|  | q34.3 | MRPL41 | NM_032477 | 132098739 | 132099406 | 137 | Mitochondrial ribosomal protein L41 |
|  | q34.3 | NTE-L | Q8TAY5 | 132153193 | 132190541 | 702 | Neuropathy Target Esterase |
|  | q34.3 | FLJ14568 |  | 132192950 | 132200987 | 327 | Unknown |
|  | q34.3 | Q9NTU2 |  | 13295160 | 132200984 | 130 | Unknown |
| AL590627 | q34.3 | Novel | ENSG00000181090 | 132289873 | 132374235 | 436 | Unknown |
| AL611925 | q34.3 | HMT1 | Q9H9B1 | 132395728 | 132553855 | 1247 | Histone methyltransferase |
| AL772363 | q34.3 | CACNA1B | Q00975 | 132562084 | 132806329 | 2357 | Calcium channel voltage-dependent |
| AL591424 | q34.3 | IL9R | ENSG00000165830 | 132821281 | 132832099 | 216 | Interleukin 9 receptor IL 9R |
|  | q34.3 | Novel | ENSG00000159247 | 132859209 | 132861370 | 425 | Tubulin pseudogene |
|  | q34.3 | Novel | ENSG00000179338 | 132868297 | 132868767 | 157 | LINE 1 Reverse Transcriptase Homologue |
| AL954642 | q34.3 | No genes |  |  |  |  |  |

## Appendix 2

Table of results the whole-genome survey. The P-values are coloured according to the level of confidence; black are L0-paralogues, green L1-paralogues, blue L2paralogues and red are L3-paralogues.

| $\frac{\tilde{0}}{\frac{0}{0}}$ |  | $\frac{\tilde{\partial}}{U}$ | ת | $\begin{aligned} & \stackrel{\rightharpoonup}{\square} \\ & \stackrel{\rightharpoonup}{5} \end{aligned}$ | T |  | O |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| III | NOTCH4 | AL390719.31.31331.88824 | 1p36.33 | 708136 | 744003 | AGRN | $1.50 \mathrm{E}-23$ |
| XII | B3GALT4 | AL162741.35.1.111409 | 1p26.33 | 919626 | 921479 | B3GALT6 | $1.40 \mathrm{E}-08$ |
| III | NOTCH4 | AL391244.11.1.67923 | 1p36.33 | 1073552 | 1087162 | NM_030937 | 9.10E-09 |
| III | BAT8 | AL391244.11.1.67923 | 1p36.33 | 1089751 | 1108843 | Novel | 7.60E-12 |
| III | NOTCH4 | AL512413.21.1.101803 | 1p36.32 | 2844459 | 2886399 | EGFL3 | $2.20 \mathrm{E}-42$ |
| XI | BTN1A1 | AL662907.11.1.64693 | 1p35.1 | 3343046 | 33466609 | Q9BVG3 | $1.10 \mathrm{E}-18$ |
| III | NOTCH4 | AL513320.27.1.132592 | 1p36.32 | 3364015 | 3405344 | EGFL3 | $2.00 \mathrm{E}-25$ |
| III | C2 | AL109811.40.1.112769 | 1p36.22 | 10930224 | 10950939 | MASP2 | $1.30 \mathrm{E}-05$ |
| XI | BTN1A1 | AC074003.3.23107.35032 | 1p36.13 | 14652770 | 14656331 | Novel | $4.20 \mathrm{E}-14$ |
| III | C6orf46/ZNF297 | AL034555.2.1.86897 | 1p36.13 | 15447174 | 15481304 | ZNF151 | $2.40 \mathrm{E}-14$ |
| I | DDR1 | AL451042.10.1.88098 | 1p36.13 | 15564788 | 15596501 | EPHA2 | $1.10 \mathrm{E}-17$ |
| XII | KIFC1 | AL663074.13.1.8581 | 1p36.12 | 20071643 | 20079710 | Novel | $2.60 \mathrm{E}-24$ |
| III | NOTCH4 | AL590103.12.1.175162 | 1p36.12 | 21183949 | 21258020 | HSPG2 | $1.10 \mathrm{E}-16$ |
| I | DDR1 | AL035703.21.1.160705 | 1p36.12 | 21925207 | 21965283 | EPHA8 | $1.40 \mathrm{E}-15$ |
| 1 | DDR1 | AL035704.9.1.113956 | 1p36.12 | 22143606 | 22277501 | EPHB2 | $3.10 \mathrm{E}-20$ |
| XII | LYPLA2L | AL031295.1.1.124001 | 1p36.11 | 23188619 | 23193014 | LYPLA2 | $9.00 \mathrm{E}-75$ |
| III | CLIC1 | AL662924.15.1.121762 | 1p35.3 | 24141534 | 24239539 | CLIC4 | $3.80 \mathrm{E}-27$ |
| I | DDR1 | AL031729.16.1.125287 | 1p36.11 | 26912974 | 26924738 | FGR | $3.20 \mathrm{E}-15$ |
| xII | COL11A2 | AC114488.1.90406.184673 | 1p35.2 | 31102432 | 31154233 | COL16A1 | $2.10 \mathrm{E}-11$ |
| XII | ZNF297 | AL033529.25.1.147167 | 1p35.1 | 31870816 | 32006551 | NM_144621 | $1.00 \mathrm{E}-13$ |
| XI | RFP | AL662907.11.1.64693 | 1p35.1 | 32565928 | 32602196 | NM_018207 | 7.60E-46 |
| III | C 2 | AC115285.1.63883.124348 | 1p35.1 | 33035623 | 33094251 | Q96Q03 | $9.80 \mathrm{E}-08$ |
| III | BF | AC115285.1.63883.124348 | 1p35.1 | 33799053 | 33862505 | Q9H4W4 | $9.50 \mathrm{E}-08$ |
| I | POU5F1 | AL139158.11.1.115614 | 1p34.3 | 37518563 | 37519168 | no gene | $4.50 \mathrm{E}-44$ |
| III | HSPA1L | AL354702.7.1.107422 | 1p34.3 | 38182110 | 38184069 | Novel | $4.30 \mathrm{E}-158$ |
| xII | ZNF297 | AL356379.10.1.64960 | 1p34.2 | 40000812 | 40017418 | NM_152373 | 7.80E-09 |
| XI | RFP/MOG/BTNL2 | AL512353.16.1.81704 | 1p34.2 | 42286363 | 42314156 | ERMAP | 6.60E-49 |
| I | DDR1 | AC093420.1.127596.194462 | 1p34.2 | 42767145 | 42789215 | TIE | $4.80 \mathrm{E}-05$ |
| II | BTNL2 | AL109659.20.1.181678 | 1p33 | 47521181 | 181364180 | genscan | $1.10 \mathrm{E}-24$ |
| XI | BTN1A1 | AL109659.20.1.181678 | 1p33 | 48243776 | 48288207 | no gene | $3.40 \mathrm{E}-29$ |
| XI | MOG | AL109659.20.1.181678 | 1p33 | 48253780 | 48253842 | genscan | $4.00 \mathrm{E}-22$ |
| XI | GPX5 | AL356976.30.1.64323 | 1p32.3 | 51957064 | 51963742 | NM_015696 | 8.30E-09 |
| I | TUBB | AL445183.19.1.193774 | 1p32.3 | 53049002 | 53152605 | SCP2 | 8.90E-12 |
| I | DDR1 | AL445205.14.1.115936 | 1p31.3 | 63525514 | 63564266 | EST gene | $3.10 \mathrm{E}-45$ |
| I | DDR1 | AC093427.2.1.131877 | 1p31.3 | 64219769 | 64351748 | JAK1 | $2.50 \mathrm{E}-09$ |
| III | C6orf29 | AC107627.2.1.90513 | 1p31.1 | 74605198 | 75011843 | NM_152697 | 8.70E-49 |
| III | MSH5 | AL445464.9.1.103097 | 1p31.1 | 75197713 | 75313965 | MSH4 | $4.30 \mathrm{E}-05$ |
| III | DDAH2 | AL078459.8.1.83946 | 1p22.3 | 84926028 | 85072691 | DDAH1 | 3.50E-15 |
| xII | COL11A2 | AL356059.27.1.76418 | 1p22.3 | 85351949 | 85791154 | NM_152890 | $1.90 \mathrm{E}-05$ |
| II | BRD2 | AC004798.1.1.42497 | 1p22.1 | 91625907 | 91677611 | BRDT | 6.50E-101 |
|  | C9orf29 | AC093429.2.1.182165 | 1p21.3 | 94491811 | 94566684 | NM_152369 | $1.30 \mathrm{E}-08$ |


| XII COL11A2 | AC093150.2.1.189945 | 1p21.1 | 104172486 | 104410718 | COL11A1 | $4.10 \mathrm{E}-42$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| III NOTCH4 | AL390252.9.1.169241 | 1p13.3 | 108785784 | 108869934 | SORT1 | $6.40 \mathrm{E}-22$ |
| III BAT1 | AL445483.13.1.164008 | 1p13.2 | 112714422 | 112726367 | DDX20 | $3.00 \mathrm{E}-14$ |
| xI MOG/BTN1A1 | AL391476.20.1.171595 | 1p13.1 | 118145476 | 118212809 | NM_024626 | $9.30 \mathrm{E}-05$ |
| III NOTCH4 | AL359752.11.1.137955 | 1p11.2 | 119292037 | 119450143 | NOTCH2 | $2.30 \mathrm{E}-61$ |
| III NOTCH4 | AL592307.24.14836.157830 | 1q21.1 | 141809266 | 141890630 | Novel | $3.20 \mathrm{E}-27$ |
| III NOTCH4 | AC018381.3.23653.71017 | 1q21.1 | 141956297 | 141968135 | Novel | 3.70E-28 |
| xI HIST1H2AC | AL591493.13.1.113370 | 1q21.2 | 145553544 | 145555199 | Histones | $3.30 \mathrm{E}-48$ |
| III BAT8 | AL590133.32.1.192096 | 1q21.3 | 146646159 | 146684482 | SETDB1 | $1.90 \mathrm{E}-12$ |
| xII ZNF297 | AL451085.20.1.182166 | 1 q 22 | 150706074 | 150720422 | ZFP67 | $5.40 \mathrm{E}-14$ |
| POU5F1 | AL139410.20.1.166288 | 1 q 22 | 151143602 | 151144684 | Q9BZW0 | $4.10 \mathrm{E}-105$ |
| III NOTCH4 | AL158169.17.1.99802 | 1q23.1 | 152575891 | 152593889 | INSRR | 6.10E-12 |
| DDR1 | AL158169.17.1.99802 | 1q23.1 | 152595949 | 152616657 | NTRK1 | $1.70 \mathrm{E}-30$ |
| xI HFE | AL138899.23.1.134137 | 1q23.1 | 153882029 | 153886978 | CD1D | $2.50 \mathrm{E}-05$ |
| III NOTCH4 | AL356104.6.1.96693 | 1q23.1 | 154745243 | 154755113 | Q8TEK2 | $4.20 \mathrm{E}-22$ |
| III HSPA1L | AL590385.22.1.110781 | 1q23.3 | 157226591 | 157228843 | HSPA6 | $6.20 \mathrm{E}-263$ |
| III CREBL1 | AL391825.15.1.211662 | 1q23.3 | 157386942 | 157579736 | ATF6 | $4.30 \mathrm{E}-25$ |
| DDR1 | AL445197.4.1.117040 | 1q23.3 | 158253102 | 158401084 | DDR2 | $1.50 \mathrm{E}-131$ |
| III PBX2 | AL357568.14.1.71359 | 1q23.3 | 160179905 | 160302546 | PBX1 | $3.40 \mathrm{E}-88$ |
| POU5F1 | AL136984.20.1.169627 | 1q24.2 | 162840972 | 163036179 | POU2F1 | $5.70 \mathrm{E}-19$ |
| xII RXRB | AL160058.8.1.155369 | 1q23.3 | 163005239 | 163049202 | RXRG | 3.00E-63 |
| xII RPS18 | AL031733.3.1.215861 | 1q24.2 | 163211499 | 163211834 | no gene | 7.20E-14 |
| III BAT2 | AL021579.1.1.99886 | 1 q 24.3 | 167083736 | 167191695 | BAT2-ISO | $1.60 \mathrm{E}-63$ |
| III TNF | Z96050.1.1.85811 | 1q24.3 | 168257203 | 168265061 | TNFSF6 | 5.90E-06 |
| III TNXB | Z94055.1.1.134539 | 1q25.1 | 170720587 | 170804587 | TNR | 6.00E-07 |
| III C6orf46 | AL136170.12.1.127541 | 1q25.1 | 171377563 | 171488882 | NM_032522 | $2.10 \mathrm{E}-33$ |
| DDR1 | AL139132.16.1.157866 | 1q25.2 | 174505391 | 174627374 | ABL2 | $7.90 \mathrm{E}-12$ |
| HLA-A/HLA-E | AL162431.17.1.139006 | 1q25.3 | 176341488 | 176402911 | STX6 | $1.60 \mathrm{E}-20$ |
| xI HLA Class I and II | AL356267.27.1.181808 | 1q25.3 | 176431452 | 176452972 | HLALS | $3.50 \mathrm{E}-31$ |
| III BAT1 | AL049557.19.1.128379 | 1q25.2 | 176601093 | 176723077 | ABL2 | $3.40 \mathrm{E}-10$ |
| III BAT8 | AL138776.10.1.100549 | 1q25.3 | 177972880 | 177984295 | RNASEL | $3.30 \mathrm{E}-05$ |
| XII RAB2L | AL590422.14.1.198210 | 1 q 25.3 | 179033557 | 179326003 | RGL1 | $8.30 \mathrm{E}-17$ |
| xII RING1 | AL109865.36.1.201823 | 1q25.3 | 180442880 | 180499976 | RNF2 | $4.20 \mathrm{E}-50$ |
| DHX16 | AL355999.9.1.76504 | 1q31.1 | 185516454 | 185517347 | genscan | $1.10 \mathrm{E}-07$ |
| XII B3GALT4 | AL390863.9.1.122864 | 1q31.2 | 188662474 | 188670039 | B3GALT2 | $2.20 \mathrm{E}-21$ |
| III NOTCH4 | AL513325.13.1.212888 | 1 q 31.3 | 192695849 | 192906025 | CRB1 | $4.20 \mathrm{E}-52$ |
| III ATP6V1G2 | AL157402.19.1.210331 | 1 q 31.3 | 193950307 | 193968515 | ATP6V1G3 | $2.40 \mathrm{E}-09$ |
| xII RXRB | AC096633.2.1.178152 | 1q32.1 | 195455200 | 195604973 | NR5A2 | $1.50 \mathrm{E}-15$ |
| xII KIFC1 | AL445483.13.1.164008 | 1q32.1 | 195979729 | 196048406 | KIF14 | $7.50 \mathrm{E}-10$ |
| III BAT1 | AL512326.24.1.189269 | 1q32.1 | 198323462 | 198369154 | NM_031306 | $4.00 \mathrm{E}-06$ |
| xII RPS18 | AL606462.5.1.112401 | 1 q 42.13 | 223356887 | 223357135 | genscan | $1.20 \mathrm{E}-40$ |
| xI RFP | AL139288.15.1.151563 | 1q42.13 | 224319970 | 224333114 | TRIM11 | $2.10 \mathrm{E}-64$ |
| xI HIST1H2AC | AL139288.15.1.151563 | 1q42.13 | 224383273 | 224384153 | H2AFL | $4.80 \mathrm{E}-49$ |
| xI $\mathrm{BTN1A1}$ | AL139288.15.1.151563 | 1q42.13 | 224436665 | 224436976 | genscan | $4.50 \mathrm{E}-64$ |
| II $\mathrm{BTNL2}$ | AL139288.15.1.151563 | 1q42.13 | 224436716 | 224436991 | genscan | 3.70E-19 |
| II ${ }^{\text {I }}$ TAP2/1 | AL121990.33.1.147913 | 1q42.13 | 225346509 | 225388622 | ABCB10 | 5.10E-24 |
| III PBX2 | AL359255.12.1.20809 | 1q42.13 | 226893037 | 227045628 | OBSCN | $5.40 \mathrm{E}-11$ |
| xI BTN1A1 | AC026657.4.97959.109520 | 1 q 42.13 | 227053394 | 227055850 | TRIM11 | $1.20 \mathrm{E}-16$ |
| XI XI MOG | AL139288.15.1.151563 | 1q42.13 | 227195475 | 227197055 | Novel | $9.50 \mathrm{E}-16$ |
| xI RFP | AL591686.9.1.150680 | 1 q 43 | 237498626 | 237934567 | NM_152666 | $2.40 \mathrm{E}-11$ |
| III C6orf46/ZNF297 | AL590483.25.118180.187060 | 1 q 44 | 239460483 | 239466676 | ZNF238 | $9.20 \mathrm{E}-16$ |
| III HSPA1L | AL390728.34.1.206255 | 1 q 44 | 242630342 | 242630950 | no gene | 5.80E-218 |
| xI RFP | AC099571.1.86529.165648 | 1q44 | 243256848 | 243277448 | NM_015431 | $1.50 \mathrm{E}-65$ |
| xI $\mathrm{BTN1A1}$ | AC099571.1.86529.165648 | 1q44 | 245957656 | 245974557 | Q9Y4N9 | 3.50E-37 |
|  |  |  |  |  |  |  |
| III NOTCH4 | AC105450.1.1.163782 | 2p25.3 | 1491150 | 1620306 | TP0 | $2.10 \mathrm{E}-07$ |
| xII KIFC1 | AC013449.8.1.120997 | 2q23.3 | 26242053 | 26297524 | KIF3C | 3.30E-37 |


| III | BAT1 | AL121658.4.1.162692 | 2p22.3 | 32334563 | 32390404 | Q96NC3 | 6.30E-05 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| XI | HIST1H2AC/NOTCH4 | AL133244.1.1.200368 | 2p22.3 | 33311500 | 33772726 | LTBP1 | $6.50 \mathrm{E}-18$ |
| III | CYP21A2 | AC009229.5.1.209156 | 2p22.2 | 38259590 | 38268136 | CYP1B1 | $9.30 \mathrm{E}-15$ |
| I | DHX16 | AC092833.4.1.143506 | 2p22.1 | 39171874 | 39237365 | NM_145646 | 5.30E-10 |
| I | DHX16 | AC018693.8.1.164125 | 2p22.1 | 39282730 | 39282825 | no gene | $1.00 \mathrm{E}-09$ |
| XI | NEFAL | AC016722.9.1.149995 | 2p21 | 47297756 | 47311689 | NM_139279 | $3.80 \mathrm{E}-32$ |
| III | MSH5 | AC009600.19.1.215260 | 2p21 | 47798999 | 47879105 | MSH2 | $5.00 \mathrm{E}-09$ |
| XI | UBD | AC079807.5.1.156175 | 2p16.3 | 48126446 | 48126718 | genscan | $5.80 \mathrm{E}-05$ |
| III | MSH5 | AC006509.15.1.124015 | 2p16.3 | 48179027 | 48202837 | MSH6 | 7.80E-08 |
| xII | B3GALT4 | AC093401.4.1.99088 | 2p15 | 62609435 | 62638037 | B3GNT1 | $2.30 \mathrm{E}-13$ |
| I | DHX16 | AC005041.2.1.191356 | 2p13.1 | 74958046 | 74966106 | NM_133637 | $1.30 \mathrm{E}-10$ |
| III | BAT2 | AC068279.6.1.135351 | 2p11.2 | 87959386 | 87959877 | no gene | $3.10 \mathrm{E}-05$ |
| III | BAT2 | AC026106.12.36729.68570 | 2p11.2 | 90750748 | 90751398 | no gene | $6.50 \mathrm{E}-05$ |
| XII | ZNF297 | AC092835.4.1.158404 | 2q-tel | 94264885 | 94283773 | ZNF2 | $3.70 \mathrm{E}-10$ |
| XI | RFP | AC018892.8.1.191055 | 2q11.2 | 96145683 | 96151491 | Novel | $1.60 \mathrm{E}-21$ |
| I | DDR1 | AC016699.10.1.54480 | 2q11.2 | 96793061 | 96808883 | ZAP70 | $3.30 \mathrm{E}-15$ |
| I | POU5F1 | AC018730.7.1.154728 | 2q12.1 | 103925142 | 103926146 | POU3F3 | $2.60 \mathrm{E}-44$ |
| XI | BTN1A1 | AC005040.2.1.189949 | 2q12.3 | 106059831 | 106060295 | genscan | 3.40E-08 |
| XII | ZNF297 | AC013268.5.1.206457 | 2q13 | 109008786 | 109017957 | NM_152518 | $4.40 \mathrm{E}-13$ |
| I | C6ORF18 | AC018737.9.1.206454 | 2q14.3 | 120015449 | 120327116 | CLASP1 | $9.70 \mathrm{E}-06$ |
| XI | RPS18 | AC018737.9.1.206454 | 2q14.3 | 120421203 | 120421337 | no gene | $9.80 \mathrm{E}-10$ |
| I | TUBB | AC018804.9.1.195514 | 2q21.1 | 128250367 | 128259530 | genscan | $3.00 \mathrm{E}-08$ |
| I | TUBB | AC073869.5.1.195280 | 2q21.2 | 129791442 | 129796126 | TUBA2 | $1.80 \mathrm{E}-10$ |
| I | MRPS18B | AC012497.8.1.212104 | 2q22.1 | 138733844 | 138734416 | genscan | $1.20 \mathrm{E}-75$ |
| XI | RXRB | AC074099.6.1.143653 | 2q24.1 | 155709873 | 155718141 | NR4A2 | $1.00 \mathrm{E}-06$ |
| XII | B3GALT4 | AC016723.11.1.202001 | 2q24.3 | 167216857 | 167269041 | B3GALT1 | 8.10E-30 |
| II | TAP2/1 | AC069137.6.1.108836 | 2q24.3 | 168321109 | 168292498 | ABCB11 | $6.90 \mathrm{E}-21$ |
| XI | COL11A2 | AC066694.7.1.120381 | 2q32.2 | 187975163 | 188013419 | COL3A1 | $5.40 \mathrm{E}-32$ |
| III | HSPA1L | AC013409.8.1.195478 | 2q34 | 208662170 | 208666396 | Novel | $1.00 \mathrm{E}-116$ |
| I | TUBB | AC068946.4.1.172260 | 2q35 | 218133730 | 218152718 | TUBA4 | $2.00 \mathrm{E}-10$ |
| I | DDR1 | AC010899.8.1.210232 | 2q36.1 | 221011996 | 221158367 | EPHA4 | $9.20 \mathrm{E}-15$ |
| III | HSPA1L | AC009302.2.1.180970 | 2q36.1 | 221548101 | 221549027 | genscan | $7.00 \mathrm{E}-113$ |
| XI | BTN1A1 | AC104772.3.1.106526 | 2q36.1 | 221566190 | 222241888 | SYFB | $1.40 \mathrm{E}-19$ |
| XI | RFP | AC104772.3.1.106526 | 2q36.1 | 222156619 | 222241888 | SYFB | $4.40 \mathrm{E}-44$ |
| XI | PRSS16 | AC008072.3.1.206177 | 2q36.1 | 223964489 | 223987825 | NM_024785 | $4.20 \mathrm{E}-10$ |
| XI | COL11A2 | AC073869.5.1.195280 | 2q36.3 | 226590998 | 226750349 | COL4A4 | 3.50E-07 |
| XI | COL11A2 | AC097662.4.37779.206758 | 2q36.3 | 226750355 | 226900581 | COL4A3 | 8.90E-12 |
| III | NOTCH4 | AC008273.2.1.151297 | 2q36.3 | 228954450 | 229310970 | NM_139072 | 3.30E-23 |
| XII | B3GALT4 | AC017104.8.1.168880 | 2q37.1 | 230992101 | 230995454 | B3GNT7 | $3.50 \mathrm{E}-15$ |
| III | NOTCH4 | AC005237.2.1.175179 | 2q37.3 | 240214701 | 240251678 | PASK | $2.30 \mathrm{E}-53$ |
| xII | KIFC1 | AC011298.6.31675.58437 | 2q37.3 | 240584194 | 240668241 | ATSV | 3.00E-06 |
|  |  |  |  |  |  |  |  |
| III | BAT8 | AC034191.5.1.172215 | 3p26.1 | 4284929 | 4298795 | SETMAR | $2.00 \mathrm{E}-25$ |
| XII | RXRB | AC090947.1.1.166043 | 3p25.2 | 12270465 | 12415723 | PPARG | 5.30E-09 |
| III | NOTCH4 | AC090509.1.1.165994 | 3p25.1 | 13551690 | 13619799 | FBLN2 | $2.40 \mathrm{E}-09$ |
| xII | RXRB | AC090937.1.1.160696 | 3p25.1 | 15002136 | 15024392 | NR2C2 | 6.60E-09 |
| XI | HMGN4 | AC027125.4.1.173836 | 3p25.1 | 15346179 | 15346391 | no gene | 1.90E-06 |
| III | BAT8 | AC090950.1.1.199282 | 3p25.1 | 15648627 | 15776696 | Y379 | 3.60E-05 |
| III | HSPA1L | AC097635.2.1.162887 | 3p24.3 | 19380503 | 19387078 | Novel | $2.90 \mathrm{E}-102$ |
| XII | ZNF297 | AC006059.3.1.185161 | 3p22.1 | 41880829 | 41889031 | NM_145166 | $1.10 \mathrm{E}-11$ |
| III | C6orf46 | AC099669.2.1.217035 | 3p21.32 | 43776685 | 43804920 | Novel | $4.10 \mathrm{E}-13$ |
| III | C6orf46 | AC124045.1.109944.135528 | 3p21.32 | 43934102 | 43945288 | NM_033210 | 5.10E-12 |
| I | DDR1 | AC104439.2.1.197279 | 3p21.32 | 45363297 | 45363752 | genscan | $7.20 \mathrm{E}-14$ |
| I | DHX16 | AC026318.7.1.19068 | 3p21.31 | 47135873 | 47174627 | DDX30 | $5.00 \mathrm{E}-25$ |
| xII | COL11A2 | AC005903.3.1.60660 | 3p21.31 | 47884518 | 47915700 | COL7A1 | $5.00 \mathrm{E}-11$ |
| III | NOTCH4 | AC005923.2.1.88326 | 3p21.31 | 47956918 | 47983375 | CELSR3 | 3.60E-22 |
| xI | GPX5 | AC121247.1.77964.92674 | 3p21.31 | 48542852 | 48544273 | GPX1 | 2.40E-34 |




| XI SMA3L | AL021368.1.1.188642 | 6p11.2 | 58109978 | 58115773 | Novel(SMA3) | .30E-41 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| III NOTCH4 | AL137007.9.1.105779 | 6 q 12 | 65571522 | 65587322 | Q9H557 | $2.30 \mathrm{E}-24$ |
| xII COL11A2 | AL080275.20.1.113983 | 6q13 | 70892928 | 70979474 | COL9A1 | $8.90 \mathrm{E}-08$ |
| xII LYPLA2L | AL365267.11.1.49616 | 6q13 | 71841661 | 71842056 | no gene | 7.60E-71 |
| III C4B | AL590428.7.1.163577 | 6 q 13 | 74364147 | 74493108 | NM_133493 | 4.10E-08 |
| XII RPS18 | AL355796.11.1.152086 | 6q14.1 | 79954508 | 79954717 | no gene | $1.60 \mathrm{E}-22$ |
| DDR1 | AL354857.13.1.199223 | 6 q 16.1 | 93918505 | 94095966 | EPHA7 | $1.20 \mathrm{E}-14$ |
| POU5F1 | AL022395.2.1.126882 | 6 q 16.2 | 99299451 | 99300710 | POU3F2 | $8.00 \mathrm{E}-43$ |
| xII HSD17B8 | AL591803.10.1.90325 | 6 q 16.2 | 99639262 | 99640282 | Novel | $1.90 \mathrm{E}-20$ |
| XII RXRB | AL078596.8.1.64183 | 6q21 | 108510126 | 108532877 | NR2E1 | $2.00 \mathrm{E}-21$ |
| XII ZNF297 | AL109947.19.1.128960 | 6q21 | 109806583 | 109827304 | Y441 | 3.50E-12 |
| DDR1 | Z97989.1.1.155937 | 6 q 21 | 112005349 | 112217491 | FYN | $2.00 \mathrm{E}-11$ |
| DDR1 | AL357141.8.1.125184 | 6q22.1 | 116285557 | 115404785 | FRK | $9.00 \mathrm{E}-20$ |
| xII COL11A2 | AL121963.10.1.107553 | 6 q 22.1 | 116462985 | 116470164 | COL10A1 | $4.00 \mathrm{E}-23$ |
| DDR1 | Z98880.1.1.108260 | 6 q 22.1 | 117632394 | 117769882 | ROS1 | $2.60 \mathrm{E}-14$ |
| XII RPS18 | AL357084.12.1.76042 | 6q24.1 | 141090774 | 141091166 | genscan | $1.60 \mathrm{E}-48$ |
| TUBB | AL031320.6.1.133574 | 6q24.2 | 143380844 | 143380963 | genscan | $1.10 \mathrm{E}-51$ |
| XII RPS18 | AL078581.11.1.102019 | 6q25.1 | 149763293 | 149791539 | KATNA1 | 8.40E-51 |
| III HSPA1L | AL590413.18.1.104939 | 6q25.1 | 151621254 | 151668524 | NM_017909 | 1.70E-16 |
| xI MAS1L | AL035691.17.1.129968 | 6q25.3 | 160201536 | 160202670 | MAS1 | 3.10E-36 |
| XII KIFC1 | AL589733.20.1.201088 | 6 q 27 | 168140261 | 168167477 | KIF25 | $4.00 \mathrm{E}-07$ |
| III NOTCH4 | AL078605.30.1.119563 | 6 q 27 | 170231439 | 170329846 | NM_032448 | 3.70E-41 |
|  |  |  |  |  |  |  |
| III CYP21A2 | AC073957.7.1.196204 | 7p22.3 | 667370 | 673509 | NM_017781 | 2.60E-09 |
| III BAT8 | AC005995.3.1.80010 | 7p22.1 | 5716846 | 5720381 | Novel | 3.80E-07 |
| III C6orf46 | AC073343.6.1.173967 | 7p22.1 | 6374466 | 6390938 | Z325 | 3.10E-14 |
| III C4B | AC060834.8.1.113686 | 7p21.3 | 9410581 | 9410991 | genscan | $4.50 \mathrm{E}-06$ |
| III HSPA1L | AC009945.2.1.75517 | 7p21.3 | 10135315 | 10136415 | genscan | $2.30 \mathrm{E}-231$ |
| III NOTCH4 | AC013470.10.1.170723 | 7p21.3 | 12014883 | 12054396 | Q96SQ3 | $1.00 \mathrm{E}-08$ |
| II TAP2/1 | AC002486.1.1.79611 | 7p21.1 | 20327136 | 20342642 | O 14573 | $6.30 \mathrm{E}-24$ |
| II TAP2/1 | AC005060.3.1.120169 | 7p21.1 | 20365471 | 20439590 | Novel | $1.80 \mathrm{E}-20$ |
| POU5F1 | AC005483.1.1.161667 | 7p14.1 | 39025428 | 39150485 | NM_007252 | $1.80 \mathrm{E}-11$ |
| xI HIST1H2AC | AC004854.3.1.98697 | 7p13 | 44512586 | 44533943 | H2-like | $7.00 \mathrm{E}-15$ |
| xI POM121L2 | AC074397.7.1.114576 | 7 p 12.1 | 52567227 | 52568144 | Q8N7R1 | 8.00E-26 |
| III C6orf26 | AC073057.6.1.178105 | 7p11.2 | 56890588 | 56890821 | genscan | 5.90E-05 |
| xII ZNF297 | AC115220.1.1.115916 | 7q11.21 | 62137099 | 62202401 | Novel | 7.80E-08 |
| xI SMA3L | AC115220.1.1.115916 | 7 q 11.21 | 62213350 | 62213517 | genscan | $6.70 \mathrm{E}-11$ |
| XII ZNF297 | AC092685.2.1.183263 | 7q11.21 | 63492669 | 63505908 | NM_152626 | $1.30 \mathrm{E}-10$ |
| xI SMA3L | AC073261.8.1.93403 | 7q11.21 | 64065461 | 64086982 | GUSB | 1.00E-24 |
| III BAT2 | AC073089.5.1.171788 | 7q11.21 | 65101611 | 65344287 | NM_018264 | 3.10E-24 |
| III BAT2 | AC091738.4.1.131928 | 7q11.23 | 70715527 | 70834138 | Novel | 2.00E-22 |
| xI POM121L2 | AC005488.2.1.185737 | 7q11.23 | 70990215 | 71062258 | POM121 | 5.30E-92 |
| XI POM121L2 | AC073841.9.1.55588 | 7q11.23 | 71351007 | 71352683 | EST gene | 2.90E-72 |
| xI RFP | AC073841.9.1.55588 | 7q11.23 | 71357485 | 71363082 | WBSCR20A | 8.90E-39 |
| xI POM121L2 | AC006014.3.1.127761 | 7q11.23 | 73578273 | 73650919 | POM121 | 7.40E-71 |
| II TAP2/1 | AC005045.2.1.123947 | 7q21.12 | 85566663 | 85640217 | ABCB4 | 8.00E-22 |
| II TAP2/1 | AC005068.2.1.98472 | 7 q 21.12 | 85668428 | 85877856 | ABCB1 | $4.90 \mathrm{E}-25$ |
| xII COL11A2 | AC002528.1.1.141120 | 7q21.3 | 92559772 | 92595972 | COL1A2 | 8.10E-24 |
| III HSPA1L | AC004957.1.1.160687 | 7q21.3 | 95968910 | 95969113 | no gene | 3.30E-93 |
| xI BTN1A1/RFP | AC011904.3.1.113879 | 7q22.1 | 98022613 | 98051761 | TRIM4 | $2.30 \mathrm{E}-19$ |
| XI HLA Class I | AC004522.2.1.100096 | 7q22.1 | 98099206 | 98108247 | AZGP1 | $1.10 \mathrm{E}-24$ |
| DDR1 | AC011895.4.1.172358 | 7 q 22.1 | 98934759 | 98959566 | EPHB4 | $8.80 \mathrm{E}-21$ |
| I HLA-E | AC006329.5.1.145253 | 7q22.1 | 99414126 | 99414392 | genscan | $1.10 \mathrm{E}-05$ |
| DDR1 | AC004416.1.1.32173 | 7 q 31.2 | 114790113 | 114916094 | MET | $1.20 \mathrm{E}-13$ |
| xII LYPLA2L | AC073054.2.1.154419 | 7q21.32 | 121348077 | 121348109 | genscan | $1.20 \mathrm{E}-37$ |
| III VARS2 | AC008038.1.1.202945 | 7 q 33 | 131061808 | 131063239 | Novel | $1.00 \mathrm{E}-11$ |
| I TUBB | AC083874.2.1.186281 | 7 q 33 | 132762314 | 132762403 | genscan | $4.00 \mathrm{E}-09$ |



| III BAT2 | AL354877.25.1.116236 | 9 q 31.3 | 106181071 | 106289393 | NM_173521 | $3.30 \mathrm{E}-17$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| xII ZNF297 | AL162588.22.1.76606 | 9 q 31.3 | 107536344 | 107551166 | ZFP37 | $7.80 \mathrm{E}-09$ |
| III NOTCH4 | AL162425.15.1.177728 | 9 q 31.3 | 108581009 | 108678635 | Novel | 6.30E-28 |
| xII COL11A2 | AL445543.20.1.140327 | 9 q 31.3 | 108662161 | 108805998 | Q96JF7 | $2.60 \mathrm{E}-13$ |
| III ATP6V1G2 | AL160275.14.1.189709 | 9 q 32 | 109082196 | 109092823 | ATP6V1G1 | $1.50 \mathrm{E}-12$ |
| III TNF | AL390240.18.1.93876 | 9 q 32 | 109283763 | 109300763 | TNFSF15 | 3.80E-10 |
| III TNXB | AL162425.15.1.177728 | $9 \mathrm{q33.1}$ | 109514975 | 109612609 | TNC | $7.80 \mathrm{E}-25$ |
| TUBB | AL589703.6.1.48697 | 9 q 33.1 | 112631091 | 112631204 | genscan | $1.60 \mathrm{E}-10$ |
| xII B3GALT4 | AL161911.17.1.109176 | 9 q 33.2 | 115207621 | 115207998 | genscan | $6.40 \mathrm{E}-31$ |
| III C4B | AC006430.22.1.194799 | 9 q 33.2 | 115361172 | 115459110 | C5 | $5.70 \mathrm{E}-20$ |
| III C6orf46 | AC007066.4.1.190815 | 9 q 33.2 | 117340094 | 117340094 | BIOR | $9.80 \mathrm{E}-65$ |
| III NOTCH4 | AL445489.10.1.175869 | 9 q 33.3 | 117788495 | 118338969 | NM_024820 | $2.20 \mathrm{E}-76$ |
| xII RXRB | AL354979.17.1.85997 | 9 q 33.3 | 118928956 | 119180139 | NR6A1 | $9.70 \mathrm{E}-13$ |
| III HSPA1L | AL354710.17.1.131708 | 9 q 33.3 | 119643682 | 119650159 | HSPA5 | 8.1E-161 |
| III PBX2 | AL445186.4.1.156124 | 9 q 33.3 | 120156161 | 120376205 | PBX3 | $9.10 \mathrm{E}-85$ |
| III C6orf46/ZNF297 | AL161731.20.1.182452 | 9 q 33.3 | 121213845 | 121244041 | ZNF297B | $7.30 \mathrm{E}-33$ |
| xII C6orf46/ZNF297 | AL354944.22.1.49144 | 9 q 33.3 | 121269484 | 121289729 | Q8NCN2 | $9.50 \mathrm{E}-39$ |
| DDR1 | AL161733.20.1.176466 | 9 q 34.12 | 125136236 | 125309589 | ABL1 | $8.50 \mathrm{E}-12$ |
| III AIF1 | AL157938.22.1.197019 | 9 q 34.12 | 125518441 | 125545061 | NM_031426 | $1.20 \mathrm{E}-56$ |
| III BAT2 | AL358781.19.1.147492 | 9 q 34.13 | 125852061 | 125869120 | NM_032640 | 2.20E-65 |
| xII RAB2L | AL162417.23.1.152863 | 9 q 34.2 | 127529965 | 127553410 | RALGDS | $3.70 \mathrm{E}-29$ |
| II $\operatorname{BRD2}$ | AL445931.29.1.175033 | 9 q 34.2 | 128566862 | 128602533 | BRD3 | $1.90 \mathrm{E}-133$ |
| xII RXRB | AL669970.6.1.58552 | 9 q 34.2 | 129062693 | 129101647 | RXRA | 6.30E-88 |
| XII COL11A2 | AL603650.10.1.131466 | 9 q 34.3 | 129302868 | 129503955 | COL5A1 | $2.10 \mathrm{E}-43$ |
| III NOTCH4 | AL390778.30.1.221373 | 9 q 34.3 | 129736484 | 129782241 | OLFM1 | $4.60 \mathrm{E}-11$ |
| III NOTCH4 | AL353615.27.1.37093 | 9 q 34.3 | 130006614 | 130009927 | NM_173520 | 6.00E-10 |
| XII ZNF297 | AL591038.9.1.51295 | 9 q 34.3 | 130674721 | 130713948 | NM_144653 | $7.90 \mathrm{E}-15$ |
| III NOTCH4 | AL592301.14.1.188462 | 9 q 34.3 | 131078383 | 131129726 | NOTCH1 | $2.40 \mathrm{E}-224$ |
| III EGFL8 | AL590226.23.1.149567 | 9 q 34.3 | 131242795 | 131256617 | ZNEU1 | $9.70 \mathrm{E}-12$ |
| III AGPAT1 | AL590226.23.1.149567 | 9 q 34.3 | 131257082 | 131271362 | AGPAT2 | $2.50 \mathrm{E}-29$ |
| III CLIC1 | AC068451.2.53215.58850 | 9 q 34.3 | 131578574 | 131580507 | CLIC3 | $3.30 \mathrm{E}-35$ |
| III BAT8 | AL611925.20.31668.168509 | 9 q 34.3 | 132395728 | 132553855 | HMT1 | 7.30E-142 |
|  |  |  |  |  |  |  |
| TUBB | AL713922.8.1.121218 | 10p15.3 | 33000 | 35178 | TUBBL | 2.70E-190 |
| III NOTCH4 | AL513304.27.1.163243 | 10p15.3 | 1427949 | 1428792 | no gene | $3.20 \mathrm{E}-06$ |
| xII KIFC1 | AL161932.15.1.143423 | 10p11.22 | 3016668 | 32061904 | KIF5B | $1.00 \mathrm{E}-06$ |
| III HSPA1L | AC069544.9.1.214866 | 10p13 | 14843884 | 14877306 | NM_016299 | $1.00 \mathrm{E}-15$ |
| III BAT8 | AC069544.9.1.214866 | 10p13 | 14884428 | 14909880 | SU92 | $1.40 \mathrm{E}-17$ |
| III NOTCH4 | AL133415.12.1.179912 | 10p13 | 17152297 | 17207242 | DNMT2 | $1.10 \mathrm{E}-15$ |
| xII HKE4 | AL590111.14.1.41069 | 10p12.33 | 17957452 | 18048843 | NM_152725 | $7.10 \mathrm{E}-08$ |
| xII RPS18 | AL513128.11.1.184685 | 10p12.2 | 22534350 | 22534484 | no gene | $1.20 \mathrm{E}-05$ |
| XII ZNF297 | AL117337.25.1.161452 | 10q11.21 | 37982417 | 38009185 | ZNF25 | $1.00 \mathrm{E}-07$ |
| xII ZNF297 | AL161931.13.1.19853 | 10q11.21 | 38043229 | 38099906 | ZNF33A | $1.30 \mathrm{E}-10$ |
| XII ZNF297 | AL022345.2.1.146328 | 10q11.21 | 42553027 | 42602464 | ZNF11B | $1.30 \mathrm{E}-10$ |
| III C6orf46 | AL353801.13.1.222490 | 10q11.21 | 44964852 | 44969243 | ZNF22 | $4.10 \mathrm{E}-14$ |
| III BAT8 | AL359377.18.1.172177 | 10q21.2 | 60813515 | 61174843 | ANK3 | $6.70 \mathrm{E}-05$ |
| POU5F1 | AL356741.11.1.87244 | 10q21.3 | 68768389 | 68953381 | Q9HCH9 | $1.40 \mathrm{E}-75$ |
| III BAT1 | AL359844.15.1.171364 | 10q22.1 | 69527140 | 69554693 | DDX21 | $1.20 \mathrm{E}-05$ |
| III BAT1 | AC016394.13.1.149726 | 10q22.2 | 73713068 | 73782589 | Q9Y2I0 | $1.90 \mathrm{E}-10$ |
| xI HIST1H2AC | AL391421.27.1.168239 | 10q22.3 | 78922958 | 78923248 | no gene | $1.00 \mathrm{E}-14$ |
| III BAT1 | AL365434.12.1.158357 | 10q23.31 | 91694792 | 91695643 | Genscan | $7.30 \mathrm{E}-17$ |
| III BAT1 | AL731553.9.1.161141 | 10q23.31 | 91759982 | 91760050 | Genscan | $7.40 \mathrm{E}-17$ |
| III BAT1 | AL158040.13.1.213648 | 10q23.32 | 92777959 | 92779325 | Novel | $1.50 \mathrm{E}-24$ |
| XII KIFC1 | AL356128.27.1.191935 | 10q23.33 | 93574641 | 93636806 | KIF11 | $1.50 \mathrm{E}-11$ |
| III CYP21A2 | AL359672.19.1.143181 | 10q23.33 | 95689793 | 95722511 | CYP2C8 | 3.20E-05 |
| III NOTCH4 | AL442123.12.1.96660 | 10q24.1 | 97651046 | 97838934 | SLIT1 | 6.90E-33 |
| XII ZNF297 | AL135791.12.1.66975 | 10q24.1 | 97820294 | 3785029 | Q9NQN2 | 7.80E-09 |


| II | TAP2 | AL392107.16.1.94970 | 10q24.2 | 100776166 | 100845227 | ABCC2 | 7.70E-05 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| III | CYP21A2 | AL358790.22.1.131753 | 10q24.32 | 103483494 | 103490378 | CYP17 | $4.20 \mathrm{E}-12$ |
| XI | RFP | AL391121.29.1.166600 | 10q24.32 | 103638012 | 103651712 | TRIM8 | $1.90 \mathrm{E}-07$ |
| I | DHX16 | AL360176.22.1.155699 | 10q26.2 | 126728551 | 126773529 | DDX32 | $1.10 \mathrm{E}-21$ |
| III | CYP21A2 | AL161645.14.1.161644 | 10q26.3 | 134255131 | 134266884 | CYP2E | $2.00 \mathrm{E}-07$ |
| XI | MAS1L | AC108448.5.135208.198047 | 11p15.4 | 3499638 | 3500522 | Novel | 5.70E-29 |
| XI | RFP/RING1 | AC009758.8.1.141485 | 11p15.4 | 4708183 | 4716972 | SSA1 | $9.40 \mathrm{E}-71$ |
| xI | RFP | AC090719.8.1.179177 | 11p15.4 | 4921932 | 4931481 | NM_018073 | 6.50E-72 |
| XI | BTN1A1 | AC009758.8.1.141485 | 11p15.4 | 4972222 | 4981011 | SSA1 | 6.10E-38 |
| XI | BTN1A1 | AC090719.8.1.179177 | 11p15.4 | 5185974 | 5195520 | Novel | $1.40 \mathrm{E}-35$ |
| XI | RFP | AC015691.6.1.203036 | 11p15.4 | 5919434 | 5967728 | TRIM6 | $1.30 \mathrm{E}-45$ |
| XI | RFP | AC109341.7.1.202761 | 11p15.4 | 5986894 | 6008393 | TRIM5 | $9.10 \mathrm{E}-44$ |
| XI | BTN1A1 | AC015691.6.1.203036 | 11p15.4 | 6372568 | 6413722 | TRIM34 | $1.70 \mathrm{E}-16$ |
| XI | BTN1A1 | AC109341.7.1.202761 | 11p15.4 | 6459104 | 6478807 | TRIM22 | $1.70 \mathrm{E}-16$ |
| III | CYP21A2 | AC018795.10.1.187836 | 11p15.2 | 15932556 | 15932621 | no gene | $2.90 \mathrm{E}-18$ |
| III | CYP21A2 | AC090835.6.82428.167443 | 11p15.2 | 16080713 | 16094757 | Novel | 3.10E-19 |
| XI | MAS1L | AC090099.10.28570.173306 | 11p15.1 | 19101039 | 19102007 | MRGX3 | $1.70 \mathrm{E}-39$ |
| XI | MAS1L | AC107948.7.1.156839 | 11p15.1 | 19137100 | 19138068 | MRGX4 | 3.30E-38 |
| xI | MAS1L | AC023078.9.1.163718 | 11p15.1 | 19899153 | 19900121 | MRGX1 | $2.00 \mathrm{E}-40$ |
| XI | MAS1L | AC023078.9.1.163718 | 11p15.1 | 19926836 | 19991360 | Novel | $2.40 \mathrm{E}-17$ |
| XI | MAS1L | AC027026.9.1.155376 | 11p15.1 | 20020747 | 20021739 | MRGX2 | $1.10 \mathrm{E}-35$ |
| xII | KIFC1 | AC023206.6.1.208561 | 11p14.1 | 28817128 | 28904683 | NM_031217 | $5.40 \mathrm{E}-07$ |
| III | BF | AL354921.12.1.106657 | 11p13 | 37005965 | 37099743 | Q96JW2 | $2.60 \mathrm{E}-06$ |
| III | NOTCH4 | AC061999.6.1.182549 | 11p12 | 37290819 | 37297112 | RAG2 | 3.90E-26 |
| XII | RXRB | AC090589.8.1.190017 | 11p11.2 | 48157255 | 48168103 | NR1H3 | $1.40 \mathrm{E}-06$ |
| XII | RXRB | AC018410.19.7721.155276 | 11p11.2 | 48168666 | 48229300 | MADD | $1.10 \mathrm{E}-06$ |
| xII | HKE4 | AC090559.5.26090.106816 | 11p11.2 | 48306544 | 48315768 | NM_152264 | 8.60E-14 |
| XII | RXRB | AP001453.4.1.166300 | 11q13.1 | 65754594 | 65765769 | ESRRA | $9.70 \mathrm{E}-18$ |
| III | NOTCH4 | AP000769.4.1.114794 | 11q13.1 | 66974259 | 66987851 | SCYL1 | $1.20 \mathrm{E}-19$ |
| III | NOTCH4 | AP001362.5.1.211382 | 11q13.1 | 67025483 | 67041797 | Novel | $1.70 \mathrm{E}-22$ |
| xI | MAS1L | AP000808.4.1.176380 | 11q13.3 | 70444307 | 70445269 | Q8TDS7 | $7.50 \mathrm{E}-35$ |
| XI | MAS1L | AP003071.2.1.192759 | 11q13.3 | 70468658 | 70477508 | MRGF | $4.00 \mathrm{E}-27$ |
| XI | HIST1H2AC | AP002336.3.1.112484 | 11q13.3 | 71639671 | 71753357 | PPFIA1 | $4.50 \mathrm{E}-14$ |
| III | NOTCH4 | AP000867.4.1.199996 | 11q13.4 | 72870983 | 72871905 | Q8NH65 | 3.20E-07 |
| I | C6ORF18 | AP000719.4.1.196424 | 11q13.4 | 73253747 | 73331398 | NUMA1 | $1.90 \mathrm{E}-06$ |
| XII | B3GALT4 | AP000752.4.1.194140 | 11q13.5 | 78289628 | 78290785 | NM_138706 | 5.70E-25 |
| III | NOTCH4 | AP002768.3.1.186084 | 11q14.1 | 79903349 | 79952134 | Q9P2P4 | $1.50 \mathrm{E}-09$ |
| XI | PRSS16 | AP001646.4.1.182328 | 11q14.1 | 84074231 | 84150294 | PRCP | 4.10E-06 |
| III | BAT1 | AP003390.1.1.221091 | 11q23.3 | 91694792 | 91695643 | Genscan | 2.10E-106 |
| I | TUBB | AP002364.3.1.165702 | 11q14.3 | 92344989 | 92345090 | genscan | $1.50 \mathrm{E}-11$ |
| I | TUBB | AP002799.3.1.177564 | 11q14.3 | 94012104 | 94012214 | genscan | $2.30 \mathrm{E}-14$ |
| III | NOTCH4 | AP003171.2.1.137000 | 11q14.3 | 94081540 | 94134035 | Q8TDW7 | $2.90 \mathrm{E}-10$ |
| III | BAT8 | AP000786.4.1.75440 | 11q21 | 95734866 | 95740452 | NM_017704 | 7.20E-06 |
| III | BAT8 | AP002840.2.1.177034 | 11q23.2 | 114770675 | 114783056 | Q98NFD2 | $3.30 \mathrm{E}-15$ |
| III | NOTCH4 | AP002840.2.1.177034 | 11q23.1 | 114792387 | 114857963 | DRD2 | 2.10E-10 |
| III | BAT8 | AP001267.4.1.194310 | $11 q 23.3$ | 119819041 | 119907224 | MLL | $2.50 \mathrm{E}-05$ |
| XI | HIST1H2AC | AP003391.1.1.46239 | 11q23.3 | 120476378 | 120477968 | H2AFX | $2.80 \mathrm{E}-42$ |
| III | BAT1 | AP000713.2.1.11316 | 11q23.3 | 120964857 | 120979716 | DDX6 | $1.20 \mathrm{E}-06$ |
| I | POU5F1 | AP001150.4.1.157282 | 11q23.3 | 121622699 | 121702405 | POU2F3 | $6.50 \mathrm{E}-21$ |
| III | BAT1 | AP001994.4.1.167376 | 11q23.3 | 121762568 | 121762732 | No gene | $1.50 \mathrm{E}-105$ |
| III | HSPA1L | AP000926.5.1.196973 | 11q24.1 | 124441468 | 124446116 | HSPA8 | $9.10 \mathrm{E}-243$ |
| III | BAT1 | AP000842.4.1.179369 | 11q24.2 | 127774844 | 147793446 | DDX25 | $1.80 \mathrm{E}-10$ |
| III | C6orf46/ZNF297 | AP001183.4.1.174526 | 11q24.3 | 131612944 | 131697119 | NM_014155 | $7.80 \mathrm{E}-15$ |
| III | BAT1 | AC019227.4.1.190314 | 11q24.3 | 132166105 | 132166485 | Genscan | $1.50 \mathrm{E}-13$ |
| I | PPP1R10 | AP000824.4.1.186920 | 11q24.3 | 132172516 | 132173124 | genscan | 7.20E-17 |
| I | PPP1R10 | AP003486.2.1.217488 | 11q24.3 | 132258421 | 132299008 | SNXJ | $9.60 \mathrm{E}-17$ |


| III BAT1 | AP000435.5.1.124067 | 11q12.1 | 60403473 | 60403808 | Genscan | 3.00E-12 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| III HSPA1L | AC007207.22.1.191877 | 12p13.32 | 4100374 | 4101084 | genscan | 1.80E-215 |
| xII TAPBP | AC005840.2.1.140026 | 12p13.31 | 6535709 | 6550143 | TAPBP-R | $3.30 \mathrm{E}-05$ |
| III BF | AC006512.12.1.157115 | 12p13.31 | 7087044 | 7087106 | no gene | $3.10 \mathrm{E}-06$ |
| III C2 | AC006512.12.1.157115 | 12p13.31 | 7243215 | 7245179 | C10 | 6.10E-09 |
| III C4B | AC006581.16.1.172931 | 12p13.31 | 8712438 | 8724661 | Novel | $2.80 \mathrm{E}-05$ |
| III C4B | AC007436.1.1.163881 | 12p13.31 | 8928367 | 8976544 | A2M | 3.20E-09 |
| III C4B | AC010175.4.1.127277 | 12p13.31 | 9009493 | 9069023 | PZP | $6.20 \mathrm{E}-09$ |
| III BAT1 | AC007215.43.2235.65215 | 12p13.2 | 12695938 | 12712573 | NM_016355 | $1.60 \mathrm{E}-11$ |
| xI HIST1H2AC | AC010168.6.1.104926 | 12p12.3 | 15072102 | 15073039 | H2AFJ | $1.10 \mathrm{E}-44$ |
| xII COL11A2 | AC004801.1.1.193561 | 12q13.11 | 48379436 | 48410949 | COL2A1 | $2.80 \mathrm{E}-38$ |
| III BAT1 | AC025557.4.146238.171945 | 12q13.13 | 49116936 | 49138712 | NM_004818 | $1.10 \mathrm{E}-14$ |
| TUBB | AC011603.33.10243.45426 | 12q13.12 | 49484144 | 49487748 | TUBA1 | $9.00 \mathrm{E}-11$ |
| TUBB | AC010173.22.67252.90665 | 12q13.12 | 49586964 | 49595224 | TUBA6 | $2.20 \mathrm{E}-12$ |
| TUBB | AC010173.22.160578.20759 | 12q13.12 | 49655804 | 49660085 | TUBA1 | $1.00 \mathrm{E}-11$ |
| xII RXRB | AC025259.48.1.210158 | 12q13.13 | 52474503 | 52482549 | NR4A1 | $1.10 \mathrm{E}-07$ |
| III BAT1 | AC055716.24.1.110819 | 12q13.13 | 53260460 | 53260801 | Genscan | $5.40 \mathrm{E}-27$ |
| III BAT1 | AC068988.19.27848.161382 | 12q13.13 | 53292388 | 53292489 | Genscan | $7.70 \mathrm{E}-27$ |
| III BAT1 | AC073573.27.1.157807 | 12q13.13 | 53706088 | 53706432 | Genscan | $4.30 \mathrm{E}-35$ |
| III BAT8 | AC073896.29.107190.140910 | 12q13.2 | 56645899 | 56649310 | NM_173594 | $2.30 \mathrm{E}-05$ |
| XII ZNF297 | AC026120.33.1.171998 | 12q13.3 | 57617302 | 57624914 | Y352 | $1.10 \mathrm{E}-11$ |
| III BAT1 | AC117498.1.134066.149599 | 12q14.1 | 61110934 | 61180767 | Novel | $1.50 \mathrm{E}-15$ |
| XI NOL5B | AC027288.26.1.177080 | 12q12.2 | 80316560 | 80316925 | genscan | 6.20E-24 |
| xI BTN1A1 | AC009771.13.122068.178104 | 12q23.3 | 107466485 | 107466640 | no gene | $2.10 \mathrm{E}-30$ |
| xI MAS1L | AC063957.22.1.71430 | 12q23.3 | 108566149 | 108613888 | CMKLR1 | $8.80 \mathrm{E}-05$ |
| III HSPA1L | AC005805.9.96579.142875 | 12q24.11 | 111438197 | 111439237 | Novel | 1.20E-134 |
| III CLIC1 | AC078875.25.5011.18452 | 12q24.31 | 120214564 | 120215259 | Novel | $1.60 \mathrm{E}-14$ |
| xII B3GALT4 | AC048338.22.82693.113969 | 12q24.31 | 122667939 | 122671768 | B3GNT4 | $2.10 \mathrm{E}-23$ |
| II ${ }^{\text {TAP2/1 }}$ | AC026362.34.74237.162900 | 12q24.31 | 123114813 | 123152304 | ABCB9 | $5.50 \mathrm{E}-45$ |
| DHX16 | AC093719.6.127047.199959 | 12q24.31 | 125177591 | 125220663 | DDX37 | $8.20 \mathrm{E}-17$ |
| XII ZNF297 | AC026786.5.1.160615 | 12q24.33 | 133310141 | 133338979 | ZNF10 | 6.10E-10 |
| xII RXRB | AL359457.12.1.129779 | 13q12.11 | 14106712 | 14124427 | ESRRAP | $3.40 \mathrm{E}-27$ |
| xII RXRB | AL158032.32.1.172004 | 13q12.11 | 15813801 | 15815722 | Novel | $4.50 \mathrm{E}-27$ |
| TUBB | AL139327.18.1.149559 | 13q12.11 | 17727916 | 17735936 | TUBA2 | $1.10 \mathrm{E}-09$ |
| III BAT1 | AL354828.12.1.168114 | 13q12.12 | 21259290 | 21260180 | Genscan | 1.10E-111 |
| DDR1 | AL591024.14.1.76721 | 13q12.2 | 22557753 | 22654705 | FLT3 | $9.00 \mathrm{E}-05$ |
| xI POM121L2 | AL359741.9.1.139877 | 13q12.3 | 23332361 | 23332804 | genscan | 1.20E-19 |
| xI POM121L2 | AL596092.8.1.153841 | 13q12.3 | 23579447 | 24059956 | O94872 | $2.70 \mathrm{E}-15$ |
| III HSPA1L | AL137142.20.1.113850 | 13q12.3 | 25697387 | 25722697 | H105 | $8.20 \mathrm{E}-22$ |
| III BAT1 | AL138822.13.1.126502 | 13q12.3 | 27152990 | 27154150 | Genscan | $1.50 \mathrm{E}-50$ |
| xI HIST1H2AC | AL159980.14.1.162044 | 13q13.3 | 31050674 | 31050910 | genscan | $5.60 \mathrm{E}-20$ |
| III BAT1 | AL138706.9.1.195032 | 13q13.3 | 35499252 | 35499851 | Genscan | $1.40 \mathrm{E}-45$ |
| III BAT8 | AL136218.26.1.159863 | 13q14.2 | 44005950 | 44053746 | C13ORF4 | 3.20E-06 |
| xII RXRB | AL138997.18.1.172342 | 13q21.1 | 50568900 | 50569076 | genscan | 5.20E-14 |
| III BAT1 | AL161901.18.1.150054 | 13q21.2 | 59178906 | 59179631 | Genscan | $1.90 \mathrm{E}-31$ |
| xI RFP | AL136145.23.1.83809 | 13q21.32 | 60838247 | 60838498 | genscan | $9.90 \mathrm{E}-09$ |
| DHX16 | AC001226.1.1.106988 | 13q22.3 | 71554239 | 71557564 | Novel | $4.40 \mathrm{E}-10$ |
| POU5F1 | AL445209.4.1.157302 | 13q31.1 | 73168139 | 73172615 | POU4F1 | $7.40 \mathrm{E}-28$ |
| II $\mathrm{TAP2/1}$ | AL157818.12.1.182485 | 13q32.1 | 90059271 | 90340865 | ABCC4 | $7.60 \mathrm{E}-05$ |
| xI HIST1H2AC | AL160155.19.1.149478 | 13q32.3 | 94254802 | 94255185 | H2A-like | $1.60 \mathrm{E}-11$ |
| XII COL11A2 | AL390755.5.1.186120 | $13 q 34$ | 105188574 | 105346678 | COL4A1 | $3.30 \mathrm{E}-17$ |
| XII COL11A2 | AL159153.17.1.102319 | 13q34 | 105346805 | 105553028 | COL4A2 | $2.40 \mathrm{E}-16$ |
| III NOTCH4 | AL137002.19.1.132933 | $13 q 34$ | 108397279 | 108411519 | F7 | $2.60 \mathrm{E}-18$ |
| III NOTCH4 | AL161774.49.1.162296 | $13 q 34$ | 110946220 | 111086222 | RASA3 | $9.60 \mathrm{E}-09$ |
|  |  |  |  |  |  |  |


| II PSMB8 | AL132780.5.1.191946 | $14 q 11.2$ | 17282361 | 17291410 | PSMB5 | 2.40E-67 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| xI HMGN4 | AL163052.4.1.181905 | 14q12 | 23108107 | 23108319 | no gene | $8.20 \mathrm{E}-06$ |
| TUBB | AL445383.5.1.172914 | $14 q 21.2$ | 41065751 | 41065876 | genscan | $7.00 \mathrm{E}-10$ |
| XII RXRB | AL161756.6.1.176257 | $14 q 23.2$ | 58487079 | 58598473 | ESR2 | 8.90E-05 |
| III HSPA1L | AL049869.6.1.195840 | 14q23.3 | 58801222 | 58803614 | HSPA2 | 4.80E-266 |
| xI GPX5 | AL139022.4.1.190517 | $14 q 23.3$ | 59199531 | 59203136 | GPX2 | $1.50 \mathrm{E}-27$ |
| III BAT1 | AL391262.3.1.171296 | 14 q 24.1 | 67056068 | 67056841 | Genscan | $1.00 \mathrm{E}-18$ |
| III NOTCH4 | AC005479.2.1.140425 | 14 q 24.3 | 68764077 | 68777511 | NPC2 | $3.70 \mathrm{E}-22$ |
| xII RXRB | AC008050.6.1.176975 | 14 q 24.3 | 70654841 | 70785295 | ESRRB | $5.10 \mathrm{E}-09$ |
| xII RPS18 | AL122020.5.1.149904 | $14 q 32.11$ | 85048919 | 85049456 | Novel | 4.40E-53 |
| III NOTCH4 | AL132711.4.1.184924 | 14 q 32.2 | 95016286 | 95017418 | no gene | $6.90 \mathrm{E}-22$ |
| III C6orf46/ZNF297 | AL590327.3.1.59297 | 14q32.33 | 99258499 | 99259764 | Novel | 3.20E-14 |
| III NOTCH4 | AL512356.5.1.158468 | 14q32.33 | 99443586 | 99452823 | C14orf79 | $1.60 \mathrm{E}-59$ |
| III NOTCH4 | AL512355.5.1.196132 | 14q32.33 | 99772045 | 99852517 | 060342 | $1.90 \mathrm{E}-54$ |
| III ATP6V1G2 | AL122127.6.1.169802 | 14q32.33 | 103287219 | 103287536 | no gene | $1.00 \mathrm{E}-07$ |
| II TAP1 | AC116165.3.1.90200 | 15q11.2 | 16305068 | 16351483 | Novel | 1.70E-35 |
| II TAP2 | AC116165.3.1.90200 | $15 q 11.2$ | 16305068 | 16351483 | Novel | $7.20 \mathrm{E}-22$ |
| II $\mathrm{TAP1}$ | AC016033.7.99902.141149 | $15 q 11.2$ | 16392186 | 16403533 | Novel | $7.70 \mathrm{E}-36$ |
| II TAP2 | AC016033.7.99902.141149 | $15 q 11.2$ | 16392186 | 16403533 | Novel | $7.50 \mathrm{E}-23$ |
| xI POM121L2 | AC090983.10.101166.203171 | $15 q 11.2$ | 17724332 | 17724397 | no gene | $2.20 \mathrm{E}-11$ |
| II ${ }^{\text {I }}$ TAP2 | AC091304.12.1.179219 | 15q13.1 | 21513802 | 21524551 | Novel | 1.50E-44 |
| II $\mathrm{TAP1}$ | AC091304.12.1.179219 | $15 q 13.1$ | 21513802 | 21524551 | Novel | $2.30 \mathrm{E}-40$ |
| xI HMGN4 | AC022613.13.1.188117 | $15 q 13.1$ | 25526308 | 25530507 | HMG17 | $6.40 \mathrm{E}-06$ |
| III NOTCH4 | AC020661.8.1.191655 | $15 q 15.1$ | 34166830 | 34304183 | Q9ULG1 | $1.70 \mathrm{E}-42$ |
| II HLA Class | AC025270.6.1.128484 | $15 q 21.1$ | 37899544 | 37906166 | B2M | 7.10E-05 |
| xI $\mathrm{BTN1A1/RFP}$ | AC018901.8.1.199503 | $15 q 21.1$ | 37924579 | 37955869 | RNF36 | 1.20E-29 |
| II HLA-DPB1 | AC018901.8.1.199503 | $15 q 21.1$ | 38056731 | 38056793 | no gene | 6.90E-06 |
| III CYP21A2 | AC020705.4.136565.149466 | $15 q 21.1$ | 38739399 | 68813334 | CYP1A2 | $1.10 \mathrm{E}-12$ |
| III NOTCH4 | AC022467.7.1.193703 | $15 q 21.1$ | 41748164 | 41983082 | FBN1 | $8.10 \mathrm{E}-27$ |
| III BAT1 | AC091700.4.1.97653 | 15q22.2 | 55722396 | 55722959 | Genscan | $4.20 \mathrm{E}-08$ |
| III NOTCH4 | AC009433.11.1.169638 | 15q22.31 | 59286605 | 59645098 | NM_032445 | $4.90 \mathrm{E}-28$ |
| III BAT8 | AC067837.6.1.173919 | 15q23 | 61668952 | 61687004 | FEM1B | $1.70 \mathrm{E}-09$ |
| III BAT8 | AC021553.14.1.185596 | $15 q 23$ | 61692853 | 61823052 | ITGA11 | 2.50E-07 |
| XII RXRB | AC104938.2.66191.114293 | $15 q 23$ | 65200660 | 65208271 | NR2E3 | $3.40 \mathrm{E}-22$ |
| III RNF5 | AC048383.8.169960.172969 | $15 q 23$ | 66533763 | 66534050 | genscan | 2.30E-74 |
| II BTNL2 | AC022188.7.15746.68046 | $15 q 24.1$ | 67107924 | 67122957 | NM_025240 | 5.80E-18 |
| III CYP21A2 | AC020705.4.92855.102206 | $15 q 24.1$ | 68848252 | 68854305 | CYP1A1 | $4.90 \mathrm{E}-15$ |
| I $\quad$ DDR1 | AC027243.13.89123.218680 | 15q24.2 | 69598117 | 69693731 | ETFA | $1.90 \mathrm{E}-13$ |
| xI MOG | AC022188.7.15746.68046 | 15q24.1 | 70012753 | 70027796 | NM_025240 | $9.70 \mathrm{E}-10$ |
| III CYP21A2 | AC091230.8.108454.128536 | $15 q 24.1$ | 70970184 | 70976444 | Novel | $9.00 \mathrm{E}-12$ |
| I $\mathrm{DDR1}$ | AC011966.7.1.167862 | $15 q 25.3$ | 81649264 | 82028917 | NTRK3 | $7.20 \mathrm{E}-24$ |
| xII KIFC1 | AC079075.5.54114.209978 | $15 q 26.1$ | 83693866 | 83715674 | ANPEP | $1.10 \mathrm{E}-15$ |
| xI HIST1H2AC | AC091544.9.1.126968 | 15q26.1 | 87091764 | 87110331 | H2 -like | $9.40 \mathrm{E}-17$ |
| xIIRXRB | AC016251.9.1.182943 | $15 q 26.2$ | 90630767 | 90631006 | no gene | $4.20 \mathrm{E}-43$ |
| I ${ }^{\text {I }}$ DDR1 | AC069029.9.1.191018 | $15 q 26.3$ | 93033248 | 93342019 | IGF1R | $3.10 \mathrm{E}-07$ |
|  |  |  |  |  |  |  |
| xI $\mathrm{BTN1A1/RFP}$ | AJ003147.1.1.239566 | 16p13.3 | 3325667 | 3340266 | MEFV | $2.70 \mathrm{E}-35$ |
| II BRD2 | AC004651.1.1.42016 | 16p13.3 | 3810213 | 3964357 | CREBBP | $1.80 \mathrm{E}-05$ |
| xII B3GALT4 | AC040160.4.1.209574 | $16 q 22.1$ | 6761048 | 67659124 | FHOD1 | $3.70 \mathrm{E}-19$ |
| II TAP2 | AC025778.7.1.207614 | 16p13.12 | 15526117 | 15599260 | ABCB6 | $1.30 \mathrm{E}-06$ |
| III NOTCH4 | AC106796.1.45233.67716 | 16p12.3 | 19774406 | 19794065 | UMOD | $2.00 \mathrm{E}-11$ |
| xI HMGN4 | AC093509.2.1.120576 | 16p12.1 | 25470563 | 25470814 | Q96C64 | $3.90 \mathrm{E}-06$ |
| xII KIFC1 | AC023831.8.22510.115251 | 16p11.2 | 30014062 | 30032892 | QPRT | $2.00 \mathrm{E}-09$ |
| III C6orf46 | AC002310.1.1.120955 | 16p11.2 | 31053573 | 31058082 | NM_033410 | 5.30E-09 |
| III C6orf46 | AC093249.3.1.185664 | 16p11.2 | 31102367 | 31110170 | Q96CS4 | 5.30E-08 |
| XII ZNF297 | AC106886.2.20127.148471 | 16p11.2 | 31281559 | 31287006 | Q9UEG4 | 6.00E-10 |



| TUBB | AC010503.8.1.141295 | 19p13.3 | 6562943 | 6570948 | TUBBL | 1.30E-202 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| III TNF | AC008760.7.1.200167 | 19p13.3 | 6733175 | 673234 | TNFSF14 | $6.20 \mathrm{E}-10$ |
| III C4B | AC008760.7.1.200167 | 19p13.3 | 6746489 | 6789295 | C3 | 3.50E-27 |
| III NOTCH4 | AC020895.8.1.139846 | 19p13.3 | 6959105 | 7022006 | EMR1 | $1.00 \mathrm{E}-08$ |
| DDR1 | AC010311.9.1.91172 | 19p13.2 | 7254547 | 7432507 | INSR | 3.10E-12 |
| xII LYPLA2L | AC010336.7.1.160769 | 19p13.2 | 8042351 | 8049685 | Novel | 3.30E-96 |
| III NOTCH4 | AC022146.6.66353.150193 | 19p13.2 | 8235200 | 8317297 | FBN3 | 5.30E-34 |
| III EGFL8 | AC022146.6.66353.150193 | 19p13.2 | 8275726 | 8322330 | NM_032447 | 2.60E-08 |
| xII COL11A2 | AC008742.8.1.194623 | 19p13.2 | 10191743 | 10242653 | COL5A3 | 3.10E-67 |
| DDR1 | AC011557.6.1.30505 | 19p13.2 | 10684031 | 10714039 | TYK2 | $2.20 \mathrm{E}-07$ |
| III LSM2 | AC011475.6.1.179953 | 19p13.2 | 10932292 | 10932453 | no gene | 5.70E-23 |
| III C6orf29 | AC011475.6.1.179953 | 19p13.2 | 10959135 | 10978061 | CTL2 | 5.20E-59 |
| xII RAB2L | AC024575.6.1.119638 | 19p13.2 | 11718017 | 11752815 | Q8TEP0 | 1.30E-24 |
| XII ZNF297 | AC011446.6.1.115932 | 19p13.2 | 13622357 | 13628643 | STX10 | $2.20 \mathrm{E}-14$ |
| III BAT1 | AC008569.7.1.227245 | 19p13.13 | 14887089 | 14897635 | DDX39 | 4.10E-98 |
| III NOTCH4 | AC005327.1.1.37988 | 19p13.12 | 15236788 | 15282936 | EMR2 | 5.70E-05 |
| III EGFL8 | AC004663.1.1.41150 | 19p13.12 | 15649643 | 15690991 | NOTCH3 | 6.00E-05 |
| III NOTCH4 | AC004663.1.1.41150 | 19p13.12 | 15664050 | 15705404 | NOTCH3 | 7.70E-227 |
| II BRD2 | AC114486.2.1.179070 | 19p13.12 | 15741907 | 15784868 | BRD4 | $2.30 \mathrm{E}-90$ |
| xII RXRB | AC010646.5.1.41461 | 19p13.12 | 17734984 | 17748449 | NR2F6 | $7.00 \mathrm{E}-41$ |
| xII B3GALT4 | AC008761.7.1.226170 | 19p13.12 | 18106912 | 18149110 | Q9UPW8 | 1.10E-12 |
| xIIB3GALT4 | AC005952.1.1.39976 | 19p13.11 | 18298235 | 18315904 | B3GNT3 | 2.50E-14 |
| XII RPS18 | AC020904.7.1.148824 | 19p13.11 | 18551604 | 18551837 | EST gene | 5.30E-46 |
| III BAT1 | AC002985.1.1.38041 | 19p13.11 | 19422473 | 19431417 | NM_019070 | 1.50E-05 |
| III PBX2 | AC011448.4.1.165122 | 19p13.11 | 20063771 | 20120711 | PBX4 | 2.10E-68 |
| xII ZNF297 | AC008751.6.1.169089 | 19p13.11 | 21436099 | 21452779 | ZNF85 | $2.20 \mathrm{E}-10$ |
| III C6orf46 | AC016628.6.1.41153 | 19p13.11 | 23871643 | 23887148 | Novel | $6.70 \mathrm{E}-16$ |
| XII ZNF297 | AC020910.7.1.203201 | 19q13.12 | 35697932 | 35713073 | Q96NL3 | 2.30E-11 |
| III BAT8 | AD000671.1.1.46251 | 19q13.12 | 36657876 | 36678735 | TRX2 | 1.70E-05 |
| XII ZNF297 | AC092295.2.1.165566 | 19q13.12 | 37465837 | 37479151 | EST gene | $1.00 \mathrm{E}-10$ |
| III C6orf46 | AC008806.4.1.135173 | 19q13.13 | 38293492 | 38349772 | NM_152484 | 5.30E-10 |
| xII ZNF297 | AC022148.5.1.198751 | 19q13.13 | 38430631 | 38431506 | Q8N3U1 | $1.00 \mathrm{E}-10$ |
| III NOTCH4 | AC011500.7.1.200430 | $19 \mathrm{q13.2}$ | 40327364 | 40358466 | SUPT5H | 1.10E-27 |
| III NOTCH4 | AC010412.8.1.155085 | 19q13.2 | 41494937 | 41527447 | LTBP4 | $1.50 \mathrm{E}-33$ |
| III CYP21A2 | AC008537.5.1.169089 | 19q13.2 | 41988964 | 41996369 | CYP2A6 | 1.60E-09 |
| I DDR1 | AC011510.7.1.129402 | 19q13.2 | 42116547 | 42159395 | AXL | 5.40E-09 |
| III CYP21A2 | AC008962.9.1.154169 | 19q13.2 | 42259850 | 42273778 | CYP2F1 | 2.90E-08 |
| XII B3GALT4 | AC011526.7.1.40887 | $19 \mathrm{q13.2}$ | 42323217 | 42324407 | Novel | $6.40 \mathrm{E}-20$ |
| III CYP21A2 | AC011510.7.1.129402 | 19p13.2 | 42338667 | 42352612 | CYP2S1 | $9.30 \mathrm{E}-06$ |
| I POU5F1 | AC024076.4.1.39443 | 19q13.2 | 42986837 | 43028331 | POU2F2 | $4.30 \mathrm{E}-23$ |
| III NOTCH4 | AC011497.6.1.168586 | 19q13.2 | 43248294 | 43273290 | EGFL4 | $4.00 \mathrm{E}-09$ |
| I DHX16 | AC008754.8.1.66792 | 19p13.32 | 48246893 | 48270700 | DDX34 | 7.80E-27 |
| I DHX16 | AC073548.4.1.66051 | 19q13.32 | 48322806 | 48366009 | SLC8A2 | 2.20E-17 |
| xI HLA Class I | AC010619.7.1.179394 | 19q13.33 | 50384629 | 50397727 | FCGRT | 8.50E-10 |
| XII RXRB | AC008655.7.1.123149 | 19p13.33 | 51241040 | 51247541 | NR1H2 | 1.10E-06 |
| xI MAS1L | AC005946.1.1.37392 | 19q13.33 | 52688362 | 52689423 | FPRL2 | $9.40 \mathrm{E}-06$ |
| III C6orf46 | AC010320.9.1.220458 | 19q13.41 | 53262462 | 53283017 | Q96JK0 | 3.60E-15 |
| III C6orf46 | AC022150.6.1.228156 | 19q13.41 | 53461403 | 53462023 | ZNF137 | $9.00 \mathrm{E}-16$ |
| XII ZNF297 | AC013256.1.1.36095 | 19q13.43 | 57406251 | 57442939 | NM_022103 | $1.40 \mathrm{E}-10$ |
| xII ZNF297 | AC005498.1.1.37321 | 19q13.43 | 57504539 | 57522397 | ZFP28 | $2.80 \mathrm{E}-10$ |
| XII ZNF297 | AC003682.1.1.153875 | 19q13.43 | 58536894 | 58544255 | Q9BWM5 | 1.10E-11 |
| III C6orf46 | AC003682.1.1.153875 | 19q13.43 | 58579587 | 58587258 | ZNF134 | 1.60E-15 |
| III C6orf46 | AC003006.1.1.84114 | 19q13.43 | 58734983 | 58745942 | NM_017652 | 5.20E-12 |
| III C6orf46 | AC012313.7.1.185417 | 19q13.43 | 59398153 | 59405560 | ZNF132 | 1.70E-25 |
| xII ZNF297 | AC012313.7.1.185417 | 19q13.43 | 59478868 | 59485159 | NM_032792 | 5.20E-29 |
|  |  |  |  |  |  |  |
| xI NOL5B | AL049712.12.1.159272 | 20p13 | 2580791 | 2587039 | NOL5A | $4.00 \mathrm{E}-29$ |


| III NOTCH4 | AL035456.26.1.125952 | 20p12.2 | 10566334 | 10602636 | JAG1 | $1.30 \mathrm{E}-49$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| xII KIFC1 | AL049794.16.1.119696 | 20p12.1 | 16200749 | 16502021 | C200RF23 | $1.30 \mathrm{E}-09$ |
| III NOTCH4 | AL049651.2.1.97912 | 20p11.21 | 22964121 | 22965287 | SSTR4 | $4.00 \mathrm{E}-10$ |
| III EGFL8 | AL118508.27.1.123832 | 20p11.21 | 23048052 | 23055034 | C1QR1 | $1.90 \mathrm{E}-05$ |
| III NOTCH4 | AL118508.27.1.123832 | 20p11.21 | 23054616 | 23054911 | Q8WY72 | 1.90E-16 |
| xI BTN1A1 | AL080312.14.1.94664 | 20p11.21 | 25027858 | 25028403 | genscan | $1.60 \mathrm{E}-08$ |
| DDR1 | AL049539.21.1.111694 | 20q11.21 | 30388101 | 30437940 | HCK | $6.80 \mathrm{E}-11$ |
| xII KIFC1 | AL121897.32.1.145414 | 20q11.21 | 30613467 | 30669435 | KIF3B | $3.10 \mathrm{E}-46$ |
| DDR1 | AL133293.28.1.68662 | 20q11.23 | 35700500 | 35722250 | SRC | $3.00 \mathrm{E}-15$ |
| DHX16 | AL023803.3.1.155379 | 20q11.2 | 37279429 | 37356793 | DDX35 | $2.10 \mathrm{E}-19$ |
| xII RXRB | AL132772.14.1.83798 | 20q13.12 | 42718338 | 42747410 | HNFA4 | $4.50 \mathrm{E}-26$ |
| xII ZNF297 | AL354745.11.1.13535 | 20q13.12 | 44818128 | 44830619 | ZNF334 | $1.60 \mathrm{E}-05$ |
| III BAT1 | AL049766.14.1.110293 | 20q13.13 | 47524305 | 47549031 | DDX27 | $1.70 \mathrm{E}-10$ |
| TUBB | AL109840.24.1.142094 | 20q13.32 | 57282669 | 57290069 | TUBBL | 3.02E-165 |
| III NOTCH4 | AL354836.13.1.141056 | 20q13.33 | 60601582 | 60607445 | ADRM1 | 2.50E-09 |
| III NOTCH4 | AL121673.41.1.151163 | 20q13.33 | 61421476 | 61437370 | C20orf59 | $2.90 \mathrm{E}-07$ |
| DDR1 | AL121829.30.1.113196 | 20q13.33 | 61996950 | 62006900 | PTK6 | $3.20 \mathrm{E}-14$ |
| xII ZNF297 | AL121845.20.1.120917 | 20q13.33 | 62212439 | 62299987 | Novel | $3.90 \mathrm{E}-12$ |
| III BAT5 | AL118506.27.1.139505 | 20q13.33 | 62330271 | 62331761 | C20ORF135 | $1.50 \mathrm{E}-117$ |
|  |  |  |  |  |  |  |
| III HSPA1L | AF130358.2.1.197778 | 21q11.2 | 12307991 | 12372209 | ABCC13 | $1.80 \mathrm{E}-44$ |
| III HSPA1L | AF130249.1.1.97083 | 21q11.2 | 12405307 | 12417341 | STCH | 3.30E-46 |
| III CLIC1 | AP000330.2.1.170377 | 21q22.12 | 32702115 | 32750955 | CLIC6 | $2.60 \mathrm{E}-38$ |
| XII B3GALT4 | AF064860.2.1.170121 | 21q22.2 | 37690022 | 37690381 | genscan | $9.90 \mathrm{E}-32$ |
| III BAT8 | AP001615.1.1.124516 | 21q22.3 | 39783391 | 39784221 | genscan | $4.60 \mathrm{E}-17$ |
| XII ZNF297 | AP001620.1.1.95449 | 21q22.3 | 40039452 | 40061155 | ZNF295 | $5.40 \mathrm{E}-10$ |
| xI HIST1H2AC | AB001523.1.1.122638 | 21q22.3 | 42024993 | 42118907 | TMEM1 | 7.20E-08 |
| III NOTCH4 | AP001067.1.1.148845 | 21q22.3 | 42510546 | 42724266 | C21orf29 | $2.10 \mathrm{E}-24$ |
| III NOTCH4 | AL163301.2.1.340000 | 21q22.3 | 43278171 | 43300571 | C21orf80 | $5.40 \mathrm{E}-06$ |
| xII COL11A2 | AL163302.2.1.340000 | 21q22.3 | 43527445 | 43550695 | SLC19A1 | $9.70 \mathrm{E}-12$ |
| III BAT1 | AP001604.1.1.186930 | 21q21.3 | 25401349 | 25401540 | genscan | 4.90E-09 |
|  |  |  |  |  |  |  |
| TUBB | AC008079.23.1.170102 | 22q11.21 | 15544495 | 15554618 | TUBA8 | $4.00 \mathrm{E}-10$ |
| XI POM121L2 | AC008103.27.1.98557 | 22q11.21 | 15773964 | 15776531 | C22.2 | 5.60E-08 |
| xI POM121L2 | AC000095.3.1.43728 | 22q11.21 | 15945799 | 15947779 | C22.3 | $3.00 \mathrm{E}-10$ |
| III NOTCH4 | AC005500.2.1.192592 | 22q11.21 | 17480798 | 17552052 | SRC2 | $1.00 \mathrm{E}-09$ |
| III NOTCH4 | AC007731.14.1.182617 | 22q11.21 | 17480798 | 17552052 | SRC2 | 2.60E-09 |
| xI POM121L2 | AC007050.25.1.163908 | 22q11.21 | 17742343 | 17744900 | C22.3 | $1.50 \mathrm{E}-09$ |
| III C6orf46/ZNF297 | AP000557.2.1.150036 | 22q11.21 | 18470386 | 18504441 | H1C2 | 6.00E-19 |
| II HLA-DRB3/1 | D87023.1.1.40392 | 22q11.22 | 19936243 | 19936975 | IGLC1 | $2.80 \mathrm{E}-06$ |
| xI POM121L2 | AP000354.1.1.164756 | 22q11.23 | 21343934 | 21357627 | NM_014549 | $9.60 \mathrm{E}-10$ |
| xI POM121L2 | AP000356.1.1.163795 | 22q11.23 | 21749568 | 21750854 | POM121L1 | $1.70 \mathrm{E}-10$ |
| DDR1 | AL022329.9.1.221507 | 22q12.1 | 22656954 | 22816015 | ADRBK2 | $6.00 \mathrm{E}-21$ |
| xI BTN1A1/RNF | AC002059.3.1.173029 | 22q12.2 | 26530668 | 26534540 | RFPL1 | $2.40 \mathrm{E}-26$ |
| III RNF5 | AC002073.1.1.128978 | 22q12.2 | 28252236 | 28299047 | Q96GF1 | $8.10 \mathrm{E}-20$ |
| xI HIST1H2AC | AL096701.14.1.168110 | 22q12.2 | 28613161 | 28613624 | novel | $2.50 \mathrm{E}-07$ |
| xI BTN1A1/RFP | AL008723.8.1.154414 | 22q12.3 | 29282473 | 29295511 | RFPL2 | 5.70E-26 |
| xI BTN1A1/RFP | AL021937.1.1.173354 | 22q12.3 | 29447342 | 29453195 | RFPL3 | $5.70 \mathrm{E}-26$ |
| III BAT1 | Z97056.1.1.124990 | 22q13.1 | 35496212 | 35516829 | DDX17 | $2.00 \mathrm{E}-05$ |
| II ${ }^{\text {BRD2 }}$ | AL096765.12.1.13053 | 22q13.2 | 38102320 | 38190075 | EP300 | $1.20 \mathrm{E}-05$ |
| III CYP21A2 | AL021878.1.1.114847 | 22q13.2 | 39138588 | 39142847 | CYP2D6 | $3.30 \mathrm{E}-09$ |
| III NOTCH4 | Z98047.1.1.47542 | 22q13.31 | 42534087 | 42532337 | FBLN1 | $5.30 \mathrm{E}-12$ |
| III NOTCH4 | AL031588.1.1.127168 | 22q13.31 | 43322995 | 43499263 | CELSR1 | 1.20E-09 |
|  |  |  |  |  |  |  |
| III BAT1 | AC117517.7.1.121628 | Xp22.11 | 21589340 | 21590458 | genscan | $4.40 \mathrm{E}-37$ |
| xI HIST1H2AC | AL121577.1.1.175531 | Xq21.1 | 35832664 | 35878934 | XK | $2.40 \mathrm{E}-08$ |
| xI HIST1H2AC | AL121578.1.1.337101 | Xp11.4 | 36141216 | 36141440 | genscan | 2.80E-08 |


| III CLIC1 | AL391259.15.1.163520 | Xp11.4 | 38963014 | 38963730 | Genscan | $2.90 \mathrm{E}-07$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| III BAT1 | AL391647.16.1.60310 | Xp11.4 | 39441330 | 39472404 | DDX39 | $6.20 \mathrm{E}-07$ |
| xII ZNF297 | AL590223.12.1.40331 | Xp11.3 | 45567068 | 45603010 | ZNF41 | $4.60 \mathrm{E}-10$ |
| xII ZNF297 | Z98304.1.1.209618 | Xp11.23 | 46096233 | 46103478 | Q96QH7 | $4.70 \mathrm{E}-10$ |
| III BAT8 | AC115618.1.1.158455 | Xp11.23 | 46756067 | 46756093 | no gene | $3.40 \mathrm{E}-15$ |
| III BAT8 | AF196970.1.1.112595 | Xp11.23 | 46815791 | 46828063 | SUV39H1 | $1.30 \mathrm{E}-15$ |
| III BAT1 | AL445236.22.1.149749 | Xp11.22 | 50567899 | 50607906 | Novel | $9.90 \mathrm{E}-39$ |
| xII HSD17B8 | Z97054.1.1.132805 | Xp11.22 | 51162495 | 51165605 | HADH2 | 3.60E-06 |
| xII KIFC1 | AL357752.19.1.178868 | Xq13.1 | 66987254 | 67117990 | KIF4A | $2.70 \mathrm{E}-08$ |
| III BAT1 | AL359740.24.1.98104 | Xq13.2 | 70525227 | 70526105 | genscan | $1.00 \mathrm{E}-13$ |
| II $\mathrm{TAP2/1}$ | AL359545.12.1.127243 | Xq13.3 | 71447688 | 71550705 | ABCB7 | $2.90 \mathrm{E}-08$ |
| xII KIFC1 | AL021786.2.1.70665 | Xq21.1 | 75540478 | 75573738 | Novel | $1.40 \mathrm{E}-15$ |
| POU5F1 | Z82170.1.1.127247 | Xq21.1 | 79839811 | 79841286 | POU3F4 | $6.20 \mathrm{E}-39$ |
| III BAT1 | AL136362.10.1.135240 | Xq21.31 | 88337615 | 88338796 | EST gene | $1.30 \mathrm{E}-57$ |
| TUBB | AL390840.17.1.197611 | Xq21.32 | 88819807 | 88819917 | genscan | $1.50 \mathrm{E}-09$ |
| XII COL11A2 | AL136080.6.1.116106 | Xq23 | 104474931 | 104758796 | COL4A6 | $2.50 \mathrm{E}-15$ |
| XII COL11A2 | AL031622.1.1.104674 | Xq23 | 104759239 | 105016860 | COL4A5 | $1.80 \mathrm{E}-17$ |
| III HSPA1L | AC004822.1.1.127824 | Xq23 | 111134972 | 111136228 | genscan | $1.30 \mathrm{E}-208$ |
| III VARS2 | AC005000.2.1.107314 | Xq23 | 112024040 | 112063337 | Novel | $3.30 \mathrm{E}-05$ |
| TUBB | AC003012.1.1.104810 | Xq24 | 112252763 | 112252876 | genscan | $4.60 \mathrm{E}-12$ |
| XII ZNF297 | AC002086.1.1.112686 | Xq24 | 116370267 | 116377851 | NM_006777 | $6.50 \mathrm{E}-09$ |
| III HSPA1L | AC002377.1.1.141779 | Xq24 | 117230333 | 117231259 | genscan | $1.50 \mathrm{E}-221$ |
| III HSPA1L | AL391241.21.1.157860 | Xq25 | 120232224 | 120232373 | genscan | $9.40 \mathrm{E}-65$ |
| III NOTCH4 | AL627231.9.1.146366 | Xq25 | 121306552 | 121307673 | Novel | $6.10 \mathrm{E}-12$ |
| xII ZNF297 | AL590282.6.1.139296 | Xq26.3 | 131228672 | 131323794 | ZNF75 | $3.70 \mathrm{E}-10$ |
| III C6orf46 | U82670.3.1.279526 | Xq28 | 149081175 | 149084483 | ZNF275 | 5.30E-12 |
| III CLIC1 | AL356738.14.1.174693 | Xq28 | 150871755 | 150929271 | CLIC2 | 8.80E-52 |
| xI HIST1H2AC | AC019175.4.37111.45694 | Xq28 | 151078382 | 151078898 | H2AFB | $1.80 \mathrm{E}-13$ |
| xI HIST1H2AC | AL592156.4.1.134995 | Xq21.1 | 35423125 | 35423349 | genscan | $2.00 \mathrm{E}-11$ |
| III BAT1 | AC010129.3.1.44145 | Yp11.2 | 5171386 | 5172558 | Novel | $6.30 \mathrm{E}-59$ |
| III BAT1 | AC004474.1.1.148280 | Yq11.21 | 14326902 | 14356562 | DBY | $4.00 \mathrm{E}-05$ |

## Appendix 3

Primers used to amplify a paralogue specific probe for use in Northern blot, Dot blot and Southern blot analyses. ' $T$ ' stands for the annealing temperature.

| Gene | Primer | Sequence | $\begin{gathered} T \\ \left({ }^{\circ} \mathrm{C}\right) \end{gathered}$ | Size <br> (bp) |
| :---: | :---: | :---: | :---: | :---: |
| AIF1 | F | TGACCATGCTGATGTATGAGGAAAAAGCGA | 62 | 200 |
|  | R | GATCTGGAGGAGGGGGTAAT |  |  |
| AIF1-L | F | TGACCATGTTAAGGGAGGAGAGCAAGCA | 62 | 251 |
|  | R | CTGAGCCCTTAGCCAGAGAA |  |  |
| BRD2 | F | TGACCATGGAGGGATGCAGGGACATTT | 62 | 411 |
|  | R | AACAAAGACAGTCCAGGGGA |  |  |
| BRDT | F | TGACCATGGGGTACCATTGATATGACCCTT | 62 | 199 |
|  | R | CTGTTTAATCATTTTAGAGCAGTCA |  |  |
| BRD3 | F | TGACCATGGACAGATGGATGTCGCACAC | 62 | 425 |
|  | R | CAAATGACAAGGACAATGCG |  |  |
| BRD4 | F | TGACCATGGTGAAAGGGACAGGACTCCA | 65 | 508 |
|  | R | CAGTGAGAAGCATGCTGTGG |  |  |
| C4 | F | TGACCATGAGAGATGACTCCGCGTCTGT | 65 | 395 |
|  | R | ATTCTCCTTCTGCCCCAGAT |  |  |
| C3 | F | TGACCATGCATTCCCCCACTCCAGATAA | 65 | 214 |
|  | R | ACATGAAGGTGAGGCAGGTC |  |  |
| C5 | F | TGACCATGTTGCACTTATGGACTCCTGTTG | 65 | 352 |
|  | R | GATCAGTTTCCTGTTCCTTGGT |  |  |
| CLIC1 | F | TGACCATGAAGTACCGGGGATTCACCAT | 65 | 310 |
|  | R | СТTTСССТСАТССССТСТTС |  |  |
| CLIC4 | F | TGACCATGGGAGATTGGAGTCTGAATGGA | 65 | 384 |
|  | R | AATGGGTTTAAGGGCACAGA |  |  |
| CLIC3 | F | TGACCATGGTACGCCGCTACCTGGAC | 65 | 153 |
|  | R | CCCGACAAAGATGCCTTTATT |  |  |
| CLIC5 | F | TGACCATGTGTTGATGCCAAAATACCCA | 65 | 427 |
|  | R | GACCACCTCCTAAATGTGGC |  |  |
| CLIC6 | F | TGACCATGTGTGGCCAAGAAGTACAGAGAT | 65 | 146 |
|  | R | TTGCAACATCTGAATATGCG |  |  |
| CLIC2 | F | TGACCATGGAATTCTCAGGAGTCTGGCG | 65 | 350 |
|  | R | GCAGTGGTTTGCCATACAGA |  |  |
| GPX5 | F | TGACCATGTAGCAATGGGGTCACAGTCA | 65 | 277 |
|  | R | TCCTCTCCAGGTGCCATAAC |  |  |
| GPX4 | F | TGACCATGTCCACAAGTGTGTGGCCC | 65 | 186 |
|  | R | CACAAGGTAGCCAGGGGTG |  |  |
| GPX3 | F | TGACCATGAACCCAAAGGAAAAACCAGC | 62 | 451 |
|  | R | GAGTCTCAAGCCAGTGGACC |  |  |
| GPX1 | F | TGACCATGCTCTTCGAGAAGTGCGAGGT | 65 | 439 |
|  | R | ACTGGGATCAACAGGACCAG |  |  |
| GPX2 | F | TGACCATGTCCTACTCCATCCAGTCCTGA | 62 | 256 |
|  | R | CTTCACGCCTCTCAGACACC |  |  |
| NOTCH4 | F | TGACCATGCATTAAAAGGCAGGCTGGAA | 65 | 475 |
|  | R | CATCCCCACAGTGGAGTTCT |  |  |
| NOTCH2 | F | TGACCATGATGAGGAGGACAACACTGCC | 65 | 395 |
|  | R | GCATCACAGCCAATTGCTTA |  |  |
| NOTCH1 | F | TGACCATGCAATACTGCATCCATGGCCT | 65 | 244 |


|  | R | GTCCCTGAGCAACCATCTGT |  |  |
| :--- | :--- | :--- | :--- | :--- |
| NOTCH3 | F | TGACCATGATGTTCCATAGCCTTGCTGG | 65 | 294 |
|  | R | GGGAATTCAGCTACACAGGG |  |  |
| PBX2 | F | TGACCATGGCAGGGCTGGACTCAGTAAT | 62 | 409 |
|  | R | CACTTCCAACCTGTCCCAGT |  |  |
| PBX1 | F | TGACCATGCAGGAGGGAGGGTTTCTCTC | 62 | 267 |
|  | R | TCAGTGATATGAGAGAGGGCG |  |  |
| PBX3 | F | TGACCATGCGAGTGTGGAAACATTGGGT | 62 | 325 |
|  | R | TCAATCCAGGGTGTAATCCA |  |  |
| PBX4 | F | TGACCATGGTTTGGGGGATAAGCAGGAA | 62 | 286 |
|  | R | GAAAATCTGTGCCCAGTCCT |  |  |
| RXRB | F | TGACCATGAAGAAATGCCAGTGGTGGAG | 62 | 263 |
|  | R | AAAGGAGCCCCAAAGAGAAG |  |  |
| RXRG | F | TGACCATGTCCTGACTAATCCCAGAGGG | 62 | 215 |
|  | R | CATAGCCTGCGGGAAACTT |  |  |
| RXRA | F | TGACCATGTATACTTGGATATGGCGGGG | 65 | 299 |
|  | R | CGGAGAAGCCACTTCACAGT |  |  |
| TUBB_6p21.3 | F | TGACCATGAGAGCAACATGAACGACCTG | 65 | 200 |
|  | R | TGGAGGGAGATTGAAAGTGG |  |  |
| TUBB2_18p11.3 | F | TGACCATG TTCCTTCTTGAACCCTGGTG | 65 | 225 |
|  | R | TTTATTTTGTGGCCCCTCAG |  |  |
| TUBB5_19p13.3 | F | TGACCATGCTGAATCCCCTCTGACTCCA | 65 | 293 |
|  | R | CCTCTCTTCCTCACAGGCAC |  |  |
| TUBB4QL_10p15.3 | F | TGACCATGACAGCATCTGGTTTTGCCTC | 65 | 130 |
|  | R | CCACTGGAATGCTTGTTCCT |  |  |
| TUBB4_16q24.3 | F | TGACCATGCAGCTGGAGTGAGAGGCAG | 65 | 201 |
|  | R | GCCTGGAGCTGCAATAAGAC | 65 | 396 |
| TUBB1_20q13.3 | F | TGACCATGTGCACTCACCATTAGCTTCG |  |  |
|  | R | TAGTCAGGCACCTGGCTCTT |  |  |
|  |  |  | 6 |  |

## Appendix 4

Primers used to generate paralogue specific PCR products for each paralogue. The products were used to spot on to the microarrays and were also labelled and used to hybridise to the 'Paralogue Microarray'. 'T' stands for the annealing temperature. They were also used in the RT-PCR experiments.

| Gene | Primer | Sequence | $\begin{gathered} T \\ \left({ }^{\circ} \mathrm{C}\right) \end{gathered}$ | Size <br> (bp) |
| :---: | :---: | :---: | :---: | :---: |
| AIF1 | F | TGACCATGCTGATGTATGAGGAAAAAGCGA | 62.5 | 200 |
|  | R | GATCTGGAGGAGGGGGTAAT |  |  |
| AIF1-L | F | TGACCATGTTAAGGGAGGAGAGCAAGCA | 62.5 | 251 |
|  | R | CTGAGCCCTTAGCCAGAGAA |  |  |
| BRD2 | F | TGACCATGGAGGGATGCAGGGACATTT | 62.5 | 411 |
|  | R | AACAAAGACAGTCCAGGGGA |  |  |
| BRDT | F | TGACCATGGGGTACCATTGATATGACCCTT | 62.5 | 199 |
|  | R | CTGTTTAATCATTTTAGAGCAGTCA |  |  |
| BRD3 | F | TGACCATGGACAGATGGATGTCGCACAC | 62.5 | 425 |
|  | R | CAAATGACAAGGACAATGCG |  |  |
| BRD4 | F | TGACCATGGTGAAAGGGACAGGACTCCA | 65 | 508 |
|  | R | CAGTGAGAAGCATGCTGTGG |  |  |
| C4 | F | TGACCATGAGAGATGACTCCGCGTCTGT | 65 | 395 |
|  | R | ATTCTCCTTCTGCCCCAGAT |  |  |
| C3 | F | TGACCATGCATTCCCCCACTCCAGATAA | 65 | 214 |
|  | R | ACATGAAGGTGAGGCAGGTC |  |  |
| C5 | F | TGACCATGTTGCACTTATGGACTCCTGTTG | 65 | 352 |
|  | R | GATCAGTTTCCTGTTCCTTGGT |  |  |
| CLIC1 | F | TGACCATGAAGTACCGGGGATTCACCAT | 62.5 | 310 |
|  | R | CTTTCССТСАТССССТСTTC |  |  |
| CLIC4 | F | TGACCATGGGAGATTGGAGTCTGAATGGA | 65 | 384 |
|  | R | AATGGGTTTAAGGGCACAGA |  |  |
| CLIC3 | F | TGACCATGGTACGCCGCTACCTGGAC | 65 | 153 |
|  | R | CCCGACAAAGATGCCTTTATT |  |  |
| CLIC5 | F | TGACCATGTGTTGATGCCAAAATACCCA | 65 | 427 |
|  | R | GACCACCTCCTAAATGTGGC |  |  |
| CLIC6 | F | TGACCATGTGTGGCCAAGAAGTACAGAGAT | 65 | 146 |
|  | R | TTGCAACATCTGAATATGCG |  |  |
| CLIC2 | F | TGACCATGGAATTCTCAGGAGTCTGGCG | 65 | 350 |
|  | R | GCAGTGGTTTGCCATACAGA |  |  |
| GPX5 | F | TGACCATGTAGCAATGGGGTCACAGTCA | 62.5 | 277 |
|  | R | TCCTCTCCAGGTGCCATAAC |  |  |
| GPX4 | F | TGACCATGTCCACAAGTGTGTGGCCC | 62.5 | 186 |
|  | R | CACAAGGTAGCCAGGGGTG |  |  |
| GPX3 | F | TGACCATGTCTGGGTCTACCACACTCCC | 62.5 | 329 |
|  | R | GAGTCTCAAGCCAGTGGACC |  |  |
| GPX1 | F | TGACCATGCTCTTCGAGAAGTGCGAGGT | 62.5 | 439 |
|  | R | ACTGGGATCAACAGGACCAG |  |  |
| GPX2 | F | TGACCATGTCCTACTCCATCCAGTCCTGA | 62.5 | 256 |
|  | R | CTTCACGCCTCTCAGACACC |  |  |
| NOTCH4 | F | TGACCATGCATTAAAAGGCAGGCTGGAA | 62.5 | 475 |
|  | R | CATCCCCACAGTGGAGTTCT |  |  |
| NOTCH2 | F | TGACCATGATGAGGAGGACAACACTGCC | 65 | 395 |
|  | R | GCATCACAGCCAATTGCTTA |  |  |


| NOTCH1 | F | TGACCATGCAATACTGCATCCATGGCCT | 65 | 244 |
| :--- | :---: | :--- | :--- | :--- |
|  | R | GTCCCTGAGCAACCATCTGT |  |  |
| NOTCH3 | F | TGACCATGATGTTCCATAGCCTTGCTGG | 65 | 294 |
|  | R | GGGAATTCAGCTACACAGGG |  |  |
| PBX2 | F | TGACCATGGCAGGGCTGGACTCAGTAAT | 62.5 | 409 |
|  | R | CACTTCCAACCTGTCCCAGT |  |  |
| PBX1 | F | TGACCATGCAGGAGGGAGGGTTTCTCTC | 62.5 | 267 |
|  | R | TCAGTGATATGAGAGAGGGCG |  |  |
| PBX3 | F | TGACCATGACCGAGTGTGGAAACATTGG | 62.5 | 328 |
|  | R | TTCAATCCAGGGTGTAATCCA |  |  |
| PBX4 | F | TGACCATGAAGTTTGGGGGATAAGCAGG | 62.5 | 288 |
|  | R | GAAAATCTGTGCCCAGTCCTA |  |  |
| RXRB | F | TGACCATGGCCTTCCTCCTCTCAAACCT | 62.5 | 263 |
|  | R | CTCCACCACTGGCATTTCTT |  |  |
| RXRG | F | TGACCATGCGATCTAGAGGCAGATTCCTGA | 62.5 | 231 |
|  | R | CATAGCCTGCGGGAAACTT |  |  |
| RXRA | F | TGACCATGTATACTTGGATATGGCGGGG | 65 | 299 |
|  | R | CGGAGAAGCCACTTCACAGT |  |  |
| TUBB_6p21.3 | F | TGACCATGACCAACCAGGTGCTGAAAAC | 65 | 242 |
|  | R | TGGAGGGAGATTGAAAGTGG |  |  |
| TUBB2_18p11.3 | F | TGACCATG TTCCTTCTTGAACCCTGGTG | 65 | 225 |
|  | R | TTTATTTTGTGGCCCCTCAG |  |  |
| TUBB5_19p13.3 | F | TGACCATGCTGAATCCCCTCTGACTCCA | 62.5 | 293 |
|  | R | CCTCTCTTCCTCACAGGCAC |  |  |
| TUBB4QL_10p15.3 | F | TGACCATGACAGCATCTGGTTTTGCCTC | 65 | 130 |
|  | R | CCACTGGAATGCTTGTTCCT |  |  |
| TUBB4_16q24.3 | F | TGACCATGCAGCTGGAGTGAGAGGCAG | 65 | 201 |
|  | R | GCCTGGAGCTGCAATAAGAC |  |  |
| TUBB1_20q13.3 | F | TGACCATGTGCACTCACCATTAGCTTCG | 65 | 396 |
|  | R | TAGTCAGGCACCTGGCTCTT |  |  |

## Appendix 5

Summary of in-silico results.

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- |

## In-silico results continued (part 2 of 3 ).

| Gene | $$ | 录 |  | $\left\|\begin{array}{c} \tilde{\text { un }} \\ \underline{E} \\ \tilde{U} \end{array}\right\|$ |  | $\left\|\begin{array}{c} \tilde{\Xi} \\ \frac{\tilde{0}}{2} \\ \dot{\omega} \end{array}\right\|$ | $\stackrel{\Im}{3}$ |  |  |  | $\begin{aligned} & \text { ? } \\ & \text { O} \\ & \text { E } \\ & \text { U } \\ & 0 \end{aligned}$ | $\begin{gathered} \overline{\tilde{u}} \\ \boldsymbol{\infty} \end{gathered}$ | $\begin{aligned} & \tilde{U} \\ & \mathrm{~F} \end{aligned}$ |  |  | $$ | $\begin{aligned} & 0 \\ & 0 \\ & \dot{z} \end{aligned}$ | $\begin{aligned} & \text { I } \\ & \text { J } \\ & \text { Ex } \\ & \text { E } \end{aligned}$ | $\underset{\sim}{g}$ |  | $\left\|\begin{array}{c} 0 \\ 0 \\ 0 \\ 3 \\ E \\ 0 \\ 0 \end{array}\right\|$ | Thyroid gland | $\begin{aligned} & \dot{\Xi} \\ & : \stackrel{\rightharpoonup}{\mathbf{E}} \\ & \dot{E} \end{aligned}$ | 易 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| AIF1_6p21.33 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 |
| AIF1-L_9q34.12 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 |
| BRD2_6p21.32 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| BRDT_1p22.1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| BRD3_9q34.2 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| BRD4_19p13.12 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0 |
| C4_6p21.33 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 1 |
| C5_9q33.2 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| C3_19p13.3 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0 |
| CLIC1_6p21.33 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 |
| CLIC4_1p35.3 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 |
| CLIC3_9q34.3 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| CLIC5_6p21.1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CLIC6_21q22.12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| CLIC2_Xq28 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
| GPX5_6p22.1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GPX4_19p13.3 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 0 |
| GPX1_3p21.31 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| GPX3_5q33.1 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| GPX2_14q23.3 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| NOTCH4_6p21.33 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| NOTCH2_1p11.2 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 0 |
| NOTCH1_9q34.3 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| NOTCH3_19p13.12 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| PBX2_6p21.33 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 |
| PBX1_1q23.3 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| PBX3_9q33.3 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 |
| PBX4_19p13.11 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| RXRB_6p21.32 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 |
| RXRG_1q23.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| RXRA_9q34.2 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
| TUBB_6p21.3 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 |
| TUBB4_16q24.3 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 |
| TUBBL_18p11.3 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| TUBB5_19p13.3 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| TUBB1_20q13.3 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |

In-silico results continued (part 3 of 3).

| Gene |  | $\begin{aligned} & \text { T } \\ & \frac{0}{6} \\ & \text { R } \\ & \text { B } \\ & 8 \end{aligned}$ | $\frac{5}{5}$ | ED |  |  | E 0 0 0.0 0.3 | $\begin{aligned} & \text { B } \\ & \stackrel{0}{E} \\ & 0 \end{aligned}$ | $\begin{aligned} & \text { Q } \\ & 0 \\ & 0 \\ & 0 \\ & 2 \end{aligned}$ | $\begin{gathered} \text { O } \\ \text { B } \\ \text { F } \\ \hline \end{gathered}$ |  |  | $\begin{aligned} & 5 \\ & \frac{5}{3} \\ & \frac{5}{3} \end{aligned}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| AIF1_6p21.33 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 |
| AIF1-L_9q34.12 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 |
| BRD2_6p21.32 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 |
| BRDT_1p22.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| BRD3_9q34.2 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 |
| BRD4_19p13.12 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 |
| C4_6p21.33 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 1 |
| C5_9q33.2 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 1 |
| C3_19p13.3 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 |
| CLIC1_6p21.33 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 |
| CLIC4_1p35.3 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 |
| CLIC3_9q34.3 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 |
| CLIC5_6p21.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| CLIC6_21q22.12 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| CLIC2_Xq28 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 |
| GPX5_6p22.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GPX4_19p13.3 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 |
| GPX1_3p21.31 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| GPX3_5q33.1 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| GPX2_14q23.3 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| NOTCH4_6p21.33 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| NOTCH2_1p11.2 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 |
| NOTCH1_9q34.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| NOTCH3_19p13.12 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 1 |
| PBX2_6p21.33 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 |
| PBX1_1q23.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 |
| PBX3_9q33.3 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 1 |
| PBX4_19p13.11 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| RXRB_6p21.32 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 1 |
| RXRG_1q23.3 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 |
| RXRA_9q34.2 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 |
| TUBB_6p21.3 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 |
| TUBB4_16q24.3 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 1 |
| TUBBL_18p11.3 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 1 |
| TUBB5_19p13.3 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| TUBB1_20q13.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |

## Appendix 6

## Summary of dot blot results

| Gene | 药 |  | $\begin{gathered} 0 \\ \frac{0}{3} \\ \frac{1}{3} \\ i \end{gathered}$ | $\begin{aligned} & 0 \\ & 0.0 \\ & 0 \\ & 0.0 \\ & 0.0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0 \\ & 0.5 \\ & 0.3 \\ & 0 \\ & 0 \end{aligned}$ | $$ | Paracentral gyrus of cerebral cortex | $\underset{\sim}{0}$ |  |  |  |  | $\begin{array}{r} 5 \\ \frac{0}{0} \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ \hline \end{array}$ |  | Medulla oblongata | E |  | $\begin{array}{r} \text { a } \\ \text { E } \\ \text { Z } \\ \text { In } \end{array}$ | $\begin{array}{r} \tilde{y} \\ \text { y } \\ \text { \| } \end{array}$ | $\begin{array}{\|c} 9 \\ 0 \\ 0 \\ \hline \end{array}$ |  |  |  | 7 0 0 0 0 0 0 0 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| AIF1_6p21.33 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| AIF1-L_9q34.12 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| BRD2_6p21.32 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| BRDT_1p22.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| BRD3_9q34.2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| BRD4_19p13.12 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| C4_6p21.33 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| C5_9q33.2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 |
| C3_19p13.3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| CLIC1_6p21.33 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| CLIC4_1p35.3 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| CLIC3_9q34.3 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| CLIC5_6p21.1 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 |
| CLIC6_21q22.12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CLIC2_Xq28 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GPX5_6p22.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GPX4_19p13.3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| GPX1_3p21.31 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| GPX3_5q33.1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| GPX2_14q23.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| NOTCH4_6p21.33 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| NOTCH2_1p11.2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| NOTCH1_9q34.3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 |
| NOTCH3_19p13.12 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| PBX2_6p21.33 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| PBX1_1q23.3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| PBX3_9q33.3 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| PBX4_19p13.11 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| RXRB_6p21.32 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| RXRG_1q23.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| RXRA_9q34.2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| TUBB_6p21.3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| TUBB4QL_10p15.3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| TUBB4_16q24.3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 |
| TUBBL_18p11.3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| TUBB5_19p13.3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 |
| TUBB1_20q13.3 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

## Dot blot results continued (2 of 3).

| Gene |  |  | $\begin{array}{\|c\|} 5 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 000 \\ 0 \end{array}$ | $\begin{gathered} \tilde{3} \\ \mathbf{E} \\ 0 \\ 0 \end{gathered}$ |  |  | $\begin{array}{r} \text { I } \\ \stackrel{3}{\mathbf{3}} \end{array}$ |  |  |  | $\begin{aligned} & 0 \\ & 0.0 \\ & 0 \\ & 0 \\ & 0 \\ & 0 \\ & 0 \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ |  | $\begin{gathered} \underline{E} \\ \underset{y}{3} \\ \cline { 1 - 2 } \end{gathered}$ | 空 |  | $\frac{5}{\text { 5 }}$ | $$ |  |  |  |  | $\underset{3}{9}$ |  | $\begin{aligned} & \frac{\pi}{0} \\ & \frac{0}{0} \end{aligned}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| AIF1_6p21.33 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| AIF1-L_9q34.12 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 0 |
| BRD2_6p21.32 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| BRDT_1p22.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| BRD3_9q34.2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| BRD4_19p13.12 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 |
| C4_6p21.33 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| C5_9q33.2 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 |
| C3_19p13.3 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 |
| CLIC1_6p21.33 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| CLIC4_1p35.3 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| CLIC3_9q34.3 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 |
| CLIC5_6p21.1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CLIC6_21q22.12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| CLIC2_Xq28 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GPX5_6p22.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GPX4_19p13.3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| GPX1_3p21.31 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| GPX3_5q33.1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| GPX2_14q23.3 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| NOTCH4_6p21.33 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 1 |
| NOTCH2_1p11.2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| NOTCH1_9q34.3 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| NOTCH3_19p13.12 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| PBX2_6p21.33 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| PBX1_1q23.3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| PBX3_9q33.3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| PBX4_19p13.11 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 |
| RXRB_6p21.32 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| RXRG_1q23.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| RXRA_9q34.2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| TUBB_6p21.3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| TUBB4QL_10p15.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| TUBB4_16q24.3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| TUBBL_18p11.3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| TUBB5_19p13.3 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 |
| TUBB1_20q13.3 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 0 |

## Dot blot results continued (3 of 3).

| Gene | \% | $\begin{aligned} & 0 \\ & 0 \\ & 0 \\ & 0 \\ & \text { in } \\ & \hline \end{aligned}$ |  | $\begin{aligned} & 3 \\ & 0 \\ & 0 \end{aligned}$ | $\stackrel{\vdots}{\hdashline}$ | $\begin{aligned} & \text { u} \\ & 0 \\ & 0 \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{gathered} \frac{a}{3} \\ \frac{0}{6} \\ \frac{1}{2} \\ \frac{1}{6} \end{gathered}$ | $\begin{gathered} \square \\ 0 \\ 0 \\ \cdot 0 \\ 0 \\ n \\ n \end{gathered}$ |  | Leukemia, HL-60 | $\begin{aligned} & n \\ & 0 \\ & 0 \\ & \underset{y}{u} \\ & x \end{aligned}$ |  | $\begin{aligned} & \underset{8}{8} \\ & E \\ & \underset{y}{z} \\ & \underset{z}{z} \end{aligned}$ |  |  |  | Lung carcinoma, A549 |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| AIF1_6p21.33 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| AIF1-L_9q34.12 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 |
| BRD2_6p21.32 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| BRDT_1p22.1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| BRD3_9q34.2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| BRD4_19p13.12 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 |
| C4_6p21.33 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| C5_9q33.2 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 |
| C3_19p13.3 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| CLIC1_6p21.33 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| CLIC4_1p35.3 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CLIC3_9q34.3 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 |
| CLIC5_6p21.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| CLIC6_21q22.12 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CLIC2_Xq28 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GPX5_6p22.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GPX4_19p13.3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| GPX1_3p21.31 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| GPX3_5q33.1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| GPX2_14q23.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| NOTCH4_6p21.33 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| NOTCH2_1p11.2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| NOTCH1_9q34.3 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| NOTCH3_19p13.12 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| PBX2_6p21.33 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| PBX1_1q23.3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| PBX3_9q33.3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| PBX4_19p13.11 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| RXRB_6p21.32 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| RXRG_1q23.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| RXRA_9q34.2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| TUBB_6p21.3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| TUBB4QL_10p15.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| TUBB4_16q24.3 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| TUBBL_18p11.3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| TUBB5_19p13.3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0 |
| TUBB1_20q13.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

## Appendix 7

Northern blot results and transcript sizes（kb）．The most dominant transcripts are in bold．

| Gene | ざ | E | U U U | $\stackrel{g}{\Xi}$ | $\stackrel{\searrow}{\vdots}$ |  | 気 | y 0 0 End |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| AIF1＿6p21．33 | $\begin{gathered} - \\ 3.0 \\ 1.25 \\ 0.6 \end{gathered}$ | $3.0$ | $\begin{gathered} 3.0 \\ 1.25 \end{gathered}$ | $3.0$ | $\begin{gathered} 1.25 \\ 0.6 \end{gathered}$ | $\begin{gathered} \hline 5.0 \\ 3.0 \\ - \\ 0.6 \end{gathered}$ | $\begin{gathered} - \\ 3.0 \\ - \\ 0.6 \end{gathered}$ | $\begin{gathered} \hline- \\ 3.0 \\ - \\ 0.6 \end{gathered}$ |
| AIF1－L＿9q34．12 | 3.4 | 3.4 | 3.4 | 0 | 0 | 0 | 3.4 | 0 |
| BRD2＿6p21．32 | $\begin{aligned} & \hline 4.6 \\ & 3.8 \end{aligned}$ | 4.6 3.8 | $\begin{aligned} & 4.6 \\ & 3.8 \end{aligned}$ | $\begin{aligned} & 4.6 \\ & 3.8 \end{aligned}$ | $\begin{aligned} & \hline 4.6 \\ & 3.8 \\ & \hline \end{aligned}$ | $\begin{aligned} & 4.6 \\ & 3.8 \end{aligned}$ | $\begin{aligned} & \hline 4.6 \\ & 3.8 \end{aligned}$ | 4.6 3.8 |
| BRDT＿1p22．1 | $7.0$ | $7.0$ | $7.0$ | 0 | $7.0$ | $7.0$ | $\begin{gathered} 7.0 \\ - \\ - \end{gathered}$ | $\begin{aligned} & \hline 7.0 \\ & 4.0 \\ & 3.5 \end{aligned}$ |
| BRD3＿9q34．2 | 6.5 | 6.5 | 6.5 | 6.5 | 6.5 | 6.5 | 6.5 | 6.5 |
| BRD4＿19p13．12 | $\begin{aligned} & 6.0 \\ & 4.4 \\ & \hline \end{aligned}$ | $\begin{aligned} & 6.0 \\ & 4.4 \\ & \hline \end{aligned}$ | $\begin{aligned} & 6.0 \\ & 4.4 \end{aligned}$ | $\begin{aligned} & 6.0 \\ & 4.4 \\ & \hline \end{aligned}$ | $\begin{aligned} & 6.0 \\ & 4.4 \end{aligned}$ | $\begin{aligned} & 6.0 \\ & 4.4 \end{aligned}$ | $\begin{aligned} & \hline 6.0 \\ & 4.4 \end{aligned}$ | 6.0 4.4 |
| C4＿6p21．33 | 0 | 0 | 0 | 0 | 5.4 | 0 | 5.4 | 0 |
| C5＿9q33．2 | 0 | 0 | 0 | 0 | $\begin{aligned} & \hline 6.0 \\ & 5.0 \\ & 4.2 \\ & 1.6 \\ & 1.0 \\ & \hline \end{aligned}$ | 0 | $5.0$ | $5.0$ $4.2$ |
| C3＿19p13．3 | 0 | 0 | 0 | 0 | 5.0 | 0 | 0 | 0 |
| CLIC1＿6p21．33 | $\begin{gathered} 1.25 \\ 1.1 \\ \hline \end{gathered}$ | 0 | $\begin{gathered} 1.25 \\ 1.1 \\ \hline \end{gathered}$ | 1.251 .1 | $\begin{gathered} 1.25 \\ 1.1 \\ \hline \end{gathered}$ | $\begin{gathered} 1.25 \\ 1.1 \\ \hline \end{gathered}$ | $\begin{gathered} 1.25 \\ 1.1 \\ \hline \end{gathered}$ | $\begin{gathered} 1.25 \\ 1.1 \\ \hline \end{gathered}$ |
| CLIC4＿1p35．3 | 4.0 | 0 | 4.0 | 4.0 | 4.0 | 4.0 | 4.0 | 0 |
| CLIC3＿9q34．3 | $4.4$ | 0 | $\begin{gathered} \hline 5.5 \\ - \\ 2.6 \\ \mathbf{0 . 7} \\ \hline \end{gathered}$ | $0.7$ | $0.7$ | - 4.4 - | - 4.4 - - | - 4.4 - |
| CLIC5＿6p21．1 | 0 | $\begin{aligned} & 2.7 \\ & 2.4 \end{aligned}$ | 0 | 2.7 <br> - | 2.7 <br> - | 0 | $\begin{aligned} & 2.7 \\ & 2.4 \end{aligned}$ | 2.7 <br> - |
| CLIC6＿21q22．12 | $\begin{aligned} & \hline 6.0 \\ & 3.8 \\ & 3.0 \\ & 2.3 \\ & \hline \end{aligned}$ | 0 | 0 | $\begin{aligned} & 3.8 \\ & 3.0 \end{aligned}$ | $\overline{0}$ | 6.0 3.8 - | $\begin{aligned} & - \\ & 0 \\ & \hline \end{aligned}$ | - <br> - <br> 3.0 <br>  |
| CLIC2＿Xq28 | $\begin{gathered} 1.7 \\ 1.25 \end{gathered}$ | 0 | $\begin{gathered} 1.7 \\ 1.25 \end{gathered}$ | $\begin{gathered} \hline 1.7 \\ 1.25 \end{gathered}$ | $\begin{gathered} \hline 1.7 \\ 1.25 \end{gathered}$ | $\begin{gathered} 1.7 \\ 1.25 \end{gathered}$ | $\begin{gathered} 1.7 \\ 1.25 \end{gathered}$ | $\begin{gathered} \hline 1.7 \\ 1.25 \end{gathered}$ |
| GPX5＿6p22．1 | $\begin{aligned} & 0.8 \\ & 0.6 \end{aligned}$ | $\overline{-}$ | $0.6$ | 0 | $\begin{gathered} \hline- \\ 0.8 \\ 0.6 \end{gathered}$ | $\begin{aligned} & \hline 3.8 \\ & 0.8 \\ & 0.6 \end{aligned}$ | 0 | $\begin{gathered} \hline- \\ 0.8 \\ 0.6 \end{gathered}$ |
| GPX4＿19p13．3 | $\begin{aligned} & \hline 4.4 \\ & 2.6 \\ & 2.0 \\ & \mathbf{0 . 9} \\ & \hline \end{aligned}$ | $\begin{array}{r} - \\ 0.9 \\ \hline \end{array}$ | $\begin{array}{r} - \\ 2.6 \\ 2.0 \\ \mathbf{0 . 9} \\ \hline \end{array}$ | $0.9$ | $\begin{aligned} & \hline 4.4 \\ & 2.6 \\ & 2.0 \\ & \mathbf{0 . 9} \\ & \hline \end{aligned}$ | $\begin{gathered} 4.4 \\ - \\ 2.0 \\ \mathbf{0 . 9} \\ \hline \end{gathered}$ | $\begin{aligned} & 2.0 \\ & \mathbf{0 . 9} \\ & \hline \end{aligned}$ | $0.9$ |
| GPX1＿3p21．31 | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 |
| GPX3＿5q33．1 | $0.7$ | 0 | $0.7$ | $0.7$ | $\begin{aligned} & \hline 1.8 \\ & \mathbf{0 . 7} \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 1.8 \\ & 0.7 \\ & \hline \end{aligned}$ | $0.7$ | $0.7$ |
| GPX2＿14q23．3 | 0 | 0 | 0 | 0 | 0 | 0 | 0.9 | 0 |
| NOTCH4＿6p21．33 | $\begin{aligned} & 7.8 \\ & 6.8 \\ & 2.4 \end{aligned}$ | － | $\begin{aligned} & 7.5 \\ & 6.8 \end{aligned}$ | $\begin{aligned} & \hline 7.5 \\ & 6.8 \end{aligned}$ | $2.4$ | $\begin{aligned} & 6.8 \\ & 2.4 \\ & \hline \end{aligned}$ | 6.8 | - <br> 6.8 <br> 2.4 |


|  | - | 1.6 | - | - | - | - | - | 1.6 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 0.8 | - | 0.8 | - | 0.8 | 0.8 | - | 0.8 |
| NOTCH2_1p11.2 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
|  | 1.9 | - | 1.9 | 1.9 | 1.9 | 1.9 | 1.9 | 1.9 |
| NOTCH1_9q34.3 | 9.3 | 0 | 9.3 | 0 | 9.3 | 9.3 | 9.3 | 0 |
| NOTCH3_19p13.12 | 8 | 8 | 8 | 0 | 8 | 8 | 8 | 8 |
| PBX2_6p21.33 | 3.2 | 3.2 | 3.2 | 3.2 | 3.2 | 3.2 | 3.2 | 3.2 |
| PBX1_1q23.3 | 7.5 | 7.5 | 7.5 | 7.5 | 7.5 | 7.5 | 7.5 | 7.5 |
|  | - | - | - | - | - | 4.4 | - | 4.4 |
|  | 2.9 | - | 2.9 | 2.9 | 2.9 | 2.9 | 2.9 | 2.9 |
|  | - | - | - | - | - | 2.6 | - | - |
| PBX3_9q33.3 | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 | 0 | 2.5 |
|  | 2.2 | - | - | - | - | 2.2 |  | 2.2 |
|  | 1.4 | - | - | - | - | - |  | - |
| PBX4_19p13.11 | - | - | - | 0 | - | 6.0 | - | - |
|  | 4.5 | 4.5 | 4.5 |  | 4.5 | 4.5 | 4.5 | 4.5 |
|  | 1.4 | - | 1.4 |  | 1.4 | 1.4 | - | 1.4 |
|  | 1.2 | - | 1.2 |  | 1.2 | - | - | - |
| RXRB_6p21.32 | 7.7 | - | - | 0 | - | 7.7 | - | - |
|  | 2.8 | 2.8 | 2.8 |  | - | 2.8 | 2.8 | 2.8 |
|  | 1.7 | - | - |  | 1.7 | 1.7 | - | - |
| RXRG_1q23.3 | 1.7 | 0 | 2.8 | 0 |  |  |  |  |
|  |  |  |  |  | $1.5$ | 1.7 | 0 | 1.5 |
|  |  |  | 0.9 |  |  |  |  |  |
| RXRA_9q34.2 | 5.4 | 5.4 | 5.4 | 0 | 5.4 | 5.4 | 0 | 0 |
| TUBB_6p21.3 | - | - | 5.1 | - | - | - | - | - |
|  | 4.8 | - | - | - | - | - | - | - |
|  | 4.0 | - | - | - | - | 4.8 | - | - |
|  | 2.5 | 2.5 | - | - |  | 4.0 | - | - |
|  | 1.7 | 1.7 | 1.7 | 1.7 | 1.7 | 1.7 | 1.7 | 1.7 |
|  | - | - | - | - | - | 1.35 | - | 1.35 |
| TUBB4QL_10p15.3 | 0 | 2.8 | 0 | 0 | 0 | 0 | 0 | 0 |
| TUBB4_16q24.3 | 1.7 | 1.7 | 1.7 | 1.7 | 1.7 | 1.7 | 1.7 | 1.7 |
|  | 1.3 | 1.3 | 1.3 | 1.3 | 1.3 | 1.3 | 1.3 | 1.3 |
| TUBBL_18p11.1 | 1.3 | 1.3 | 1.3 | 1.3 | 1.3 | 1.3 | 1.3 | 1.3 |
| TUBB5_19p13.3 | 0 | 2.3 | 0 | 0 | 0 | 0 | 0 | 2.3 |
| TUBB1_20q13.32 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

## Appendix 8

Summary of microarray results.

| Gene |  | E |  | $\frac{\tilde{y y}}{\frac{0}{5}}$ | $\begin{gathered} \text { nu } \\ \text { Non } \\ \hline \end{gathered}$ | 言 |  | : | $\underset{A}{\underset{A}{A}}$ | $\begin{aligned} & \text { O. } \\ & \underset{\Xi}{n} \\ & \hat{D} \\ & \text { Din } \end{aligned}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| AIF1_6p21.33 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 |
| AIF1-L_9q34.12 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| BRD2_6p21.32 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| BRDT_1p22.1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| BRD3_9q34.2 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 |
| BRD4_19p13.12 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| C4_6p21.33 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| C5_9q33.2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| C3_19p13.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CLIC1_6p21.33 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| CLIC4_1p35.3 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 |
| CLIC3_9q34.3 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CLIC5_6p21.1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| CLIC6_21q22.12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CLIC2_Xq28 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| GPX5_6p22.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GPX4_19p13.3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| GPX1_3p21.31 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| GPX3_5q33.1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| GPX2_14q23.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| NOTCH4_6p21.33 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| NOTCH2_1p11.2 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 |
| NOTCH1_9q34.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| NOTCH3_19p13.12 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 |
| PBX2_6p21.33 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PBX1_1q23.3 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 |
| PBX3_9q33.3 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 |
| PBX4_19p13.11 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 |
| RXRB_6p21.32 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 |
| RXRG_1q23.3 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| RXRA_9q34.2 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 1 |
| TUBB_6p21.3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 |
| TUBB4QL_10p15.3 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 |
| TUBB4_16q24.3 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| TUBBL_18p11.3 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 |
| TUBB5_19p13.3 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| TUBB1_20q13.3 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |

## Appendix 9

Comparison of three methods used to generate the expression profiles for nine MHC paralogous gene families. The differences between the three methods are highlighted in yellow for the nine tissues common to each method.

| Gene | Adrenal gland |  |  | Brain |  |  | Skeletal muscle |  |  | Spleen |  |  | Testis |  |  | Kidney |  |  | T cell |  |  | B cell |  |  | Lung |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | M | D | S | M | D | S | M | D | S | M | D | S | M | D | S | $\mathbf{M}$ | D | S | M | D | S | M | D | S | M | D | S |
| AIF1_6p21.33 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| AIF1-L_9q34.12 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| BRD2_6p21.32 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| BRDT_1p22.1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| BRD3_9q34.2 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 |
| BRD4_19p13.12 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 |
| C4_6p21.33 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 |
| C5_9q33.2 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| C3_19p13.3 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 |
| CLIC1_6p21.33 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| CLIC4_1p35.3 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 |
| CLIC3_9q34.3 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| CLIC5_6p21.1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CLIC6_21q22.12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| CLIC2_Xq28 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| GPX5_6p22.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GPX4_19p13.3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| GPX1_3p21.31 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| GPX3_5q33.1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| GPX2_14q23.3 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| NOTCH4_6p21.33 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| NOTCH2_1p11.2 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 |
| NOTCH1_9q34.3 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| NOTCH3_19p13.12 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 |
| PBX2_6p21.33 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| PBX1_1q23.3 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 |
| PBX3_9q33.3 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 1 |
| PBX4_19p13.11 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 |
| RXRB_6p21.32 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| RXRG_1q23.3 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| RXRA_9q34.2 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| TUBB_6p21.3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| TUBB5_19p13.3 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 1 |
| TUBB4_16q24.3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 1 |
| TUBB2_18p11.1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| TUBB1_20q13.32 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Total differences | 5 | 3 | 9 | 4 | 1 | 8 | 5 | 4 | 5 | 3 | 5 | 7 | 4 | 4 | 5 | 16 | 1 | 8 | 3 | 2 | 5 | 2 | 2 | 5 | 15 | 0 | 10 |
| \% difference | 14 | 8 | 25 | 11 | 3 | 22 | 14 | 11 | 14 | 8 | 14 | 19 | 11 | 11 | 14 | 44 | 3 | 22 | 8 | 6 | 14 | 6 | 6 | 14 | 42 | 0 | 28 |

## Appendix 1

Summary of the annotation of the chromosomal region 9 q 32 to 9 q 34.3 . Putative paralogues are in bold text.

| $\frac{0}{0}$ |  | 0 0 5 0 0 0 0 0 0 | SPTR, Refseq or Ensembl entry |  | $\begin{aligned} & \text { I } \\ & \text { J } \\ & \text { N } \\ & \text { N } \\ & \text { N } \end{aligned}$ |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| AL160275 | q32 | ATP6V1G1 | 075348 | 109082196 | 109092823 | 118 | Vacuolar ATP synthase subunit |
|  | q32 | NM_153045 | Q8ND43 | 109118880 | 109140873 | 281 | Unknown |
| AL390240 | q32 | TNFSF15 | 095150 | 109283763 | 109300582 | 251 | Tumor necrosis factor ligand |
| AL133412 | q32 | TNFSF8 | P32971 | 109398384 | 109424753 | 234 | Tumor necrosis factor ligand |
| AL162425 | q33.1 | TNC | P24821 | 109514975 | 109612609 | 2201 | Tenascin precursor |
| AL355601 | q33.1 | NM_017418 | O17418 | 109636267 | 109897093 | 95 | Deleted in esophageal cancer 1 |
| AL731824 | q33.1 | No genes |  |  |  |  |  |
| AL714001 | q33.1 | No genes |  |  |  |  |  |
| AL691420 | q33.1 | No genes |  |  |  |  |  |
| AL731897 | q33.1 | No genes |  |  |  |  |  |
| AL731813 | q33.1 | No genes |  |  |  |  |  |
| AL732367 | q33.1 | EST-YD1 | Q9P2X8 | 110398837 | 110399090 | 84 | EST-YD1 protein |
| AL691426 | q33.1 | No genes |  |  |  |  |  |
| AL353141 | q33.1 | No genes |  |  |  |  |  |
| AL137024 | q33.1 | PAPPA | Q13219 | 110677328 | 110808083 | 716 | Pregnancy associated plasma protein A |
| AL669963 | q33.1 | No genes |  |  |  |  |  |
| AL133282 | q33.1 | ASTN2 | O75129 | 110836698 | 111823883 | 1321 | Astrotactin 1 |
|  | q33.1 | Novel | ENSG00000179990 | 110963536 | 110981401 | 73 | Unknown |
| AL133284 | q33.1 | TRIM32 | Q13049 | 111098800 | 111112220 | 653 | Zing finger protein HT2A |
| AL157829 | q33.1 | Novel | ENSG00000136913 | 111196159 | 111196227 | 23 | Unknown |
|  | q33.1 | FLJ20958 | Q9BQ00 | 111205755 | 111205826 | 24 | Unknown |
| AL392085 | q33.1 | No genes |  |  |  |  |  |
| AL354981 | q33.1 | No genes |  |  |  |  |  |
| AL355608 | q33.1 | No genes |  |  |  |  |  |
| AL358792 | q33.1 | No genes |  |  |  |  |  |
| AL445644 | q33.1 | No genes |  |  |  |  |  |
| AL161630 | q33.1 | Novel | ENSG00000179956 | 112057445 | 112065871 | 72 | Unknown |
| AL160272 | q33.1 | TLR4 | O00206 | 112113140 | 112124614 | 839 | TOLL-like receptor 4 precursor |
| AL354754 | q33.1 | No genes |  |  |  |  |  |
| AL445663 | q33.1 | No genes |  |  |  |  |  |
| AL158831 | q33.1 | No genes |  |  |  |  |  |
| AL365195 | q33.1 | No genes |  |  |  |  |  |
| AL445440 | q33.1 | No genes |  |  |  |  |  |
| AL355592 | q33.1 | No genes |  |  |  |  |  |
| AL589703 | q33.1 | No genes |  |  |  |  |  |


| AL157780 | q33.1 | No genes |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| AL512602 | q33.1 | No genes |  |  |  |  |  |
| AL445310 | q33.1 | No genes |  |  |  |  |  |
| AL353773 | q33.1 | DCBBR1 | O14618 | 113575169 | 113778264 | 761 | Deleted in bladder cancer chromosome region |
| AL138894 | q33.1 | No genes |  |  |  |  |  |
| AL353630 | q33.1 | No genes |  |  |  |  |  |
| AC006288 | q33.1 | No genes |  |  |  |  |  |
| AL445683 | q33.1 | No genes |  |  |  |  |  |
| AL354931 | q33.1 | No genes |  |  |  |  |  |
| AL441989 | q33.1 | No genes |  |  |  |  |  |
| AL355589 | q33.1 | No genes |  |  |  |  |  |
| AL592549 | q33.1 | No genes |  |  |  |  |  |
| AL353736 | q33.1 | No genes |  |  |  |  |  |
| AL391870 | q33.2 | CDK5RAP2 | Q9NV90 | 114797706 | 114988994 | 943 | CDK5 regulatory subunit associated protein 2 |
| AL590642 | q33.2 | No genes |  |  |  |  |  |
| AL138836 | q33.2 | EGFL5 | Q9H1U4 | 115009649 | 115068409 | 401 | EGF like domain multiple 5 protein |
|  | q33.2 | Novel | ENSG00000176341 | 115098762 | 115122988 | 236 | Unknown |
| AL161911 | q33.2 | FBXW2 | Q9UKT8 | 115160814 | 115202253 | 454 | F-BOX/WD-repeat protein 2 |
|  | q33.2 | PSMD5 | Q16401 | 115224889 | 115251748 | 504 | 26S proteasome non-ATPase regulatory subunit 5 |
|  | q33.2 | Novel | ENSG00000180095 | 115251902 | 115263209 | 105 | Unknown |
| AL354792 | q33.2 | Q9UFS9 | Q9UFS9 | 115264535 | 115286029 | 473 | Transcription factor |
| AC006430 | q33.2 | PRO1995 | Q9P1F7 | 115299108 | 115300075 | 105 | Unknown |
|  | q33.2 | TRAF1 | EBI6 | 115311227 | 115337603 | 350 | TNF receptor associated factor 1 |
|  | q33.2 | C5 | P01031 | 115361172 | 11549110 | 1676 | Complement C5 precursor |
| AL137068 | q33.2 | Novel | ENSG00000171635 | 115499108 | 115516745 | 219 | Testis specfic |
|  | q33.2 | CEP1 | O07018 | 115521379 | 115586444 | 1800 | Centrosomal protein 1 |
|  | q33.2 | RAB14 | P35287 | 115586971 | 115610724 | 215 | Ras-related protein |
| AL513122 | q33.2 | Novel | ENSG00000180552 | 115647510 | 115648753 | 409 | Unknown |
|  | q33.2 | MOST2 | Q9NRJ2 | 115689602 | 115694364 | 209 | MOST2 protein |
|  | q33.2 | GSN | O06396 | 115708681 | 115741676 | 782 | Gelosin precursor, plasma |
| AL161784 | q33.2 | EPB72 | P27105 | 115747913 | 115779060 | 288 | Erythrocyte band 7 integral membrane protein |
| AL359644 | q33.2 | Novel | ENSG00000165196 | 115868813 | 115888025 | 174 | Unknown |
| AL357936 | q33.2 | No genes |  |  |  |  |  |
| AL365274 | q33.2 | DAP2IP | Q8TDL2 | 115974718 | 116194365 | 964 | DOC-2/DAB2 interactive protein |
| AL450285 | q33.2 | Novel |  |  |  |  |  |
| AL596244 | q33.2 | Novel |  |  |  |  |  |
| AL445587 | q33.2 | Novel | ENSG00000171539 | 116362696 | 116383814 | 140 | Unknown |
| AL442634 | q33.2 | Q8NHH0 | Q8NHH0 | 116397745 | 116502441 | 538 | Unknown |
| AL162423 | q33.2 | NDUFA8 | P51970 | 116552893 | 116568579 | 172 | NADH-Ubiquinone oxidoreductase subunit |
| AL162424 | q33.2 | LHX6 | Q9UPM6 | 116611414 | 11667540 | 363 | LIM/Homeobox protein |
|  | q33.2 | NM_033117 | Q96H35 | 116648845 | 11667367 | 190 | Unknown |
|  | q33.2 | NM_138777 | Q9BU92 | 116679683 | 116732299 | 262 | RIKEN cDNA D02 |
|  | q33.2 | PTGS1 | P23219 | 116779785 | 116804538 | 596 | Prostaglandin G/H synthase 1 precursor |
| AL359636 | q33.2 | OR | Q8NGS3 | 116885796 | 116886761 | 322 | Olfactory receptor |
|  |  | OR | OR1J5 | 116919637 | 116920575 | 313 | Olfactory receptor |
|  |  | OR | Q8NGS1 | 116927976 | 116928914 | 313 | Olfactory receptor |
|  |  | OR | OR1N1 | 116935199 | 116936125 | 309 | Olfactory receptor |
|  |  | OR | Q8NGR9 | 116960247 | 116962994 | 316 | Olfactory receptor |
|  |  | OR | Q8NGR8 | 116976386 | 116977312 | 309 | Olfactory receptor |
| Al162254 | q33.2 | OR | Q9UDD7 | 117016871 | 117017632 | 254 | Olfactory receptor |
|  |  | OR | OR1Q1 | 117023573 | 117024514 | 314 | Olfactory receptor |
| AC006313 | q33.2 | OR | Q8NGR6 | 117037417 | 117038367 | 295 | Olfactory receptor |
|  |  | OR | Q8NH94 | 117070551 | 117071480 | 317 | Olfactory receptor |
|  |  | OR | Q8NH93 | 117083965 | 117084936 | 324 | Olfactory receptor |
|  |  | OR | Q8NGR5 | 117132825 | 117133757 | 311 | Olfactory receptor |


|  |  | OR | Q96R80 | 117158887 | 117159534 | 216 | Olfactory receptor |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | OR | Q8WVK7 | 117170703 | 117171065 | 121 | Olfactory receptor |
| AL359512 | q33.2 | OR | Q8NGR3 | 117208958 | 117209905 | 316 | Olfactory receptor |
|  | q33.2 | PDCL | Q13371 | 117226985 | 117237466 | 301 | Phosdusin-like protein |
|  | q33.2 | MNAB | O18835 | 117253391 | 117314050 | 1191 | Membrane associated binding protein |
| AL731645 | q33.2 | ZID | Q15916 | 117317457 | 117320910 | 424 | Zinc finger protein |
|  | q33.2 | BIOR | Q9HCK0 | 117326928 | 117340094 | 441 | Zinc finger protein |
|  | q33.2 | GAPCenA | Q9Y3P9 | 117349852 | 117513707 | 997 | RAB6 GTPase activating protein |
| AL358946 | q33.3 | No genes |  |  |  |  |  |
| AL365338 | q33.2 | NM_030814 | Q9H2N8 | 117518337 | 117522309 | 167 | Unknown |
|  | q33.2 | STRBP | Q96S19 | 117533552 | 117593141 | 658 | RNA binding protein |
| AL365504 | q33.3 | PRO226 | Q9P180 | 117674928 | 117675167 | 80 | Unknown |
| AL445489 | q33.3 | FLJ38464 | Q8N930 | 117782642 | 117787587 | 215 | Unknown |
|  | q33.3 | FLJ00224 | Q8TEH3 | 117788495 | 118338969 | 896 | Unknown |
| AL161790 | q33.3 | No genes |  |  |  |  |  |
| AL390774 | q33.3 | No genes |  |  |  |  |  |
| AL158208 | q33.3 | No genes |  |  |  |  |  |
| AC006450 | q33.3 | LHX2 | P50458 | 118420439 | 118441992 | 406 | LIM/Homeobox protein |
| AL158052 | q33.3 | No genes |  |  |  |  |  |
| A1445284 | q33.3 | No genes |  |  |  |  |  |
| AL162724 | q33.3 | NEK6 | Q9HC98 | 118666435 | 118761271 | 338 | Serine-threonine protein kinase |
| AL137846 | q33.3 | PSMB7 | Q99436 | 118762294 | 118824271 | 277 | Proteasome subunit beta type 7 |
|  | q33.3 | Q8NH12 | Q8NH12 | 118874053 | 118892161 | 984 | Seven transmembrane helix receptor |
| AL354979 | q33.3 | NR5A1 | Q13285 | 118890062 | 118916249 | 461 | Steroidogenic factor 1 |
|  | q33.3 | NR6A1 | Q15406 | 118928956 | 119180139 | 476 | Orphan nuclear receptor |
| AL669818 | q33.3 | No genes |  |  |  |  |  |
| AL158075 | q33.3 | No genes |  |  |  |  |  |
| AL354928 | q33.3 | FLJ90228 | Q8NCI9 | 119186100 | 119223707 | 318 | Unknown |
|  | q33.3 | Novel | ENSG00000136918 | 119263034 | 119266399 | 233 | Unknown |
|  | q33.3 | RPL35 | P42766 | 119266713 | 119270796 | 141 | 60S ribosomal protein L35 |
|  | q33.3 | NM_030978 | Q9BPX5 | 119278120 | 119286561 | 159 | Actin related protein |
|  | q33.3 | GOLGA1 | Q92805 | 119287196 | 119349928 | 767 | Golgin 97,gap junction protein |
| AL451125 | q33.3 | FLJ40705 | Q8N1I4 | 119360938 | 119552351 | 629 | Unknown |
| AL445930 | q33.3 | PPP6C | O00743 | 119557957 | 119598620 | 305 | Serine/threonine protein phospatase 6 |
|  | q33.3 | Novel | ENSG00000173602 | 119603477 | 119604650 | 282 | 40S ribosomal protein |
| AL354710 | q33.3 | P40 | O00568 | 119609374 | 119642831 | 372 | RAB9 effector P40 |
|  | q33.3 | HSPA5 | P11021 | 119643682 | 119650159 | 654 | 78 KDA Glucose regulated protein |
|  | q33.3 | Novel | ENSG00000176094 | 119672414 | 119672919 | 158 | 40S ribosomal protein |
| AL627223 | q33.3 | FLJ20119 | Q9NXQ1 | 119670661 | 119773833 | 833 | Unknown |
| AL359632 | q33.3 | MAPKAP1 | Q9BPZ7 | 119846225 | 120116031 | 486 | MAP kinase interacting protein 1 |
| AL162584 | q33.3 | Novel | ENSG00000178022 | 120004502 | 120005454 | 316 | Unknown |
| AL358074 | q33.3 | SIN1 |  | 119846225 | 120116031 | 522 | SAPK interacting protein 1 |
|  | q33.3 | NM_016158 | Q9UN39 | 120153187 | 120155380 | 129 | Erythrocyte transmembrane protein |
| AL627303 | q33.3 | No genes |  |  |  |  |  |
| AL445186 | q33.3 | PBX3 | P40426 | 120156161 | 120376205 | 434 | Pre-B-cell leukaemia transcription factor 3 |
| AL589923 | q33.3 | No genes |  |  |  |  |  |
| AL445664 | q33.3 | No genes |  |  |  |  |  |
| AL162391 | q33.3 | No genes |  |  |  |  |  |
| AC006443 | q33.3 | FLJ00022 | Q9H7P6 | 120735668 | 120915859 | 344 | Unknown |
| AL356309 | q33.3 | No genes |  |  |  |  |  |
| AL161908 | q33.3 | No genes |  |  |  |  |  |
| AL161731 | q33.3 | LMX1B | O60663 | 121023337 | 121105270 | 379 | LIM/Homeobox protein |
|  | q33.3 | Q8N243 | Q8N243 | 121212014 | 121214492 | 115 | Unknown |
|  | q33.3 | ZNF297B | O43298 | 121213845 | 121244041 | 467 | Zinc finger 297B |
| AL354944 | q33.3 | KIAA1993 | Q8NCN2 | 121269484 | 121289729 | 532 | Unknown |


| AL160169 | q33.3 | No genes |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| AL356862 | q33.3 | RalGPS1A | Q8WUV7 | 121323592 | 121631982 | 590 | Ral guanine nuceotide factor |
|  | q33.3 | ANGPTL2 | Q9UKU9 | 121496150 | 121531456 | 493 | Angiopoietin-related protein 2 |
| AL357623 | q33.3 | No genes |  |  |  |  |  |
| AL450263 | q33.3 | Novel | ENSG00000176889 | 121633429 | 121650133 | 78 | Unknown |
|  | q33.3 | NM_032293 | Q9BQH6 | 121673400 | 121802357 | 802 | Unknown |
| AL445222 | q33.3 | SLC2A8 | Q9NY64 | 121806004 | 121816716 | 477 | Solute carrier family 2 |
|  | q33.3 | RPL12 | P30050 | 128564940 | 121860226 | 164 | 60S ribosomal protein L12 |
|  | q33.3 | FLJ31641 | Q96MZ7 | 121860323 | 121912317 | 696 | Unknown |
|  | q33.3 | Novel | ENSG00000176217 | 121901370 | 121904622 | 109 | Unknown |
|  | q33.3 | $\begin{gathered} \text { NBL_HUMA } \\ \mathrm{N} \\ \hline \end{gathered}$ | Q96TA1 | 121914157 | 121987798 | 733 | Niban-like protein. |
| AL390116 | q33.3 | No genes |  |  |  |  |  |
| AL162426 | q34.11 | STXBP1 | Q64320 | 122021098 | 122101525 | 594 | Syntaxin binding protein 1 |
|  | q34.11 | Novel | ENSG00000160401 | 122108029 | 122124506 | 785 | Unknown |
|  | q34.11 | FLJ00176 | Q8TEL7 | 122124875 | 122140409 | 867 | Unknown |
|  | q34.11 | TOR2A | Q96LSL7 | 122140333 | 122144087 | 253 | Torsin family 2 , member A |
|  | q34.11 | SH2D3C | Q9Y2X5 | 122147126 | 122187504 | 703 | SH2 Domain containing protein 3 |
| AL162586 | q34.11 | CDK9 | P50750 | 122194861 | 122198896 | 372 | Cell division protein kinase 9 |
|  | q34.11 | Novel | ENSG00000177953 | 122199888 | 122201861 | 85 | Unknown |
|  | q34.11 | FPGS | Q05932 | 122211733 | 122222873 | 587 | Folypolyglutamate synthase |
|  | q34.11 | FLJ33157 | Q96LW6 | 122225388 | 122225972 | 195 | Unknown |
|  | q34.11 | ENG | P17813 | 122224494 | 122263514 | 658 | Endoglin procursor |
| AL157935 | q34.11 | AK1 | P00568 | 122275199 | 122286472 | 194 | Adenylate kinase isoenzyme 1 |
|  | q34.11 | FLJ13838 | Q9H8A2 | 122294130 | 122308407 | 352 | Beta-N-Acetylgalactosaminide |
|  | q34.11 | SIAT7D | Q9H4F1 | 122316695 | 122325831 | 298 | Sialyltransferase |
|  | q34.11 | Novel | ENSG00000167103 | 122330677 | 122339810 | 471 | Kinase |
|  | q34.11 | Novel | ENSG00000136908 | 122343908 | 122347297 | 162 | Unknown |
|  | q34.11 | FLJ00179 | Q8TEL4 | 122349392 | 122356974 | 194 | Unknown |
|  | q34.11 | NM_018033 | Q9NW83 | 122374689 | 122375144 | 152 | Unknown |
| AL360268 | q34.11 | Q8WU12 | Q8WU12 | 122472894 | 122475975 | 172 | Unknown |
| AL590708 | q34.11 | KIAA1896 | Q96PZ1 | 122500273 | 122518054 | 568 | Mitochondrial solute carrier |
|  | q34.11 | PTGES2 | Q9H7Z7 | 122529502 | 122537271 | 379 | Prostaglandin E synthase 2 |
|  | q34.11 | Q9N1Y9 | Q9N1Y9 | 122537454 | 122538008 | 185 | Unknown |
|  | q34.11 | LCN2 | P80188 | 122558275 | 122562260 | 192 | Lipocalin |
|  | q34.11 | C9orf16 | Q9BUW7 | 122569160 | 122572735 | 83 | Unknown |
|  | q34.11 | CIZ1 | Q9ULV3 | 122574874 | 122613197 | 967 | Zinc finger protein |
|  | q34.11 | DNM1 | Q05193 | 122612217 | 122664055 | 864 | Dynamin-1 |
|  | q34.11 | GOLGA2 | Q08379 | 122665504 | 122684750 | 1008 | Golgin-95 |
| AL590722 | q34.11 | Q8N2W6 | Q8N2W6 | 122685026 | 122697798 | 209 | Unknown |
|  | q34.11 | FLJ21673 | Q9H6Y8 | 122709723 | 122710145 | 423 | Unknown |
| AL359091 | q34.11 | FLJ11094 | O95900 | 122717908 | 122731245 | 331 | Unknown |
|  | q34.11 | C0Q4 | Q9Y3A0 | 122731344 | 122742880 | 265 | Coenzyme Q biosynthesis protein 4 |
|  | q34.11 | SLC27A4 | O95186 | 122749454 | 122770025 | 640 | Fatty acid transport protein 4 |
|  | q34.11 | NM_030914 | Q9BTM9 | 122780169 | 122799542 | 101 | Unknown |
|  | q34.11 | KIAA1502 | Q9P226 | 122820574 | 122846159 | 560 | Cerebral cell adhesion molecule |
|  | q34.11 | ODF2 | O14721 | 122864961 | 122909768 | 638 | Outer dense fibre of sperm tails 2 |
| AL445287 | q34.11 | GLE1L | 075458 | 122913513 | 122951096 | 698 | Gle-1 like RNA export mediator |
| AL356481 | q34.11 | SPTAN1 | Q13813 | 122961411 | 123042401 | 2474 | Spectrin alpha chain |
|  | q34.11 | NM_052844 | Q9BV46 | 123042469 | 123065595 | 522 | Unknown |
|  | q34.11 | SET | Q01105 | 123092703 | 123105196 | 290 | SET (HLA-DR associated protein II) |
| AL359678 | q34.11 | No genes |  |  |  |  |  |
| AL441992 | q34.11 | PKNbeta | O13355 | 123111331 | 123129414 | 889 | Protein kinase |
|  | q34.11 | ZDHHC12 | O32799 | 123129677 | 123132930 | 267 | Zinc finger protein |
|  | q34.11 | ZYG | O00156 | 123138594 | 123180701 | 766 | ZYG homologue |
|  | q34.11 | FLJ10743 | Q9NVG8 | 123196140 | 123219240 | 275 | Unknown |


|  | q34.11 | ENDOG | Q14249 | 123227276 | 123231484 | 297 | Endonuclease G |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | q34.11 | HSPC109 | Q9P041 | 123228459 | 123238629 | 384 | Unknown |
|  | q34.11 | CCBL1 | Q16773 | 123241750 | 123290846 | 422 | Cyoplasmic cysteine |
| AL672142 | q34.11 | KIAA1437 | Q9P2B1 | 123294854 | 12336844 | 811 | Unknown |
|  | q34.11 | Q96GM4 | Q96GM4 | 123329703 | 123351210 | 206 | Unknown |
|  | q34.11 | KIAA1094 | Q9UPQ8 | 123354339 | 123356427 | 538 | Unknown |
| AL592211 | q34.11 | KIAA0169 | Q14675 | 123357991 | 123415903 | 1739 | Unknown |
|  | q34.11 | SH3GLB2 | Q9BRZ5 | 123416600 | 123437108 | 130 | SH3-containing protein |
|  | q34.11 | FLJ00199 | Q9TEJ6 | 123445452 | 123480880 | 383 | Unknown |
|  | q34.11 | Q96GF8 | Q96GF8 | 123489937 | 123499243 | 237 | Unknown |
| AL158151 | q34.11 | CRAT | P43155 | 123503602 | 123519612 | 626 | Cartinine o-acetyltransferase |
|  | q34.11 | PPP2R4 | Q15257 | 123519773 | 123557754 | 358 | Protein phosphatase 2A |
|  | q34.11 | Novel | ENSG00000167133 | 123585649 | 123586860 | 290 | Unknown |
| AL161785 | q34.11 | FLJ35269 | Q8NAJ2 | 123729824 | 123733713 | 232 | Unknown |
| AL353803 | q34.11 | FLJ34873 | Q8NAS2 | 123745332 | 123747103 | 144 | Unknown |
| AL391056 | q34.11 | Novel | ENSG00000179068 | 123897948 | 123913240 | 98 | Unknown |
|  | q34.11 | FLJ35803 | Q8NA65 | 124021035 | 124029584 | 377 | Unknown |
| AL590369 | q34.11 | AD003 | Q9UI28 | 124034981 | 124044744 | 223 | Adrenal gland protein |
|  | q34.11 | ASB6 | Q9NWX5 | 124043412 | 124050973 | 421 | Ankyrin repeat containing protein |
|  | q34.11 | PMX2 | Q99811 | 12074444 | 124131482 | 253 | Paired mesoderm protein |
|  | q34.11 | PTGES | O14684 | 124147139 | 124161855 | 152 | Prostaglandin E synthase |
| AL592219 | q34.11 | No genes |  |  |  |  |  |
| AL158207 | q34.11 | TOR1B | O14657 | 124211961 | 124220092 | 336 | Torsin B precursor |
|  | q34.11 | DYT1 | Q96CA0 | 124221751 | 124232942 | 336 | Torsin A precursor |
|  | q34.11 | HSPC220 | Q9NZ63 | 124236100 | 124244083 | 289 | Unknown |
|  | q34.11 | USP20 | Q9Y2K6 | 124244254 | 12490636 | 914 | Ubiquitin carboxyl-terminal hydrolase |
|  | q34.11 | FNBP1 | Q96RU3 | 124295995 | 124451976 | 672 | Thyroid receptor interacting protein |
| AL136141 | q34.11 | GPR107 | Q96T26 | 124462729 | 124548972 | 416 | G Protein-coupled receptor |
| AL392105 | q34.11 | No genes |  |  |  |  |  |
| AL360004 | q34.11 | FREQ | P36610 | 124581381 | 124645435 | 190 | Neuronal calcium sensor 1 |
|  | q34.11 | Novel | ENSG00000178890 | 124674690 | 124718869 | 822 | Unknown |
| 50 kb Gap |  |  |  |  |  |  |  |
| AL354898 | q34.11 | Q8NDA2 | Q8NDA2 | 124808356 | 124841498 | 1187 | Unknown |
|  | q34.11 | FLJ23816 | Q8TCI8 | 124852198 | 124856039 | 220 | Unknown |
|  | q34.11 | ASS | P00966 | 124866845 | 124923190 | 412 | Argininosuccinate synthase |
| AL353695 | q34.11 | No genes |  |  |  |  |  |
| AL359092 | q34.11 | FUBP3 | Q92946 | 125001544 | 125060268 | 542 | Fuse binding protein 3 |
|  | q34.12 | PRDM12 | Q9H4Q4 | 125086510 | 125104913 | 367 | PR domain containing protein 12 |
|  | q34.12 | RRP4 | Q13868 | 125115687 | 125126785 | 293 | Exosome complex exonuclease RRP4 |
| AL161733 | q34.12 | ABL1 | P00519 | 125136236 | 125309589 | 1130 | Abelson murine leukaemia viral oncogene |
|  | q34.12 | FLJ14810 | Q96SJ7 | 125324358 | 125360767 | 198 | Unknown |
| AL583807 | q34.12 | LAMC3 | Q9Y6N6 | 125431028 | 125516389 | 1575 | Laminin gamma-3 chain precursor |
| AL355872 | q34.12 | No genes |  |  |  |  |  |
| AL157938 | q34.12 | AIF1L | Q9BQI0 | 125518441 | 125545061 | 150 | Ionised cacium binding adaptor molecule 2 |
|  | q34.13 | NUP214 | P35658 | 125547506 | 125656586 | 2140 | Nuclear pore complex protein |
|  | q34.13 | Q8N2W3 | Q8N2W3 | 125679994 | 125698463 | 191 | Unknown |
| AL354855 | q34.13 | FLJ90726 | Q8NBV4 | 125711653 | 12731177 | 271 | Unknown |
|  | q34.13 | Novel | ENSG00000130710 | 125729227 | 125729298 | 24 | Unknown |
| AL358781 | q34.13 | BAT2L | Q9BU62 | 125852061 | 125869120 | 325 | HLA-B associated transcript |
|  | q34.13 | LQFBS-1 | O95209 | 125921328 | 125922066 | 245 | Unknown |
|  | q34.13 | POMT1 | Q9UNT2 | 125924841 | 125945722 | 747 | Protein-o-mannosyltransferase 1 |
|  | q34.13 | $\begin{gathered} \hline \text { UCK1_HUM } \\ \text { AN } \\ \hline \end{gathered}$ | Q9HA47 | 125945717 | 125953181 | 201 | Uridine cytidine kinase 1 |
| AL160276 | q34.13 | GRF2 | Q13905 | 126000707 | 126159454 | 1077 | Guanine nucleotide releasing factor 2 |
| AL160271 | q34.13 | CRSP8 | O95401 | 126282028 | 126512112 | 273 | Cofactor required transcriptional activation |
| AL603649 | q34.13 | No genes |  |  |  |  |  |


| AL713892 | q34.13 | No genes |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| AL691506 | q34.13 | No genes |  |  |  |  |  |
| AL513102 | q34.13 | No genes |  |  |  |  |  |
| AL353631 | q34.13 | No genes |  |  |  |  |  |
| AL159997 | q34.13 | KIAA1857 | Q96JH0 | 126594193 | 126675069 | 541 | Netrin G2 |
|  | q34.13 | KIAA0625 | Q8WX33 | 126693686 | 126761056 | 915 | Unknown |
| AL353701 | q34.13 | TTF1 | Q15361 | 126808230 | 126835074 | 882 | Transcription termination factor |
| AL354735 | q34.13 | Novel | ENSG00000178595 | 126930940 | 126975292 | 179 | Unknown |
|  | q34.13 | BARHL1 | Q9BZE3 | 127014851 | 127022519 | 327 | BARH (Drosophila)-like 1 |
| AL160165 | q34.13 | DDX31 | Q96NY2 | 127026534 | 127102646 | 851 | DEAD/H Box Helicase |
|  | q34.13 | GTF3C4 | Q9UKN8 | 127102586 | 127122695 | 822 | General transcription factor |
| AL445645 | q34.13 | FLJ32704 | Q96MA6 | 127157823 | 127310564 | 479 | Unknown |
|  | q34.13 | C9orf9 | Q96E40 | 127310608 | 127322275 | 222 | Unknown |
|  | q34.13 | TSC1 | Q92574 | 127323595 | 127376866 | 1164 | Tuberous sclerosis 1 gene |
|  | q34.13 | Novel | ENSG00000176140 | 127379314 | 127383801 | 47 | Unknown |
| AL593851 | q34.13 | GFI1B | O95270 | 127418923 | 127426295 | 330 | Growth factor independent 1B |
| AL162417 | q34.2 | GTF3C5 | Q9H4P2 | 127462958 | 12790748 | 528 | General transcription factor |
|  | q34.2 | CEL | P19835 | 127494229 | 127504006 | 756 | Carboxyl ester lipase |
|  | q34.2 | NM_173692 |  | 127513557 | 127514144 | 196 | Unknown |
|  | q34.2 | CELL | Q14018 | 127514780 | 127519600 | 59 | Carboxyl ester lipase-like |
|  | q34.2 | RALGDS | Q12967 | 127529965 | 127553410 | 914 | Ral Guanine nucleotide |
|  | q34.2 | FRS | Q9UKI5 | 127585198 | 127596144 | 347 | Forssman synthetase |
| AL732364 | q34.2 | OBPIIB | Q9NPH6 | 127637537 | 127641486 | 170 | Odorant binding protein 2B |
| AL158826 | q34.2 | ABO | P16442 | 127687850 | 127694413 | 287 | ABO blood group system |
|  | q34.2 | SURF6 | O75683 | 127754393 | 127759885 | 361 | SURFEIT locus protein 6 |
|  | q34.2 | SURF5 | Q15528 | 127764596 | 127771813 | 200 | SURFEIT locus protein 5 |
|  | q34.2 | SURF3 | P11518 | 127771906 | 127775122 | 265 | SURFEIT locus protein 3 |
|  | q34.2 | Q9H3B2 | Q9H3B2 | 127774377 | 127775089 | 101 | Unknown |
|  | q34.2 | SURF1 | Q15526 | 127775504 | 127780202 | 300 | SURFEIT locus protein 1 |
|  | q34.2 | SURF2 | Q15527 | 127780269 | 127784875 | 256 | SURFEIT locus protein 2 |
|  | q34.2 | SURF4 | O15260 | 127785181 | 127799817 | 269 | SURFEIT locus protein 4 |
|  | q34.2 | Q8NE28 | Q8NE28 | 127800125 | 127828061 | 651 | Unknown |
|  | q34.2 | Novel | ENSG00000175977 | 127821374 | 127824619 | 97 | Unknown |
|  | q34.2 | XPMC2H | Q9GZR2 | 127828027 | 127840010 | 422 | Prevents mitotic catastrophe 2 |
|  | q34.2 | ADAMTS13 | Q96L37 | 127843961 | 127881349 | 1427 | Von Willebrand factor-cleaving protease |
| AL593848 | q34.2 | C9orf7 | Q9UGQ2 | 127881962 | 127892726 | 172 | Unknown |
|  | q34.2 | SLC2A6 | Q8NCC2 | 127893058 | 127901068 | 515 | Solute carrier family 2 |
| BX324209 | q34.2 | No genes |  |  |  |  |  |
| AC002321 | q34.2 | No genes |  |  |  |  |  |
| <5 kb Gap |  |  |  |  |  |  |  |
| AC002101 | q34.2 | No genes |  |  |  |  |  |
| AL365494 | q34.2 | DBH | P09172 | 128007020 | 128030001 | 603 | Dopamine beta-monooxygenase precursor |
|  | q34.2 | SARDH | Q9UL10 | 128056341 | 128124046 | 832 | Sarcosine dehydrogenase |
|  | q34.2 | PP3781 | Q8WY83 | 123131956 | 128132329 | 124 | Unknown |
| AL590710 | q34.2 | Novel | ENSG00000176983 | 128211430 | 128251481 | 432 | Unknown |
|  | q34.2 | SARDH | Q9UL10 | 128252348 | 128272381 | 396 | Unknown |
| AL357934 | q34.2 | VAV2 | P52735 | 128297977 | 12826304 | 878 | Oncogene VAV-2 protein |
| AL445931 | q34.2 | Novel | ENSG00000179483 | 128559910 | 128562122 | 119 | Unknown |
|  | q34.2 | BRD3 | Q15059 | 128566862 | $\mathbf{1 2 8 6 0 2 5 3 3}$ | 726 | Bromodomain containing protein3 |
|  | q34.2 | Novel | ENSG00000179457 | 128588311 | 128592826 | 216 | Unknown |
| AL591386 | q34.2 | No genes |  |  |  |  |  |
| 200kb Gap |  |  |  |  |  |  |  |
| AL354796 | q34.2 | No genes |  |  |  |  |  |
| AL683798 | q34.2 | No genes |  |  |  |  |  |
| 13 kb Gap |  |  |  |  |  |  |  |


| AL669970 | q34.2 | RXRA | P19793 | 129062693 | 129101647 | 453 | Retinoid X receptor, alpha |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| AL591890 | q34.3 | COL5A1 | Q96HC0 | 129302868 | 129503955 | 590 | Collagen alpha 1 (V) chain precursor |
| AL603650 | q34.3 | FCN2 | Q15485 | 129541874 | 129548582 | 313 | Ficolin 2 precursor |
| AL353611 | q34.3 | FCN1 | O00602 | 129570647 | 129579025 | 326 | Ficolin 1 precursor |
| AL159992 | q34.3 | No genes |  |  |  |  |  |
| AL390778 | q34.3 | OLFM1 | Q9BWJ9 | 129736484 | 129782241 | 467 | Olfactomedin related ER localised protein |
| AL353615 | q34.3 | NM_173520 | Q8N4C0 | 130006614 | 130009927 | 152 | Unknown |
| AL161452 | q34.3 | Novel | ENSG00000178197 | 130131516 | 130144083 | 96 | Unknown |
|  | q34.3 | NM_014811 | Q9Y4D3 | 130146060 | 130152258 | 1209 | Unknown |
|  | q34.3 | NM_144654 | Q8WU44 | 130158546 | 130165104 | 92 | Unknown |
|  | q34.3 | MRPS2 | Q9Y399 | 130164060 | 130168038 | 296 | Mitochondrial ribosomal protein S2 |
|  | q34.3 | LCN1 | P31025 | 130184820 | 130189897 | 176 | Lipocalin 1 |
|  | q34.3 | OBPIIA | Q9NY56 | 130209504 | 130213321 | 170 | Odorant-binding protein 2A |
| AL354761 | q34.3 | PAEP | P09466 | 130225123 | 130230141 | 157 | Progestagen associated endometrial |
|  | q34.3 | Novel | ENSG00000176541 | 130238316 | 130250477 | 104 | Unknown |
| AL158822 | q34.3 | MUPL | Q8WX39 | 130326687 | 130329116 | 172 | Putative MUP-like lipocalin |
|  | q34.3 | Q8NEE3 | Q8NEE3 | 130356772 | 130362893 | 348 | Unknown |
|  | q34.3 | KCNT1 | Q9WX41 | 130365551 | 130455523 | 1151 | Unknown |
| AL353636 | q34.3 | NM_018627 | Q9WX42 | 130472946 | 130570503 | 1298 | Unknown |
| AL355574 | q34.3 | GPDR1 | Q9BSL1 | 130596334 | 130624745 | 405 | Glialblastoma related protein |
|  | q34.3 | NM_144653 | Q96BF6 | 130674721 | 130713948 | 587 | Unknown |
| AL591038 | q34.3 | Novel | ENSG00000180858 | 130715097 | 130738981 | 273 | Unknown |
| AL138781 | q34.3 | Q96GU2 | Q96GU2 | 130777953 | 130782228 | 29 | Unknown |
|  | q34.3 | Q8N3G2 | Q8N3G2 | 130869698 | 130887479 | 541 | Unknown |
|  | q34.3 | LHX3 | Q9UBR4 | 130859621 | 130868480 | 397 | LIM Homeobox gene 3 |
| 30 kb Gap |  |  |  |  |  |  |  |
| AL603784 | q34.3 | AGS3 | Q9UFS8 | 130939617 | 130943166 | 530 | Unknown |
| AL592301 | q34.3 | CARD9 | Q9H257 | 130947895 | 130957602 | 536 | Caspase recruitment protein |
|  | q34.3 | SNAPC4 | Q9Y6P7 | 130959516 | 130982736 | 1469 | Small nuclear RNA activating complex |
|  | q34.3 | SDCCAG3 | O60525 | 130985862 | 130994412 | 192 | Serologically defined colon cancer antigen |
|  | q34.3 | INPP5E | Q10713 | 130994603 | 131007700 | 525 | Mitochondrial processing peptidase subunit |
|  | q34.3 | PPI5PIV | Q9NRR6 | 131012558 | 131023761 | 644 | Phosphatidylinositol $(4,5)$ bisphosphate 5phophatase |
|  | q34.3 | KIAA0310 | Q96HP1 | 131024036 | 131059908 | 1433 | Unknown |
|  | q34.3 | NM_152571 | Q8N9P6 | 131067482 | 131070005 | 203 | Unknown |
|  | q34.3 | NOTCH1 | P46531 | 131078383 | 131129726 | 2559 | Neurogenic locus NOTCH homologue protein |
| AL590226 | q34.3 | Novel | ENSG00000180360 | 131211094 | 131230721 | 251 | Unknown |
|  | q34.3 | Q9P058 | Q9P058 | 131232664 | 131244366 | 146 | Unknown |
|  | q34.3 | ZNEU1 | Q9UHF1 | 131242795 | 131256617 | 273 | ZNEU1/NEU1 protein |
|  | q34.3 | AGPAT2 | 015120 | $\mathbf{1 3 1 2 5 7 0 8 2}$ | 131271362 | 278 | Acylglycerol-phophate-acyltransferase 2 |
|  | q34.3 | NM_152421 | Q8WYU5 | 131296511 | 131307989 | 431 | Unknown |
| AL355987 | q34.3 | NM_032887 | Q96IC0 | 131309173 | 131312123 | 37 | Unknown |
|  | q34.3 | Novel | ENSG00000169672 | 131313093 | 131332422 | 726 | Unknown |
|  | q34.3 | FLJ33328 | Q8NBE9 | 131338327 | 131341477 | 333 | Unknown, has IG_MHC domain |
|  | q34.3 | FLJ10101 | Q96BU21 | 131383198 | 131425126 | 307 | Unknown |
|  | q34.3 | FLJ30985 | Q96NE7 | 131387866 | 131392787 | 197 | Unknown |
|  | q34.3 | Nov-01 | ENSG00000054148 | 131433033 | 131434977 | 186 | Unknown |
|  | q34.3 | Novel | ENSG00000148406 | 131436356 | 131438789 | 350 | Unknown |
|  | q34.3 | Novel | ENSG00000179285 | 131439193 | 131440765 | 264 | Unknown |
|  | q34.3 | Q8NCX7 | Q8NCX7 | 131440944 | 131444739 | 236 | Unknown |
|  | q34.3 | EDF1 | O60869 | 131446058 | 131450225 | 148 | Endothelial differentiation-related factor 1 |
| AL449425 | q34.3 | TRAF2 | TRA2_HUMAN | 131482651 | 131510546 | 501 | TNF receptor associated factor 2 |
| AL807752 | q34.3 | NM_018998 | Q969U6 | 131524374 | 131528545 | 566 | Unknown |
|  | q34.3 | C8G | P07360 | 131529200 | 131530906 | 198 | Complement component 8, gamma subunit |
|  | q34.3 | PTGDS | P41222 | 131561509 | 131565680 | 190 | Prostaglandin D2 synthase |
|  | q34.3 | Novel | ENSG00000176785 | 131567941 | 131570349 | 137 | Unknown |


|  | q34.3 | CLIC3 | 095833 | 131578574 | 131580807 | 207 | Chloride intracellular channel protein 3 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | q34.3 | ABCA2 | Q9BZC7 | 131591173 | 131612250 | 2440 | ATP-binding cassette, subfamily A, member 2 |
|  | q34.3 | Q9BUH6 | Q9BUH6 | 131576357 | 131577915 | 212 | Unknown |
|  | q34.3 | FUT7 | Q11130 | 131614669 | 131615685 | 339 | Fucosyltransferase 7 |
| AL929554 | q34.3 | Q8N224 | Q8N224 | 131618602 | 131619006 | 135 | Unknown |
|  | q34.3 | NPDC1 | Q9NQX5 | 131623413 | 131630157 | 325 | Neuronal proliferation protein 1 |
|  | q34.3 | ENTPD2 | Q9Y5L3 | 131632616 | 131638290 | 494 | Ectonucleoside triphosphate diphosphydrolase 2 |
|  | q34.3 | Q8TEI1 | Q8TEI1 | 131662043 | 131670905 | 270 | Unknown |
|  | q34.3 | Q8WUC7 | Q8WUC7 | 131669250 | 131671114 | 104 | Unknown |
|  | q34.3 | MAN1B1 | Q9UKM7 | 131671245 | 131695076 | 699 | Endoplasmic reticulum mannosidase |
|  | q34.3 | Novel | ENSG00000179395 | 131687948 | 131691411 | 989 | Unknown |
|  | q34.3 | DPP7 | Q9UHL4 | 131696546 | 131699393 | 331 | Dipeptidyl-peptidase |
|  | q34.3 | GRIN1 | Q05586 | 131724505 | 131753424 | 928 | Glutamate receptor subunit zeta 1 |
|  | q34.3 | NM_013366 | Q9UJX6 | 131759296 | 131773049 | 822 | Anaphase-promoting complex subunit 2 |
|  | q34.3 | SSNA1 | O43805 | 131773159 | 131774882 | 119 | Sjorgen's syndrome nuclear autoantigen 1 |
|  | q34.3 | FLJ90254 | Q8NCH2 | 131776627 | 131784420 | 433 | Unknown |
|  | q34.3 | NM_053045 | Q969S6 | 131788473 | 131790029 | 136 | Unknown |
| BX255925 | q34.3 | Unfinished |  |  |  |  |  |
| BX322799 | q34.3 | Unfinished |  |  |  |  |  |
| AL365502 | q34.3 | AD038 | Q96F01 | 132035782 | 132039264 | 205 | AD038 protein, function unknown |
|  | q34.3 | NM_152285 | Q8N5I2 | 132039236 | 132048941 | 433 | Unknown |
|  | q34.3 | MZIP | Q96E35 | 132064147 | 132072376 | 227 | Melanin-concentrating hormone receptor 1 |
|  | q34.3 | NM_138778 | Q9BTV6 | 132075663 | 132096389 | 484 | Unknown |
|  | q34.3 | MRPL41 | NM_032477 | 132098739 | 132099406 | 137 | Mitochondrial ribosomal protein L41 |
|  | q34.3 | NTE-L | Q8TAY5 | 132153193 | 132190541 | 702 | Neuropathy Target Esterase |
|  | q34.3 | FLJ14568 |  | 132192950 | 132200987 | 327 | Unknown |
|  | q34.3 | Q9NTU2 |  | 13295160 | 132200984 | 130 | Unknown |
| AL590627 | q34.3 | Novel | ENSG00000181090 | 132289873 | 132374235 | 436 | Unknown |
| AL611925 | q34.3 | HMT1 | Q9H9B1 | 132395728 | 132553855 | 1247 | Histone methyltransferase |
| AL772363 | q34.3 | CACNA1B | Q00975 | 132562084 | 132806329 | 2357 | Calcium channel voltage-dependent |
| AL591424 | q34.3 | IL9R | ENSG00000165830 | 132821281 | 132832099 | 216 | Interleukin 9 receptor IL 9R |
|  | q34.3 | Novel | ENSG00000159247 | 132859209 | 132861370 | 425 | Tubulin pseudogene |
|  | q34.3 | Novel | ENSG00000179338 | 132868297 | 132868767 | 157 | LINE 1 Reverse Transcriptase Homologue |
| AL954642 | q34.3 | No genes |  |  |  |  |  |

## Appendix 2

Table of results the whole-genome survey. The P-values are coloured according to the level of confidence; black are L0-paralogues, green L1-paralogues, blue L2paralogues and red are L3-paralogues.

| $\begin{array}{\|c\|c}  & \tilde{0} \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \\ 0 & 0 \end{array}$ | $\frac{\ddot{0}}{0}$ | 旡 | 会 | 츤 | $\begin{aligned} & \text { J } \\ & \text { N } \\ & \text { N } \\ & \text { N } \\ & \end{aligned}$ | \#10 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| III NOTCH4 | AL390719.31.31331.88824 | 1p36.33 | 708136 | 744003 | AGRN | $1.50 \mathrm{E}-23$ |
| xII B3GALT4 | AL162741.35.1.111409 | 1p26.33 | 919626 | 921479 | B3GALT6 | $1.40 \mathrm{E}-08$ |
| III NOTCH4 | AL391244.11.1.67923 | 1p36.33 | 1073552 | 1087162 | NM_030937 | $9.10 \mathrm{E}-09$ |
| III BAT8 | AL391244.11.1.67923 | 1p36.33 | 1089751 | 1108843 | Novel | $7.60 \mathrm{E}-12$ |
| III NOTCH4 | AL512413.21.1.101803 | 1p36.32 | 2844459 | 2886399 | EGFL3 | $2.20 \mathrm{E}-42$ |
| xI BTN1A1 | AL662907.11.1.64693 | 1 p 35.1 | 3343046 | 33466609 | Q9BVG3 | $1.10 \mathrm{E}-18$ |
| III NOTCH4 | AL513320.27.1.132592 | 1p36.32 | 3364015 | 3405344 | EGFL3 | $2.00 \mathrm{E}-25$ |
| III C2 | AL109811.40.1.112769 | 1p36.22 | 10930224 | 10950939 | MASP2 | $1.30 \mathrm{E}-05$ |
| xI BTN1A1 | AC074003.3.23107.35032 | 1p36.13 | 14652770 | 14656331 | Novel | $4.20 \mathrm{E}-14$ |
| III C6orf46/ZNF297 | AL034555.2.1.86897 | 1p36.13 | 15447174 | 15481304 | ZNF151 | $2.40 \mathrm{E}-14$ |
| DDR1 | AL451042.10.1.88098 | 1p36.13 | 15564788 | 15596501 | EPHA2 | $1.10 \mathrm{E}-17$ |
| XII KIFC1 | AL663074.13.1.8581 | 1p36.12 | 20071643 | 20079710 | Novel | $2.60 \mathrm{E}-24$ |
| III NOTCH4 | AL590103.12.1.175162 | 1p36.12 | 21183949 | 21258020 | HSPG2 | $1.10 \mathrm{E}-16$ |
| DDR1 | AL035703.21.1.160705 | 1p36.12 | 21925207 | 21965283 | EPHA8 | $1.40 \mathrm{E}-15$ |
| DDR1 | AL035704.9.1.113956 | 1p36.12 | 22143606 | 22277501 | EPHB2 | $3.10 \mathrm{E}-20$ |
| xII LYPLA2L | AL031295.1.1.124001 | 1p36.11 | 23188619 | 23193014 | LYPLA2 | $9.00 \mathrm{E}-75$ |
| III CLIC1 | AL662924.15.1.121762 | 1 p 35.3 | 24141534 | 24239539 | CLIC4 | $3.80 \mathrm{E}-27$ |
| DDR1 | AL031729.16.1.125287 | 1p36.11 | 26912974 | 26924738 | FGR | $3.20 \mathrm{E}-15$ |
| xIICOL11A2 | AC114488.1.90406.184673 | 1 p 35.2 | 31102432 | 31154233 | COL16A1 | $2.10 \mathrm{E}-11$ |
| xII ZNF297 | AL033529.25.1.147167 | 1 p 35.1 | 31870816 | 32006551 | NM_144621 | $1.00 \mathrm{E}-13$ |
| xI RFP | AL662907.11.1.64693 | 1 p 35.1 | 32565928 | 32602196 | NM_018207 | 7.60E-46 |
| III C2 | AC115285.1.63883.124348 | 1 p 35.1 | 33035623 | 33094251 | Q96Q03 | $9.80 \mathrm{E}-08$ |
| III BF | AC115285.1.63883.124348 | 1 p 35.1 | 33799053 | 33862505 | Q9H4W4 | $9.50 \mathrm{E}-08$ |
| I POU5F1 | AL139158.11.1.115614 | 1 p 34.3 | 37518563 | 37519168 | no gene | $4.50 \mathrm{E}-44$ |
| III HSPA1L | AL354702.7.1.107422 | 1 p 34.3 | 38182110 | 38184069 | Novel | $4.30 \mathrm{E}-158$ |
| XII ZNF297 | AL356379.10.1.64960 | 1 p 34.2 | 40000812 | 40017418 | NM_152373 | $7.80 \mathrm{E}-09$ |
| xI RFP/MOG/BTNL2 | AL512353.16.1.81704 | 1 p 34.2 | 42286363 | 42314156 | ERMAP | $6.60 \mathrm{E}-49$ |
| DDR1 | AC093420.1.127596.194462 | 1 p 34.2 | 42767145 | 42789215 | TIE | $4.80 \mathrm{E}-05$ |
| II BTNL2 | AL109659.20.1.181678 | 1p33 | 47521181 | 181364180 | genscan | 1.10E-24 |
| xI BTN1A1 | AL109659.20.1.181678 | 1p33 | 48243776 | 48288207 | no gene | 3.40E-29 |
| xI MOG | AL109659.20.1.181678 | 1p33 | 48253780 | 48253842 | genscan | $4.00 \mathrm{E}-22$ |
| xI GPX5 | AL356976.30.1.64323 | 1 p 32.3 | 51957064 | 51963742 | NM_015696 | $8.30 \mathrm{E}-09$ |
| TUBB | AL445183.19.1.193774 | 1 p 32.3 | 53049002 | 53152605 | SCP2 | $8.90 \mathrm{E}-12$ |
| I DDR1 | AL445205.14.1.115936 | 1 p 31.3 | 63525514 | 63564266 | EST gene | $3.10 \mathrm{E}-45$ |
| DDR1 | AC093427.2.1.131877 | 1 p 31.3 | 64219769 | 64351748 | JAK1 | $2.50 \mathrm{E}-09$ |
| III C6orf29 | AC107627.2.1.90513 | 1 p 31.1 | 74605198 | 75011843 | NM_152697 | $8.70 \mathrm{E}-49$ |
| III MSH5 | AL445464.9.1.103097 | 1 p 31.1 | 75197713 | 75313965 | MSH4 | $4.30 \mathrm{E}-05$ |
| III DDAH2 | AL078459.8.1.83946 | 1 p 22.3 | 84926028 | 85072691 | DDAH1 | $3.50 \mathrm{E}-15$ |
| xIICOL11A2 | AL356059.27.1.76418 | 1 p 22.3 | 85351949 | 85791154 | NM_152890 | $1.90 \mathrm{E}-05$ |
| II BRD2 | AC004798.1.1.42497 | 1 p 22.1 | 91625907 | 91677611 | BRDT | $6.50 \mathrm{E}-101$ |
| III C9orf29 | AC093429.2.1.182165 | 1 p 21.3 | 94491811 | 94566684 | NM_152369 | $1.30 \mathrm{E}-08$ |


| xIICOL11A2 | AC093150.2.1.189945 | 1 p 21.1 | 104172486 | 104410718 | COL11A1 | $4.10 \mathrm{E}-42$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| III NOTCH4 | AL390252.9.1.169241 | 1 p 13.3 | 108785784 | 108869934 | SORT1 | $6.40 \mathrm{E}-22$ |
| III BAT1 | AL445483.13.1.164008 | 1 p 13.2 | 112714422 | 112726367 | DDX20 | $3.00 \mathrm{E}-14$ |
| XI MOG/BTN1A1 | AL391476.20.1.171595 | 1p13.1 | 118145476 | 118212809 | NM_024626 | $9.30 \mathrm{E}-05$ |
| III NOTCH4 | AL359752.11.1.137955 | 1 p 11.2 | 119292037 | 119450143 | NOTCH2 | $2.30 \mathrm{E}-61$ |
| III NOTCH4 | AL592307.24.14836.157830 | 1 q 21.1 | 141809266 | 141890630 | Novel | $3.20 \mathrm{E}-27$ |
| III NOTCH4 | AC018381.3.23653.71017 | 1 q 21.1 | 141956297 | 141968135 | Novel | $3.70 \mathrm{E}-28$ |
| xI HIST1H2AC | AL591493.13.1.113370 | 1 q 21.2 | 145553544 | 145555199 | Histones | $3.30 \mathrm{E}-48$ |
| III BAT8 | AL590133.32.1.192096 | 1 q 21.3 | 146646159 | 146684482 | SETDB1 | $1.90 \mathrm{E}-12$ |
| XII ZNF297 | AL451085.20.1.182166 | 1 q 22 | 150706074 | 150720422 | ZFP67 | $5.40 \mathrm{E}-14$ |
| I POU5F1 | AL139410.20.1.166288 | 1 q 22 | 151143602 | 151144684 | Q9BZW0 | $4.10 \mathrm{E}-105$ |
| III NOTCH4 | AL158169.17.1.99802 | 1 q 23.1 | 152575891 | 152593889 | INSRR | $6.10 \mathrm{E}-12$ |
| I DDR1 | AL158169.17.1.99802 | 1 q 23.1 | 152595949 | 152616657 | NTRK1 | $1.70 \mathrm{E}-30$ |
| xI HFE | AL138899.23.1.134137 | 1 q 23.1 | 153882029 | 153886978 | CD1D | $2.50 \mathrm{E}-05$ |
| III NOTCH4 | AL356104.6.1.96693 | 1 q 23.1 | 154745243 | 154755113 | Q8TEK2 | $4.20 \mathrm{E}-22$ |
| III HSPA1L | AL590385.22.1.110781 | 1 q 23.3 | 157226591 | 157228843 | HSPA6 | $6.20 \mathrm{E}-263$ |
| III CREBL1 | AL391825.15.1.211662 | 1 q 23.3 | 157386942 | 157579736 | ATF6 | $4.30 \mathrm{E}-25$ |
| I DDR1 | AL445197.4.1.117040 | 1 q 23.3 | 158253102 | 158401084 | DDR2 | $1.50 \mathrm{E}-131$ |
| III PBX2 | AL357568.14.1.71359 | 1 q 23.3 | 160179905 | 160302546 | PBX1 | $3.40 \mathrm{E}-88$ |
| I POU5F1 | AL136984.20.1.169627 | 1 q 24.2 | 162840972 | 163036179 | POU2F1 | 5.70E-19 |
| XIIRXRB | AL160058.8.1.155369 | 1 q 23.3 | 163005239 | 163049202 | RXRG | $3.00 \mathrm{E}-63$ |
| XII RPS18 | AL031733.3.1.215861 | 1 q 24.2 | 163211499 | 163211834 | no gene | $7.20 \mathrm{E}-14$ |
| III BAT2 | AL021579.1.1.99886 | 1 q 24.3 | 167083736 | 167191695 | BAT2-ISO | $1.60 \mathrm{E}-63$ |
| III TNF | Z96050.1.1.85811 | 1 q 24.3 | 168257203 | 168265061 | TNFSF6 | $5.90 \mathrm{E}-06$ |
| III TNXB | Z94055.1.1.134539 | 1 q 25.1 | 170720587 | 170804587 | TNR | 6.00E-07 |
| III C6orf46 | AL136170.12.1.127541 | 1 q 25.1 | 171377563 | 171488882 | NM_032522 | $2.10 \mathrm{E}-33$ |
| I DDR1 | AL139132.16.1.157866 | 1 q 25.2 | 174505391 | 174627374 | ABL2 | $7.90 \mathrm{E}-12$ |
| I HLA-A/HLA-E | AL162431.17.1.139006 | 1 q 25.3 | 176341488 | 176402911 | STX6 | $1.60 \mathrm{E}-20$ |
| xI HLA Class I and II | AL356267.27.1.181808 | 1 q 25.3 | 176431452 | 176452972 | HLALS | $3.50 \mathrm{E}-31$ |
| III BAT1 | AL049557.19.1.128379 | 1 q 25.2 | 176601093 | 176723077 | ABL2 | $3.40 \mathrm{E}-10$ |
| III BAT8 | AL138776.10.1.100549 | 1 q 25.3 | 177972880 | 177984295 | RNASEL | $3.30 \mathrm{E}-05$ |
| xII RAB2L | AL590422.14.1.198210 | 1 q 25.3 | 179033557 | 179326003 | RGL1 | $8.30 \mathrm{E}-17$ |
| xII RING1 | AL109865.36.1.201823 | 1 q 25.3 | 180442880 | 180499976 | RNF2 | $4.20 \mathrm{E}-50$ |
| I DHX16 | AL355999.9.1.76504 | 1 q 31.1 | 185516454 | 185517347 | genscan | $1.10 \mathrm{E}-07$ |
| xII B3GALT4 | AL390863.9.1.122864 | 1 q 31.2 | 188662474 | 188670039 | B3GALT2 | $2.20 \mathrm{E}-21$ |
| III NOTCH4 | AL513325.13.1.212888 | 1 q 31.3 | 192695849 | 192906025 | CRB1 | $4.20 \mathrm{E}-52$ |
| III ATP6V1G2 | AL157402.19.1.210331 | 1 q 31.3 | 193950307 | 193968515 | ATP6V1G3 | $2.40 \mathrm{E}-09$ |
| XII RXRB | AC096633.2.1.178152 | 1 q 32.1 | 195455200 | 195604973 | NR5A2 | $1.50 \mathrm{E}-15$ |
| XII KIFC1 | AL445483.13.1.164008 | 1 q 32.1 | 195979729 | 196048406 | KIF14 | $7.50 \mathrm{E}-10$ |
| III BAT1 | AL512326.24.1.189269 | 1 q 32.1 | 198323462 | 198369154 | NM_031306 | $4.00 \mathrm{E}-06$ |
| xII RPS18 | AL606462.5.1.112401 | 1 q 42.13 | 223356887 | 223357135 | genscan | $1.20 \mathrm{E}-40$ |
| XI RFP | AL139288.15.1.151563 | 1 q 42.13 | 224319970 | 224333114 | TRIM11 | $2.10 \mathrm{E}-64$ |
| xI HIST1H2AC | AL139288.15.1.151563 | 1 q 42.13 | 224383273 | 224384153 | H2AFL | 4.80E-49 |
| xI $\mathrm{BTN1A1}$ | AL139288.15.1.151563 | 1 q 42.13 | 224436665 | 224436976 | genscan | $4.50 \mathrm{E}-64$ |
| II ${ }^{\text {I }}$ BTNL2 | AL139288.15.1.151563 | 1 q 42.13 | 224436716 | 224436991 | genscan | 3.70E-19 |
| II TAP2/1 | AL121990.33.1.147913 | 1 q 42.13 | 225346509 | 225388622 | ABCB10 | $5.10 \mathrm{E}-24$ |
| III PBX2 | AL359255.12.1.20809 | 1 q 42.13 | 226893037 | 227045628 | OBSCN | $5.40 \mathrm{E}-11$ |
| xI BTN1A1 | AC026657.4.97959.109520 | 1 q 42.13 | 227053394 | 227055850 | TRIM11 | $1.20 \mathrm{E}-16$ |
| xI MOG | AL139288.15.1.151563 | 1 q 42.13 | 227195475 | 227197055 | Novel | $9.50 \mathrm{E}-16$ |
| xI RFP | AL591686.9.1.150680 | 1 q 43 | 237498626 | 237934567 | NM_152666 | $2.40 \mathrm{E}-11$ |
| III C6orf46/ZNF297 | AL590483.25.118180.187060 | 1 q 44 | 239460483 | 239466676 | ZNF238 | $9.20 \mathrm{E}-16$ |
| III HSPA1L | AL390728.34.1.206255 | 1 q 44 | 242630342 | 242630950 | no gene | 5.80E-218 |
| xI RFP | AC099571.1.86529.165648 | 1 q 44 | 243256848 | 243277448 | NM_015431 | $1.50 \mathrm{E}-65$ |
| xI $\mathrm{BTN1A1}$ | AC099571.1.86529.165648 | 1 q 44 | 245957656 | 245974557 | Q9Y4N9 | $3.50 \mathrm{E}-37$ |
|  |  |  |  |  |  |  |
| III NOTCH4 | AC105450.1.1.163782 | 2p25.3 | 1491150 | 1620306 | TP0 | $2.10 \mathrm{E}-07$ |
| XII KIFC1 | AC013449.8.1.120997 | 2 q 23.3 | 26242053 | 26297524 | KIF3C | 3.30E-37 |


|  | BAT1 | AL121658.4.1.162692 | 2p22.3 | 32334563 | 32390404 | Q96NC3 | 6.30E-05 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| XI | HIST1H2AC/NOTCH4 | AL133244.1.1.200368 | 2p22.3 | 33311500 | 33772726 | LTBP1 | $6.50 \mathrm{E}-18$ |
| III | CYP21A2 | AC009229.5.1.209156 | 2p22.2 | 38259590 | 38268136 | CYP1B1 | $9.30 \mathrm{E}-15$ |
| I D | DHX16 | AC092833.4.1.143506 | 2p22.1 | 39171874 | 39237365 | NM_145646 | $5.30 \mathrm{E}-10$ |
| I D | DHX16 | AC018693.8.1.164125 | 2p22.1 | 39282730 | 39282825 | no gene | $1.00 \mathrm{E}-09$ |
| XI | NEFAL | AC016722.9.1.149995 | 2p21 | 47297756 | 47311689 | NM_139279 | 3.80E-32 |
| III | MSH5 | AC009600.19.1.215260 | 2p21 | 47798999 | 47879105 | MSH2 | $5.00 \mathrm{E}-09$ |
| xI | UBD | AC079807.5.1.156175 | 2p16.3 | 48126446 | 48126718 | genscan | $5.80 \mathrm{E}-05$ |
| III | MSH5 | AC006509.15.1.124015 | 2p16.3 | 48179027 | 48202837 | MSH6 | $7.80 \mathrm{E}-08$ |
| xII | B3GALT4 | AC093401.4.1.99088 | 2p15 | 62609435 | 62638037 | B3GNT1 | $2.30 \mathrm{E}-13$ |
| I D | DHX16 | AC005041.2.1.191356 | 2p13.1 | 74958046 | 74966106 | NM_133637 | $1.30 \mathrm{E}-10$ |
| III | BAT2 | AC068279.6.1.135351 | 2p11.2 | 87959386 | 87959877 | no gene | $3.10 \mathrm{E}-05$ |
| III | BAT2 | AC026106.12.36729.68570 | 2p11.2 | 90750748 | 90751398 | no gene | $6.50 \mathrm{E}-05$ |
|  | ZNF297 | AC092835.4.1.158404 | 2q-tel | 94264885 | 94283773 | ZNF2 | $3.70 \mathrm{E}-10$ |
| XI | RFP | AC018892.8.1.191055 | 2q11.2 | 96145683 | 96151491 | Novel | $1.60 \mathrm{E}-21$ |
| I D | DDR1 | AC016699.10.1.54480 | 2q11.2 | 96793061 | 96808883 | ZAP70 | $3.30 \mathrm{E}-15$ |
| I P | POU5F1 | AC018730.7.1.154728 | 2q12.1 | 103925142 | 103926146 | POU3F3 | $2.60 \mathrm{E}-44$ |
| xI | BTN1A1 | AC005040.2.1.189949 | 2q12.3 | 106059831 | 106060295 | genscan | $3.40 \mathrm{E}-08$ |
|  | ZNF297 | AC013268.5.1.206457 | 2q13 | 109008786 | 109017957 | NM_152518 | $4.40 \mathrm{E}-13$ |
| 1 | C6ORF18 | AC018737.9.1.206454 | 2q14.3 | 120015449 | 120327116 | CLASP1 | $9.70 \mathrm{E}-06$ |
| xII | RPS18 | AC018737.9.1.206454 | 2q14.3 | 120421203 | 120421337 | no gene | $9.80 \mathrm{E}-10$ |
| I | TUBB | AC018804.9.1.195514 | 2q21.1 | 128250367 | 128259530 | genscan | $3.00 \mathrm{E}-08$ |
| I | TUBB | AC073869.5.1.195280 | 2q21.2 | 129791442 | 129796126 | TUBA2 | $1.80 \mathrm{E}-10$ |
| I | MRPS18B | AC012497.8.1.212104 | 2 q 22.1 | 138733844 | 138734416 | genscan | $1.20 \mathrm{E}-75$ |
| xII | RXRB | AC074099.6.1.143653 | 2q24.1 | 155709873 | 155718141 | NR4A2 | $1.00 \mathrm{E}-06$ |
| XII | B3GALT | AC016723.11.1.202001 | 2q24.3 | 167216857 | 167269041 | B3GAL | $8.10 \mathrm{E}-30$ |
| II | TAP2/1 | AC069137.6.1.108836 | 2q24.3 | 168321109 | 168292498 | ABCB11 | $6.90 \mathrm{E}-21$ |
| XII | COL11A2 | AC066694.7.1.120381 | 2q32.2 | 187975163 | 188013419 | COL3A1 | $5.40 \mathrm{E}-32$ |
| III | HSPA1L | AC013409.8.1.195478 | 2q34 | 208662170 | 208666396 | Novel | $1.00 \mathrm{E}-116$ |
| I | TUBB | AC068946.4.1.172260 | 2 q 35 | 218133730 | 218152718 | TUBA4 | $2.00 \mathrm{E}-10$ |
| I D | DDR1 | AC010899.8.1.210232 | 2q36.1 | 221011996 | 221158367 | EPHA4 | $9.20 \mathrm{E}-15$ |
| III | HSPA1L | AC009302.2.1.180970 | 2 q 36.1 | 221548101 | 221549027 | genscan | $7.00 \mathrm{E}-113$ |
| XI | BTN1A1 | AC104772.3.1.106526 | 2 q 36.1 | 221566190 | 222241888 | SYFB | $1.40 \mathrm{E}-19$ |
| XI | RFP | AC104772.3.1.106526 | 2 q 36.1 | 222156619 | 222241888 | SYFB | 4.40E-44 |
| XI | PRSS16 | AC008072.3.1.206177 | 2 q 36.1 | 223964489 | 223987825 | NM_024785 | $4.20 \mathrm{E}-10$ |
| XI | COL11A2 | AC073869.5.1.195280 | 2q36.3 | 226590998 | 226750349 | COL4A4 | $3.50 \mathrm{E}-07$ |
| xI | COL11A2 | AC097662.4.37779.206758 | 2 q 36.3 | 226750355 | 226900581 | COL4A3 | $8.90 \mathrm{E}-12$ |
| III | NOTCH4 | AC008273.2.1.151297 | 2q36.3 | 228954450 | 229310970 | NM_139072 | $3.30 \mathrm{E}-23$ |
|  | B3GALT4 | AC017104.8.1.168880 | 2 q 37.1 | 230992101 | 230995454 | B3GNT7 | $3.50 \mathrm{E}-15$ |
| III | NOTCH4 | AC005237.2.1.175179 | 2q37.3 | 240214701 | 240251678 | PASK | $2.30 \mathrm{E}-53$ |
| xII | KIFC1 | AC011298.6.31675.58437 | 2 q 37.3 | 240584194 | 240668241 | ATSV | $3.00 \mathrm{E}-06$ |
|  |  |  |  |  |  |  |  |
| III | BAT8 | AC034191.5.1.172215 | 3p26.1 | 4284929 | 4298795 | SETMAR | $2.00 \mathrm{E}-25$ |
| xII | RXRB | AC090947.1.1.166043 | 3p25.2 | 12270465 | 12415723 | PPARG | $5.30 \mathrm{E}-09$ |
| III | NOTCH4 | AC090509.1.1.165994 | 3p25.1 | 13551690 | 13619799 | FBLN2 | $2.40 \mathrm{E}-09$ |
| xII | RXRB | AC090937.1.1.160696 | 3p25.1 | 15002136 | 15024392 | NR2C2 | $6.60 \mathrm{E}-09$ |
| xI | HMGN4 | AC027125.4.1.173836 | 3p25.1 | 15346179 | 15346391 | no gene | $1.90 \mathrm{E}-06$ |
| III | BAT8 | AC090950.1.1.199282 | 3 p 25.1 | 15648627 | 15776696 | Y379 | $3.60 \mathrm{E}-05$ |
| III HS | HSPA1L | AC097635.2.1.162887 | 3p24.3 | 19380503 | 19387078 | Novel | $2.90 \mathrm{E}-102$ |
|  | ZNF297 | AC006059.3.1.185161 | 3p22.1 | 41880829 | 41889031 | NM_145166 | $1.10 \mathrm{E}-11$ |
| III | C6orf46 | AC099669.2.1.217035 | 3p21.32 | 43776685 | 43804920 | Novel | $4.10 \mathrm{E}-13$ |
| III | C6orf46 | AC124045.1.109944.135528 | 3 p 21.32 | 43934102 | 43945288 | NM_033210 | $5.10 \mathrm{E}-12$ |
| I | DDR1 | AC104439.2.1.197279 | 3 p 21.32 | 45363297 | 45363752 | genscan | $7.20 \mathrm{E}-14$ |
| I | DHX16 | AC026318.7.1.19068 | 3 p 21.31 | 47135873 | 47174627 | DDX30 | $5.00 \mathrm{E}-25$ |
|  | COL11A2 | AC005903.3.1.60660 | 3 p 21.31 | 47884518 | 47915700 | COL7A1 | $5.00 \mathrm{E}-11$ |
|  | NOTCH4 | AC005923.2.1.88326 | 3p21.31 | 47956918 | 47983375 | CELSR3 | $3.60 \mathrm{E}-22$ |
|  | GPX5 | AC121247.1.77964.92674 | 3 p 21.31 | 48542852 | 48544273 | GPX1 | $2.40 \mathrm{E}-34$ |


| III | NOTCH4 | AC112215.1.181144.198956 | 3 p 21.31 | 51781935 | 51811071 | STAB1 | $1.20 \mathrm{E}-16$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| I | ABCF1 | AC021123.4.149752.161126 | $3 q-$-tel | 91147420 | 91149286 | Novel | $1.50 \mathrm{E}-63$ |
| I | DDR1 | AC107028.4.1.185539 | 3 q 11.2 | 92010160 | 92148744 | EPHA3 | $1.20 \mathrm{E}-15$ |
| xII | RPS18 | AC108715.2.1.176462 | 3 q 11.2 | 94194400 | 94194576 | no gene | $2.40 \mathrm{E}-15$ |
|  | RPS18 | AC108695.2.1.190845 | 3 q 11.2 | 94194185 | 94194358 | Novel | $4.30 \mathrm{E}-24$ |
| XII | COL11A2 | AC069222.23.1.117000 | 3 q 12.1 | 96016863 | 96137341 | COL8A1 | $3.50 \mathrm{E}-23$ |
| I | POU5F1 | AC117460.7.1.183595 | 3q12.1 | 97141764 | 97141988 | EST gene | $2.20 \mathrm{E}-18$ |
| I | TUBB | AC046144.15.1.188840 | 3q13.11 | 100051837 | 100051959 | genscan | $2.00 \mathrm{E}-11$ |
| xI | RPS18 | AC073861.18.98940.165924 | 3q12.3 | 100725089 | 100725481 | EST gene | $4.20 \mathrm{E}-62$ |
| XII | ZNF297 | AC084198.24.86116.155268 | 3q12.3 | 100797978 | 100825652 | NM_014415 | $3.60 \mathrm{E}-12$ |
| I | POU5F1 | AC079945.13.52386.74222 | 3q21.3 | 128590475 | 128590648 | genscan | $4.70 \mathrm{E}-55$ |
| III | NOTCH4 | AC080007.26.1.168551 | 3q21.3 | 129795525 | 129875755 | WDR10 | $8.50 \mathrm{E}-10$ |
| III | HSPA1L | AC020632.16.1.162029 | 3q22.1 | 133021872 | 133186190 | NM_153240 | $1.90 \mathrm{E}-22$ |
| I | DDR1 | AC092969.6.71736.203901 | 3q22.2 | 135625566 | 135694383 | Novel | $5.10 \mathrm{E}-21$ |
| III | HSPA1L | AC117478.3.1.77155 | 3q22.3 | 138390731 | 138391456 | genscan | $4.20 \mathrm{E}-215$ |
| III | PBX2 | AC018450.26.1.191474 | 3q24 | 139874190 | 139875716 | PBXP1 | $4.50 \mathrm{E}-161$ |
| III | C6orf46/ZNF297 | AC010184.18.1.190580 | 3q23 | 141935447 | 141992349 | Q8NAP3 | $6.00 \mathrm{E}-07$ |
| III | BAT1 | AC112907.4.101183.186560 | 3q25.2 | 151048380 | 151140293 | Novel | $2.00 \mathrm{E}-24$ |
| xI | B3GALT4 | AC021649.18.1.209521 | 3q25.33 | 161749105 | 161770594 | B3GALT3 | $9.40 \mathrm{E}-19$ |
| III | BAT1 | AC092946.7.1.115500 | 3q27.3 | 183276473 | 183282793 | EIF4A2 | $8.70 \mathrm{E}-15$ |
| xII | B3GALT4 | AC069417.16.47453.72677 | 3q27.1 | 183826771 | 183845940 | B3GNT5 | $8.40 \mathrm{E}-28$ |
| I | ABCF1 | AC048331.32.147427.232441 | 3q27.1 | 184898582 | 184906494 | NM_018358 | $1.60 \mathrm{E}-37$ |
| I | GNL1 | AC046143.20.1.180365 | 3q29 | 197722675 | 197769579 | NM_018385 | 3.90E-07 |
|  |  |  |  |  |  |  |  |
| III | NOTCH4 | AC021118.6.1.194612 | 4p15.31 | 20338712 | 20704631 | SLIT2 | $1.00 \mathrm{E}-25$ |
| I | DHX16 | AC115110.2.23128.113396 | 4p15.2 | 24612486 | 24669565 | DDX15 | $4.30 \mathrm{E}-58$ |
| III | C6orf46/ZNF29 | AC105287.4.52544.192873 | 4 p 14 | 39946115 | 39947420 | Novel | $1.40 \mathrm{E}-163$ |
| II | HLA Class II | AC097451.2.1.146808 | 4 p 13 | 43676798 | 43677424 | EST gene | $1.10 \mathrm{E}-22$ |
| III | LSM2 | AC108054.2.101121.147995 | 4 p 12 | 48652844 | 48737332 | Q9P270 | $1.40 \mathrm{E}-20$ |
| I | DDR1 | AC098587.1.9710.175365 | 4 q 12 | 55065587 | 55126000 | PDGFRA | $3.00 \mathrm{E}-05$ |
| XI | RFP | AC107058.4.1.126135 | $4 \mathrm{q13.1}$ | 65884515 | 65884994 | genscan | $1.00 \mathrm{E}-24$ |
| III | BAT8 | AC053527.8.1.233250 | 4 q 13.3 | 74230262 | 74364018 | Q9H288 | $8.00 \mathrm{E}-05$ |
| XI | HIST1H2AC | AC097460.3.1.164370 | 4 q 23 | 101179583 | 101181853 | H2AFZ | $2.70 \mathrm{E}-15$ |
| III | BAT1 | AC105460.4.1.185755 | 4 q 24 | 104893633 | 104894151 | Genscan | $4.00 \mathrm{E}-10$ |
| III | CYP21A2 | AC096564.3.1.163317 | 4 q 25 | 109292353 | 109297744 | Novel | $2.10 \mathrm{E}-15$ |
| XII | LYPLA2L | AC004062.1.1.154252 | 4 q 25 | 112148688 | 112149080 | no gene | 7.40E-66 |
| I | TUBB | AC093663.4.1.171745 | 4 q 25 | 113404522 | 113404635 | genscan | $1.20 \mathrm{E}-09$ |
| I | TUBB/RNF5 | AC093816.3.1.170227 | 4 q 27 | 123297626 | 123297751 | genscan | $4.50 \mathrm{E}-36$ |
| III | BAT8/NOTCH4 | AC105421.2.1.162793 | 4 q 28.1 | 125865162 | 125873003 | YB23 | $2.50 \mathrm{E}-16$ |
| III | NOTCH4 | AC092629.2.1.148673 | 4 q 28.1 | 126653380 | 126692458 | NM_024582 | 2.20E-30 |
| III | HSPA1L | AC093591.3.1.158758 | 4 q 28.1 | 128982992 | 129034039 | OS94 | $2.00 \mathrm{E}-16$ |
| I | POU5F1 | AC093887.3.1.192886 | 4 q 31.22 | 147935518 | 147939053 | POU4F2 | $5.90 \mathrm{E}-28$ |
| II | TAP1 | AC017037.10.1.186106 | 4 q 32.1 | 159166512 | 159166844 | no gene | $8.50 \mathrm{E}-05$ |
| III | HSPA1L | AC105250.3.1.70449 | 4 q 32.3 | 165537822 | 165539805 | Novel | $3.40 \mathrm{E}-147$ |
| I | IER3 | AC106872.5.1.174535 | 4 q 32.3 | 166282549 | 166282689 | no gene | 1.10E-07 |
| XI | RFP | AC106872.5.1.174535 | 4 q 32.3 | 166359709 | 166359709 | Novel | 8.10E-63 |
| xI | BTN1A1/RFP | AC106872.5.1.174535 | 4 q 32.3 | 166381434 | 166391179 | NM_152620 | 3.00E-31 |
| XI | BTN1A1 | AC108465.3.1.48677 | 4 q 32.3 | 166812464 | 166832879 | Butyrophilin | 5.20E-34 |
| XI | RFP | AC080079.5.1.112516 | 4 q 32.3 | 167014840 | 167015103 | genscan | 7.60E-22 |
|  | HSD17B8 | AC021151.8.1.175081 | 4 q 32.3 | 170330785 | 170353453 | NM_032783 | 7.10E-06 |
| III | NOTCH4 | AC079226.7.1.184032 | 4 q 35.1 | 184330635 | 184402306 | NM_018104 | $1.30 \mathrm{E}-11$ |
| III | NOTCH4 | AC110761.3.1.153458 | 4 q 35.2 | 188188876 | 188324915 | FAT | 2.50E-13 |
| XI | BTN1A1/RFP | AC108073.2.107221.165848 | 4q35.2 | 189692345 | 189706326 | NM_173553 | 8.20E-19 |
|  |  |  |  |  |  |  |  |
| XI | POM121L2 | AC093308.2.104996.134015 | 5p14.3 | 21925895 | 21928486 | Novel | $1.10 \mathrm{E}-09$ |
| XI | SMA3L | AL157879.7.1.161460 | 5p13.3 | 34638648 | 34642503 | Novel | 2.00E-45 |
| XI | SMA3L | AC114970.1.37696.100300 | 5p13.3 | 34737381 | 34778708 | Novel | $1.40 \mathrm{E}-46$ |


| xI | POM121L2 | AC114970.1.37696.100300 | 5p13.3 | 34761244 | 34778854 | Q9H1S5 | 1.30E-10 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| I | TUBB | AC106800.1.2657.73135 | 5p12 | 43538759 | 43538860 | genscan | $8.00 \mathrm{E}-05$ |
| III | BAT1 | AC016632.6.1.176784 | 5 q 11.2 | 55195823 | 55274550 | DDX4 | $6.10 \mathrm{E}-09$ |
| XI | GPX5 | AC091977.3.1.183494 | 5q11.2 | 55884790 | 55889596 | Q8TED1 | $2.50 \mathrm{E}-05$ |
| I | DHX16 | AC020728.4.1.201404 | 5 q 11.2 | 55980727 | 56032245 | NM_019030 | $9.30 \mathrm{E}-13$ |
| III | SKIV2L | AC020728.4.1.201404 | 5 q 11.2 | 56032666 | 56149658 | KIAA0052 | $9.80 \mathrm{E}-50$ |
| xI | SMA3L | AC108108.1.77200.116688 | 5 q 13.2 | 70698028 | 70703834 | Novel (SMA3) | $2.00 \mathrm{E}-48$ |
| III | MSH5 | AC022493.12.1.153078 | 5q14.1 | 80189323 | 80411166 | MSH3 | $3.90 \mathrm{E}-15$ |
| XI | RPS18 | AC008799.6.1.123098 | 5q14.3 | 90941311 | 90941703 | genscan | $4.70 \mathrm{E}-49$ |
| xII | RXRB | AC106818.1.6855.31297 | 5 q 15 | 93388022 | 933399296 | NRF1 | $6.60 \mathrm{E}-19$ |
| I | POU5F1 | AC108102.2.1.161056 | 5q15 | 93545276 | 93545938 | genscan | $4.20 \mathrm{E}-48$ |
| III | BAT1 | AC016567.8.1.159734 | 5 q 15 | 97361820 | 97362176 | Genscan | $1.30 \mathrm{E}-11$ |
| XI | POM121L2 | AC114324.1.39743.91827 | 5q21.1 | 99294853 | 99295455 | ne | $6.90 \mathrm{E}-07$ |
| XI | SMA3L | AC114324.1.39743.91827 | 5q21.1 | 99303064 | 99303249 | genscan | $8.30 \mathrm{E}-27$ |
| XI | SMA3L | AC092278.3.1.123469 | 5q21.1 | 99829117 | 99834848 | Novel (SMA3) | 1.30E-42 |
| III | LSM2/DDR | AC109481.3.1.20673 | 5q21.3 | 108524961 | 108964792 | FER | $9.90 \mathrm{E}-36$ |
| I | DHX16 | AC093208.2.1.112115 | 5q22.2 | 113296938 | 113337241 | Novel | $7.10 \mathrm{E}-07$ |
| III | BAT8 | AC010226.5.1.147140 | 5 q 22.3 | 115264395 | 115288381 | FEM1C | $7.20 \mathrm{E}-06$ |
| xI | HMGN4 | AC109456.3.1.121848 | 5q23.1 | 115322895 | 115323107 | no gene | $5.80 \mathrm{E}-05$ |
| III | NOTCH4 | AC008682.6.1.217221 | 5 q 23.2 | 127062260 | 127232628 | NM_032446 | $1.30 \mathrm{E}-18$ |
| III | NOTCH4 | AC010424.9.1.192282 | 5 q 23.2 | 127289102 | 127326544 | NM_130809 | $9.10 \mathrm{E}-10$ |
| III | NOTCH4 | AC025169.5.1.161920 | 5 q 23.2 | 128029494 | 128309063 | FBN2 | $4.50 \mathrm{E}-35$ |
| III | HSPA1L | AC005373.1.1.112220 | 5 q 23.3 | 129911964 | 129912584 | genscan | $6.20 \mathrm{E}-159$ |
| xI | KIFC1 | AC004237.1.1.38715 | 5 q 23.3 | 132479552 | 132517394 | KIF3A | $4.20 \mathrm{E}-18$ |
| III | HSPA1L | AC113410.2.1.123851 | 5q31.1 | 132834893 | 132887389 | HSPA4 | $3.00 \mathrm{E}-19$ |
| III | BAT1 | AC010301.7.1.155067 | 5q31.1 | 133745073 | 133815582 | NM_014829 | $1.40 \mathrm{E}-09$ |
| xI | HIST1H2AC | AC026691.5.1.135062 | 5q31.1 | 135237074 | 135302580 | H2AFY | $2.10 \mathrm{E}-21$ |
| III | HSPA1L | AC011385.6.1.134599 | 5 q 31.2 | 138566125 | 138586223 | HSPA9B | $2.50 \mathrm{E}-72$ |
| I | POU5F1 | AC011396.4.1.87692 | 5 q 32 | 146300493 | 146301825 | POU4F3 | $5.50 \mathrm{E}-28$ |
| III | ATP6V1G2 | AC008385.7.1.151712 | 5 q 33.1 | 150765251 | 150795891 | Novel | $1.50 \mathrm{E}-06$ |
| xI | GPX5 | AC008666.5.1.99108 | 5 q 33.1 | 151002039 | 151004829 | GPX3 | $4.20 \mathrm{E}-64$ |
| XII | KIFC1 | AC008410.5.53020.91332 | 5 q 33.2 | 154988937 | 154992638 | Novel | $1.80 \mathrm{E}-38$ |
| III | NOTCH4 | AC011369.4.1.141529 | 5 q 34 | 167774142 | 168258463 | Novel | $8.20 \mathrm{E}-10$ |
| III | NOTCH4 | AC011365.4.1.81930 | 5 q 34 | 168684275 | 168685047 | Novel | $7.40 \mathrm{E}-29$ |
| xII | ZNF297 | AC104117.1.114225.124230 | 5q35.3 | 179277145 | 179302355 | Q8N9F8 | $5.60 \mathrm{E}-10$ |
| XI | BTN1A1/MOG | AC016572.6.1.143687 | 5q35.3 | 180455914 | 180507663 | Butyrophilin | 3.30E-54 |
| XI | BTN1A1/MOG | AC091874.2.1.13312 | 5q35.3 | 180545631 | 180563128 | BTNL3 | $4.10 \mathrm{E}-32$ |
| XI | BTN1A1 | AC091874.2.13413.147570 | 5q35.3 | 180597001 | 180613745 | Butyrophilin | 9.10E-53 |
| XI | BTN1A1 | AC008443.9.1.120524 | 5 q 35.3 | 180699946 | 180712464 | Q8WV44 | $4.00 \mathrm{E}-31$ |
| XI | BTN1A1/MOG/BTNL2 | AC022413.4.1.166525 | 5q35.3 | 181312424 | 181364180 | NM_024850 | $5.60 \mathrm{E}-26$ |
| II | BTNL2 | AC091874.2.13413.147570 | 5q35.3 | 181402141 | 181419638 | Butyrophilin | $7.20 \mathrm{E}-23$ |
| II | BTNL2 | AC091874.2.1.13312 | 5q35.3 | 181453511 | 151470537 | NM_152547 | $2.70 \mathrm{E}-27$ |
| XI | RFP | AC008443.9.1.120524 | 5 q 35.3 | 181733455 | 181735630 | TRIM7 | 3.80E-58 |
|  |  |  |  |  |  |  |  |
| I | TUBB | AL031963.40.1.149546 | 6p25.2 | 3138899 | 3142759 | TUBBL | $2.40 \mathrm{E}-208$ |
| I | TUBB | AL445309.13.1.136587 | 6p25.2 | 3209729 | 3212968 | TUBBL | $2.40 \mathrm{E}-208$ |
|  | RPS18 | AL359643.27.1.166863 | 6p25.1 | 4964305 | 4964649 | genscan | $7.50 \mathrm{E}-35$ |
| III | C6orf46 | AL161903.19.1.47104 | 6 p 21.32 | 33384295 | 33421772 | SYNGAP1 | $3.30 \mathrm{E}-17$ |
|  | ZNF297 | AL161903.19.1.47104 | 6 p 21.32 | 33407966 | 33421769 | NM_152735 | $2.90 \mathrm{E}-50$ |
|  | RXRB | AL022721.1.1.170245 | 6 p 21.31 | 35306800 | 35392369 | PPARD | $5.50 \mathrm{E}-09$ |
| xII | KIFC1 | AL590387.7.1.76075 | 6p21.2 | 39560349 | 39603922 | Novel | $1.20 \mathrm{E}-12$ |
| I | TUBB | AL136089.15.1.99479 | 6p21.2 | 39962644 | 39962751 | genscan | $1.00 \mathrm{E}-10$ |
| I | DDR1 | AL355385.15.1.129884 | 6p21.1 | 43040485 | 43125871 | PTK7 | $2.20 \mathrm{E}-17$ |
| XI | BTN1A1 | AL512353.16.1.81704 | 6p34.2 | 43256510 | 43284362 | ERMAP | $2.60 \mathrm{E}-68$ |
| II | TAP2/1 | AL359813.23.1.102892 | 6p21.1 | 43391706 | 43414579 | ABCB10 | $2.00 \mathrm{E}-15$ |
|  | NOTCH4 | AL359813.23.1.102892 | 6p21.1 | 43414506 | 43420784 | NM_023932 | $5.70 \mathrm{E}-28$ |
|  | CLIC1 | AL357057.19.1.58133 | 6p21.1 | 45865819 | 46044480 | CLIC5 | 8.00E-53 |



| DDR1 | AC104597.3.1.161425 | 7 q 34 | 140878465 | 140894489 | EPHB6 | 2.70E-09 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| DDR1 | AC092214.3.1.72045 | 7 q 34 | 141413870 | 141431627 | EPHA1 | 1.40E-16 |
| III C6orf46/ZNF297 | AC073422.8.1.80743 | 7 q 36.1 | 147046333 | 147070069 | Novel | $2.00 \mathrm{E}-05$ |
| III C6orf46/ZNF297 | AC073314.4.1.73888 | 7 q 36.1 | 147374895 | 147404413 | NM_015694 | $7.40 \mathrm{E}-05$ |
| II TAP2/1 | AC010973.6.1.222605 | 7 q 36.1 | 148971967 | 148989086 | ABCB8 | $8.10 \mathrm{E}-24$ |
| III BAT8 | AC010973.6.1.222605 | 7 q 36.1 | 149119222 | 149130915 | ABS10 | $3.60 \mathrm{E}-06$ |
| ABCF1 | AC021097.5.1.35899 | 7 q 36.1 | 149151360 | 149170753 | ABCF2 | 1.20E-36 |
|  |  |  |  |  |  |  |
| III NOTCH4 | AC110288.6.1.84664 | 8p23.3 | 1266863 | 1277550 | Novel | $6.60 \mathrm{E}-11$ |
| III BF | AC023296.6.1.189532 | 8p23.2 | 2642344 | 3292997 | CSMD1 | $3.00 \mathrm{E}-06$ |
| III C2 | AC023296.6.1.189532 | 8 p 23.2 | 2953246 | 3468313 | CSMD1 | $3.60 \mathrm{E}-05$ |
| III BAT1 | AC012119.7.1.154898 | 8p21.2 | 23396081 | 23396278 | Genscan | $3.10 \mathrm{E}-06$ |
| III HSPA1L | AC090820.6.1.138021 | 8p12 | 30546063 | 30546623 | genscan | $7.10 \mathrm{E}-170$ |
| III RNF5 | AC069120.4.60762.91265 | 8p11.23 | 38073473 | 38073760 | genscan | $6.20 \mathrm{E}-73$ |
| III ATP6V1G2 | AC120036.3.58309.177413 | 8q-tel | 46087951 | 46088247 | genscan | $5.50 \mathrm{E}-08$ |
| XII RING1 | AC016113.9.1.185419 | 8 q 11.23 | 53945099 | 53945155 | no gene | 2.20E-19 |
| xIILYPLA2L | AC060764.10.163950.18377 | 8 q 11.23 | 54898165 | 54953804 | LYPLA1 | $2.10 \mathrm{E}-27$ |
| DDR1 | AC046176.11.1.132489 | 8 q 12.1 | 56731370 | 56862134 | LYN | $2.10 \mathrm{E}-12$ |
| xI HIST1H2AC | AC084251.13.1.181400 | 8 q 13.3 | 70956550 | 70956840 | no gene | 3.70E-18 |
| XII RPS18 | AC022730.7.1.155468 | 8 q 13.3 | 71276927 | 71277244 | genscan | 1.30E-31 |
| XII RXRB | AC040917.6.1.158031 | 8 q 21.11 | 76308140 | 76464431 | HNF4G | $5.80 \mathrm{E}-28$ |
| XII ZNF297 | AC009812.17.1.155405 | 8 q 21.13 | 81446105 | 81481018 | NM_023929 | $2.30 \mathrm{E}-10$ |
| I TUBB | AC007992.12.1.146921 | 8 q 22.1 | 96147896 | 96147985 | genscan | 1.40E-09 |
| POU5F1 | AP002851.2.1.200610 | 8 q 22.3 | 103702017 | 103702310 | no gene | 1.70E-17 |
| III BF | AC007719.7.1.150831 | 8 q 23.3 | 112280606 | 112310596 | Novel | $3.10 \mathrm{E}-05$ |
| xI HIST1H2AC | AC022360.23.1.171991 | 8 q 23.3 | 112695588 | 112695632 | no gene | $3.60 \mathrm{E}-05$ |
| III C2 | AC007719.7.1.150831 | 8 q 23.3 | 113296979 | 113550957 | Q96PZ3 | $9.60 \mathrm{E}-05$ |
| I DDR1 | AC022239.14.1.171829 | 8 q 23.1 | 113344396 | 11414823 | BLK | $6.00 \mathrm{E}-10$ |
| XII ZNF297 | AC105210.4.125110.131923 | 8 q 24.3 | 145036223 | 145040537 | Q96C28 | 1.20E-07 |
| xII HKE4 | AC022505.17.153698.191078 | 8 q 24.3 | 145675676 | 145680153 | SLC39A4 | $7.40 \mathrm{E}-08$ |
| xII KIFC1 | AC084125.8.1.197314 | 8 q 24.3 | 145729611 | 145737380 | NM_145754 | $2.40 \mathrm{E}-17$ |
| III NOTCH4 | AC084125.4.1.26696 | 8 q 24.3 | 145753310 | 145765393 | PPP1R16A | $2.60 \mathrm{E}-12$ |
| III C6orf46 | AF235103.3.1.344150 | 8 q 24.3 | 146143706 | 146164020 | ZNF64 | 1.10E-14 |
|  |  |  |  |  |  |  |
| DDR1 | AL161450.14.1.171146 | 9 p 24.1 | 5003251 | 5108156 | JAK2 | 1.60E-06 |
| xII RING1 | AL162411.23.1.59964 | 9 p 24.1 | 6650955 | 6651159 | no gene | $7.00 \mathrm{E}-39$ |
| III CLIC1 | AC017067.4.1.191373 | 9 p 21.3 | 23075247 | 23075813 | genscan | 1.30E-48 |
| xI NOL5B | AL445623.2.1.198637 | 9 p 21.3 | 23903514 | 23903843 | genscan | 1.10E-15 |
| III HSPA1L | AL353745.7.1.174850 | 9 p 21.1 | 31159147 | 31159635 | genscan | $5.50 \mathrm{E}-17$ |
| II BRD2 | AL589642.6.1.92982 | 9 p 21.1 | 32799398 | 32805026 | TAF1L | $2.80 \mathrm{E}-08$ |
| XII ZNF297 | AL158155.24.1.192336 | 9 p 13.2 | 37607553 | 37634838 | NM_014872 | 2.30E-10 |
| III C6orf46 | AL353770.18.1.130898 | 9 p 13.1 | 39619983 | 39630670 | Q96M55 | 1.10E-14 |
| III CYP21A2 | AL359997.8.1.169102 | 9q21.13 | 66702026 | 66702607 | genscan | 1.20E-14 |
| xIILYPLA2L | AL353637.16.1.133212 | 9 q 21.2 | 71442203 | 71442490 | no gene | 3.50E-59 |
| III BAT1 | AL158047.9.1.201629 | 9q21.32 | 75746587 | 75747222 | Genscan | $2.30 \mathrm{E}-19$ |
| xII KIFC1 | AL354733.15.1.189579 | 9q21.32 | 78368024 | 78383954 | Novel | 5.50E-27 |
| I DDR1 | AL445532.8.1.171629 | 9q21.33 | 79138134 | 79490850 | NTRK2 | 1.80E-35 |
| XII ZNF297 | AL136981.22.1.182280 | 9 q 22.31 | 87336127 | 87368066 | Q9H559 | $2.80 \mathrm{E}-10$ |
| xI GABBR1 | AL445495.5.1.155837 | 9q22.33 | 92793899 | 93215009 | GPR51 | 1.60E-09 |
| xIICOL11A2 | AL354923.12.1.134965 | 9q22.33 | 93449719 | 93576588 | COL15A1 | 3.10E-12 |
| III C6orf29 | AL450265.11.1.68871 | 9 q 31.1 | 99804995 | 99897178 | CTL1 | 1.40E-12 |
| III C9orf29 | AL450265.11.1.68871 | 9 q 31.1 | 99804995 | 99897178 | NM_022109 | 1.40E-12 |
| III BF | AL158158.14.1.194835 | 9 q 31.3 | 103971543 | 103990925 | Novel | 1.70E-11 |
| III C2 | AL158158.14.1.194835 | 9 q 31.3 | 104860730 | 104923764 | NM_153366 | $2.50 \mathrm{E}-15$ |
| III NOTCH4 | AL354982.12.1.119077 | 9 q 31.3 | 104936930 | 105074331 | Novel | 1.20E-33 |
| I DDR1 | AL157881.14.1.162726 | 9 q 31.3 | 105163309 | 105295448 | MUSK | 1.80E-41 |
| III C6orf46 | AL159168.15.1.129010 | 9 q 31.3 | 106019666 | 106038882 | Q8TF39 | $1.80 \mathrm{E}-14$ |


| III BAT2 | AL354877.25.1.116236 | 9 q 31.3 | 106181071 | 106289393 | NM_173521 | $3.30 \mathrm{E}-17$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| xII ZNF297 | AL162588.22.1.76606 | 9 q 31.3 | 107536344 | 107551166 | ZFP37 | $7.80 \mathrm{E}-09$ |
| III NOTCH4 | AL162425.15.1.177728 | 9 q 31.3 | 108581009 | 108678635 | Novel | $6.30 \mathrm{E}-28$ |
| xII COL11A2 | AL445543.20.1.140327 | 9 q 31.3 | 108662161 | 108805998 | Q96JF7 | $2.60 \mathrm{E}-13$ |
| III ATP6V1G2 | AL160275.14.1.189709 | 9 q 32 | 109082196 | 109092823 | ATP6V1G1 | $1.50 \mathrm{E}-12$ |
| III TNF | AL390240.18.1.93876 | 9 q 32 | 109283763 | 109300763 | TNFSF15 | $3.80 \mathrm{E}-10$ |
| III TNXB | AL162425.15.1.177728 | 9 q 33.1 | 109514975 | 109612609 | TNC | $7.80 \mathrm{E}-25$ |
| TUBB | AL589703.6.1.48697 | 9 q 33.1 | 112631091 | 112631204 | genscan | $1.60 \mathrm{E}-10$ |
| xII B3GALT4 | AL161911.17.1.109176 | 9 q 33.2 | 115207621 | 115207998 | genscan | $6.40 \mathrm{E}-31$ |
| III C4B | AC006430.22.1.194799 | 9 q 33.2 | 115361172 | 115459110 | C5 | $5.70 \mathrm{E}-20$ |
| III C6orf46 | AC007066.4.1.190815 | 9 q 33.2 | 117340094 | 117340094 | BIOR | $9.80 \mathrm{E}-65$ |
| III NOTCH4 | AL445489.10.1.175869 | 9 q 33.3 | 117788495 | 118338969 | NM_024820 | $2.20 \mathrm{E}-76$ |
| xII RXRB | AL354979.17.1.85997 | 9 q 33.3 | 118928956 | 119180139 | NR6A1 | $9.70 \mathrm{E}-13$ |
| III HSPA1L | AL354710.17.1.131708 | 9 q 33.3 | 119643682 | 119650159 | HSPA5 | $8.1 \mathrm{E}-161$ |
| III PBX2 | AL445186.4.1.156124 | 9 q 33.3 | 120156161 | 120376205 | PBX3 | $9.10 \mathrm{E}-85$ |
| III C6orf46/ZNF297 | AL161731.20.1.182452 | 9 q 33.3 | 121213845 | 121244041 | ZNF297B | $7.30 \mathrm{E}-33$ |
| xII C6orf46/ZNF297 | AL354944.22.1.49144 | 9 q 33.3 | 121269484 | 121289729 | Q8NCN2 | $9.50 \mathrm{E}-39$ |
| DDR1 | AL161733.20.1.176466 | 9 q 34.12 | 125136236 | 125309589 | ABL1 | $8.50 \mathrm{E}-12$ |
| III AIF1 | AL157938.22.1.197019 | 9 q 34.12 | 125518441 | 125545061 | NM_031426 | $1.20 \mathrm{E}-56$ |
| III BAT2 | AL358781.19.1.147492 | 9 q 34.13 | 125852061 | 125869120 | NM_032640 | 2.20E-65 |
| xII RAB2L | AL162417.23.1.152863 | 9 q 34.2 | 127529965 | 127553410 | RALGDS | $3.70 \mathrm{E}-29$ |
| II BRD 2 | AL445931.29.1.175033 | 9 q 34.2 | 128566862 | 128602533 | BRD3 | $1.90 \mathrm{E}-133$ |
| xII RXRB | AL669970.6.1.58552 | 9 q 34.2 | 129062693 | 129101647 | RXRA | $6.30 \mathrm{E}-88$ |
| xIICOL11A2 | AL603650.10.1.131466 | 9 q 34.3 | 129302868 | 129503955 | COL5A1 | $2.10 \mathrm{E}-43$ |
| III NOTCH4 | AL390778.30.1.221373 | 9 q 34.3 | 129736484 | 129782241 | OLFM1 | $4.60 \mathrm{E}-11$ |
| III NOTCH4 | AL353615.27.1.37093 | 9 q 34.3 | 130006614 | 130009927 | NM_173520 | $6.00 \mathrm{E}-10$ |
| XII ZNF297 | AL591038.9.1.51295 | 9 q 34.3 | 130674721 | 130713948 | NM_144653 | $7.90 \mathrm{E}-15$ |
| III NOTCH4 | AL592301.14.1.188462 | 9 q 34.3 | 131078383 | 131129726 | NOTCH1 | $2.40 \mathrm{E}-224$ |
| III EGFL8 | AL590226.23.1.149567 | 9 q 34.3 | 131242795 | 131256617 | ZNEU1 | $9.70 \mathrm{E}-12$ |
| III AGPAT1 | AL590226.23.1.149567 | 9 q 34.3 | 131257082 | 131271362 | AGPAT2 | $2.50 \mathrm{E}-29$ |
| III CLIC1 | AC068451.2.53215.58850 | 9 q 34.3 | 131578574 | 131580507 | CLIC3 | $3.30 \mathrm{E}-35$ |
| III BAT8 | AL611925.20.31668.168509 | 9 q 34.3 | 132395728 | 132553855 | HMT1 | $7.30 \mathrm{E}-142$ |
| TUBB | AL713922.8.1.121218 | 10p15.3 | 33000 | 35178 | TUBBL | 2.70E-190 |
| III NOTCH4 | AL513304.27.1.163243 | 10p15.3 | 1427949 | 1428792 | no gene | $3.20 \mathrm{E}-06$ |
| xII KIFC1 | AL161932.15.1.143423 | 10p11.22 | 3016668 | 32061904 | KIF5B | $1.00 \mathrm{E}-06$ |
| III HSPA1L | AC069544.9.1.214866 | 10p13 | 14843884 | 14877306 | NM_016299 | $1.00 \mathrm{E}-15$ |
| III BAT8 | AC069544.9.1.214866 | 10p13 | 14884428 | 14909880 | SU92 | $1.40 \mathrm{E}-17$ |
| III NOTCH4 | AL133415.12.1.179912 | 10p13 | 17152297 | 17207242 | DNMT2 | $1.10 \mathrm{E}-15$ |
| xII HKE4 | AL590111.14.1.41069 | 10p12.33 | 17957452 | 18048843 | NM_152725 | $7.10 \mathrm{E}-08$ |
| xII RPS18 | AL513128.11.1.184685 | 10p12.2 | 22534350 | 22534484 | no gene | $1.20 \mathrm{E}-05$ |
| XII ZNF297 | AL117337.25.1.161452 | 10 q 11.21 | 37982417 | 38009185 | ZNF25 | $1.00 \mathrm{E}-07$ |
| xII ZNF297 | AL161931.13.1.19853 | 10 q 11.21 | 38043229 | 38099906 | ZNF33A | $1.30 \mathrm{E}-10$ |
| xII ZNF297 | AL022345.2.1.146328 | 10q11.21 | 42553027 | 42602464 | ZNF11B | $1.30 \mathrm{E}-10$ |
| III C6orf46 | AL353801.13.1.222490 | 10q11.21 | 44964852 | 44969243 | ZNF22 | $4.10 \mathrm{E}-14$ |
| III BAT8 | AL359377.18.1.172177 | 10q21.2 | 60813515 | 61174843 | ANK3 | $6.70 \mathrm{E}-05$ |
| POU5F1 | AL356741.11.1.87244 | 10q21.3 | 68768389 | 68953381 | Q9HCH9 | $1.40 \mathrm{E}-75$ |
| III BAT1 | AL359844.15.1.171364 | 10q22.1 | 69527140 | 69554693 | DDX21 | $1.20 \mathrm{E}-05$ |
| III BAT1 | AC016394.13.1.149726 | 10q22.2 | 73713068 | 73782589 | Q9Y2I0 | $1.90 \mathrm{E}-10$ |
| xI HIST1H2AC | AL391421.27.1.168239 | 10q22.3 | 78922958 | 78923248 | no gene | $1.00 \mathrm{E}-14$ |
| III BAT1 | AL365434.12.1.158357 | 10q23.31 | 91694792 | 91695643 | Genscan | $7.30 \mathrm{E}-17$ |
| III BAT1 | AL731553.9.1.161141 | 10q23.31 | 91759982 | 91760050 | Genscan | $7.40 \mathrm{E}-17$ |
| III BAT1 | AL158040.13.1.213648 | 10q23.32 | 92777959 | 92779325 | Novel | $1.50 \mathrm{E}-24$ |
| xII KIFC1 | AL356128.27.1.191935 | 10 q 23.33 | 93574641 | 93636806 | KIF11 | $1.50 \mathrm{E}-11$ |
| III CYP21A2 | AL359672.19.1.143181 | 10q23.33 | 95689793 | 95722511 | CYP2C8 | $3.20 \mathrm{E}-05$ |
| III NOTCH4 | AL442123.12.1.96660 | 10q24.1 | 97651046 | 97838934 | SLIT1 | 6.90E-33 |
| xII ZNF297 | AL135791.12.1.66975 | 10q24.1 | 97820294 | 3785029 | Q9NQN2 | 7.80E-09 |


| II TAP2 | AL392107.16.1.94970 | 10q24.2 | 100776166 | 100845227 | ABCC2 | $7.70 \mathrm{E}-05$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| III CYP21A2 | AL358790.22.1.131753 | 10q24.32 | 103483494 | 103490378 | CYP17 | $4.20 \mathrm{E}-12$ |
| xI RFP | AL391121.29.1.166600 | 10q24.32 | 103638012 | 103651712 | TRIM8 | $1.90 \mathrm{E}-07$ |
| DHX16 | AL360176.22.1.155699 | 10q26.2 | 126728551 | 126773529 | DDX32 | $1.10 \mathrm{E}-21$ |
| III CYP21A2 | AL161645.14.1.161644 | 10q26.3 | 134255131 | 134266884 | CYP2E | $2.00 \mathrm{E}-07$ |
|  |  |  |  |  |  |  |
| xI MAS1L | AC108448.5.135208.198047 | 11 p 15.4 | 3499638 | 3500522 | Novel | 5.70E-29 |
| xI $\mathrm{xFP} /$ RING1 | AC009758.8.1.141485 | 11 p 15.4 | 4708183 | 4716972 | SSA1 | $9.40 \mathrm{E}-71$ |
| xI RFP | AC090719.8.1.179177 | 11p15.4 | 4921932 | 4931481 | NM_018073 | 6.50E-72 |
| xI BTN1A1 <br> II  | AC009758.8.1.141485 | 11p15.4 | 4972222 | 4981011 | SSA1 | 6.10E-38 |
| xI $\mathrm{BTN1A1}$ | AC090719.8.1.179177 | 11p15.4 | 5185974 | 5195520 | Novel | $1.40 \mathrm{E}-35$ |
| xI RFP | AC015691.6.1.203036 | 11p15.4 | 5919434 | 5967728 | TRIM6 | $1.30 \mathrm{E}-45$ |
| XI RFP | AC109341.7.1.202761 | 11 p 15.4 | 5986894 | 6008393 | TRIM5 | $9.10 \mathrm{E}-44$ |
| xI <br> BTN1A1 | AC015691.6.1.203036 | 11p15.4 | 6372568 | 6413722 | TRIM34 | $1.70 \mathrm{E}-16$ |
| xI BTN1A1 | AC109341.7.1.202761 | 11 p 15.4 | 6459104 | 6478807 | TRIM22 | $1.70 \mathrm{E}-16$ |
| III CYP21A2 | AC018795.10.1.187836 | 11 p 15.2 | 15932556 | 15932621 | no gene | $2.90 \mathrm{E}-18$ |
| III CYP21A2 | AC090835.6.82428.167443 | 11 p 15.2 | 16080713 | 16094757 | Novel | $3.10 \mathrm{E}-19$ |
| XI MAS1L | AC090099.10.28570.173306 | 11 p 15.1 | 19101039 | 19102007 | MRGX3 | $1.70 \mathrm{E}-39$ |
| XI MAS1L | AC107948.7.1.156839 | 11p15.1 | 19137100 | 19138068 | MRGX4 | $3.30 \mathrm{E}-38$ |
| XI $\mathrm{MAS1L}$ | AC023078.9.1.163718 | 11 p 5.1 | 19899153 | 19900121 | MRGX1 | $2.00 \mathrm{E}-40$ |
| xI MAS1L | AC023078.9.1.163718 | 11p15.1 | 19926836 | 19991360 | Novel | $2.40 \mathrm{E}-17$ |
| xI MAS1L | AC027026.9.1.155376 | 11 p 15.1 | 20020747 | 20021739 | MRGX2 | $1.10 \mathrm{E}-35$ |
| xII KIFC1 | AC023206.6.1.208561 | 11p14.1 | 28817128 | 28904683 | NM_031217 | $5.40 \mathrm{E}-07$ |
| III BF | AL354921.12.1.106657 | 11 p 13 | 37005965 | 37099743 | Q96JW2 | $2.60 \mathrm{E}-06$ |
| III NOTCH4 | AC061999.6.1.182549 | 11 p 12 | 37290819 | 37297112 | RAG2 | $3.90 \mathrm{E}-26$ |
| xII RXRB | AC090589.8.1.190017 | 11p11.2 | 48157255 | 48168103 | NR1H3 | $1.40 \mathrm{E}-06$ |
| xII RXRB | AC018410.19.7721.155276 | 11 p 11.2 | 48168666 | 48229300 | MADD | $1.10 \mathrm{E}-06$ |
| xII HKE4 | AC090559.5.26090.106816 | 11 p 11.2 | 48306544 | 48315768 | NM_152264 | $8.60 \mathrm{E}-14$ |
| xII RXRB | AP001453.4.1.166300 | 11q13.1 | 65754594 | 65765769 | ESRRA | $9.70 \mathrm{E}-18$ |
| III NOTCH4 | AP000769.4.1.114794 | 11q13.1 | 66974259 | 66987851 | SCYL1 | $1.20 \mathrm{E}-19$ |
| III NOTCH4 | AP001362.5.1.211382 | 11 q 13.1 | 67025483 | 67041797 | Novel | $1.70 \mathrm{E}-22$ |
| XI MAS1L | AP000808.4.1.176380 | 11 q 13.3 | 70444307 | 70445269 | Q8TDS7 | $7.50 \mathrm{E}-35$ |
| xI MAS1L | AP003071.2.1.192759 | $11 \mathrm{q13.3}$ | 70468658 | 70477508 | MRGF | $4.00 \mathrm{E}-27$ |
| xI HIST1H2AC | AP002336.3.1.112484 | 11 q 13.3 | 71639671 | 71753357 | PPFIA1 | $4.50 \mathrm{E}-14$ |
| III NOTCH4 | AP000867.4.1.199996 | 11 q 13.4 | 72870983 | 72871905 | Q8NH65 | $3.20 \mathrm{E}-07$ |
| I C6ORF18 | AP000719.4.1.196424 | 11 q 13.4 | 73253747 | 73331398 | NUMA1 | $1.90 \mathrm{E}-06$ |
| xII B3GALT4 | AP000752.4.1.194140 | 11 q 13.5 | 78289628 | 78290785 | NM_138706 | $5.70 \mathrm{E}-25$ |
| III NOTCH4 | AP002768.3.1.186084 | 11 q 14.1 | 79903349 | 79952134 | Q9P2P4 | $1.50 \mathrm{E}-09$ |
| xI PRSS16 | AP001646.4.1.182328 | 11q14.1 | 84074231 | 84150294 | PRCP | $4.10 \mathrm{E}-06$ |
| III BAT1 | AP003390.1.1.221091 | 11 q 23.3 | 91694792 | 91695643 | Genscan | 2.10E-106 |
| TUBB | AP002364.3.1.165702 | 11 q 14.3 | 92344989 | 92345090 | genscan | $1.50 \mathrm{E}-11$ |
| I TUBB | AP002799.3.1.177564 | 11q14.3 | 94012104 | 94012214 | genscan | $2.30 \mathrm{E}-14$ |
| III NOTCH4 | AP003171.2.1.137000 | 11q14.3 | 94081540 | 94134035 | Q8TDW7 | $2.90 \mathrm{E}-10$ |
| III BAT8 | AP000786.4.1.75440 | 11q21 | 95734866 | 95740452 | NM_017704 | 7.20E-06 |
| III BAT8 | AP002840.2.1.177034 | 11q23.2 | 114770675 | 114783056 | Q98NFD2 | $3.30 \mathrm{E}-15$ |
| III NOTCH4 | AP002840.2.1.177034 | 11 q 23.1 | 114792387 | 114857963 | DRD2 | $2.10 \mathrm{E}-10$ |
| III BAT8 | AP001267.4.1.194310 | 11 q 23.3 | 119819041 | 119907224 | MLL | $2.50 \mathrm{E}-05$ |
| xI HIST1H2AC | AP003391.1.1.46239 | 11 q 23.3 | 120476378 | 120477968 | H2AFX | $2.80 \mathrm{E}-42$ |
| III BAT1 | AP000713.2.1.11316 | 11 q 23.3 | 120964857 | 120979716 | DDX6 | $1.20 \mathrm{E}-06$ |
| I POU5F1 | AP001150.4.1.157282 | 11q23.3 | 121622699 | 121702405 | POU2F3 | $6.50 \mathrm{E}-21$ |
| III BAT1 | AP001994.4.1.167376 | 11q23.3 | 121762568 | 121762732 | No gene | $1.50 \mathrm{E}-105$ |
| III HSPA1L | AP000926.5.1.196973 | 11q24.1 | 124441468 | 124446116 | HSPA8 | $9.10 \mathrm{E}-243$ |
| III BAT1 | AP000842.4.1.179369 | 11q24.2 | 127774844 | 147793446 | DDX25 | $1.80 \mathrm{E}-10$ |
| III C6orf46/ZNF297 | AP001183.4.1.174526 | 11 q 24.3 | 131612944 | 131697119 | NM_014155 | $7.80 \mathrm{E}-15$ |
| III BAT1 | AC019227.4.1.190314 | 11 q 24.3 | 132166105 | 132166485 | Genscan | $1.50 \mathrm{E}-13$ |
| PPP1R10 | AP000824.4.1.186920 | 11 q 24.3 | 132172516 | 132173124 | genscan | $7.20 \mathrm{E}-17$ |
| I PPP1R10 | AP003486.2.1.217488 | 11q24.3 | 132258421 | 132299008 | SNXJ | $9.60 \mathrm{E}-17$ |


|  | BAT1 | AP000435.5.1.124067 | 11q12.1 | 60403473 | 60403808 | Genscan | $3.00 \mathrm{E}-12$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| III | HSPA1L | AC007207.22.1.191877 | 12p13.32 | 4100374 | 4101084 | genscan | $1.80 \mathrm{E}-215$ |
|  | TAPBP | AC005840.2.1.140026 | 12p13.31 | 6535709 | 6550143 | TAPBP-R | 3.30E-05 |
|  | BF | AC006512.12.1.157115 | 12p13.31 | 7087044 | 7087106 | no gene | $3.10 \mathrm{E}-06$ |
| III | C 2 | AC006512.12.1.157115 | 12p13.31 | 7243215 | 7245179 | C10 | 6.10E-09 |
| III | C4B | AC006581.16.1.172931 | 12p13.31 | 8712438 | 8724661 | Novel | $2.80 \mathrm{E}-05$ |
| III | C4B | AC007436.1.1.163881 | 12p13.31 | 8928367 | 8976544 | A2M | 3.20E-09 |
| III | C4B | AC010175.4.1.127277 | 12p13.31 | 9009493 | 9069023 | PZP | $6.20 \mathrm{E}-09$ |
| III | BAT1 | AC007215.43.2235.65215 | 12p13.2 | 12695938 | 12712573 | NM_016355 | $1.60 \mathrm{E}-11$ |
| XI | HIST1H2AC | AC010168.6.1.104926 | 12p12.3 | 15072102 | 15073039 | H2AFJ | $1.10 \mathrm{E}-44$ |
|  | COL11A2 | AC004801.1.1.193561 | 12q13.11 | 48379436 | 48410949 | COL2A1 | $2.80 \mathrm{E}-38$ |
| III | BAT1 | AC025557.4.146238.171945 | 12q13.13 | 49116936 | 49138712 | NM_004818 | $1.10 \mathrm{E}-14$ |
| I | TUBB | AC011603.33.10243.45426 | 12q13.12 | 49484144 | 49487748 | TUBA1 | $9.00 \mathrm{E}-11$ |
| I | TUBB | AC010173.22.67252.90665 | 12q13.12 | 49586964 | 49595224 | TUBA6 | $2.20 \mathrm{E}-12$ |
| I | TUBB | AC010173.22.160578.20759 | 12q13.12 | 49655804 | 49660085 | TUBA1 | $1.00 \mathrm{E}-11$ |
| xI | RXRB | AC025259.48.1.210158 | 12 q 13.13 | 52474503 | 52482549 | NR4A1 | $1.10 \mathrm{E}-07$ |
| III | BAT1 | AC055716.24.1.110819 | 12 q 13.13 | 53260460 | 53260801 | Genscan | $5.40 \mathrm{E}-27$ |
| III | BAT1 | AC068988.19.27848.161382 | 12 q 13.13 | 53292388 | 53292489 | Genscan | $7.70 \mathrm{E}-27$ |
| III | BAT1 | AC073573.27.1.157807 | 12q13.13 | 53706088 | 53706432 | Genscan | $4.30 \mathrm{E}-35$ |
| III | BAT8 | AC073896.29.107190.140910 | 12q13.2 | 56645899 | 56649310 | NM_173594 | $2.30 \mathrm{E}-05$ |
| xII | ZNF297 | AC026120.33.1.171998 | 12q13.3 | 57617302 | 57624914 | Y352 | $1.10 \mathrm{E}-11$ |
| III | BAT1 | AC117498.1.134066.149599 | 12 q 14.1 | 61110934 | 61180767 | Novel | $1.50 \mathrm{E}-15$ |
| xI | NOL5B | AC027288.26.1.177080 | 12q12.2 | 80316560 | 80316925 | genscan | 6.20E-24 |
| XI | BTN1A1 | AC009771.13.122068.178104 | 12q23.3 | 107466485 | 107466640 | no gene | 2.10E-30 |
| XI | MAS1L | AC063957.22.1.71430 | 12q23.3 | 108566149 | 108613888 | CMKLR1 | $8.80 \mathrm{E}-05$ |
| III | HSPA1L | AC005805.9.96579.142875 | 12q24.11 | 111438197 | 111439237 | Novel | $1.20 \mathrm{E}-134$ |
| III | CLIC1 | AC078875.25.5011.18452 | 12q24.31 | 120214564 | 120215259 | Novel | $1.60 \mathrm{E}-14$ |
| xII | B3GALT4 | AC048338.22.82693.113969 | 12q24.31 | 122667939 | 122671768 | B3GNT4 | $2.10 \mathrm{E}-23$ |
| II | TAP2/1 | AC026362.34.74237.162900 | 12q24.31 | 123114813 | 123152304 | ABCB9 | $5.50 \mathrm{E}-45$ |
| I | DHX16 | AC093719.6.127047.199959 | 12q24.31 | 125177591 | 125220663 | DDX37 | $8.20 \mathrm{E}-17$ |
| xII | ZNF297 | AC026786.5.1.160615 | 12q24.33 | 133310141 | 133338979 | ZNF10 | $6.10 \mathrm{E}-10$ |
|  |  |  |  |  |  |  |  |
| XI | RXRB | AL359457.12.1.129779 | 13q12.11 | 14106712 | 14124427 | ESRRAP | $3.40 \mathrm{E}-27$ |
| xII | RXRB | AL158032.32.1.172004 | 13q12.11 | 15813801 | 15815722 | Novel | $4.50 \mathrm{E}-27$ |
| I | TUBB | AL139327.18.1.149559 | 13q12.11 | 17727916 | 17735936 | TUBA2 | $1.10 \mathrm{E}-09$ |
| III | BAT1 | AL354828.12.1.168114 | 13q12.12 | 21259290 | 21260180 | Genscan | 1.10E-111 |
| I | DDR1 | AL591024.14.1.76721 | 13 q 12.2 | 22557753 | 22654705 | FLT3 | $9.00 \mathrm{E}-05$ |
| xI | POM121L2 | AL359741.9.1.139877 | 13 q 12.3 | 23332361 | 23332804 | genscan | 1.20E-19 |
| XI | POM121L2 | AL596092.8.1.153841 | 13q12.3 | 23579447 | 24059956 | O94872 | 2.70E-15 |
| III | HSPA1L | AL137142.20.1.113850 | 13q12.3 | 25697387 | 25722697 | H105 | $8.20 \mathrm{E}-22$ |
| III | BAT1 | AL138822.13.1.126502 | 13 q 12.3 | 27152990 | 27154150 | Genscan | $1.50 \mathrm{E}-50$ |
| XI | HIST1H2AC | AL159980.14.1.162044 | 13 q 13.3 | 31050674 | 31050910 | genscan | $5.60 \mathrm{E}-20$ |
| III | BAT1 | AL138706.9.1.195032 | 13q13.3 | 35499252 | 35499851 | Genscan | $1.40 \mathrm{E}-45$ |
| III | BAT8 | AL136218.26.1.159863 | 13q14.2 | 44005950 | 44053746 | C13ORF4 | $3.20 \mathrm{E}-06$ |
| xII | RXRB | AL138997.18.1.172342 | 13q21.1 | 50568900 | 50569076 | genscan | $5.20 \mathrm{E}-14$ |
| III | BAT1 | AL161901.18.1.150054 | 13q21.2 | 59178906 | 59179631 | Genscan | $1.90 \mathrm{E}-31$ |
| XI | RFP | AL136145.23.1.83809 | 13q21.32 | 60838247 | 60838498 | genscan | $9.90 \mathrm{E}-09$ |
| I | DHX16 | AC001226.1.1.106988 | 13 q 22.3 | 71554239 | 71557564 | Novel | $4.40 \mathrm{E}-10$ |
| I | POU5F1 | AL445209.4.1.157302 | 13q31.1 | 73168139 | 73172615 | POU4F1 | $7.40 \mathrm{E}-28$ |
| II | TAP2/1 | AL157818.12.1.182485 | 13 q 32.1 | 90059271 | 90340865 | ABCC4 | $7.60 \mathrm{E}-05$ |
| xI | HIST1H2AC | AL160155.19.1.149478 | 13 q 32.3 | 94254802 | 94255185 | H2A-like | $1.60 \mathrm{E}-11$ |
|  | COL11A2 | AL390755.5.1.186120 | 13 q 34 | 105188574 | 105346678 | COL4A1 | $3.30 \mathrm{E}-17$ |
| xII | COL11A2 | AL159153.17.1.102319 | 13 q 34 | 105346805 | 105553028 | COL4A2 | $2.40 \mathrm{E}-16$ |
| III | NOTCH4 | AL137002.19.1.132933 | 13 q 34 | 108397279 | 108411519 | F7 | $2.60 \mathrm{E}-18$ |
| III | NOTCH4 | AL161774.49.1.162296 | 13 q 34 | 110946220 | 111086222 | RASA3 | $9.60 \mathrm{E}-09$ |
|  |  |  |  |  |  |  |  |


| II PSMB8 | AL132780.5.1.191946 | 14q11.2 | 17282361 | 17291410 | PSMB5 | $2.40 \mathrm{E}-67$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| xI HMGN4 | AL163052.4.1.181905 | 14 q 12 | 23108107 | 23108319 | no gene | $8.20 \mathrm{E}-06$ |
| TUBB | AL445383.5.1.172914 | 14q21.2 | 41065751 | 41065876 | genscan | $7.00 \mathrm{E}-10$ |
| xIIRXRB | AL161756.6.1.176257 | 14q23.2 | 58487079 | 58598473 | ESR2 | $8.90 \mathrm{E}-05$ |
| III HSPA1L | AL049869.6.1.195840 | 14q23.3 | 58801222 | 58803614 | HSPA2 | $4.80 \mathrm{E}-266$ |
| xI GPX5 | AL139022.4.1.190517 | 14q23.3 | 59199531 | 59203136 | GPX2 | $1.50 \mathrm{E}-27$ |
| III BAT1 | AL391262.3.1.171296 | 14q24.1 | 67056068 | 67056841 | Genscan | $1.00 \mathrm{E}-18$ |
| III NOTCH4 | AC005479.2.1.140425 | 14q24.3 | 68764077 | 68777511 | NPC2 | $3.70 \mathrm{E}-22$ |
| xII RXRB | AC008050.6.1.176975 | 14q24.3 | 70654841 | 70785295 | ESRRB | $5.10 \mathrm{E}-09$ |
| xII RPS18 | AL122020.5.1.149904 | 14 q 32.11 | 85048919 | 85049456 | Novel | $4.40 \mathrm{E}-53$ |
| III NOTCH4 | AL132711.4.1.184924 | 14 q 32.2 | 95016286 | 95017418 | no gene | $6.90 \mathrm{E}-22$ |
| III C6orf46/ZNF297 | AL590327.3.1.59297 | 14 q 32.33 | 99258499 | 99259764 | Novel | $3.20 \mathrm{E}-14$ |
| III NOTCH4 | AL512356.5.1.158468 | 14 q 32.33 | 99443586 | 99452823 | C14orf79 | $1.60 \mathrm{E}-59$ |
| III NOTCH4 | AL512355.5.1.196132 | 14 q 32.33 | 99772045 | 99852517 | O60342 | $1.90 \mathrm{E}-54$ |
| III ATP6V1G2 | AL122127.6.1.169802 | 14 q 32.33 | 103287219 | 103287536 | no gene | $1.00 \mathrm{E}-07$ |
|  |  |  |  |  |  |  |
| II TAP1 | AC116165.3.1.90200 | 15 q 11.2 | 16305068 | 16351483 | Novel | $1.70 \mathrm{E}-35$ |
| II TAP2 | AC116165.3.1.90200 | 15q11.2 | 16305068 | 16351483 | Novel | $7.20 \mathrm{E}-22$ |
| II $\mathrm{TAP1}$ | AC016033.7.99902.141149 | 15 q 11.2 | 16392186 | 16403533 | Novel | $7.70 \mathrm{E}-36$ |
| II TAP2 | AC016033.7.99902.141149 | 15q11.2 | 16392186 | 16403533 | Novel | $7.50 \mathrm{E}-23$ |
| xI POM121L2 | AC090983.10.101166.203171 | 15 q 11.2 | 17724332 | 17724397 | no gene | $2.20 \mathrm{E}-11$ |
| II TAP2 <br> II TAP1 | AC091304.12.1.179219 | 15 q 13.1 | 21513802 | 21524551 | Novel | $1.50 \mathrm{E}-44$ |
| II $\mathrm{TAP1}$ | AC091304.12.1.179219 | 15 q 13.1 | 21513802 | 21524551 | Novel | $2.30 \mathrm{E}-40$ |
| xI HMGN4 | AC022613.13.1.188117 | 15q13.1 | 25526308 | 25530507 | HMG17 | $6.40 \mathrm{E}-06$ |
| III NOTCH4 | AC020661.8.1.191655 | 15q15.1 | 34166830 | 34304183 | Q9ULG1 | $1.70 \mathrm{E}-42$ |
| II HLA Class II | AC025270.6.1.128484 | 15 q 21.1 | 37899544 | 37906166 | B2M | $7.10 \mathrm{E}-05$ |
| xI BTN1A1/RFP | AC018901.8.1.199503 | 15 q 21.1 | 37924579 | 37955869 | RNF36 | 1.20E-29 |
| II HLA-DPB1 | AC018901.8.1.199503 | 15 q 21.1 | 38056731 | 38056793 | no gene | $6.90 \mathrm{E}-06$ |
| III CYP21A2 | AC020705.4.136565.149466 | 15 q 21.1 | 38739399 | 68813334 | CYP1A2 | $1.10 \mathrm{E}-12$ |
| III NOTCH4 | AC022467.7.1.193703 | 15 q 21.1 | 41748164 | 41983082 | FBN1 | $8.10 \mathrm{E}-27$ |
| III BAT1 | AC091700.4.1.97653 | 15 q 22.2 | 55722396 | 55722959 | Genscan | $4.20 \mathrm{E}-08$ |
| III NOTCH4 | AC009433.11.1.169638 | 15 q 22.31 | 59286605 | 59645098 | NM_032445 | $4.90 \mathrm{E}-28$ |
| III BAT8 | AC067837.6.1.173919 | 15 q 23 | 61668952 | 61687004 | FEM1B | $1.70 \mathrm{E}-09$ |
| III BAT8 | AC021553.14.1.185596 | 15 q 23 | 61692853 | 61823052 | ITGA11 | $2.50 \mathrm{E}-07$ |
| xII RXRB | AC104938.2.66191.114293 | 15 q 23 | 65200660 | 65208271 | NR2E3 | $3.40 \mathrm{E}-22$ |
| III RNF5 | AC048383.8.169960.172969 | 15 q 23 | 66533763 | 66534050 | genscan | 2.30E-74 |
| II BTNL2 | AC022188.7.15746.68046 | 15 q 24.1 | 67107924 | 67122957 | NM_025240 | $5.80 \mathrm{E}-18$ |
| III CYP21A2 | AC020705.4.92855.102206 | 15 q 24.1 | 68848252 | 68854305 | CYP1A1 | $4.90 \mathrm{E}-15$ |
| DDR1 | AC027243.13.89123.218680 | 15 q 24.2 | 69598117 | 69693731 | ETFA | $1.90 \mathrm{E}-13$ |
| xI MOG | AC022188.7.15746.68046 | 15q24.1 | 70012753 | 70027796 | NM_025240 | $9.70 \mathrm{E}-10$ |
| III CYP21A2 | AC091230.8.108454.128536 | 15 q 24.1 | 70970184 | 70976444 | Novel | $9.00 \mathrm{E}-12$ |
| DDR1 | AC011966.7.1.167862 | 15 q 25.3 | 81649264 | 82028917 | NTRK3 | $7.20 \mathrm{E}-24$ |
| xII KIFC1 | AC079075.5.54114.209978 | 15 q 26.1 | 83693866 | 83715674 | ANPEP | $1.10 \mathrm{E}-15$ |
| xI HIST1H2AC | AC091544.9.1.126968 | 15 q 26.1 | 87091764 | 87110331 | H2 -like | $9.40 \mathrm{E}-17$ |
| xII RXRB | AC016251.9.1.182943 | 15 q 26.2 | 90630767 | 90631006 | no gene | $4.20 \mathrm{E}-43$ |
| DDR1 | AC069029.9.1.191018 | 15 q 26.3 | 93033248 | 93342019 | IGF1R | 3.10E-07 |
|  |  |  |  |  |  |  |
| xI BTN1A1/RFP | AJ003147.1.1.239566 | 16p13.3 | 3325667 | 3340266 | MEFV | 2.70E-35 |
| II BRD2 | AC004651.1.1.42016 | 16p13.3 | 3810213 | 3964357 | CREBBP | $1.80 \mathrm{E}-05$ |
| xII B3GALT4 | AC040160.4.1.209574 | 16q22.1 | 6761048 | 67659124 | FHOD1 | $3.70 \mathrm{E}-19$ |
| II TAP2 | AC025778.7.1.207614 | 16p13.12 | 15526117 | 15599260 | ABCB6 | $1.30 \mathrm{E}-06$ |
| III NOTCH4 | AC106796.1.45233.67716 | 16p12.3 | 19774406 | 19794065 | UMOD | $2.00 \mathrm{E}-11$ |
| xI HMGN4 | AC093509.2.1.120576 | 16p12.1 | 25470563 | 25470814 | Q96C64 | $3.90 \mathrm{E}-06$ |
| xII KIFC1 | AC023831.8.22510.115251 | 16p11.2 | 30014062 | 30032892 | QPRT | $2.00 \mathrm{E}-09$ |
| III C6orf46 | AC002310.1.1.120955 | 16p11.2 | 31053573 | 31058082 | NM_033410 | $5.30 \mathrm{E}-09$ |
| III C6orf46 | AC093249.3.1.185664 | 16p11.2 | 31102367 | 31110170 | Q96CS4 | $5.30 \mathrm{E}-08$ |
| xII ZNF297 | AC106886.2.20127.148471 | 16p11.2 | 31281559 | 31287006 | Q9UEG4 | $6.00 \mathrm{E}-10$ |


| XI RFP | AC009088.7.1.233305 | 16p11.2 | 31722146 | 31734564 | Q8N4X6 | 1.40E-33 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| II PSMB8 | AC007494.7.1.206113 | 16q12.1 | 47130249 | 47435934 | PSMB10 | 3.80E-43 |
| II TAP1 | AC096996.1.1.194627 | 16q12.1 | 48249418 | 48329904 | ABCC11 | $2.80 \mathrm{E}-05$ |
| XI UBD | AC026473.7.1.170393 | 16q21 | 51486489 | 51486719 | genscan | $6.60 \mathrm{E}-05$ |
| xII KIFC1 | AC092118.2.1.148401 | 16q13 | 57876138 | 57920423 | KIFC3 | $1.20 \mathrm{E}-25$ |
| III BAT1 | AC004531.1.1.191565 | 16 q 22.1 | 58750455 | 58752074 | DDX28 | $2.00 \mathrm{E}-18$ |
| XIIB3GALT4 | AC074143.4.1.152953 | 16q22.1 | 67560936 | 67562065 | NM_033309 | $2.70 \mathrm{E}-19$ |
| DHX16 | AC009087.4.1.174933 | 16q22.2 | 72851029 | 72870003 | DDX38 | $2.90 \mathrm{E}-50$ |
| xII ZNF297 | AC009078.6.1.176926 | 16q23.1 | 76142879 | 76166439 | NM_153688 | $7.80 \mathrm{E}-09$ |
| III BAT1 | AC093491.2.1.162178 | 16q24.1 | 76485011 | 76485421 | Genscan | 5.20E-16 |
| III CLIC1 | AC092327.3.1.189757 | 16q24.1 | 77844902 | 77845267 | Genscan | $7.10 \mathrm{E}-08$ |
| xII ZNF297 | AC009113.5.61390.188481 | 16q24.3 | 90272052 | 90283297 | Q96MU6 | $3.70 \mathrm{E}-10$ |
| I TUBB | AC092143.3.1.183047 | 16q24.3 | 90971498 | 90989716 | TUBBL | $9.20 \mathrm{E}-195$ |
|  |  |  |  |  |  |  |
| xII ZNF297 | AC090617.7.1.169947 | 17p13.3 | 2300029 | 2302554 | HIC1 | $4.70 \mathrm{E}-10$ |
| III BAT1 | AC015799.7.1.66824 | 17p13.3 | 2858331 | 2858387 | genscan | $1.70 \mathrm{E}-20$ |
| DDR1 | AC087742.7.63895.97713 | 17p13.2 | 4468643 | 4469263 | EST gene | $4.80 \mathrm{E}-11$ |
| II PSMB9 | AC027820.9.1.56340 | 17p13.2 | 5044936 | 5047269 | PSMB6 | $3.50 \mathrm{E}-26$ |
| xII KIFC1 | AC004771.1.1.91927 | 17q13.2 | 5239168 | 5273857 | KIF1C | $8.70 \mathrm{E}-05$ |
| xII ZNF297 | AC087500.12.1.136618 | 17p13.2 | 5420893 | 5425754 | Q96JF6 | $6.10 \mathrm{E}-10$ |
| DHX16 | AC004148.1.1.118276 | 17p13.2 | 5683637 | 5710243 | DDX33 | $2.10 \mathrm{E}-45$ |
| DDR1 | AC113189.3.50089.71700 | 17p13.1 | 8014004 | 8022650 | TNK1 | $1.10 \mathrm{E}-16$ |
| III BAT1 | AC016876.5.1.48645 | 17p13.1 | 8215901 | 8221709 | EIF4A1 | 3.20E-18 |
| III BAT1 | AC007421.12.1.95240 | 17p13.1 | 8215901 | 8221709 | EIF4A1 | $1.30 \mathrm{E}-05$ |
| XII RPS18 | AC013248.5.1.66571 | 17p12 | 15723309 | 15723764 | Novel | $5.60 \mathrm{E}-60$ |
| XII ZNF297 | AC005324.1.1.176643 | 17p12 | 16717966 | 16767419 | ZNF386 | $2.20 \mathrm{E}-10$ |
| III C6orf46 | AJ009612.5.1.148978 | 17p11.2 | 17565367 | 17583130 | ZNF287 | $4.10 \mathrm{E}-13$ |
| III C6orf46 | AC005822.1.1.169931 | 17p11.2 | 17634716 | 17638760 | YD49 | $4.10 \mathrm{E}-14$ |
| XII ZNF297 | AC026271.6.1.171978 | 17p11.2 | 20226123 | 20246008 | Novel | $1.70 \mathrm{E}-10$ |
| III PBX2 | AC087499.8.20079.65528 | 17p11.2 | 20668666 | 20668839 | genscan | $2.80 \mathrm{E}-05$ |
| xI UBD | AC087575.3.156902.181085 | 17q | 24638783 | 24639010 | UBB | $1.30 \mathrm{E}-12$ |
| FLOT1 | AC024267.9.50190.98519 | $17 \mathrm{q11.2}$ | 29105687 | 29123905 | FLOT2 | $1.70 \mathrm{E}-31$ |
| xII RXRB | AC068669.4.36251.62842 | 17q21.1 | 40302169 | 40309811 | NR1D1 | $6.20 \mathrm{E}-10$ |
| xII RXRB | AC080112.4.61535.75578 | 17 q 21.2 | 40640652 | 40689179 | RARA | $7.90 \mathrm{E}-13$ |
| III NOTCH4 | AC006070.1.1.161987 | 17q21.2 | 41487285 | 41488289 | KRTAP9-9 | $4.80 \mathrm{E}-18$ |
| III NOTCH4 | AC003958.1.1.127834 | 17q21.2 | 41624135 | 41630437 | KRTHA3B | $6.70 \mathrm{E}-10$ |
| I DHX16 | AC068675.9.124153.141665 | 17q21.31 | 143738377 | 43778728 | DDX8 | $4.80 \mathrm{E}-52$ |
| xII KIFC1 | AC015936.7.29291.133312 | 17q21.31 | 145189863 | 45189988 | no gene | $1.50 \mathrm{E}-05$ |
| XIICOL11A2 | AC015909.8.44136.121814 | 17q21.33 | 347864916 | 47882452 | COL1A1 | $4.00 \mathrm{E}-32$ |
| xII KIFC1 | AC019315.9.1.152057 | 17q22 | 54381662 | 54383970 | NM_032559 | $6.40 \mathrm{E}-24$ |
| xI RFP | AC004584.1.1.104871 | 17 q 23.2 | 57450065 | 57472912 | ZNF147 | $3.60 \mathrm{E}-19$ |
| I DHX16 | AC004167.1.1.124876 | 17q23.2 | 60092562 | 60135284 | NM_024612 | $4.60 \mathrm{E}-25$ |
| I DHX16 | AC005702.1.1.147686 | 17q23.2 | 60503679 | 60528304 | Novel | $7.50 \mathrm{E}-15$ |
| III BAT1 | AC015651.18.1.191583 | 17 q 23.3 | 64290823 | 64323079 | NM_007372 | $1.20 \mathrm{E}-08$ |
| III CLIC1 | AC004805.1.1.184263 | 17q24.1 | 64773117 | 64773701 | Novel | $5.70 \mathrm{E}-08$ |
| III BAT1 | AC009994.6.166827.180372 | 17q24.2 | 68976215 | 68982889 | DDX5 | $2.00 \mathrm{E}-07$ |
| III BAT1 | AC087741.2.60294.77121 | 17q25.3 | 81412654 | 81424538 | IF4N | $6.80 \mathrm{E}-06$ |
|  |  |  |  |  |  |  |
| I TUBB | AP001005.5.1.137000 | 18p11.32 | 235028 | 37159 | TUBBL | $2.80 \mathrm{E}-184$ |
| III BAT1 | AP002449.2.169334.172757 | 18p11.21 | 12998814 | 12998903 | genscan | 7.60E-17 |
| II C6orf10 | AC006238.1.1.211945 | $18 \mathrm{ql11.2}$ | 23904177 | 23904497 | genscan | $2.10 \mathrm{E}-06$ |
| xII ZNF297 | AC105101.6.1.172381 | 18q12.1 | 45351393 | 45363238 | 075453 | $5.40 \mathrm{E}-18$ |
|  |  |  |  |  |  |  |
| xII ZNF297 | AC006130.1.1.84984 | 19p13.3 | 2936627 | 2947795 | NM_024967 | $4.90 \mathrm{E}-11$ |
| I DDR1 | AC005777.1.1.43190 | 19p13.3 | 3847245 | 3871088 | MATX | $9.30 \mathrm{E}-07$ |
| xII ZNF297 | AC016586.7.116093.145761 | 19p13.3 | 4117018 | 4136099 | O00456 | $5.40 \mathrm{E}-16$ |
| III BAT8 | AC005523.1.1.41468 | 19p13.3 | 4860388 | 4864189 | FEM1A | $2.70 \mathrm{E}-09$ |


| I | TUBB | AC010503.8.1.141295 | 19p13.3 | 6562943 | 6570948 | TUBBL | $1.30 \mathrm{E}-202$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| III | TNF | AC008760.7.1.200167 | 19p13.3 | 6733175 | 673234 | TNFSF14 | $6.20 \mathrm{E}-10$ |
| III | C4B | AC008760.7.1.200167 | 19p13.3 | 6746489 | 6789295 | C3 | $3.50 \mathrm{E}-27$ |
| III | NOTCH4 | AC020895.8.1.139846 | 19p13.3 | 6959105 | 7022006 | EMR1 | $1.00 \mathrm{E}-08$ |
| I | DDR1 | AC010311.9.1.91172 | 19p13.2 | 7254547 | 7432507 | INSR | $3.10 \mathrm{E}-12$ |
| xII | LYPLA2L | AC010336.7.1.160769 | 19p13.2 | 8042351 | 8049685 | Novel | $3.30 \mathrm{E}-96$ |
| III | NOTCH4 | AC022146.6.66353.150193 | 19p13.2 | 8235200 | 8317297 | FBN3 | $5.30 \mathrm{E}-34$ |
| III | EGFL8 | AC022146.6.66353.150193 | 19p13.2 | 8275726 | 8322330 | NM_032447 | $2.60 \mathrm{E}-08$ |
| xII | COL11A2 | AC008742.8.1.194623 | 19p13.2 | 10191743 | 10242653 | COL5A3 | $3.10 \mathrm{E}-67$ |
| I | DDR1 | AC011557.6.1.30505 | 19p13.2 | 10684031 | 10714039 | TYK2 | $2.20 \mathrm{E}-07$ |
| III | LSM2 | AC011475.6.1.179953 | 19p13.2 | 10932292 | 10932453 | no gene | $5.70 \mathrm{E}-23$ |
| III | C6orf29 | AC011475.6.1.179953 | 19p13.2 | 10959135 | 10978061 | CTL2 | 5.20E-59 |
| xII | RAB2L | AC024575.6.1.119638 | 19p13.2 | 11718017 | 11752815 | Q8TEP0 | $1.30 \mathrm{E}-24$ |
| xII | ZNF297 | AC011446.6.1.115932 | 19p13.2 | 13622357 | 13628643 | STX10 | $2.20 \mathrm{E}-14$ |
| III | BAT1 | AC008569.7.1.227245 | 19p13.13 | 14887089 | 14897635 | DDX39 | 4.10E-98 |
| III | NOTCH4 | AC005327.1.1.37988 | 19p13.12 | 15236788 | 15282936 | EMR2 | $5.70 \mathrm{E}-05$ |
| III | EGFL8 | AC004663.1.1.41150 | 19p13.12 | 15649643 | 15690991 | NOTCH3 | $6.00 \mathrm{E}-05$ |
| III | NOTCH4 | AC004663.1.1.41150 | 19p13.12 | 15664050 | 15705404 | NOTCH3 | $7.70 \mathrm{E}-227$ |
| II | BRD2 | AC114486.2.1.179070 | 19p13.12 | 15741907 | 15784868 | BRD4 | $2.30 \mathrm{E}-90$ |
| xI | RXRB | AC010646.5.1.41461 | 19p13.12 | 17734984 | 17748449 | NR2F6 | $7.00 \mathrm{E}-41$ |
| xII | B3GALT4 | AC008761.7.1.226170 | 19p13.12 | 18106912 | 18149110 | Q9UPW8 | $1.10 \mathrm{E}-12$ |
| XII | B3GALT4 | AC005952.1.1.39976 | 19p13.11 | 18298235 | 18315904 | B3GNT3 | $2.50 \mathrm{E}-14$ |
| xII | RPS18 | AC020904.7.1.148824 | 19p13.11 | 18551604 | 18551837 | EST gene | 5.30E-46 |
| III | BAT1 | AC002985.1.1.38041 | 19p13.11 | 19422473 | 19431417 | NM_019070 | $1.50 \mathrm{E}-05$ |
| III | PBX2 | AC011448.4.1.165122 | 19p13.11 | 20063771 | 20120711 | PBX4 | $2.10 \mathrm{E}-68$ |
| xII | ZNF297 | AC008751.6.1.169089 | 19p13.11 | 21436099 | 21452779 | ZNF85 | $2.20 \mathrm{E}-10$ |
| III | C6orf46 | AC016628.6.1.41153 | 19p13.11 | 23871643 | 23887148 | Novel | $6.70 \mathrm{E}-16$ |
| xII | ZNF297 | AC020910.7.1.203201 | 19q13.12 | 35697932 | 35713073 | Q96NL3 | $2.30 \mathrm{E}-11$ |
| III | BAT8 | AD000671.1.1.46251 | 19 q 13.12 | 36657876 | 36678735 | TRX2 | $1.70 \mathrm{E}-05$ |
| xII | ZNF297 | AC092295.2.1.165566 | 19q13.12 | 37465837 | 37479151 | EST gene | $1.00 \mathrm{E}-10$ |
| III | C6orf46 | AC008806.4.1.135173 | 19 q 13.13 | 38293492 | 38349772 | NM_152484 | $5.30 \mathrm{E}-10$ |
| xII | ZNF297 | AC022148.5.1.198751 | 19 q 13.13 | 38430631 | 38431506 | Q8N3U1 | $1.00 \mathrm{E}-10$ |
| III | NOTCH4 | AC011500.7.1.200430 | 19q13.2 | 40327364 | 40358466 | SUPT5H | $1.10 \mathrm{E}-27$ |
| III | NOTCH4 | AC010412.8.1.155085 | 19q13.2 | 41494937 | 41527447 | LTBP4 | $1.50 \mathrm{E}-33$ |
| III | CYP21A2 | AC008537.5.1.169089 | 19q13.2 | 41988964 | 41996369 | CYP2A6 | $1.60 \mathrm{E}-09$ |
| I | DDR1 | AC011510.7.1.129402 | 19 q 13.2 | 42116547 | 42159395 | AXL | $5.40 \mathrm{E}-09$ |
| III | CYP21A2 | AC008962.9.1.154169 | 19q13.2 | 42259850 | 42273778 | CYP2F1 | $2.90 \mathrm{E}-08$ |
| xII | B3GALT4 | AC011526.7.1.40887 | 19q13.2 | 42323217 | 42324407 | Novel | $6.40 \mathrm{E}-20$ |
| III | CYP21A2 | AC011510.7.1.129402 | 19p13.2 | 42338667 | 42352612 | CYP2S1 | $9.30 \mathrm{E}-06$ |
| I | POU5F1 | AC024076.4.1.39443 | 19q13.2 | 42986837 | 43028331 | POU2F2 | $4.30 \mathrm{E}-23$ |
| III | NOTCH4 | AC011497.6.1.168586 | 19 q 13.2 | 43248294 | 43273290 | EGFL4 | $4.00 \mathrm{E}-09$ |
| I | DHX16 | AC008754.8.1.66792 | 19p13.32 | 48246893 | 48270700 | DDX34 | $7.80 \mathrm{E}-27$ |
| I | DHX16 | AC073548.4.1.66051 | 19 q 13.32 | 48322806 | 48366009 | SLC8A2 | $2.20 \mathrm{E}-17$ |
| xI | HLA Class I | AC010619.7.1.179394 | 19q13.33 | 50384629 | 50397727 | FCGRT | $8.50 \mathrm{E}-10$ |
| xII | RXRB | AC008655.7.1.123149 | 19p13.33 | 51241040 | 51247541 | NR1H2 | $1.10 \mathrm{E}-06$ |
| xI | MAS1L | AC005946.1.1.37392 | 19q13.33 | 52688362 | 52689423 | FPRL2 | $9.40 \mathrm{E}-06$ |
| III | C6orf46 | AC010320.9.1.220458 | 19q13.41 | 53262462 | 53283017 | Q96JK0 | $3.60 \mathrm{E}-15$ |
| III | C6orf46 | AC022150.6.1.228156 | 19q13.41 | 53461403 | 53462023 | ZNF137 | $9.00 \mathrm{E}-16$ |
| xII | ZNF297 | AC013256.1.1.36095 | 19 q 13.43 | 57406251 | 57442939 | NM_022103 | $1.40 \mathrm{E}-10$ |
|  | ZNF297 | AC005498.1.1.37321 | 19q13.43 | 57504539 | 57522397 | ZFP28 | $2.80 \mathrm{E}-10$ |
| xII | ZNF297 | AC003682.1.1.153875 | 19 q 13.43 | 58536894 | 58544255 | Q9BWM5 | $1.10 \mathrm{E}-11$ |
| III | C6orf46 | AC003682.1.1.153875 | 19q13.43 | 58579587 | 58587258 | ZNF134 | $1.60 \mathrm{E}-15$ |
| III | C6orf46 | AC003006.1.1.84114 | 19 q 13.43 | 58734983 | 58745942 | NM_017652 | $5.20 \mathrm{E}-12$ |
| III | C6orf46 | AC012313.7.1.185417 | 19 q 13.43 | 59398153 | 59405560 | ZNF132 | $1.70 \mathrm{E}-25$ |
| xII | ZNF297 | AC012313.7.1.185417 | 19q13.43 | 59478868 | 59485159 | NM_032792 | 5.20E-29 |
|  |  |  |  |  |  |  |  |
| XI | NOL5B | AL049712.12.1.159272 | 20p13 | 2580791 | 2587039 | NOL5A | 4.00E-29 |



| III CLIC1 | AL391259.15.1.163520 | Xp11.4 | 38963014 | 38963730 | Genscan | 2.90E-07 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| III BAT1 | AL391647.16.1.60310 | Xp11.4 | 39441330 | 39472404 | DDX39 | $6.20 \mathrm{E}-07$ |
| xII ZNF297 | AL590223.12.1.40331 | Xp11.3 | 45567068 | 45603010 | ZNF41 | $4.60 \mathrm{E}-10$ |
| XII ZNF297 | Z98304.1.1.209618 | Xp11.23 | 46096233 | 46103478 | Q96QH7 | $4.70 \mathrm{E}-10$ |
| III BAT8 | AC115618.1.1.158455 | Xp11.23 | 46756067 | 46756093 | no gene | $3.40 \mathrm{E}-15$ |
| III BAT8 | AF196970.1.1.112595 | Xp11.23 | 46815791 | 46828063 | SUV39H1 | $1.30 \mathrm{E}-15$ |
| III BAT1 | AL445236.22.1.149749 | Xp11.22 | 50567899 | 50607906 | Novel | $9.90 \mathrm{E}-39$ |
| xII HSD17B8 | Z97054.1.1.132805 | Xp11.22 | 51162495 | 51165605 | HADH2 | 3.60E-06 |
| xII KIFC1 | AL357752.19.1.178868 | Xq13.1 | 66987254 | 67117990 | KIF4A | 2.70E-08 |
| III BAT1 | AL359740.24.1.98104 | Xq13.2 | 70525227 | 70526105 | genscan | $1.00 \mathrm{E}-13$ |
| II TAP2/1 | AL359545.12.1.127243 | Xq13.3 | 71447688 | 71550705 | ABCB7 | $2.90 \mathrm{E}-08$ |
| xII KIFC1 | AL021786.2.1.70665 | Xq21.1 | 75540478 | 75573738 | Novel | $1.40 \mathrm{E}-15$ |
| POU5F1 | Z82170.1.1.127247 | Xq21.1 | 79839811 | 79841286 | POU3F4 | 6.20E-39 |
| III BAT1 | AL136362.10.1.135240 | Xq21.31 | 88337615 | 88338796 | EST gene | $1.30 \mathrm{E}-57$ |
| TUBB | AL390840.17.1.197611 | Xq21.32 | 88819807 | 88819917 | genscan | 1.50E-09 |
| XIICOL11A2 | AL136080.6.1.116106 | Xq23 | 104474931 | 104758796 | COL4A6 | $2.50 \mathrm{E}-15$ |
| XIICOL11A2 | AL031622.1.1.104674 | Xq23 | 104759239 | 105016860 | COL4A5 | $1.80 \mathrm{E}-17$ |
| III HSPA1L | AC004822.1.1.127824 | Xq23 | 111134972 | 111136228 | genscan | $1.30 \mathrm{E}-208$ |
| III VARS2 | AC005000.2.1.107314 | Xq23 | 112024040 | 112063337 | Novel | $3.30 \mathrm{E}-05$ |
| I TUBB | AC003012.1.1.104810 | Xq24 | 112252763 | 112252876 | genscan | $4.60 \mathrm{E}-12$ |
| xII ZNF297 | AC002086.1.1.112686 | Xq24 | 116370267 | 116377851 | NM_006777 | $6.50 \mathrm{E}-09$ |
| III HSPA1L | AC002377.1.1.141779 | Xq24 | 117230333 | 117231259 | genscan | $1.50 \mathrm{E}-221$ |
| III HSPA1L | AL391241.21.1.157860 | Xq25 | 120232224 | 120232373 | genscan | $9.40 \mathrm{E}-65$ |
| III NOTCH4 | AL627231.9.1.146366 | Xq25 | 121306552 | 121307673 | Novel | $6.10 \mathrm{E}-12$ |
| xII ZNF297 | AL590282.6.1.139296 | Xq26.3 | 131228672 | 131323794 | ZNF75 | $3.70 \mathrm{E}-10$ |
| III C6orf46 | U82670.3.1.279526 | Xq28 | 149081175 | 149084483 | ZNF275 | $5.30 \mathrm{E}-12$ |
| III CLIC1 | AL356738.14.1.174693 | Xq28 | 150871755 | 150929271 | CLIC2 | 8.80E-52 |
| xI HIST1H2AC | AC019175.4.37111.45694 | Xq28 | 151078382 | 151078898 | H2AFB | $1.80 \mathrm{E}-13$ |
| XI HIST1H2AC | AL592156.4.1.134995 | Xq21.1 | 35423125 | 35423349 | genscan | $2.00 \mathrm{E}-11$ |
| III BAT1 | AC010129.3.1.44145 | Yp11.2 | 5171386 | 5172558 | Novel | $6.30 \mathrm{E}-59$ |
| III BAT1 | AC004474.1.1.148280 | Yq11.21 | 14326902 | 14356562 | DBY | 4.00E-05 |

## Appendix 3

Primers used to amplify a paralogue specific probe for use in Northern blot, Dot blot and Southern blot analyses. ' $T$ ' stands for the annealing temperature.

| Gene | Primer | Sequence | $\begin{gathered} \hline T \\ \left({ }^{\circ} C\right) \end{gathered}$ | Size <br> (bp) |
| :---: | :---: | :---: | :---: | :---: |
| AIF1 | F | TGACCATGCTGATGTATGAGGAAAAAGCGA | 62 | 200 |
|  | R | GATCTGGAGGAGGGGGTAAT |  |  |
| AIF1-L | F | TGACCATGTTAAGGGAGGAGAGCAAGCA | 62 | 251 |
|  | R | CTGAGCCCTTAGCCAGAGAA |  |  |
| BRD2 | F | TGACCATGGAGGGATGCAGGGACATTT | 62 | 411 |
|  | R | AACAAAGACAGTCCAGGGGA |  |  |
| BRDT | F | TGACCATGGGGTACCATTGATATGACCCTT | 62 | 199 |
|  | R | CTGTTTAATCATTTTAGAGCAGTCA |  |  |
| BRD3 | F | TGACCATGGACAGATGGATGTCGCACAC | 62 | 425 |
|  | R | CAAATGACAAGGACAATGCG |  |  |
| BRD4 | F | TGACCATGGTGAAAGGGACAGGACTCCA | 65 | 508 |
|  | R | CAGTGAGAAGCATGCTGTGG |  |  |
| C4 | F | TGACCATGAGAGATGACTCCGCGTCTGT | 65 | 395 |
|  | R | ATTCTCCTTCTGCCCCAGAT |  |  |
| C3 | F | TGACCATGCATTCCCCCACTCCAGATAA | 65 | 214 |
|  | R | ACATGAAGGTGAGGCAGGTC |  |  |
| C5 | F | TGACCATGTTGCACTTATGGACTCCTGTTG | 65 | 352 |
|  | R | GATCAGTTTCCTGTTCCTTGGT |  |  |
| CLIC1 | F | TGACCATGAAGTACCGGGGATTCACCAT | 65 | 310 |
|  | R | CTTTCCCTCATCCCCTCTTC |  |  |
| CLIC4 | F | TGACCATGGGAGATTGGAGTCTGAATGGA | 65 | 384 |
|  | R | AATGGGTTTAAGGGCACAGA |  |  |
| CLIC3 | F | TGACCATGGTACGCCGCTACCTGGAC | 65 | 153 |
|  | R | CCCGACAAAGATGCCTTTATT |  |  |
| CLIC5 | F | TGACCATGTGTTGATGCCAAAATACCCA | 65 | 427 |
|  | R | GACCACCTCCTAAATGTGGC |  |  |
| CLIC6 | F | TGACCATGTGTGGCCAAGAAGTACAGAGAT | 65 | 146 |
|  | R | TTGCAACATCTGAATATGCG |  |  |
| CLIC2 | F | TGACCATGGAATTCTCAGGAGTCTGGCG | 65 | 350 |
|  | R | GCAGTGGTTTGCCATACAGA |  |  |
| GPX5 | F | TGACCATGTAGCAATGGGGTCACAGTCA | 65 | 277 |
|  | R | TCCTCTCCAGGTGCCATAAC |  |  |
| GPX4 | F | TGACCATGTCCACAAGTGTGTGGCCC | 65 | 186 |
|  | R | CACAAGGTAGCCAGGGGTG |  |  |
| GPX3 | F | TGACCATGAACCCAAAGGAAAAACCAGC | 62 | 451 |
|  | R | GAGTCTCAAGCCAGTGGACC |  |  |
| GPX1 | F | TGACCATGCTCTTCGAGAAGTGCGAGGT | 65 | 439 |
|  | R | ACTGGGATCAACAGGACCAG |  |  |
| GPX2 | F | TGACCATGTCCTACTCCATCCAGTCCTGA | 62 | 256 |
|  | R | CTTCACGCCTCTCAGACACC |  |  |
| NOTCH4 | F | TGACCATGCATTAAAAGGCAGGCTGGAA | 65 | 475 |
|  | R | CATCCCCACAGTGGAGTTCT |  |  |
| NOTCH2 | F | TGACCATGATGAGGAGGACAACACTGCC | 65 | 395 |
|  | R | GCATCACAGCCAATTGCTTA |  |  |
| NOTCH1 | F | TGACCATGCAATACTGCATCCATGGCCT | 65 | 244 |


|  | R | GTCCCTGAGCAACCATCTGT |  |  |
| :---: | :---: | :---: | :---: | :---: |
| NOTCH3 | F | TGACCATGATGTTCCATAGCCTTGCTGG | 65 | 294 |
|  | R | GGGAATTCAGCTACACAGGG |  |  |
| PBX2 | F | TGACCATGGCAGGGCTGGACTCAGTAAT | 62 | 409 |
|  | R | CACTTCCAACCTGTCCCAGT |  |  |
| PBX1 | F | TGACCATGCAGGAGGGAGGGTTTCTCTC | 62 | 267 |
|  | R | TCAGTGATATGAGAGAGGGCG |  |  |
| PBX3 | F | TGACCATGCGAGTGTGGAAACATTGGGT | 62 | 325 |
|  | R | TCAATCCAGGGTGTAATCCA |  |  |
| PBX4 | F | TGACCATGGTTTGGGGGATAAGCAGGAA | 62 | 286 |
|  | R | GAAAATCTGTGCCCAGTCCT |  |  |
| RXRB | F | TGACCATGAAGAAATGCCAGTGGTGGAG | 62 | 263 |
|  | R | AAAGGAGCCCCAAAGAGAAG |  |  |
| RXRG | F | TGACCATGTCCTGACTAATCCCAGAGGG | 62 | 215 |
|  | R | CATAGCCTGCGGGAAACTT |  |  |
| RXRA | F | TGACCATGTATACTTGGATATGGCGGGG | 65 | 299 |
|  | R | CGGAGAAGCCACTTCACAGT |  |  |
| TUBB_6p21.3 | F | TGACCATGAGAGCAACATGAACGACCTG | 65 | 200 |
|  | R | TGGAGGGAGATTGAAAGTGG |  |  |
| TUBB2_18p11.3 | F | TGACCATG TTCCTTCTTGAACCCTGGTG | 65 | 225 |
|  | R | TTTATTTTGTGGCCCCTCAG |  |  |
| TUBB5_19p13.3 | F | TGACCATGCTGAATCCCCTCTGACTCCA | 65 | 293 |
|  | R | CCTCTCTTCCTCACAGGCAC |  |  |
| TUBB4QL_10p15.3 | F | TGACCATGACAGCATCTGGTTTTGCCTC | 65 | 130 |
|  | R | CCACTGGAATGCTTGTTCCT |  |  |
| TUBB4_16q24.3 | F | TGACCATGCAGCTGGAGTGAGAGGCAG | 65 | 201 |
|  | R | GCCTGGAGCTGCAATAAGAC |  |  |
| TUBB1_20q13.3 | F | TGACCATGTGCACTCACCATTAGCTTCG | 65 | 396 |
|  | R | TAGTCAGGCACCTGGCTCTT |  |  |

## Appendix 4

Primers used to generate paralogue specific PCR products for each paralogue. The products were used to spot on to the microarrays and were also labelled and used to hybridise to the 'Paralogue Microarray'. ' T ' stands for the annealing temperature. They were also used in the RT-PCR experiments.

| Gene | Primer | Sequence | $\begin{gathered} T \\ \left({ }^{\circ} C\right) \\ \hline \end{gathered}$ | Size <br> (bp) |
| :---: | :---: | :---: | :---: | :---: |
| AIF1 | F | TGACCATGCTGATGTATGAGGAAAAAGCGA | 62.5 | 200 |
|  | R | GATCTGGAGGAGGGGGTAAT |  |  |
| AIF1-L | F | TGACCATGTTAAGGGAGGAGAGCAAGCA | 62.5 | 251 |
|  | R | CTGAGCCCTTAGCCAGAGAA |  |  |
| BRD2 | F | TGACCATGGAGGGATGCAGGGACATTT | 62.5 | 411 |
|  | R | AACAAAGACAGTCCAGGGGA |  |  |
| BRDT | F | TGACCATGGGGTACCATTGATATGACCCTT | 62.5 | 199 |
|  | R | CTGTTTAATCATTTTAGAGCAGTCA |  |  |
| BRD3 | F | TGACCATGGACAGATGGATGTCGCACAC | 62.5 | 425 |
|  | R | CAAATGACAAGGACAATGCG |  |  |
| BRD4 | F | TGACCATGGTGAAAGGGACAGGACTCCA | 65 | 508 |
|  | R | CAGTGAGAAGCATGCTGTGG |  |  |
| C4 | F | TGACCATGAGAGATGACTCCGCGTCTGT | 65 | 395 |
|  | R | ATTCTCCTTCTGCCCCAGAT |  |  |
| C3 | F | TGACCATGCATTCCCCCACTCCAGATAA | 65 | 214 |
|  | R | ACATGAAGGTGAGGCAGGTC |  |  |
| C5 | F | TGACCATGTTGCACTTATGGACTCCTGTTG | 65 | 352 |
|  | R | GATCAGTTTCCTGTTCCTTGGT |  |  |
| CLIC1 | F | TGACCATGAAGTACCGGGGATTCACCAT | 62.5 | 310 |
|  | R | CTTTCССТСАTCCCCTCTTC |  |  |
| CLIC4 | F | TGACCATGGGAGATTGGAGTCTGAATGGA | 65 | 384 |
|  | R | AATGGGTTTAAGGGCACAGA |  |  |
| CLIC3 | F | TGACCATGGTACGCCGCTACCTGGAC | 65 | 153 |
|  | R | CCCGACAAAGATGCCTTTATT |  |  |
| CLIC5 | F | TGACCATGTGTTGATGCCAAAATACCCA | 65 | 427 |
|  | R | GACCACCTCCTAAATGTGGC |  |  |
| CLIC6 | F | TGACCATGTGTGGCCAAGAAGTACAGAGAT | 65 | 146 |
|  | R | TTGCAACATCTGAATATGCG |  |  |
| CLIC2 | F | TGACCATGGAATTCTCAGGAGTCTGGCG | 65 | 350 |
|  | R | GCAGTGGTTTGCCATACAGA |  |  |
| GPX5 | F | TGACCATGTAGCAATGGGGTCACAGTCA | 62.5 | 277 |
|  | R | TCCTCTCCAGGTGCCATAAC |  |  |
| GPX4 | F | TGACCATGTCCACAAGTGTGTGGCCC | 62.5 | 186 |
|  | R | CACAAGGTAGCCAGGGGTG |  |  |
| GPX3 | F | TGACCATGTCTGGGTCTACCACACTCCC | 62.5 | 329 |
|  | R | GAGTCTCAAGCCAGTGGACC |  |  |
| GPX1 | F | TGACCATGCTCTTCGAGAAGTGCGAGGT | 62.5 | 439 |
|  | R | ACTGGGATCAACAGGACCAG |  |  |
| GPX2 | F | TGACCATGTCCTACTCCATCCAGTCCTGA | 62.5 | 256 |
|  | R | CTTCACGCCTCTCAGACACC |  |  |
| NOTCH4 | F | TGACCATGCATTAAAAGGCAGGCTGGAA | 62.5 | 475 |
|  | R | CATCCCCACAGTGGAGTTCT |  |  |
| NOTCH2 | F | TGACCATGATGAGGAGGACAACACTGCC | 65 | 395 |
|  | R | GCATCACAGCCAATTGCTTA |  |  |


| NOTCH1 | F | TGACCATGCAATACTGCATCCATGGCCT | 65 | 244 |
| :--- | :--- | :--- | :--- | :--- |
|  | R | GTCCCTGAGCAACCATCTGT |  |  |
| NOTCH3 | F | TGACCATGATGTTCCATAGCCTTGCTGG | 65 | 294 |
|  | R | GGGAATTCAGCTACACAGGG |  |  |
| PBX2 | F | TGACCATGGCAGGGCTGGACTCAGTAAT | 62.5 | 409 |
|  | R | CACTTCCAACCTGTCCCAGT |  |  |
| PBX1 | F | TGACCATGCAGGAGGGAGGGTTTCTCTC | 62.5 | 267 |
|  | R | TCAGTGATATGAGAGAGGGCG |  |  |
| PBX3 | F | TGACCATGACCGAGTGTGGAAACATTGG | 62.5 | 328 |
|  | R | TTCAATCCAGGGTGTAATCCA |  |  |
| PBX4 | F | TGACCATGAAGTTTGGGGGATAAGCAGG | 62.5 | 288 |
|  | R | GAAAATCTGTGCCCAGTCCTA |  |  |
| RXRB | F | TGACCATGGCCTTCCTCCTCTCAAACCT | 62.5 | 263 |
|  | R | CTCCACCACTGGCATTTCTT |  |  |
| RXRG | F | TGACCATGCGATCTAGAGGCAGATTCCTGA | 62.5 | 231 |
|  | R | CATAGCCTGCGGGAAACTT |  |  |
| RXRA | F | TGACCATGTATACTTGGATATGGCGGGG | 65 | 299 |
|  | R | CGGAGAAGCCACTTCACAGT |  |  |
| TUBB_6p21.3 | F | TGACCATGACCAACCAGGTGCTGAAAAC | 65 | 242 |
|  | R | TGGAGGGAGATTGAAAGTGG |  |  |
| TUBB2_18p11.3 | F | TGACCATG TTCCTTCTTGAACCCTGGTG | 65 | 225 |
|  | R | TTTATTTTGTGGCCCCTCAG |  |  |
| TUBB5_19p13.3 | F | TGACCATGCTGAATCCCCTCTGACTCCA | 62.5 | 293 |
|  | R | CCTCTCTTCCTCACAGGCAC |  |  |
| TUBB4QL_10p15.3 | F | TGACCATGACAGCATCTGGTTTTGCCTC | 65 | 130 |
|  | R | CCACTGGAATGCTTGTTCCT |  |  |
| TUBB4_16q24.3 | F | TGACCATGCAGCTGGAGTGAGAGGCAG | 65 | 201 |
|  | R | GCCTGGAGCTGCAATAAGAC |  |  |
| TUBB1_20q13.3 | F | TGACCATGTGCACTCACCATTAGCTTCG | 65 | 396 |
|  | R | TAGTCAGGCACCTGGCTCTT |  |  |

## Appendix 5

## Summary of in-silico results.

| Gene |  | $\underset{y}{\Xi}$ | $\underset{y}{0}$ |  | $\left\lvert\, \begin{gathered} \mathbf{y} \\ \mathbf{y} \\ \mathbf{y} \end{gathered}\right.$ | $\begin{gathered} \frac{3}{5} \\ \frac{3}{7} \end{gathered}$ |  | Oesophagus |  | $\begin{array}{\|c}  \pm \\ 3 \\ 3 \end{array}$ |  |  | $\begin{aligned} & \mathrm{E} \\ & \mathrm{e} \\ & \mathrm{e} \end{aligned}$ |  |  |  | $\left\|\begin{array}{l} 2 \\ 5 \\ 0 \\ 0 \\ 0 \end{array}\right\|$ | Genitourinary |  |  | Cervix |  | $\begin{aligned} & \hat{3} \\ & \mathbf{3} \end{aligned}$ | \% |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| AIF1_6p21.33 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 1 |
| AIF1-L_9q34.12 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 |
| BRD2_6p21.32 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 |
| BRDT_1p22.1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| BRD3_9q34.2 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 |
| BRD4_19p13.12 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 |
| C4_6p21.33 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 1 |
| C5_9q33.2 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| C3_19p13.3 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| CLIC1_6p21.33 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 |
| CLIC4_1p35.3 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 1 |
| CLIC3_9q34.3 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| CLIC5_6p21.1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 |
| CLIC6_21q22.12 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CLIC2_Xq28 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 1 |
| GPX5_6p22.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GPX4_19p13.3 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 |
| GPX1_3p21.31 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| GPX3_5q33.1 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 |
| GPX2_14q23.3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 1 |
| NOTCH4_6p21.33 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 1 |
| NOTCH2_1p11.2 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 |
| NOTCH1_9q34.3 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| NOTCH3_19p13.12 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 1 |
| PBX2_6p21.33 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 0 |
| PBX1_1q23.3 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 1 |
| PBX3_9q33.3 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| PBX4_19p13.11 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| RXRB_6p21.32 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 |
| RXRG_1q23.3 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| RXRA_9q34.2 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 |
| TUBB_6p21.3 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 |
| TUBB4_16q24.3 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 |
| TUBBL_18p11.3 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 1 |
| TUBB5_19p13.3 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| TUBB1_20q13.3 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

In-silico results continued (part 2 of 3 ).

| Gene | $$ |  | $\begin{gathered} \mathbf{E} \\ \mathbf{S} \\ \mathbf{S} \\ \mathbb{E} \end{gathered}$ | $\begin{array}{\|c} \underset{0}{2} \\ \text { E } \\ 0 \\ 0 \end{array}$ |  | $\begin{gathered} 5 \\ \frac{5}{3} \\ 5 \\ 5 \end{gathered}$ |  |  | Lymph node |  | $\begin{gathered} \text { a } \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \end{gathered}$ | $$ | $\underset{\substack{2 \\ i}}{\underset{\sim}{2}}$ |  | $\begin{array}{\|c} \stackrel{y}{0} \\ 0 \\ 0 \\ 0 \\ 3 \\ 3 \end{array}$ | $\begin{array}{\|c\|} \hline 2 \\ \frac{2}{9} \\ 9 \end{array}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \\ & 2 \end{aligned}$ |  | $\stackrel{8}{3}$ |  |  |  |  | 気 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| AIF1_6p21.33 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 |
| AIF1-L_9q34.12 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 |
| BRD2_6p21.32 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| BRDT_1p22.1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| BRD3_9q34.2 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| BRD4_19p13.12 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0 |
| C4_6p21.33 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 1 |
| C5_9q33.2 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| C3_19p13.3 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0 |
| CLIC1_6p21.33 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 |
| CLIC4_1p35.3 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 |
| CLIC3_9q34.3 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| CLIC5_6p21.1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CLIC6_21q22.12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| CLIC2_Xq28 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
| GPX5_6p22.1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GPX4_19p13.3 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 0 |
| GPX1_3p21.31 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| GPX3_5q33.1 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| GPX2_14q23.3 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| NOTCH4_6p21.33 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| NOTCH2_1p11.2 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 0 |
| NOTCH1_9q34.3 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| NOTCH3_19p13.12 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| PBX2_6p21.33 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 |
| PBX1_1q23.3 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| PBX3_9q33.3 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 |
| PBX4_19p13.11 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| RXRB_6p21.32 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 |
| RXRG_1q23.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| RXRA_9q34.2 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
| TUBB_6p21.3 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 |
| TUBB4_16q24.3 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 |
| TUBBL_18p11.3 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| TUBB5_19p13.3 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| TUBB1_20q13.3 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |

In-silico results continued (part 3 of 3 ).

| Gene | $\begin{aligned} & \text { E } \\ & 00 \\ & 0 \\ & 0 \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & \text { E } \\ & \text { B } \\ & \text { B } \\ & \text { B } \\ & 0 \end{aligned}$ | $\frac{5}{5}$ | $\stackrel{y}{3}$ | $\begin{aligned} & \stackrel{0}{0} \\ & \stackrel{0}{3} \\ & \hline \end{aligned}$ | $\begin{aligned} & \text { İ } \\ & 0 \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & \text { 気 } \\ & 0 \end{aligned}$ |  | $\begin{aligned} & \stackrel{\rightharpoonup}{3} \\ & \stackrel{y}{*} \end{aligned}$ | $\begin{aligned} & \text { O } \\ & \stackrel{0}{0} \\ & 0 \end{aligned}$ | $\begin{aligned} & 0 \\ & \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ | 柴 |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| AIF1_6p21.33 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 |
| AIF1-L_9q34.12 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 |
| BRD2_6p21.32 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 |
| BRDT_1p22.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| BRD3_9q34.2 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 |
| BRD4_19p13.12 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 |
| C4_6p21.33 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 1 |
| C5_9q33.2 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 1 |
| C3_19p13.3 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 |
| CLIC1_6p21.33 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 |
| CLIC4_1p35.3 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 |
| CLIC3_9q34.3 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 |
| CLIC5_6p21.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| CLIC6_21q22.12 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| CLIC2_Xq28 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 |
| GPX5_6p22.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GPX4_19p13.3 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 |
| GPX1_3p21.31 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| GPX3_5q33.1 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| GPX2_14q23.3 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| NOTCH4_6p21.33 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| NOTCH2_1p11.2 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 |
| NOTCH1_9q34.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| NOTCH3_19p13.12 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 1 |
| PBX2_6p21.33 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 |
| PBX1_1q23.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 |
| PBX3_9q33.3 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 1 |
| PBX4_19p13.11 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| RXRB_6p21.32 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 1 |
| RXRG_1q23.3 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 |
| RXRA_9q34.2 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 |
| TUBB_6p21.3 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 |
| TUBB4_16q24.3 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 1 |
| TUBBL_18p11.3 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 1 |
| TUBB5_19p13.3 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| TUBB1_20q13.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |

## Appendix 6

## Summary of dot blot results

| Gene | $\begin{aligned} & \text { E } \\ & 0 \\ & 0 \end{aligned}$ |  |  | $\begin{array}{\|c\|} 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \end{array}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \\ & 0 \\ & 0 \\ & 0.5 \\ & 0 \\ & 0 \end{aligned}$ |  | Paracentral gyrus of cerebral cortex | $\stackrel{\ddots}{\mathbf{3}}$ |  |  | $\begin{aligned} & 5 \\ & 0 \\ & 0 \\ & 0 \\ & 0 \\ & 0 \\ & 5 \\ & 0 \\ & 0 \end{aligned}$ |  | $\left\|\begin{array}{c} a \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \end{array}\right\|$ | $\begin{array}{r} 6 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \end{array}$ |  |  | Accumbens nucleus |  | $\begin{array}{\|c} \mathbf{y} \\ 0 \\ 0 \\ 0 \end{array}$ | $\begin{aligned} & 5 \\ & \frac{3}{3} \end{aligned}$ |  |  | $\begin{gathered} 1 \\ 0 \\ 0 \\ 0.0 \\ 0.0 \\ 0 \\ 0 \end{gathered}$ |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| AIF1_6p21.33 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| AIF1-L_9q34.12 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| BRD2_6p21.32 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| BRDT_1p22.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| BRD3_9q34.2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| BRD4_19p13.12 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| C4_6p21.33 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| C5_9q33.2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 |
| C3_19p13.3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| CLIC1_6p21.33 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| CLIC4_1p35.3 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| CLIC3_9q34.3 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| CLIC5_6p21.1 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 |
| CLIC6_21q22.12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CLIC2_Xq28 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GPX5_6p22.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GPX4_19p13.3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| GPX1_3p21.31 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| GPX3_5q33.1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| GPX2_14q23.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| NOTCH4_6p21.33 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| NOTCH2_1p11.2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| NOTCH1_9q34.3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 |
| NOTCH3_19p13.12 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| PBX2_6p21.33 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| PBX1_1q23.3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| PBX3_9q33.3 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| PBX4_19p13.11 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| RXRB_6p21.32 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| RXRG_1q23.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| RXRA_9q34.2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| TUBB_6p21.3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| TUBB4QL_10p15.3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| TUBB4_16q24.3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 |
| TUBBL_18p11.3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| TUBB5_19p13.3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 |
| TUBB1_20q13.3 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

Dot blot results continued（2 of 3）．

| Gene |  | $\begin{array}{\|c\|} \hline 5 \\ 3 \\ 3 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ \hline \end{array}$ | $\left.\begin{gathered} 5 \\ 0 \\ 0 \\ 30 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \end{gathered} \right\rvert\,$ |  | $\begin{array}{\|c} \text { In } \\ \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \end{array}$ |  | $$ | $$ |  | $\begin{array}{\|c\|} 80 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 5 \\ 0 \\ 0 \\ 0 \end{array}$ |  | $\begin{gathered} 00 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \end{gathered}$ | $\begin{aligned} & \text { E } \\ & \text { 葡 } \\ & \cline { 1 - 2 } \end{aligned}$ |  |  | $\begin{aligned} & 5 \\ & \frac{1}{3} \\ & \sqrt[3]{4} \end{aligned}$ | $\begin{gathered} 气 \\ \vdots \\ \vdots \\ \hat{3} \end{gathered}$ | Pripheral blood leukocyte |  |  |  | $\stackrel{80}{5}$ | $\begin{array}{r} 5 \\ 5 \\ 0 \\ 0 \\ 2 \end{array}$ | 宕 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| AIF1＿6p21．33 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| AIF1－L＿9q34．12 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 0 |
| BRD2＿6p21．32 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| BRDT＿1p22．1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| BRD3＿9q34．2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| BRD4＿19p13．12 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 |
| C4＿6p21．33 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| C5＿9q33．2 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 |
| C3＿19p13．3 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 |
| CLIC1＿6p21．33 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| CLIC4＿1p35．3 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| CLIC3＿9q34．3 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 |
| CLIC5＿6p21．1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CLIC6＿21q22．12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| CLIC2＿Xq28 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GPX5＿6p22．1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GPX4＿19p13．3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| GPX1＿3p21．31 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| GPX3＿5q33．1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| GPX2＿14q23．3 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| NOTCH4＿6p21．33 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 1 |
| NOTCH2＿1p11．2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| NOTCH1＿9q34．3 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| NOTCH3＿19p13．12 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| PBX2＿6p21．33 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| PBX1＿1q23．3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| PBX3＿9q33．3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| PBX4＿19p13．11 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 |
| RXRB＿6p21．32 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| RXRG＿1q23．3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| RXRA＿9q34．2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| TUBB＿6p21．3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| TUBB4QL＿10p15．3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| TUBB4＿16q24．3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| TUBBL＿18p11．3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| TUBB5＿19p13．3 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 |
| TUBB1＿20q13．3 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 0 |

Dot blot results continued（3 of 3）．

| Gene | $\begin{gathered} 2 \\ 5 \\ 5 \\ 5 \end{gathered}$ |  | $\begin{aligned} & \text { n } \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 2 \\ & 0 \\ & 0 \end{aligned}$ | $\stackrel{\vdots}{3}$ | $\begin{aligned} & \tilde{y} \\ & 0 \\ & 0 \\ & \mathbf{E} \\ & \mathbf{E} \end{aligned}$ |  | $\begin{aligned} & 3 \\ & 3 \\ & 30 \\ & 3 \\ & 3 \\ & 3 \\ & 3 \\ & 7 \end{aligned}$ |  |  | $\left.\begin{array}{\|c} \tilde{n} \\ \vdots \\ \vdots ⿹ 勹 巳 y \end{array} \right\rvert\,$ |  | $\begin{aligned} & 3 \\ & 0 \\ & - \\ & \frac{3}{3} \\ & \frac{3}{3} \end{aligned}$ | $\begin{aligned} & \text { 을 } \\ & 0 \\ & 0 \\ & : 0 \\ & 0 \\ & 0 \end{aligned}$ | Burkitt＇s lymphoma，Daudi |  | Lung carcinoma，A549 | $\begin{aligned} & 5 \\ & 0 \\ & 0 \\ & 0 \\ & 0 \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{gathered} 1 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \end{gathered}$ | 䓌 |  | $\begin{gathered} \text { n } \\ 0 \\ 0 \\ 5 \\ 5 \\ 0 \\ 0 \\ 5 \end{gathered}$ | 2 |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| AIF1＿6p21．33 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| AIF1－L＿9q34．12 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 |
| BRD2＿6p21．32 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| BRDT＿1p22．1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| BRD3＿9q34．2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| BRD4＿19p13．12 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 |
| C4＿6p21．33 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| C5＿9q33．2 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 |
| C3＿19p13．3 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| CLIC1＿6p21．33 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| CLIC4＿1p35．3 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CLIC3＿9q34．3 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 |
| CLIC5＿6p21．1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| CLIC6＿21q22．12 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CLIC2＿Xq28 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GPX5＿6p22．1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GPX4＿19p13．3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| GPX1＿3p21．31 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| GPX3＿5q33．1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| GPX2＿14q23．3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| NOTCH4＿6p21．33 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| NOTCH2＿1p11．2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| NOTCH1＿9q34．3 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| NOTCH3＿19p13．12 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| PBX2＿6p21．33 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| PBX1＿1q23．3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| PBX3＿9q33．3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| PBX4＿19p13．11 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| RXRB＿6p21．32 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| RXRG＿1q23．3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| RXRA＿9q34．2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| TUBB＿6p21．3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| TUBB4QL＿10p15．3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| TUBB4＿16q24．3 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| TUBBL＿18p11．3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| TUBB5＿19p13．3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0 |
| TUBB1＿20q13．3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

## Appendix 7

Northern blot results and transcript sizes（kb）．The most dominant transcripts are in bold．

| Gene | Nu | 忥 | E U U Z | $\stackrel{80}{E}$ | さ̀ |  | 令 | 边 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| AIF1＿6p21．33 | $\begin{gathered} - \\ 3.0 \\ 1.25 \\ 0.6 \\ \hline \end{gathered}$ | $3.0$ | $\begin{gathered} 3.0 \\ 1.25 \end{gathered}$ | $3.0$ | $\begin{gathered} 1.25 \\ 0.6 \\ \hline \end{gathered}$ | $\begin{gathered} 5.0 \\ 3.0 \\ - \\ 0.6 \end{gathered}$ | $\begin{gathered} - \\ 3.0 \\ - \\ 0.6 \end{gathered}$ | $\begin{gathered} 3.0 \\ - \\ 0.6 \\ \hline \end{gathered}$ |
| AIF1－L＿9q34．12 | 3.4 | 3.4 | 3.4 | 0 | 0 | 0 | 3.4 | 0 |
| BRD2＿6p21．32 | $\begin{aligned} & 4.6 \\ & 3.8 \end{aligned}$ | $\begin{aligned} & 4.6 \\ & 3.8 \end{aligned}$ | $\begin{aligned} & 4.6 \\ & 3.8 \end{aligned}$ | $\begin{aligned} & 4.6 \\ & 3.8 \\ & \hline \end{aligned}$ | $\begin{aligned} & 4.6 \\ & 3.8 \end{aligned}$ | $\begin{aligned} & 4.6 \\ & 3.8 \end{aligned}$ | $\begin{aligned} & 4.6 \\ & 3.8 \\ & \hline \end{aligned}$ | $\begin{aligned} & 4.6 \\ & 3.8 \end{aligned}$ |
| BRDT＿1p22．1 | $7.0$ | $7.0$ | $7.0$ | 0 | $7.0$ | $7.0$ | $\begin{gathered} 7.0 \\ - \\ - \end{gathered}$ | $\begin{aligned} & \hline 7.0 \\ & 4.0 \\ & 3.5 \end{aligned}$ |
| BRD3＿9q34．2 | 6.5 | 6.5 | 6.5 | 6.5 | 6.5 | 6.5 | 6.5 | 6.5 |
| BRD4＿19p13．12 | $\begin{aligned} & \hline 6.0 \\ & 4.4 \end{aligned}$ | $\begin{aligned} & \hline 6.0 \\ & 4.4 \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 6.0 \\ & 4.4 \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 6.0 \\ & 4.4 \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 6.0 \\ & 4.4 \end{aligned}$ | $\begin{aligned} & \hline 6.0 \\ & 4.4 \end{aligned}$ | $\begin{aligned} & \hline 6.0 \\ & 4.4 \end{aligned}$ | $\begin{aligned} & \hline 6.0 \\ & 4.4 \\ & \hline \end{aligned}$ |
| C4＿6p21．33 | 0 | 0 | 0 | 0 | 5.4 | 0 | 5.4 | 0 |
| C5＿9q33．2 | 0 | 0 | 0 | 0 | $\begin{aligned} & \hline 6.0 \\ & \mathbf{5 . 0} \\ & 4.2 \\ & 1.6 \\ & 1.0 \\ & \hline \end{aligned}$ | 0 | $\begin{gathered} - \\ 5.0 \\ - \\ - \end{gathered}$ | $\begin{gathered} - \\ 5.0 \\ 4.2 \\ - \end{gathered}$ |
| C3＿19p13．3 | 0 | 0 | 0 | 0 | 5.0 | 0 | 0 | 0 |
| CLIC1＿6p21．33 | $\begin{gathered} 1.25 \\ 1.1 \end{gathered}$ | 0 | $\begin{gathered} 1.25 \\ 1.1 \\ \hline \end{gathered}$ | 1.251 .1 | $\begin{gathered} 1.25 \\ 1.1 \end{gathered}$ | $\begin{gathered} 1.25 \\ 1.1 \end{gathered}$ | $\begin{gathered} 1.25 \\ 1.1 \end{gathered}$ | $\begin{gathered} 1.25 \\ 1.1 \end{gathered}$ |
| CLIC4＿1p35．3 | 4.0 | 0 | 4.0 | 4.0 | 4.0 | 4.0 | 4.0 | 0 |
| CLIC3＿9q34．3 | $4.4$ | 0 | $\begin{gathered} 5.5 \\ - \\ 2.6 \\ \mathbf{0 . 7} \\ \hline \end{gathered}$ | $0.7$ | $0.7$ | - 4.4 - | $4.4$ | $4.4$ |
| CLIC5＿6p21．1 | 0 | $\begin{aligned} & \hline 2.7 \\ & 2.4 \end{aligned}$ | 0 | $2.7$ | 2.7 | 0 | $\begin{aligned} & \hline 2.7 \\ & 2.4 \end{aligned}$ | $2.7$ |
| CLIC6＿21q22．12 | $\begin{aligned} & 6.0 \\ & \mathbf{3 . 8} \\ & 3.0 \\ & 2.3 \end{aligned}$ | 0 | 0 | $\begin{aligned} & 3.8 \\ & 3.0 \end{aligned}$ | $0$ | 6.0 3.8 - | $0$ | $3.0$ |
| CLIC2＿Xq28 | $\begin{gathered} 1.7 \\ 1.25 \end{gathered}$ | 0 | $\begin{gathered} 1.7 \\ 1.25 \end{gathered}$ | $\begin{gathered} 1.7 \\ 1.25 \end{gathered}$ | $\begin{gathered} 1.7 \\ 1.25 \end{gathered}$ | $\begin{gathered} 1.7 \\ 1.25 \end{gathered}$ | $\begin{gathered} 1.7 \\ 1.25 \end{gathered}$ | $\begin{gathered} \hline 1.7 \\ 1.25 \end{gathered}$ |
| GPX5＿6p22．1 | $\begin{aligned} & 0.8 \\ & 0.6 \\ & \hline \end{aligned}$ | $0.8$ | $0.6$ | 0 | $\begin{gathered} - \\ 0.8 \\ 0.6 \\ \hline \end{gathered}$ | $\begin{aligned} & 3.8 \\ & 0.8 \\ & 0.6 \end{aligned}$ | 0 | $\begin{aligned} & 0.8 \\ & 0.6 \end{aligned}$ |
| GPX4＿19p13．3 | $\begin{aligned} & \hline 4.4 \\ & 2.6 \\ & 2.0 \\ & \mathbf{0 . 9} \\ & \hline \end{aligned}$ | $0.9$ | $\begin{array}{r} - \\ 2.6 \\ 2.0 \\ \mathbf{0 . 9} \\ \hline \end{array}$ | $\overline{0.9}$ | $\begin{aligned} & \hline 4.4 \\ & 2.6 \\ & 2.0 \\ & \mathbf{0 . 9} \\ & \hline \end{aligned}$ | $\begin{gathered} 4.4 \\ - \\ 2.0 \\ \mathbf{0 . 9} \end{gathered}$ | $\begin{gathered} - \\ - \\ 2.0 \\ \mathbf{0 . 9} \end{gathered}$ | $\begin{gathered} - \\ - \\ - \\ 0.9 \end{gathered}$ |
| GPX1＿3p21．31 | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 |
| GPX3＿5q33．1 | $0.7$ | 0 | $0.7$ | $0.7$ | $\begin{aligned} & 1.8 \\ & \mathbf{0 . 7} \end{aligned}$ | $\begin{aligned} & 1.8 \\ & 0.7 \\ & \hline \end{aligned}$ | $0.7$ | $0.7$ |
| GPX2＿14q23．3 | 0 | 0 | 0 | 0 | 0 | 0 | 0.9 | 0 |
| NOTCH4＿6p21．33 | $\begin{aligned} & \hline 7.8 \\ & 6.8 \\ & 2.4 \\ & \hline \end{aligned}$ | － | $\begin{aligned} & \hline 7.5 \\ & 6.8 \end{aligned}$ | $\begin{aligned} & \hline 7.5 \\ & 6.8 \end{aligned}$ | $2.4$ | $\begin{aligned} & 6.8 \\ & 2.4 \\ & \hline \end{aligned}$ | $6.8$ | $\begin{aligned} & 6.8 \\ & 2.4 \end{aligned}$ |



## Appendix 8

Summary of microarray results.

| Gene |  |  |  | $\frac{5}{4}$ | 耧 | $\left(\text { coluply }_{1}\right)<\varepsilon_{\sigma z}$ | E | : | $\underset{N}{i}$ | $\begin{aligned} & \text { Bos } \\ & \stackrel{B}{S} \\ & \hat{S} \end{aligned}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| AIF1_6p21.33 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 |
| AIF1-L_9q34.12 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| BRD2_6p21.32 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| BRDT_1p22.1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| BRD3 9q34.2 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 |
| BRD4_19p13.12 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| C4_6p21.33 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| C5_9q33.2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| C3_19p13.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CLIC1_6p21.33 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| CLIC4_1p35.3 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 |
| CLIC3_9q34.3 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CLIC5 6p21.1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| CLIC6_21q22.12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CLIC2_Xq28 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| GPX5 6p22.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GPX4_19p13.3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| GPX1_3p21.31 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| GPX3_5q33.1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| GPX2 14q23.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| NOTCH4_6p21.33 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| NOTCH2_1p11.2 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 |
| NOTCH1_9q34.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| NOTCH3_19p13.12 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 |
| PBX2_6p21.33 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PBX1_1q23.3 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 |
| PBX3 9q33.3 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 |
| PBX4_19p13.11 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 |
| RXRB_6p21.32 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 |
| RXRG_1q23.3 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| RXRA 9q34.2 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 1 |
| TUBB_6p21.3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 |
| TUBB4QL_10p15.3 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 |
| TUBB4_16q24.3 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| TUBBL_18p11.3 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 |
| TUBB5_19p13.3 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| TUBB1_20q13.3 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |

## Appendix 9

Comparison of three methods used to generate the expression profiles for nine MHC paralogous gene families. The differences between the three methods are highlighted in yellow for the nine tissues common to each method.

| Gene | Adrenal gland |  |  | Brain |  |  | Skeletal muscle |  |  | Spleen |  |  | Testis |  |  | Kidney |  |  | T cell |  |  | B cell |  |  | Lung |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | M | D | S | M | D | S | M | D | S | M | D | S | M | D | S | M | D | S | M | D | S | M | D | S | M | D | S |
| AIF1_6p21.33 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| AIF1-L_9q34.12 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| BRD2_6p21.32 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| BRDT_1p22.1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| BRD3_9q34.2 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 |
| BRD4_19p13.12 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 |
| C4_6p21.33 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 |
| C5_9q33.2 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| C3_19p13.3 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 |
| CLIC1_6p21.33 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| CLIC4_1p35.3 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 |
| CLIC3_9q34.3 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| CLIC5_6p21.1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CLIC6_21q22.12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| CLIC2_Xq28 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| GPX5_6p22.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GPX4_19p13.3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| GPX1_3p21.31 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| GPX3 5q33.1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| GPX2_14q23.3 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| NOTCH4_6p21.33 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| NOTCH2_1p11.2 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 |
| NOTCH1_9q34.3 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| NOTCH3_19p13.12 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 |
| PBX2 6p21.33 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| PBX1_1q23.3 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 |
| PBX3_9q33.3 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 1 |
| PBX4_19p13.11 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 |
| RXRB_6p21.32 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| RXRG_1q23.3 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| RXRA 9q34.2 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| TUBB_6p21.3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| TUBB5_19p13.3 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 1 |
| TUBB4_16q24.3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 1 |
| TUBB2_18p11.1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| TUBB1_20q13.32 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Total differences | 5 | 3 | 9 | 4 | 1 | 8 | 5 | 4 | 5 | 3 | 5 | 7 | 4 | 4 | 5 | 16 | 1 | 8 | 3 | 2 | 5 | 2 | 2 | 5 | 15 | 0 | 10 |
| \% difference | 14 | 8 | 25 | 11 | 3 | 22 | 14 | 11 | 14 | 8 | 14 | 19 | 11 | 11 | 14 | 44 | 3 | 22 | 8 | 6 | 14 | 6 | 6 | 14 | 42 | 0 | 28 |


[^0]:    ${ }^{1}$ Paralogues (or paralogous genes) are genes found within the same species which have arisen by duplication of a common ancestral gene.
    ${ }^{2}$ 'Paralogue specific' indicates that the PCR primers and product have been designed to be specific to a particular paralogue and not to cross-hybridise with other members of the same paralogous gene family which might share high sequence homology.

[^1]:    * paracentral gyrus

[^2]:    ${ }^{1}$ each paralogue specific PCR product was spotted in quadruplicate in two separate locations on the microarray and the experiments were repeated three times

